EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 135

Results Generated From:
Embase <1980 to 2026 Week 11>
Embase Weekly Updates (updates since 2026-03-06) - (135 records)

<1>
Accession Number
628228241
Title
Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous
Coronary Intervention: Impact on Platelet Activity, Myocardial
Microvascular Function and Infarct Size: A Randomized Controlled Trial.
Source
Thrombosis and Haemostasis. 119(7) (pp 1171-1181), 2019. Date of
Publication: 24 Jun 2019.
Author
Ubaid S.; Ford T.J.; Berry C.; Murray H.M.; Wrigley B.; Khan N.; Thomas
M.R.; Armesilla A.L.; Townend J.N.; Khogali S.S.; Munir S.; Martins J.;
Hothi S.S.; McAlindon E.J.; Cotton J.M.
Institution
(Ubaid, Wrigley, Khan, Khogali, Munir, Martins, Hothi, McAlindon, Cotton)
Heart and Lung Centre, New Cross Hospital, Wolverhampton, United Kingdom
(Ford, Berry) Golden Jubilee National Hospital, Glasgow, United Kingdom
(Ford, Berry) British Heart Foundation, Glasgow Cardiovascular Research
Centre, University of Glasgow, Glasgow, United Kingdom
(Murray) Robertson Centre for Biostatistics, Institute of Health and
Wellbeing, University of Glasgow, Glasgow, United Kingdom
(Thomas) Institute of Cardiovascular Sciences, College of Medical and
Dental Sciences, University of Birmingham, Birmingham, United Kingdom
(Armesilla, Cotton) School of Pharmacy, University of Wolverhampton,
Wolverhampton, United Kingdom
(Townend) Queen Elizabeth Hospital, Birmingham, United Kingdom
Publisher
Georg Thieme Verlag
Abstract
Background Oral P2Y12 inhibitors take more than 2 hours to achieve full
effect in healthy subjects and this action is further delayed in patients
with acute myocardial infarction. Intravenous P2Y12 inhibition might lead
to more timely and potent anti-platelet effect in the context of emergency
primary angioplasty, improving myocardial recovery. Objectives This
article compares the efficacy of intravenous cangrelor versus ticagrelor
in a ST-elevation myocardial infarction (STEMI) population treated with
primary percutaneous coronary intervention (PPCI). Materials and Methods
In an open-label, prospective, randomized controlled trial, 100 subjects
with STEMI were assigned 1:1 to intravenous cangrelor or oral ticagrelor.
The co-primary endpoints were platelet P2Y12 inhibition at infarct vessel
balloon inflation time, 4 and 24 hours. Secondary endpoints included
indices of coronary microcirculatory function: index of microvascular
resistance (IMR), initial infarct size (troponin at 24 hours) and final
infarct size at 12 weeks (cardiac magnetic resonance). Secondary endpoints
included indices of coronary microcirculatory function (index of
microvascular resistance [IMR]), initial infarct size (troponin at 24
hours), final infarct size at 12 weeks (cardiac magnetic resonance),
corrected thrombolysis in myocardial infarction (TIMI) frame count, TIMI
flow grade, myocardial perfusion grade, and ST-segment resolution
(ClinicalTrials.gov NCT02733341). Results P2Y12 inhibition at first
balloon inflation time was significantly greater in cangrelor-treated
patients (cangrelor P2Y12 reaction unit [PRU] 145.2 +/- 50.6 vs.
ticagrelor 248.3 +/- 55.1). There was no difference in mean PRU at 4 and
24 to 36 hours post-dosing. IMR, final infarct size, angiographic and
electrocardiographic measures of reperfusion were all similar between
groups. Conclusion Cangrelor produces more potent P2Y12 inhibition at the
time of first coronary balloon inflation time compared with ticagrelor.
Despite this enhanced P2Y12 inhibition, coronary microvascular function
and final infarct size did not differ between groups.<br/>Copyright &#xa9;
2019 Georg Thieme Verlag KG Stuttgart - New York.

<2>
Accession Number
631460332
Title
A Prospective Randomized Clinical Trial of Efficacy of Algorithm-Based
Point of Care Guided Hemostatic Therapy in Cyanotic Congenital Heart
Disease Surgical Patients.
Source
Journal of Cardiac Critical Care. 3(1) (pp 8-16), 2019. Date of
Publication: 31 Jan 2020.
Author
Karanjkar A.; Kapoor P.M.; Sharan S.; Bhardwaj V.; Malik V.; Hasija S.;
Choudhury A.; Chowdhury U.K.; Rajashekar P.
Institution
(Karanjkar, Kapoor, Sharan, Bhardwaj, Malik, Hasija, Choudhury) Department
of Cardiac Anaesthesia, Cardiothoracic Centre, All India Institute of
Medical Sciences, New Delhi, India
(Chowdhury, Rajashekar) Department of Cardiothoracic and Vascular Surgery,
Cardiothoracic Centre, All India Institute of Medical Sciences, New Delhi,
India
(Kapoor) Department of Cardiac Anaesthesia, Cardiothoracic Centre, All
India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
Publisher
Thieme Medical and Scientific Publishers Pvt Ltd
Abstract
Objective Point of care (POC) testing-based algorithm-guided hemostatic
therapy has been used in adult as well as pediatric cardiac surgical
patients to administer blood components. The authors hypothesized that
implementation of POC-based algorithm in pediatric cyanotic congenital
surgical patients would reduce the exposure to blood component therapy and
improve the clinical outcome. Design Prospective randomized control trial.
Setting Single-center academic institute. Participants One hundred seventy
pediatric congenital cyanotic surgical patients. Intervention
Implementation of POC and conventional tests-based algorithms.
Measurements and Main Results Algorithm-based blood component therapy was
administered in each group. There were no group differences regarding the
demographic, clinical, and laboratory characteristics. Amount of packed
red blood cells (PRBCs), fresh frozen plasma (FFP), platelets, and
cryoprecipitate (primary outcomes) administered was significantly lower in
POC group than that in the conventional group (p < 0.001). Among the
secondary outcomes, the chest drain output at 6, 12, and 24 hours and
number of re-explorations was comparable among both the groups. The
duration of mechanical ventilation, duration of intensive care unit (ICU)
stay, and hospital stay was significantly short in POC group (p = 0.008,
<0.001 and 0.019, respectively). Conclusion Implementation of POC-based
algorithm-guided hemostatic therapy reduced the exposure to blood and
blood component therapy and was associated with reduced ICU and hospital
stay in pediatric congenital cyanotic surgical patients.<br/>Copyright
&#xa9; 2020 Official Publication of The Simulation Society (TSS),
accredited by International Society of Cardiovascular Ultrasound (ISCU).

<3>
Accession Number
2032961919
Title
Comparative Efficacy of Antithrombotic Strategies in Bioprosthetic Aortic
Valve Replacement: A Network Meta-Analysis.
Source
Angiology. 77(4) (pp 426-438), 2026. Date of Publication: 01 Apr 2026.
Author
Naito N.; Takagi H.
Institution
(Naito, Takagi) Department of Cardiovascular Surgery, Shizuoka Medical
Center, Shizuoka, Japan
Publisher
SAGE Publications Inc.
Abstract
This meta-analysis evaluates outcomes in patients undergoing bioprosthetic
aortic valve replacement (bAVR), comparing different antithrombotic
strategies. We conducted a systematic search through May 2024. A standard
meta-analysis compared outcomes between patients who received
anticoagulation therapy (AC) and those who did not. Therapeutic categories
were subdivided into four groups: AC alone, AC with antiplatelet therapy
(AP), AP alone, and no antithrombotic therapy. A network meta-analysis was
performed for these categories. The review included 16 studies, comprising
a total of 59,054 patients. There was no significant difference in
all-cause mortality rates (HR: hazard ratio [95% CI: confidence interval]
= 0.98 [0.77-1.25], P = .88) or thromboembolic events (HR [95% CI] = 0.91
[0.65-1.28], P = .60) between patients with and without AC. However,
bleeding events were significantly higher in patients receiving AC (HR
[95% CI] = 1.55 [1.20-2.00], P < .01). Network meta-analysis showed that
AP alone was associated with lower mortality rates compared with other
therapeutic categories. Additionally, AP alone was associated with fewer
bleeding events compared with AC alone and AC with AP. This meta-analysis
suggests that AP alone in patients undergoing bAVR is associated with
superior outcomes compared with other antithrombotic
strategies.<br/>Copyright &#xa9; The Author(s) 2025

<4>
Accession Number
626818204
Title
Predicting the Quality of Warfarin Therapy: Reframing the Question.
Source
Thrombosis and Haemostasis. 119(4) (pp 509-511), 2019. Date of
Publication: 18 Mar 2019.
Author
Barnes G.D.
Institution
(Barnes) Department of Internal Medicine, University of Michigan, Frankel
Cardiovascular Center, Ann Arbor, MI, United States
Publisher
Georg Thieme Verlag

<5>
Accession Number
631460325
Title
Vitamin D Deficiency and Its Response to Supplementation as Stoss Therapy
in Children with Cyanotic Congenital Heart Disease Undergoing Open Heart
Surgery.
Source
Journal of Cardiac Critical Care. 3(1) (pp 17-23), 2019. Date of
Publication: 31 Jan 2020.
Author
Sahu M.K.; Bipin C.; Niraghatam H.V.; Karanjkar A.; Singh S.P.; Rajashekar
P.; Ramakrishnan L.; Devagourou V.; Upadhyay A.D.; Choudhary S.K.
Institution
(Sahu, Bipin, Niraghatam, Singh, Rajashekar, Devagourou, Choudhary)
Department of Cardiothoracic and Vascular Surgery, CN Centre, All India
Institute of Medical Sciences, New Delhi, India
(Karanjkar) Department of Cardiac Anaesthesiology, CN Centre, All India
Institute of Medical Sciences, New Delhi, India
(Ramakrishnan) Department of Laboratory Medicine, CN Centre, All India
Institute of Medical Sciences, New Delhi, India
(Upadhyay) Department of Biostatistics, All India Institute of Medical
Sciences, New Delhi, India
(Sahu) Department of Cardiothoracic and Vascular Surgery, CTVS Office, CN
Centre, All India Institute of Medical Sciences, New Delhi, India
Publisher
Thieme Medical and Scientific Publishers Pvt Ltd
Abstract
Background Data from many studies suggest that patients with congenital
heart disease are vitamin D (vitD) deficient. Following cardiac surgery as
a result of intraoperative institution of cardiopulmonary bypass (CPB),
serum vitD levels become even low. This may affect postoperative
convalescence in terms of mechanical ventilation, inotropic support,
infection, and so forth. Objective We intended to study the prevalence of
vitD deficiency pre and post cardiac surgery and the effect of vitD
supplementation (stoss therapy) on postoperative convalescence of the
children with tetralogy of Fallot (TOF) undergoing intracardiac repair
(ICR). Methodology In this randomized controlled trial (RCT), 60 children
younger than 18 years with TOF and serum vitD levels < 20ng/dL were
randomized into two groups. The study group received vitD supplementation
as stoss therapy at 10,000 units/kg body weight. All these children
underwent ICR with CPB. Demographic data, preoperative, intraoperative,
and postoperative variables were compared between the study and the
control groups. Results Prevalence of severe vitD deficiency was 93.1%.
When compared with the control group, study group showed higher serum vitD
levels in the immediate preoperative period (p = 0.001), postoperative
period following CPB (p = 0.012), and on the first postoperative day (p =
0.003). No statistically significant difference was observed in
postoperative mechanical ventilation (p = 0.35), intensive care unit (ICU)
stay (p = 0.15), and inotropic duration (p = 0.19). Conclusion Children
with TOF are highly deficient of vitD, its level falls further after CPB,
and supplementing vitD preoperatively does not influence postoperative
recovery pattern. Supplementation of vitD as stoss therapy was useful in
raising the serum levels before and after cardiac surgery.<br/>Copyright
&#xa9; 2020 Official Publication of The Simulation Society (TSS),
accredited by International Society of Cardiovascular Ultrasound (ISCU).

<6>
[Use Link to view the full text]
Accession Number
2043528781
Title
Potential Double Counting in Meta-Analysis of Combined Heart-liver
Transplantation.
Source
Transplantation. Publish Ahead of Print (no pagination), 2026. Date of
Publication: 2026.
Author
Nakayama T.; Attia A.; Ahn D.J.; Sasaki K.
Institution
(Nakayama, Attia, Ahn, Sasaki) Division of Abdominal Transplantation,
Stanford Transplant Outcomes Research Center (STORC), Stanford University
Medical Center, Stanford, CA, United States
Publisher
Lippincott Williams and Wilkins

<7>
Accession Number
2041445932
Title
Effect of Dexmedetomidine on Endothelial Glycocalyx in Patients Undergoing
Cardiac Surgery with Cardiopulmonary Bypass.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(3) (pp 805-813),
2026. Date of Publication: 01 Mar 2026.
Author
Fan Y.; Chen B.; Fang F.; Gao W.; Wu Q.; Wang W.; He G.
Institution
(Fan) Department of Anesthesiology, Women's Hospital School of Medicine
Zhejiang University, Zhejiang Province, Hangzhou, China
(Chen) Department of Anesthesiology, Taizhou Hospital of Zhejiang Province
affiliated to Wenzhou Medical University, Zhejiang, Linhai, China
(Fang) Department of Anaesthesiology, The First Affiliated Hospital,
Zhejiang University School of Medicine, Zhejiang Province, Hangzhou, China
(Gao, Wu, Wang, He) Department of Anesthesiology, The First Affiliated
Hospital of Wenzhou Medical University, Zhejiang Province, Wenzhou, China
Publisher
W.B. Saunders
Abstract
Objective: To evaluate the protective role of dexmedetomidine on
endothelial glycocalyx in cardiac surgery patients undergoing
cardiopulmonary bypass (CPB). <br/>Design(s): Randomized controlled trial.
<br/>Setting(s): Single-center study conducted from June 2022 to December
2022. <br/>Participant(s): Fifty-eight patients who underwent elective
valvular cardiac surgery with CPB. <br/>Intervention(s): Patients were
randomly assigned to either the dexmedetomidine group (n = 29) or the
saline group (n = 29), with infusion starting 10 minutes before anesthesia
induction and continuing throughout the maintenance phase.
<br/>Measurements and Main Results: Radial artery blood samples were
collected at 4 time points: T1, before anesthesia induction; T2, 5 minutes
after aortic unclamping; T3, 1 hour postoperatively; and T4, 24 hours
postoperatively. The primary endpoint was plasma syndecan-1 concentration,
and secondary endpoints were heparin sulfate and tumor necrosis
factor-alpha (TNF-alpha) levels, and long-term clinical outcomes. Compared
with controls, the dexmedetomidine group showed significantly less
glycocalyx shedding, an effect that persisted throughout CPB and recovery.
TNF-alpha levels were significantly lower at T2-T3, along with reduced
lactate levels on aortic unclamping. <br/>Conclusion(s): Dexmedetomidine
preserves endothelial glycocalyx integrity and attenuates systemic
inflammation in CPB patients.<br/>Copyright &#xa9; 2025 Elsevier Inc.

<8>
Accession Number
633005883
Title
Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the
Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.
Source
Thrombosis and Haemostasis. 121(2) (pp 140-149), 2021. Date of
Publication: 01 Feb 2021.
Author
Boriani G.; Ruff C.T.; Kuder J.F.; Shi M.; Lanz H.J.; Antman E.M.;
Braunwald E.; Giugliano R.P.
Institution
(Boriani) Cardiology Division, Department of Biomedical, Metabolic and
Neural Sciences, University of Modena and Reggio Emilia, Modena University
Hospital, Modena, Italy
(Ruff, Kuder, Antman, Braunwald, Giugliano) Timi Study Group, Division of
Cardiovascular Medicine, Brigham and Women's Hospital and Department of
Medicine, Harvard Medical School, Boston, MA, United States
(Shi) Daiichi Sankyo Inc., Basking Ridge, NJ, United States
(Lanz) Daiichi Sankyo Europe GmbH, Munich, Germany
Publisher
Georg Thieme Verlag
Abstract
Background a The effects of anticoagulants at extremes of body weight (BW)
are not well described. The aim of this study was to analyze the
pharmacokinetics/pharmacodynamics and clinical outcomes in patients
randomized to warfarin, higher dose edoxaban (HDER), and lower dose
edoxaban (LDER) regimens at extremes of BW in ENGAGE AF-TIMI 48. Methods
and Results a We analyzed three BW groups: low BW (LBW: <5th percentile,
<=55 kg, N = 1,082), middle BW (MBW: 45th-55th percentile, 79.8-84 kg, N =
2,153), and high BW (HBW: >95th percentile, >=120 kg, N = 1,093). In the
warfarin arm, LBW patients had higher rates of stroke/systemic embolism
(SSE: 6.5 vs. 4.7 in MBW vs. 1.6% in HBW, P <inf>trend</inf>< 0.001),
major bleeding (MB: 9.3 vs. 7.7 vs. 6.5%, P <inf>trend</inf>= 0.08), and
worse net clinical outcome of systemic embolic event, MB, or death (31.5
vs. 19.1 vs. 16.0%, P <inf>trend</inf>< 0.0001). The time-in-Therapeutic
range with warfarin was lowest in LBW patients (63.0 vs. 69.3 vs. 70.1%
patients, P <inf>trend</inf>< 0.001). The pharmacokinetic/pharmacodynamic
profile of edoxaban was consistent across BW groups. The risk of SSE was
similar between HDER and warfarin for each of the three weight groups (P
<inf>int</inf>= 0.52, P <inf>int-Trend</inf>= 0.86). MB was reduced by
LDER versus warfarin (P <inf>int</inf>= 0.061, P <inf>int-Trend</inf>=
0.023), especially in LBW patients. Net clinical outcomes were improved by
HDER versus warfarin (P <inf>int</inf>= 0.087, P <inf>int-Trend</inf>=
0.027), especially in LBW patients. Conclusion a Patients with LBW in
ENGAGE AF-TIMI 48 had in general a more fragile clinical status and poorer
international normalized ratio control. The
pharmacokinetic/pharmacodynamic profile of edoxaban was consistent across
extremes of BW, resulting in similar efficacy compared with warfarin,
while major or clinically relevant non-MB and net outcomes were most
favorable with edoxaban as compared to warfarin in LBW
patients.<br/>Copyright &#xa9; 2021 Georg Thieme Verlag. All rights
reserved.

<9>
Accession Number
635378130
Title
Tranexamic Acid in Neuroanesthesia and Neurocritical Care: Time for Its
Critical Appraisal.
Source
Journal of Neuroanaesthesiology and Critical Care. 6(3) (pp 257-266),
2019. Article Number: JNACC1900159. Date of Publication: 20 Dec 2019.
Author
Hooda B.; Muthuchellappan R.
Institution
(Hooda) Department of Anaesthesiology and Critical Care, Army Hospital
Research and Referral, New Delhi, India
(Muthuchellappan) Department of Neuroanaesthesia and Neurocritical Care,
National Institute of Mental Health and Neurosciences (NIMHANS),
Bengaluru, Karnataka, India
Publisher
Georg Thieme Verlag
Abstract
There is a renewed interest in the use of antifibrinolytics, especially
tranexamic acid (TxA), in varied clinical settings such as trauma,
perioperative bleeding, cardiac surgery, and multilevel spine
instrumentation procedures. Because of its prothrombotic potential, the
use of TxA in neurosurgical disorders has not gained popularity since this
subset of the population is more prone to developing thromboembolic
complications. However, recent studies have shown that TxA reduces blood
loss, reduces the need for allogeneic blood transfusion, and is associated
with minimal side effects. In this narrative review, Google Scholar,
PubMed, and EMBASE databases were searched to identify publications
relevant to the current use of TxA in varied neurosurgical and critical
care settings. These publications were analyzed, and a summary of the
findings and the role of future research on this drug are presented in
this review.<br/>Copyright &#xa9; 2019 Indian Society of
Neuroanaesthesiology and Critical Care.

<10>
Accession Number
634023072
Title
Paravertebral Block versus Thoracic Epidural Analgesia for Postthoracotomy
Pain Relief: A Meta-Analysis of Randomized Trials.
Source
Thoracic and Cardiovascular Surgeon. 70(5) (pp 413-421), 2022. Date of
Publication: 10 Aug 2022.
Author
Xu M.; Hu J.; Yan J.; Yan H.; Zhang C.
Institution
(Xu, Yan) Department of Anesthesiology, Central Hospital of Wuhan, Tongji
Medical College, Huazhong University of Science and Technology, Wuhan,
China
(Hu, Yan) Department of Anesthesiology, Xiangya Hospital, Central South
University, Hunan, Changsha, China
(Zhang) Department of Cardiovascular Surgery, Xiangya Hospital, Central
South University, Hunan, Changsha, China
Publisher
Georg Thieme Verlag
Abstract
Objective Paravertebral block (PVB) and thoracic epidural analgesia (TEA)
are commonly used for postthoracotomy pain management. The purpose of this
research is to evaluate the effects of TEA versus PVB for postthoracotomy
pain relief. Methods A systematic literature search was conducted in
PubMed, EMBASE, Web of Science, and the Cochrane Library (last performed
on August 2020) to identify randomized controlled trials comparing PVB and
TEA for thoracotomy. The rest and dynamic visual analog scale (VAS)
scores, rescue analgesic consumption, the incidences of side effects were
pooled. Results Sixteen trials involving 1,000 patients were included in
this meta-analysis. The pooled results showed that the rest and dynamic
VAS at 12, 24, and rest VAS at 48 hours were similar between PVB and TEA
groups. The rescue analgesic consumption (weighted mean differences: 3.81;
95% confidence interval [CI]: 0.982-6.638, p < 0.01) and the incidence of
rescue analgesia (relative risk [RR]: 1.963; 95% CI: 1.336-2.884, p <
0.01) were less in TEA group. However, the incidence of hypotension (RR:
0.228; 95% CI: 0.137-0.380, p < 0.001), urinary retention (RR: 0.392; 95%
CI: 0.198-0.776, p < 0.01), and vomiting (RR: 0.665; 95% CI: 0.451-0.981,
p < 0.05) was less in PVB group. Conclusion For thoracotomy, PVB may
provide no superior analgesia compared with TEA but PVB can reduce side
effects. Thus, individualized treatment is recommended. Further study is
still necessary to determine which concentration of local anesthetics can
be used for PVB and can provide equal analgesic efficiency to
TEA.<br/>Copyright &#xa9; 2022 Georg Thieme Verlag. All rights reserved.

<11>
Accession Number
634475735
Title
Influence of Left Atrial Appendage Amputation on Natriuretic Peptides-A
Randomized Controlled Trial.
Source
Thoracic and Cardiovascular Surgeon. 69(2) (pp 117-123), 2021. Date of
Publication: 14 Mar 2021.
Author
Grieshaber P.; Arneth B.; Steinsberger F.; Niemann B.; Oswald I.; Renz H.;
Boning A.
Institution
(Grieshaber, Steinsberger, Niemann, Oswald, Boning) Department of Adult
and Pediatric Cardiovascular Surgery, Giessen University Hospital,
Giessen, Germany
(Arneth, Renz) Institute for Laboratory Medicine and Pathobiochemistry,
Giessen University Hospital, Giessen, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Closure or amputation of the left atrial appendage (LAA) is a
common therapy for atrial fibrillation (AF). As the LAA is a
hormone-producing organ, however, amputation is still somewhat
controversial. We examined patients after surgical AF therapy with or
without LAA amputation to determine the influence of LAA amputation on
pro-atrial natriuretic peptide (proANP) and B-type natriuretic peptide
(BNP) plasma levels and on clinical severity of heart failure.
<br/>Method(s): Twenty-one consecutive patients were prospectively
randomized to either undergo LAA amputation (n = 10) or no LAA amputation
(n = 11) between 05/2015 and 10/2015. All patients underwent coronary
and/or valve surgery and concomitant AF surgery with either cryoablation
(n = 3) or radio frequency ablation (n = 17). ProANP and BNP levels were
measured preoperatively and until 800 days postoperatively.
<br/>Result(s): Baseline proANP values were comparable between the groups
(without LAA amputation: 4.2 +/- 2.1 nmol/L, with LAA amputation: 5.6 +/-
3.6 nmol/L). Postoperatively, proANP levels rose markedly in both groups.
Even after LAA amputation, proANP levels remained elevated for 7 days
postoperatively but fell to baseline levels at day 31 and remained on
baseline level at 800 days postoperatively. ProANP levels in the LAA
amputation group (5.8-9.7 nmol/L) were not significantly lower than in the
group without LAA amputation (9.2-14.1 nmol/L; p = 0.357). BNP levels also
rose after surgery in both groups until day 7. At 800 days after surgery,
BNP levels were back at baseline levels in both groups. Clinical follow-up
at 2 years postoperatively showed no difference in heart failure symptoms
or need for heart failure medication between the groups.
<br/>Conclusion(s): In contrast to commonly held beliefs about the
endocrine and reservoir functions of the LAA, there seems to be no
clinically relevant detrimental effect of LAA amputation on natriuretic
peptide levels and severity of heart failure until up to 2 years
postoperatively.<br/>Copyright &#xa9; 2021 Georg Thieme Verlag. All rights
reserved.

<12>
Accession Number
634304153
Title
Advances in the Management of Acute Venous Thromboembolism and New
Therapeutic Agents.
Source
Seminars in Respiratory and Critical Care Medicine. 42(2) (pp 218-232),
2021. Date of Publication: 30 Mar 2021.
Author
Stevens H.; McFadyen J.; Chan N.
Institution
(Stevens, McFadyen) Atherothrombosis and Vascular Biology Program, Baker
Heart and Diabetes Institute, Melbourne, VIC, Australia
(Stevens, McFadyen) Australian Centre for Blood Diseases, Monash
University, Melbourne, VIC, Australia
(Stevens, McFadyen) Department of Clinical Haematology, Alfred Hospital,
Melbourne, VIC, Australia
(Chan) Thrombosis and Atherosclerosis Research Institute, 20 Copeland
Avenue, Hamilton, ON, Canada
Publisher
Thieme Medical Publishers, Inc.
Abstract
Important advances in the understanding and management of venous
thromboembolism (VTE) have enhanced our ability to diagnose, prevent, and
treat VTE. In this narrative review, we discuss how recent advances in the
understanding and management of VTE are changing practice, highlight
ongoing unmet needs in VTE management, and outline how novel therapeutic
targets with little or no influence on hemostasis may help address these
unmet needs.<br/>Copyright &#xa9; 2021 Georg Thieme Verlag. All rights
reserved.

<13>
Accession Number
632535903
Title
Platelet inhibition with ticagrelor versus clopidogrel in diabetic
patients after percutaneous coronary intervention for chronic coronary
syndromes.
Source
Thrombosis and Haemostasis. 120(8) (pp 1221-1229), 2020. Date of
Publication: 07 Aug 2020.
Author
Liu Z.; Tian R.; Wang Y.; Chen Q.; Li J.; Xu L.; Zhang S.
Institution
(Liu, Tian, Li, Zhang) Department of Cardiology, Peking Union Medical
College Hospital, Chinese Academy of Medical Sciences, Peking Union
Medical College, Beijing, China
(Wang) Medical Research and Biometrics Center, Fu-Wai Hospital, National
Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences,
Peking Union Medical College, Beijing, China
(Chen) Department of Laboratory Medicine, Peking Union Medical College
Hospital, Chinese Academy of Medical Sciences, Peking Union Medical
College, Beijing, China
(Xu) Clinical Pharmacology Research Center, Peking Union Medical College
Hospital, Chinese Academy of Medical Sciences, Peking Union Medical
College, Beijing, China
Publisher
Georg Thieme Verlag
Abstract
Background Clopidogrel is currently the only P2Y <inf>12</inf>inhibitor
with class I recommendation in patients after percutaneous coronary
intervention (PCI) for chronic coronary syndromes (CCS). Diabetic patients
have reduced therapeutic response to clopidogrel. Purpose This study
assessed the antiplatelet effect of ticagrelor versus clopidogrel in
diabetic patients after recent PCI for CCS. Methods Eligible patients were
randomly assigned to receive ticagrelor 90 mg twice daily or clopidogrel
75 mg once daily, in addition to aspirin 100 mg once daily for 15 days.
P2Y <inf>12</inf>reaction unit (PRU) and percent inhibition were measured
by VerifyNow P2Y <inf>12</inf>assay. High on-treatment platelet reactivity
(HOPR) was defined as PRU > 208. Bleeding was assessed by the Platelet
Inhibition and Patient Outcomes criteria. Cardiac ischemic events were
evaluated as adverse events. Results The baseline characteristics of the
patients (n = 39) were well balanced between the two groups. Both before
and 2 to 4 hours after the final study dose on day 15, PRU was lower (41.3
+/- 35.8 vs. 192.6 +/- 49.5, p < 0.001; 36.6 +/- 25.8 vs. 187.6 +/- 70.9,
p < 0.001), percent inhibition was higher (83.0% [70.5%, 96.0%] vs. 16.0%
[0%, 25.0%], p < 0.001; 85.0% [76.0%, 96.5%] vs. 25.0% [0%, 39.0%], p <
0.001), and HOPR occurred less frequently (0% [0/20] vs. 26.3% [5/19], p =
0.020; 0% [0/20] vs. 31.6% [6/19], p = 0.008) in the ticagrelor group (n =
20) compared with the clopidogrel group (n = 19). No major or minor
bleeding, or serious adverse events occurred in both groups. Conclusion
Ticagrelor achieved greater peak and trough platelet inhibition than did
clopidogrel in diabetic patients after recent PCI for CCS, which suggests
the potential use of ticagrelor in this clinical setting.<br/>Copyright
&#xa9; 2020 Georg Thieme Verlag. All rights reserved.

<14>
Accession Number
633716278
Title
Comparison of Rocuronium and Vecuronium in Patients Undergoing Elective
Ultrafast-Track Off-Pump Coronary Artery Bypass Surgery.
Source
Journal of Cardiac Critical Care. 3(2) (pp 68-76), 2019. Article Number:
JCCC320001. Date of Publication: 24 Apr 2020.
Author
Shah K.S.; Kulshrestha A.
Institution
(Shah, Kulshrestha) Department of Anaesthesia, Breach Candy Hospital,
Mumbai, Maharashtra, India
Publisher
Thieme Medical and Scientific Publishers Pvt Ltd
Abstract
Background Neuromuscular blocking drugs are necessary in cardiac surgery
to facilitate smooth intubation and ventilation conditions, avoid patient
movement, reduce oxygen consumption, and prevent shivering. Hemodynamic
stability is very essential in cardiac surgery because the coronary
reserve is below normal in such patients. Aims This study was conducted
with the objective of comparing rocuronium, the near-ideal muscle relaxant
with vecuronium, an already established neuromuscular blocking agent in
patients undergoing elective ultrafast-track off-pump coronary artery
bypass surgery (CABG). Settings and Design This prospective, randomized
comparative study included 60 patients scheduled for elective off-pump
CABG procedures under general anesthesia in the period between May 2015
and March 2016. Materials and Methods Patients were randomized in equal
numbers to either the rocuronium group or the vecuronium group, and
intubating conditions and various hemodynamic parameters were observed at
different time points. Statistical Analysis Used Categorical variables
were evaluated using the chi-square test, whereas the Student t -test or
Mann-Whitney test were used for continuous variables. Results Pulse rate
in the rocuronium group was lesser (79.97 +/- 7.42) (p < 0.05) at the time
of intubation as compared with the vecuronium group (92.33 +/- 8.93).
Systolic blood pressure was higher in the vecuronium group (150.70 +/-
14.05) at the time of intubation as compared with the rocuronium group
(130.27 +/- 9.95) (p < 0.05). Intubating conditions, mean arterial
pressure, and diastolic blood pressure changes were similar in both
groups. Conclusions Rocuronium provides good-to-excellent intubating
conditions and is devoid of any significant cardiovascular changes causing
hemodynamic instability when compared with vecuronium in patients
undergoing elective ultrafast-track off-pump CABG.<br/>Copyright &#xa9;
2019 Thieme India. All rights reserved.

<15>
Accession Number
634475739
Title
Perioperative Beta-Blocker for Atrial Fibrillation after Cardiac Surgery:
A Meta-Analysis.
Source
Thoracic and Cardiovascular Surgeon. 69(2) (pp 133-140), 2021. Date of
Publication: 14 Mar 2021.
Author
Kim S.H.; Jang M.-J.; Hwang H.Y.
Institution
(Kim, Hwang) Department of Thoracic and Cardiovascular Surgery, Seoul
National University Hospital, Seoul, South Korea
(Jang) Medical Research Collaborating Center, Seoul National University
Hospital, Seoul, South Korea
Publisher
Georg Thieme Verlag
Abstract
Background: This meta-analysis was conducted to evaluate the impact of
perioperative use of beta-blocker (BB) on postoperative atrial
fibrillation (POAF) after cardiac surgery other than isolated coronary
artery bypass grafting (CABG). <br/>Method(s): Five online databases were
searched. Studies were included if they (1) enrolled patients who
underwent cardiac surgery other than isolated CABG and (2) demonstrated
the impact of perioperative use of BB on POAF based on the randomized
controlled trial or adjusted analysis. The primary outcome was the
occurrence rates of POAF after cardiac surgery. A meta-regression and
subgroup analysis were performed according to the proportion of patients
with cardiac surgery other than isolated CABG and the timing of BB use,
respectively. <br/>Result(s): Thirteen articles (5 randomized and 8
nonrandomized studies: n = 25,496) were selected. Proportion of enrolled
patients undergoing cardiac surgery other than isolated CABG ranged from 7
to 100%. The BBs were used in preoperative, postoperative, and both
periods in 5, 5, and 3 studies, respectively. The pooled analyses showed
that the risk of POAF was significantly lower in patients with
perioperative BB than those without (odds ratio, 95% confidence interval =
0.56, 0.35-0.91 and 0.70, 0.55-0.91 in randomized and nonrandomized
studies, respectively). The risk of POAF was lower in the BB group
irrespective of the proportion of nonisolated CABG. Benefit regarding
in-hospital mortality was inconclusive. Perioperative stroke and length of
stay were not significantly different between BB and non-BB groups.
<br/>Conclusion(s): Perioperative use of BB is effective in preventing
POAF even in patients undergoing cardiac surgery other than isolated CABG,
although it did not translate into improved clinical
outcomes.<br/>Copyright &#xa9; 2021 Georg Thieme Verlag. All rights
reserved.

<16>
Accession Number
630065755
Title
Longitudinally Measured Fibrinolysis Factors are Strong Predictors of
Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT
Study.
Source
Thrombosis and Haemostasis. 119(12) (pp 1947-1955), 2019. Date of
Publication: 05 Dec 2019.
Author
Van Den Berg V.J.; Bouwens E.; Umans V.A.W.M.; De Maat M.; Manintveld
O.C.; Caliskan K.; Constantinescu A.A.; Mouthaan H.; Cornel J.-H.; Baart
S.; Akkerhuis K.M.; Boersma E.; Kardys I.
Institution
(Van Den Berg, Bouwens, Manintveld, Caliskan, Constantinescu, Baart,
Akkerhuis, Boersma, Kardys) Department of Cardiology, Erasmus MC
University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam,
Netherlands
(Van Den Berg, Umans, Cornel) Department of Cardiology, Northwest Clinics,
Alkmaar, Netherlands
(Van Den Berg, Baart) Netherlands Heart Institute, Utrecht, Netherlands
(De Maat) Department of Hematology, Erasmus MC University Medical Center
Rotterdam, Rotterdam, Netherlands
(Mouthaan) Olink Proteomics AB, Uppsala, Sweden
Publisher
Georg Thieme Verlag
Abstract
Objective This article investigates whether longitudinally measured
fibrinolysis factors are associated with cardiac events in patients with
chronic heart failure (CHF). Methods A median of 9 (interquartile range
[IQR] 5-10) serial, tri-monthly blood samples per patient were
prospectively collected in 263 CHF patients during a median follow-up of
2.2 (IQR 1.4-2.5) years. Seventy patients (cases) reached the composite
endpoint of cardiac death, heart failure hospitalization, left ventricular
assist device, or heart transplantation. From all longitudinal samples, we
selected baseline samples in all patients and the last two samples before
the event in cases or the last sample available in event-free patients.
Herein, we measured plasminogen activator inhibitor 1 (PAI-1), tissue-type
plasminogen activator (tPA), urokinase-type plasminogen activator (uPA),
and soluble urokinase plasminogen activator surface receptor (suPAR).
Associations between temporal biomarker patterns during follow-up and the
cardiac event were investigated using a joint model. Results Cases were on
average older and showed higher New York Heart Association class than
those who remained event-free. They also had lower blood pressures, and
were more likely to have diabetes, renal failure, and atrial fibrillation.
Longitudinally measured PAI-1, uPA, and suPAR were independently
associated with adverse cardiac events after correction for clinical
characteristics (hazard ratio [95% confidence interval]) per standard
deviation increase of 2.09 (1.28-3.45) for PAI-1, 1.91 (1.18-3.24) for
uPA, and 3.96 (2.48-6.63) for suPAR. Serial measurements of tPA were not
significantly associated with the event after correction for multiple
testing. Conclusion Longitudinally measured PAI-1, uPA, and suPAR are
strongly associated with adverse cardiac events during the course of CHF.
If future research confirms our results, these fibrinolytic factors may
carry potential for improved, and personalized, heart failure surveillance
and treatment monitoring.<br/>Copyright &#xa9; 2019 Georg Thieme Verlag.
All rights reserved.

<17>
[Use Link to view the full text]
Accession Number
2043505007
Title
Organ Donation and Transplantation Worldwide: The Global Observatory on
Donation and Transplantation 2024 Report.
Source
Transplantation. Publish Ahead of Print (no pagination), 2026. Date of
Publication: 2026.
Author
Martin F.; Carmona M.; Mahillo B.; Alvarez M.; Luengo A.; Chatzixiros E.;
Lopez-Fraga M.; Dominguez-Gil B.; Tullius S.G.
Institution
(Martin, Tullius) Division of Transplant Surgery and Transplant Surgery
Research Laboratory, Brigham and Women's Hospital, Harvard Medical School,
Boston, MA, United States
(Martin) Department of Surgery, CVK/CCM, Charite-Universitatsmedizin
Berlin, Berlin, Germany
(Carmona, Mahillo, Alvarez, Luengo, Dominguez-Gil) Organizacion Nacional
de Trasplantes, Ministry of Health, Madrid, Spain
(Chatzixiros) Department of Health Products Policies and Standards, World
Health Organization, World Health Organization Headquaters, Geneva,
Switzerland
(Lopez-Fraga) European Directorate for the Quality of Medicines and
HealthCare (EDQM), Council of Europe, Strasbourg, France
Publisher
Lippincott Williams and Wilkins
Abstract
Background. - Solid organ transplantation has evolved globally as an
established and life-saving treatment for patients with end-stage organ
failure. Methods. - Since 2007, the Global Observatory on Donation and
Transplantation (GODT), an initiative of the World Health Organization in
collaboration with the Organizacion Nacional de Trasplantes (Spain),
collects data and reports on the activity of World Health Organization
member states in regard to solid organ donation, transplantation, and
waitlisting. This ongoing effort provides insights into transplant
activities in countries with different healthcare systems and practices,
economic and cultural contexts, and local disease burdens. Results. - This
annual report presents activities for the year 2024 and summarizes the
developments from a global, regional, and country-specific perspective.
This report includes information from 92 countries that submitted their
data to the GODT by October 29, 2025. Descriptive statistics were applied
to analyze and present key indicators. Conclusions. - A record 173 727
solid organ transplants were performed worldwide in 2024, representing the
highest number ever reported to the GODT. This corresponds to a 2% global
increase compared with 2023, largely driven by a rise in deceased
donations, particularly the expansion of donations after the circulatory
determination of death, which accounted for 28% of all deceased donation
activity in 2024 (total deceased donations: 47 180). Despite these
achievements on a global scale, the data also indicate that major
challenges persist, including a continued shortage of organs and
pronounced geographical disparities in access to
transplantation.<br/>Copyright &#xa9; 2026

<18>
Accession Number
2040679272
Title
Peri-operative rehabilitation in patients undergoing elective cardiac
valve surgery: a randomised controlled trial.
Source
Anaesthesia. 81(3) (pp 362-372), 2026. Date of Publication: 01 Mar 2026.
Author
Liu F.; Xu M.; Zhou H.; Wang H.; Liu Y.; He X.; Huang H.; Sun T.; Jian X.;
Wu M.; Sun Y.; Cao P.; Chen J.; Guo L.; Ma H.
Institution
(Liu, Liu, Xu, Zhou, Wang, Liu, He, Chen, Guo, Ma) Department of
Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial
People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical
University, Guangdong, Guangzhou, China
(Huang, Sun, Jian, Chen, Wu) Department of Cardiac Surgery, Guangdong
Cardiovascular Institute, Guangdong Provincial People's Hospital,
Guangdong Academy of Medical Sciences, Guangdong, Guangzhou, China
(Huang, Sun, Jian, Chen, Wu) Guangdong Provincial Key Laboratory of South
China Structural Heart Disease, Guangdong Provincial People's Hospital,
Guangdong Academy of Medical Sciences, Guangdong, Guangzhou, China
(Sun, Cao) Clinical Research Center, Zhujiang Hospital, Southern Medical
University, Guangdong, Guangzhou, China
(Sun, Cao) Department of Biostatistics, School of Public Health, Southern
Medical University, Guangdong, Guangzhou, China
Publisher
John Wiley and Sons Inc
Abstract
Introduction: Patients with valvular heart disease are at high risk of
postoperative pulmonary complications, which contribute to morbidity and
mortality. However, few studies have focused specifically on
peri-operative rehabilitation in this patient population. We aimed to
evaluate whether peri-operative rehabilitation benefits patients
undergoing elective cardiac valve surgery by reducing the incidence of
postoperative pulmonary complications, the duration of postoperative
hospitalisation and mortality. <br/>Method(s): This single-centre,
randomised controlled trial compared usual care (usual care group) with a
peri-operative rehabilitation bundle (rehabilitation group) comprising
four components: education; inspiratory muscle training; active cycle of
breathing techniques; and early mobilisation. The primary outcome was a
composite measure of the occurrence of postoperative pulmonary
complications within the first 7 days; incidence of prolonged
postoperative hospitalisation > 7 days; and in-hospital all-cause
mortality. Secondary outcomes included each component of primary outcome
measure; duration of stay in the ICU; total duration of postoperative
hospitalisation; and 3-month all-cause mortality. <br/>Result(s): On an
intention-to-treat basis, data from 818 patients were analysed (419
allocated to the usual care group and 399 to the rehabilitation group).
The primary composite outcome did not differ between groups, occurring in
224/419 (53.5%) patients allocated to the usual care group and 206/399
(51.6%) patients allocated to the rehabilitation group (odds ratio 0.88,
95%CI 0.66-1.17, p = 0.376). Postoperative pulmonary complications were
present in 197 (47.1%) patients allocated to the usual care group and 161
(40.4%) patients allocated to the rehabilitation group (odds ratio 0.720,
95%CI 0.541-0.956, p = 0.023). There was no significant difference between
the groups in terms of duration of postoperative hospital stay of > 7 days
or in-hospital mortality. <br/>Discussion(s): Peri-operative
rehabilitation reduced the incidence of postoperative pulmonary
complications in patients having surgery for valvular heart disease. We
recommend incorporating comprehensive peri-operative rehabilitation into
the clinical management of these patients.<br/>Copyright &#xa9; 2025 The
Author(s). Anaesthesia published by John Wiley & Sons Ltd on behalf of
Association of Anaesthetists.

<19>
Accession Number
2043652095
Title
Low-density lipoprotein cholesterol lowering and risk of major adverse
cardiovascular events in primary prevention trials: A meta-analysis.
Source
Journal of Clinical Lipidology. (no pagination), 2026. Date of
Publication: 2026.
Author
Kalra D.K.; Ray K.K.; Bajaj A.; Kushner P.R.; Wilcox M.L.; Dicklin M.R.;
Kirkpatrick C.F.; Maki K.C.
Institution
(Kalra) Lipid Clinic and Division of Cardiology, University of Louisville
School of Medicine, (Kalra), Louisville, KY, United States
(Ray) Imperial Centre for Cardiovascular Disease Prevention, Department of
Primary Care and Public Health, Imperial College London, (Ray), London,
United Kingdom
(Bajaj) Department of Medicine, Perelman School of Medicine, University of
Pennsylvania, (Bajaj), Philadelphia, PA, United States
(Kushner) Department of Family Medicine, University of California Irvine
Medical Center, (Kushner), Orange, CA, United States
(Wilcox, Dicklin, Kirkpatrick, Maki) Midwest Biomedical Research, (Wilcox,
Dr Dicklin, Dr Kirkpatrick, and Dr Maki), Addison, IL, United States
(Kirkpatrick) Kasiska Division of Health Sciences, Idaho State University,
(Dr Kirkpatrick), Pocatello, ID, United States
(Maki) Department of Applied Health Science, School of Public Health,
Indiana University-Bloomington, (Dr Maki), Bloomington, IN, United States
Publisher
Elsevier Ltd
Abstract
BACKGROUND Analyses of statin trials by the Cholesterol Treatment
Trialists' Collaboration have suggested larger relative risk reduction
(RRR) for major adverse cardiovascular events (MACE) per 1 mmol/L (38.7
mg/dL) low-density lipoprotein cholesterol (LDL-C) lowering in primary
prevention than in secondary prevention. However, controversy remains
about the value of LDL-C lowering in primary prevention. OBJECTIVE This
meta-analysis examined the relationship between LDL-C reduction and MACE
risk in primary prevention with statin and nonstatin LDL-C-lowering
therapies in cardiovascular outcomes trials (CVOTs). METHODS PubMed and
Cochrane Central Register of Controlled Trials were searched from
inception through August 26, 2025. The primary endpoint was the pooled RRR
vs controls for 4-point composite MACE (coronary heart disease death,
nonfatal myocardial infarction, fatal and nonfatal stroke, and coronary
revascularization) per 1 mmol/L LDL-C lowering. RESULTS Eleven CVOTs of
solely primary prevention participants (n = 74,466) and 3 in which '80% of
participants were primary prevention (n = 24,071) were identified (11
statin, 1 bempedoic acid, 1 ezetimibe, 1 statin+ezetimibe). In 13 trials,
the pooled mean difference between groups in LDL-C reduction was 1.00
mmol/L (95% CI: 0.82-1.18 mmol/L) with a pooled estimate of 30% (relative
risk: 0.70; 95% CI: 0.67-0.74) RRR for 4-point MACE per 1 mmol/L LDL-C
reduction vs control. CONCLUSION In CVOTs of solely or predominantly
primary prevention participants, each 1 mmol/L reduction in LDL-C was
associated with a 30% RRR in 4-point MACE. These results strengthen the
evidence and rationale for the benefits of LDL-C lowering in primary
prevention.<br/>Copyright &#xa9; 2026 The Authors.

<20>
Accession Number
2043594595
Title
Why MICS Has Been the Future of CABG for The Last 20 Years?.
Source
European Journal of Cardio-thoracic Surgery. 68(2) (no pagination), 2026.
Article Number: ezag053. Date of Publication: 01 Feb 2026.
Author
Monteiro Neder Issa H.; Chan V.; Ruel M.
Institution
(Monteiro Neder Issa, Chan, Ruel) Division of Cardiac Surgery, University
of Ottawa Heart Institute, Ottawa, ON, Canada
Publisher
European Association for Cardio-Thoracic Surgery

<21>
Accession Number
2040996758
Title
Respiratory Reactivation of Herpes Simplex Virus-1 Following Cardiac
Surgery in Immunocompetent Individuals.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(3) (pp 994-1002),
2026. Date of Publication: 01 Mar 2026.
Author
Asiller O.O.; Fresilli S.; Damiani D.; Della Peruta M.; Prati P.;
Franceschini G.; Farinaccio A.; Moresco M.; Ajello V.
Institution
(Asiller) Department of Anesthesia and Intensive Care, Ankara University
Faculty of Medicine, Ankara, Turkey
(Fresilli, Damiani, Della Peruta) Department of Anesthesia and Intensive
Care, IRCCS San Raffaele Scientific Institute, Milan, Italy
(Prati, Franceschini, Farinaccio, Moresco, Ajello) Department of
Cardiothoracic Anesthesia, Tor Vergata University Hospital, Rome, Italy
Publisher
W.B. Saunders
Abstract
Objective: Herpes simplex virus type 1 reactivation is common in
immunocompromised patients. Its frequency and clinical significance as a
cause of pneumonia in immunocompetent patients, particularly following
cardiac surgery, remain poorly defined. This review synthesizes all the
evidence on the frequency, pathophysiology, and clinical impact of herpes
simplex virus reactivation in immunocompetent patients following cardiac
surgery. <br/>Design(s): Systematic review. <br/>Setting(s): Studies
conducted in cardiac surgery. <br/>Participant(s): Immunocompetent adults
with suspected or confirmed herpes simplex virus pneumonia after cardiac
surgery. <br/>Measurements and Main Results: Medical databases were
searched from inception to June 4, 2025. Studies reporting immunocompetent
adults with suspected and/or confirmed herpes simplex virus pneumonia
post-cardiac surgery were included. Twenty studies (published in the
period 1983-2025), including 112 patients with pneumonia and herpes
simplex virus reactivation after cardiac surgery, were identified.
Bronchoalveolar lavage was used as a diagnostic tool in 79% of cases. The
use of antiviral treatment (predominantly acyclovir) was reported in 42 of
78 patients (53%). All-cause mortality was 14 of 30 patients (46%).
<br/>Conclusion(s): Herpes simplex virus reactivation after cardiac
surgery is not frequently reported, but mortality approaches 50%. This
underscores the need for heightened awareness and targeted testing in
nonresponding pneumonias, potentially improving outcomes. Even if patients
often die with the herpes simplex virus reactivation complicating other
severe conditions, the frequency with which herpes simplex virus
reactivation itself is the primary cause of death remains uncertain.
Diagnosis relied mainly on polymerase chain reaction, and early antiviral
treatment was frequently administered. Increased clinical awareness and
further research are warranted to standardize diagnosis and optimize
management.<br/>Copyright &#xa9; 2025 Elsevier Inc.

<22>
[Use Link to view the full text]
Accession Number
2043557654
Title
Comparative Efficacy and Safety of Transcatheter Aortic Valve Replacement
Versus Surgical Aortic Valve Replacement in Patients With End-Stage Renal
Disease: A Systematic Review and Meta-Analysis.
Source
Cardiology in Review. Publish Ahead of Print (no pagination), 2025. Date
of Publication: 19 Sep 2025.
Author
Bacha Z.; Javed J.; Khattak F.; Shah I.M.; Ali M.A.; Sheraz M.; Wali E.;
Shahid I.; Farooq A.; Obaid Ullah Z.; Khan Z.; Al-Badri S.G.; Sajjad F.;
Henna F.; Irfan S.
Institution
(Bacha, Khattak, Shah, Ali, Wali, Farooq, Khan, Sajjad) From the
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
(Javed) Department of Medicine, Jinnah Sindh Medical University, Karachi,
Pakistan
(Sheraz) Department of Medicine, Continental Medical College, Lahore,
Pakistan
(Shahid) Department of Medicine, King Edward Medical University, Lahore,
Pakistan
(Obaid Ullah) Department of Medicine, Fatima Jinnah Medical University,
Lahore, Pakistan
(Al-Badri) Department of Medicine, College of Medicine, University of
Warith Al-Anbiyaa, Karbala, Iraq
(Henna) Department of Medicine, Dubai Medical College for Girls, Dubai,
United Arab Emirates
(Irfan) Department of Medicine, Department of Preventive medicine,
Ministry of Health, Kuwait
Publisher
Lippincott Williams and Wilkins
Abstract
End-stage renal disease (ESRD) severely elevates the risks of aortic
stenosis interventions. While surgical aortic valve replacement (SAVR) has
traditionally been the gold standard treatment, transcatheter aortic valve
replacement (TAVR) has been introduced as a minimally invasive
alternative. This systematic review and meta-analysis aimed to evaluate
the safety and efficacy of TAVR compared with SAVR in patients with ESRD.
Adhering to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines, a comprehensive literature search of databases
PubMed, Embase, and Web of Science up to March 2025 found 7 cohort studies
comprising 15, 462 patients. Primary outcomes consisted of 30-day and
in-hospital mortality, while secondary outcomes evaluated pacemaker
implantation, complications, length of stay, costs, and discharge report.
TAVR was related to considerably lower in-hospital mortality (risk ratio,
0.52) and a pattern toward decreased 30-day mortality. It also decreased
the risks of cardiac tamponade, respiratory issues, blood transfusions,
and transfers to other facilities. No TAVR was associated with increased
rates of pacemaker implantation and vascular complications. It notably
shortened hospital stay and enhanced home discharge rates, while
healthcare costs were lower compared with SAVR. Sensitivity analyses
validated the reliability of most findings. Regardless of high
heterogeneity and limitations consisting of geographic restriction to the
United States and limited long-term outcomes, this study contributes to
evidence that TAVR may offer superior short-term outcomes for patients
with ESRD, especially those at high surgical risk. Clinical decisions
should be personalized, weighing procedural risks against impactful
benefits.<br/>Copyright &#xa9; 2025

<23>
Accession Number
2042293146
Title
Lipid-lowering therapies to target cardiac allograft vasculopathy after
heart transplantation: Current evidence and future directions.
Source
Journal of Clinical Lipidology. 20(2) (pp 262-269), 2026. Date of
Publication: 01 Feb 2026.
Author
Mansoor T.; Ismayl M.; Virani S.S.; Nambi V.; Misra A.; Jia X.; Fudim M.;
Greene S.J.; Sperling L.; Parikh S.; Rifai M.A.; Koshy S.K.G.; Abramov D.;
Minhas A.M.K.
Institution
(Mansoor, Koshy) Department of Internal Medicine, Western Michigan
University Homer Stryker M.D., School of Medicine (Drs Mansoor and Koshy),
Kalamazoo, MI, United States
(Ismayl) Department of Cardiology, Mayo Clinic (Dr Ismayl), Rochester, MN,
United States
(Virani) Department of Medicine, Aga Khan University (Dr Virani), Karachi,
Pakistan
(Virani) Department of Population Health, Aga Khan University (Dr Virani),
Nairobi, Kenya
(Nambi, Misra, Jia, Minhas) Department of Medicine, Section of Cardiology,
Baylor College of Medicine (Drs Nambi, Misra, Jia, and Minhas), Houston,
TX, United States
(Fudim, Greene) Division of Cardiology, Duke University Medical Center
(Drs Fudim, Greene), Durham, NC, United States
(Sperling) Division of Cardiology, Department of Medicine, Emory Clinical
Cardiovascular Research Institute (Dr Sperling), Atlanta, GA, United
States
(Parikh) Division of Cardiology, Henry Ford Hospital (Dr Parikh), Detroit,
MI, United States
(Rifai) Department of Cardiology, Houston Methodist DeBakey Heart and
Vascular Center (Dr Rifai), Houston, TX, United States
(Koshy) Department of Cardiology, Borgess Hospital (Dr Koshy), Kalamazoo,
MI, United States
(Abramov) Division of Cardiology, Department of Medicine, Loma Linda
University Health (Dr Abramov), Loma Linda, CA, United States
Publisher
Elsevier Ltd
Abstract
BACKGROUND Heart transplantation represents an increasingly utilized
procedure for end-stage heart failure patients. CURRENT EVIDENCE Cardiac
allograft vasculopathy (CAV) is a post-transplant complication of
pathological vasculature remodeling and remains an important cause for
long-term graft failure and mortality. Current preventive strategies for
CAV include optimization of vascular risk factors and pharmacotherapy with
statins and immunosuppressants. CONCLUSION Despite demonstrated
post-transplant mortality benefit and reduction in CAV with statins, the
role of other pharmacotherapies on CAV reduction through low-density
lipoprotein cholesterol (LDL-C) lowering remains less established. This
review explores established evidence as well as evolving pathways for
LDL-C lowering strategies to prevent CAV.<br/>Copyright &#xa9; 2025.
Published by Elsevier Inc.

<24>
Accession Number
2043311149
Title
Effect of transcutaneous electrical nerve stimulation on patients after
coronary artery bypass grafting: a systematic review and meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article
Number: 1690565. Date of Publication: 2026.
Author
Zhang E.; Kang J.; Liu Y.; Wang L.; Wan B.; Li X.
Institution
(Zhang, Kang, Liu, Wang, Wan, Li) Department of Rehabilitation Medicine,
The Second Hospital of Lanzhou University, Gansu, Lanzhou, China
Publisher
Frontiers Media SA
Abstract
Objective: This study aims to systematically evaluate the potential
effects of transcutaneous electrical nerve stimulation (TENS) on analgesic
consumption, pain relief, and pulmonary function outcomes in patients
following coronary artery bypass grafting (CABG). <br/>Method(s): A
systematic literature search was conducted across four core
databases-PubMed, Embase, Web of Science, and the Cochrane Library.
Methodological quality was evaluated using the Cochrane Risk of Bias (RoB
2.0) tool, and the certainty of evidence was evaluated using the GRADE
system. For statistical analysis, standardized mean differences (SMDs)
with 95% confidence intervals (CIs) were calculated for continuous
variables. Heterogeneity was assessed via the I² statistic
(threshold: 50%), with fixed-effects models applied when I² <=
50% or random-effects models applied when I² > 50%. Subgroup
analyses stratified by intervention duration were performed for outcomes
demonstrating significant heterogeneity (I2 >= 50%). <br/>Result(s):
First, regarding pain management, TENS demonstrated greater efficacy in
postoperative acute pain at rest (within 12 h) than control interventions
(SMD = -1.02, 95% CI: -0.23-2.28; P = 0.11), albeit with high
heterogeneity (I² = 88.50%). Postoperative chronic pain at rest
(5 days) was more pronounced (SMD = -2.00, 95% CI: -4.15-0.15; P = 0.07).
Second, in terms of pulmonary recovery, TENS significantly improved forced
expiratory volume within 1 s (FEV<inf>1</inf>: SMD = 0.85, 95% CI:
0.43-1.26; P = 0.00) but not forced vital capacity (FVC: SMD = -1.02, 95%
CI: -0.23-2.28; P = 0.11), with heterogeneity levels of 54.00% and 88.50%,
respectively. Third, regarding analgesic use, TENS reduced postoperative
opioid consumption (SMD = -4.23, 95% CI: -7.31 to -1.15; P = 0.007),
although heterogeneity remained high (I² = 96.20%).
<br/>Conclusion(s): The current evidence preliminarily suggests that TENS
may reduce postoperative analgesic dependence and modestly improve
pulmonary function in patients following CABG; however, it has not
demonstrated a statistically significant advantage in pain relief. Given
the substantial heterogeneity across studies, these findings should be
interpreted with caution. Future large-scale RCTs with standardized
protocols are needed to validate these findings. Systematic Review
Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024594786,
PROSPERO CRD42024594786.<br/>Copyright 2026 Zhang, Kang, Liu, Wang, Wan
and Li.

<25>
Accession Number
2017574336
Title
Image-guided procedures in the hybrid operating room: A systematic scoping
review.
Source
PLOS ONE. 17(4 April) (no pagination), 2022. Article Number: e0266341.
Date of Publication: 01 Apr 2022.
Author
Spenkelink I.M.; Heidkamp J.; Futterer J.J.; Rovers M.M.
Institution
(Spenkelink, Heidkamp, Futterer) Department of Medical Imaging, Radboud
University Medical Center, Nijmegen, Netherlands
(Rovers) Department of Operating Rooms, Radboud Institute for Health
Sciences, Radboud University Medical Center, Nijmegen, Netherlands
(Rovers) Department of Health Evidence, Radboud Institute of Health
Sciences, Radboud University Medical Center, Nijmegen, Netherlands
Publisher
Public Library of Science
Abstract
Background The shift from open to minimally invasive procedures with
growing complexity has increased the demand for advanced intraoperative
medical technologies. The hybrid operating room (OR) combines the
functionality of a standard OR with fixed advanced imaging systems to
facilitate minimally invasive image-guided procedures. Objective This
systematic scoping review provides an overview of the use of the hybrid OR
over the years, and reports on the encountered advantages and challenges.
Methods We conducted a systematic search in PubMed, Embase, Web of
Science, and Cochrane library databases for studies that described
procedures being performed with the aid of 3D imaging in the hybrid OR.
Results The search identified 123 studies that described 44 distinct
procedures, divided over nine clinical disciplines. The number of studies
increased from two in 2010 to 15 in the first five months of 2020.
Ninety-nine (80%) of the studies described how 3D imaging was performed in
the hybrid OR; 95 (96%) used cone-beam CT; four (4%) used multi-detector
CT. Advantages and challenges of the hybrid OR were described in 94 (76%)
and 34 (35%) studies, respectively. The most frequently reported advantage
of using a hybrid OR is the achievement of more accurate treatment
results, whereas elongation of the procedure time is the most important
challenge, followed by an increase in radiation dose. Conclusion In
conclusion, the growing number of clinical disciplines that uses the
hybrid OR shows its wide functionality. To optimize its use, future
comparative studies should be conducted to investigate which procedures
really benefit from being performed in the hybrid OR.<br/>Copyright:
&#xa9; 2022 Spenkelink et al. This is an open access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.

<26>
Accession Number
635396863
Title
Efficacy and Safety of Antifibrinolytic Drugs in Pediatric Surgery: A
Systematic Review.
Source
Seminars in Thrombosis and Hemostasis. 47(5) (pp 538-568), 2021. Date of
Publication: 30 Jun 2021.
Author
Hovgesen N.T.; Larsen J.B.; Fenger-Eriksen C.; Hansen A.K.; Hvas A.-M.
Institution
(Hovgesen, Larsen, Hvas) Thrombosis and Hemostasis Research Unit,
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus,
Denmark
(Fenger-Eriksen) Department of Anesthesiology, Aarhus University Hospital,
Aarhus, Denmark
(Hansen) Neonatal Intensive Care Unit, Department of Pediatrics and
Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
(Hvas) Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Publisher
Thieme Medical Publishers, Inc.
Abstract
Antifibrinolytic drugs are used to reduce blood loss and subsequent
transfusions during surgery and following trauma, but the optimal dosing
regimen in the pediatric population is still unresolved. The aim of this
systematic review was to evaluate efficacy and safety of antifibrinolytic
drugs in pediatric surgery and trauma to determine the optimal dosing
regimen. A literature search was performed in PubMed, Embase, Cochrane,
and Web of Science on May 3, 2020. We included randomized controlled
studies investigating the effect of tranexamic acid (TXA), aprotinin, and
epsilon-aminocaproic acid, in terms of reducing blood loss, blood
transfusions, reoperations, and rebleeds in pediatric patients aged 0 to
18 years undergoing cardiac surgery, noncardiac surgery, or trauma. Fifty
randomized controlled trials (RCTs) were included; 28 RCTs investigated
cardiac surgery and 22 investigated noncardiac surgery. No RCTs regarding
trauma met the inclusion criteria. All antifibrinolytic drugs reduced
postoperative blood loss and transfusions when used in pediatric surgery.
The dosing regimen varied between studies, but similar effect sizes were
found in terms of reduced blood loss regardless of the cumulative dose
used. Few studies found adverse events, and no difference in incidence or
type of adverse events was seen between the antifibrinolytic and the
placebo group. In conclusion, use of antifibrinolytics is efficient and
safe in children undergoing surgery. We propose TXA as the drug of choice
based on its level of evidence and safety profile; we recommend a dosing
regimen composed of a loading dose of 10 to 15 mg/kg prior to surgery
followed by 1 to 5 mg/kg/h as continuous infusion throughout
surgery.<br/>Copyright &#xa9; 2021 SPIE. All rights reserved.

<27>
Accession Number
633388185
Title
Does intraoperative diuretic therapy affect the thoracic fluid content and
clinical outcome in patients undergoing mitral valve surgery?.
Source
Journal of Cardiac Critical Care. 4(2) (pp 86-90), 2020. Article Number:
JCCC2080004. Date of Publication: 07 Nov 2020.
Author
Choudhury M.; Narula J.; Saini K.; Kapoor P.M.; Kiran U.
Institution
(Choudhury, Narula, Saini, Kapoor, Kiran) Cardiothoracic Sciences Centre,
All India Institute of Medical Sciences, New Delhi, India
Publisher
Thieme Medical and Scientific Publishers Pvt Ltd
Abstract
Pulmonary congestion is inevitable in valvular heart disease. The
condition worsens when a patient undergoes cardiopulmonary bypass (CPB).
Thoracic fluid content (TFC) is an indicator of total volume status of
lung in health and disease. We hypothesize that intraoperative diuretic
therapy can improve the hemodynamic and clinical outcome in patients
undergoing mitral valve surgery by decreasing TFC as measured by impedance
cardiography (ICG). Sixty adult patients with critical mitral stenosis
scheduled for mitral valve surgery divided into diuretic (Gr D, n = 30)
and control (Gr C, n = 30) group. One mg/kg of furosemide was administered
before CPB to Gr D and similar volume of normal saline to Gr C.
Hemodynamic and TFC measurements were done by index of contractility
(ICON), NICOM monitor at baseline, before anesthesia induction (T1), post
skin closure (T2), postoperatively at 6th hour (T3), 24th hour (T4), and
48th hour (T5). The duration of mechanical ventilation (hour), intensive
care unit stay (day) and inotropic score was significantly higher in Gr C
(5.29 +/- 1.4 vs. 2.15 +/- 1.1; p = 0.001; 2.11 +/- 0.64 vs. 1.67 +/-
0.57, p = 0.002; 9 +/- 5.4 vs. 5.8 +/- 3.2, p = 0.05), respectively. Three
patients in Gr C developed respiratory complication during their course of
hospital stay. The baseline TFC value was comparable (p = 0.08). In Gr C.
it gradually increased over time and never reached the baseline value,
whereas in Gr D, there was slight increase in TFC till 6th postoperative
hour and it came below the baseline value at 48th hour. A significantly
higher TFC value in Gr C in comparison with Gr D from 6th to 48th
postoperative hour (p = 0.005, 0.000, and 0.005, respectively) was
observed. The ICON had a gradual improvement from 12th over 48th
postoperative hour in Gr D in comparison to Gr C. The systemic vascular
resistance index was decreased over time in Gr C, whereas in Gr D there
was a mild fall at the end of surgery and it came back to near the
baseline value at 48th postoperative hour. A continuous decrease in DO
<inf>2</inf>I except at 6th postoperative hour was seen in Gr C, whereas
it remained near the baseline value in Gr D. Linear regression analysis
showed significant direct correlation of TFC with intraoperative fluid
balance (r = 0.524, p = 0.001), cumulative fluid balance (r = 0.680, p =
0.000) and both peak and mean airway pressure (r = 0.436, p = 0.001 and r
= 0.548, p = 0.001, respectively). We concluded that TFC is clearly
influenced by intraoperative diuretic therapy. A decrease in TFC has an
association with better hemodynamic parameters that could find interesting
clinical applications in the decision, whether or not to include a
diuretic as a routine therapy during intraoperative management in valve
surgery patients.<br/>Copyright &#xa9; 2020 Thieme India. All rights
reserved.

<28>
Accession Number
634475740
Title
Preoperative Statin Therapy for Atrial Fibrillation and Renal Failure
after Cardiac Surgery.
Source
Thoracic and Cardiovascular Surgeon. 69(2) (pp 141-147), 2021. Date of
Publication: 14 Mar 2021.
Author
Kuhn E.W.; Liakopoulos O.J.; Choi Y.-H.; Rahmanian P.; Eghbalzadeh K.;
Slottosch I.; Deppe A.C.; Wahlers T.C.W.
Institution
(Kuhn, Liakopoulos, Choi, Rahmanian, Eghbalzadeh, Slottosch, Deppe,
Wahlers) Department of Cardiothoracic Surgery, Heart Center of the
University Hospital of Cologne, Cologne, Germany
Publisher
Georg Thieme Verlag
Abstract
Background: Performing cardiac surgery in patients with cardiovascular
risk factors incorporates a steady risk for the development of
postoperative complications. Perioperative statin intake was associated
with an improvement of perioperative outcomes in these patients. However,
the European Association for Cardio-Thoracic Surgery guidelines regarding
the perioperative statin treatment were changed recently due to large
studies reporting about relevant adverse effects related to statin
therapy. <br/>Method(s): All relevant databases were searched including
the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and
the metaRegister of Controlled Trials. Various registries were screened
(National Research Register, the ClinicalTrials.gov, and gray literature)
with search on online conference indices of relevant scientific meetings.
No language restrictions were applied. <br/>Result(s): We identified 10
randomized controlled studies summarizing 3,468 participants undergoing
various kinds of cardiac surgical procedures. All included studies
presented with marked differences regarding study design. Pooled analysis
indicated that statin pretreatment was associated with a formally reduced
incidence of postoperative atrial fibrillation (AF) (odds ratio [OR] 0.63,
95% confidence interval [CI] 0.39-1.00; p = 0.05) but with an increased
incidence of renal failure (OR 1.20, 95% CI 1.01-1.44; p = 0.04) compared
with control. Substantial heterogeneity was observed among studies
reporting about AF. <br/>Conclusion(s): Current but sparse evidence
reveals that statin pretreatment is associated with a higher rate of
postoperative renal failure compared with control therapy but is
ineffective to substantially reduce postoperative AF. Given the relevant
heterogeneity among included studies, statin pretreatment cannot be
generally recommended.<br/>Copyright &#xa9; 2021 Georg Thieme Verlag. All
rights reserved.

<29>
Accession Number
634277954
Title
Use of Pericardium for Cardiac Reconstruction Procedures in Acquired Heart
Diseases-A Comprehensive Review.
Source
Thoracic and Cardiovascular Surgeon. 69(1) (pp 83-91), 2021. Date of
Publication: 22 Feb 2021.
Author
De Martino A.; Milano A.D.; Bortolotti U.
Institution
(De Martino, Bortolotti) Section of Cardiac Surgery, University Hospital,
Pisa, Italy
(Milano) Department of Cardiac Surgery, University of Bari Aldo Moro,
Bari, Italy
Publisher
Georg Thieme Verlag
Abstract
Background: Reconstruction of cardiac structures has been the goal of many
surgeons even before the advent of open-heart procedures with
cardiopulmonary bypass. Unsatisfactory results with synthetic materials
has switched the attention to biological tissues, among which pericardium,
either autologous or of animal origin, has been widely used as patch
material. <br/>Method(s): We have reviewed the literature to assess the
effective role of pericardial tissue in the correction of various acquired
cardiac lesions. Particularly, special attention was given not only to
established techniques but also to detect any peculiar and unusual
application of pericardium. <br/>Result(s): Autologous pericardium is
frequently used as patch material particularly when limited valvular
lesions must be corrected, while xenograft pericardium appears
particularly useful in patients with endocarditis and extensive
destruction of the intracardiac structures by infection and abscesses.
Pericardium is an extremely versatile material owing to its pliability and
strength; however, it tends to calcify in the long term when in contact
with blood, although stability of the repair is maintained in most cases.
<br/>Conclusion(s): Pericardium plays an important role in various cardiac
and aortic pathologies. Tissues resistant to fibrosis and calcification to
be used as patch material are the ideal solution for more successful
cardiac reconstruction procedures and will hopefully be provided by the
ongoing research.<br/>Copyright &#xa9; 2021 Georg Thieme Verlag. All
rights reserved.

<30>
Accession Number
632515911
Title
Correlation between Age and Surgical Approach for Thoracic and Lumbar
Hemivertebra.
Source
Indian Journal of Neurosurgery. 9(2) (pp 115-121), 2020. Date of
Publication: 26 Aug 2020.
Author
Nikova A.; Chatzipaulou V.; Malkots B.; Mustafa R.M.; Valsamidou C.;
Birbilis T.
Institution
(Nikova, Chatzipaulou, Malkots, Mustafa, Valsamidou, Birbilis) Department
of Neurosurgery, Democritus University of Thrace Medical School, Dragana,
Alexandroupolis, Greece
Publisher
Georg Thieme Verlag
Abstract
Objective Hemivertebra (HV) is a congenital defect of the formation of the
spinal vertebra, which can result in scoliosis or kyphosis along with the
related symptomatology of spine deformity. More often than not, it is
linked to other abnormalities and requires attention. Its management is
surgical and it is of great importance for the physician to choose the
right approach at the right time, due to its deteriorative prognosis.
Methods Due to the interest of the subject, the authors investigated the
world literature between 1990 and 2018 and found 45 articles, reporting
thoracic, thoracolumbar, and lumbar HV in children and its postsurgical
outcome, aiming to show whether the approaches are equal in terms of the
final outcome. Results The chosen surgical method depends much on the
level of the pathology. Despite this fact, after analyzing the included
data, we found that the surgical techniques are unequal with regard to the
purpose of achieving improvement. Age, caudal and cranial curves,
segmental kyphosis, and scoliosis are factors playing a major role in
this. Conclusion If not treated, HV leads to deterioration and
dysfunction. The most optimal result, however, is achieved only when the
surgical approach is applied according to age and rest of the accompanying
factors, which should be considered in future management
planning.<br/>Copyright &#xa9; 2020 Neurological Surgeons' Society of
India.

<31>
Accession Number
2015576671
Title
Effectiveness and adverse effects of tranexamic acid in bleeding during
adenotonsillectomy: A randomized, controlled, double-blind clinical trial.
Source
International Archives of Otorhinolaryngology. 25(4) (pp E557-E562), 2021.
Date of Publication: 29 Oct 2021.
Author
Fornazieri M.A.; Lima Kubo H.K.; de Farias L.C.; da Silva A.M.F.; Duarte
Garcia E.C.; de Alcantara Lopes dos Santos G.; de Rezende Pinna F.;
Voegels R.L.
Institution
(Fornazieri, da Silva, Duarte Garcia) Department of Surgery, Universidade
Estadual de Londrina, PR, Londrina, Brazil
(Fornazieri, Lima Kubo, de Farias, da Silva) Department of Medicine,
Pontificia Universidade Catolica do Parana, PR, Londrina, Brazil
(Fornazieri, de Rezende Pinna, Voegels) Department of Otorhinolaryngology,
Universidade de Sao Paulo, SP, Sao Paulo, Brazil
(Fornazieri, de Alcantara Lopes dos Santos) Centro Londrinense de
Otorrinolaringologia, PR, Londrina, Brazil
Publisher
Georg Thieme Verlag
Abstract
Introduction Intra and postoperative bleeding are the most frequent and
feared complications in adenotonsillectomy (AT). Tranexamic acid (TXA),
which is known for its antifibrinolytic effects, has a proven benefit in
reducing bleeding in hemorrhagic trauma and cardiac surgery; however, the
effectiveness and timing of its application in AT have not yet been
established. Objectives We aimed to evaluate the efficacy of TXA in
controlling bleeding during and after AT and assess its possible adverse
effects in children. Methods The present randomized, controlled,
double-blind clinical trial included 63 children aged 2 to 12 years. They
were randomly assigned to receive either intravenous TXA (10 mg/kg) or
placebo 10 minutes before surgery. The volume of intraoperative bleeding,
presence of postoperative bleeding, and adverse effects during and 8 hours
after the surgery were assessed. Results No difference in bleeding volume
was noted between the 2 groups (mean, 122.7 ml in the TXA group versus
115.5 ml in the placebo group, p 1/4 0.36). No intraoperative or
postoperative adverse effects were noted because of TXA use. Furthermore,
no primary or secondary postoperative bleeding was observed in any of the
participants. Conclusion In our pediatric sample, TXA (10 mg/kg)
administration before AT was safely used, without any adverse effects. It
did not reduce the bleeding volume in children during this type of
surgery. Future studies should assess the use of higher doses of TXA and
its administration at other time points before or during
surgery.<br/>Copyright &#xa9; 2021. Fundacao Otorrinolaringologia. All
rights reserved.

<32>
Accession Number
633133634
Title
Video-Assisted Thoracoscopic or Conventional Thoracic Surgery in Infants
and Children: Current Evidence.
Source
European Journal of Pediatric Surgery. 31(1) (pp 54-64), 2021. Date of
Publication: 02 Feb 2021.
Author
Kiblawi R.; Zoeller C.; Zanini A.; Ure B.M.; Dingemann J.; Kuebler J.F.;
Schukfeh N.
Institution
(Kiblawi, Zoeller, Ure, Dingemann, Kuebler, Schukfeh) Department of
Pediatric Surgery, Hannover Medical School, Carl-Neuberg-Strabetae 1,
Hannover, Niedersachsen, Germany
(Zanini) Department of Pediatric Surgery, University of Witwatersrand,
Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
Publisher
Georg Thieme Verlag
Abstract
Introduction The pros and cons of video-assisted thoracoscopic versus
conventional thoracic surgery in infants and children are still under
debate. We assessed reported advantages and disadvantages of
video-assisted thoracoscopy in pediatric surgical procedures, as well as
the evidence level of the available data. Materials and Methods A
systematic literature search was performed to identify manuscripts
comparing video-assisted thoracoscopic and the respective conventional
thoracic approach in classic operative indications of pediatric surgery.
Outcome parameters were analyzed and graded for level of evidence
(according to the Oxford Centre of Evidence-Based Medicine). Results A
total of 48 comparative studies reporting on 12,709 patients, 11
meta-analyses, and one pilot randomized controlled trial including 20
patients were identified. More than 15 different types of advantages for
video-assisted thoracoscopic surgery were described, mostly with a level
of evidence 3b or 3a. Most frequently video-assisted thoracoscopic surgery
was associated with shorter hospital stay, shorter postoperative
ventilation, and shorter time to chest drain removal. Mortality rate and
severe complications did not differ between thoracoscopic and conventional
thoracic pediatric surgery, except for congenital diaphragmatic hernia
repair with a lower mortality and higher recurrence rate after
thoracoscopic repair. The most frequently reported disadvantage for
video-assisted thoracoscopic surgery was longer operative time. Conclusion
The available data point toward improved recovery in pediatric
video-assisted thoracoscopic surgery despite longer operative times.
Further randomized controlled trials are needed to justify the widespread
use of video assisted thoracoscopy in pediatric surgery.<br/>Copyright
&#xa9; 2021 Georg Thieme Verlag. All rights reserved.

<33>
Accession Number
632381656
Title
Levosimendan Reduces Mortality and Low Cardiac Output Syndrome in Cardiac
Surgery.
Source
Thoracic and Cardiovascular Surgeon. 68(5) (pp 400-408), 2020. Date of
Publication: 20 Jul 2020.
Author
Weber C.; Esser M.; Eghbalzadeh K.; Sabashnikov A.; Djordjevic I.; Maier
J.; Merkle J.; Choi Y.-H.; Madershahian N.; Liakopoulos O.; Deppe A.C.;
Wahlers T.C.W.
Institution
(Weber, Esser, Eghbalzadeh, Sabashnikov, Djordjevic, Maier, Merkle, Choi,
Madershahian, Liakopoulos, Deppe, Wahlers) Department of Cardiothoracic
Surgery, University of Cologne, Kerpener Street 62, Cologne, Germany
Publisher
Georg Thieme Verlag
Abstract
Background There has been conflicting evidence concerning the effect of
levosimendan on clinical outcomes in patients undergoing cardiac surgery.
Therefore, we performed a systematic review and conducted this
meta-analysis to provide evidence for/against the administration of
levosimendan in cardiac surgery patients. Methods We performed a
meta-analysis from literature search in PubMed, EMBASE, and Cochrane
Library. Only randomized controlled trials comparing the administration of
levosimendan in cardiac surgery patients with a control group (other
inotrope, standard therapy/placebo, or an intra-aortic balloon pump) were
included. In addition, at least one clinical outcome had to be mentioned:
Mortality, myocardial infarction, low cardiac output syndrome (LCOS),
acute kidney injury, renal replacement therapy, atrial fibrillation,
prolonged inotropic support, length of intensive care unit, and hospital
stay. The pooled treatment effects (odds ratio [OR], 95% confidence
intervals [CI]) were assessed using a fixed or random effects model.
Results The literature search retrieved 27 randomized, controlled trials
involving a total of 3,198 patients. Levosimendan led to a significant
reduction in mortality (OR: 0.67; 95% CI: 0.49-0.91; p = 0.0087).
Furthermore, the incidence of LCOS (OR: 0.56, 95% CI: 0.42-0.75; p <
0.0001), acute kidney injury (OR: 0.63; 95% CI: 0.46-0.86; p = 0.0039),
and renal replacement therapy (OR: 0.70; 95% CI: 0.50-0.98; p = 0.0332)
was significantly decreased in the levosimendan group. Conclusion Our
meta-analysis suggests beneficial effects for the prophylactic use of
levosimendan in patients with severely impaired left ventricular function
undergoing cardiac surgery. The administration of levosimendan was
associated with a reduced mortality, less LCOS, and restored adequate
organ perfusion reflected in less acute kidney injury.<br/>Copyright
&#xa9; 2020 Georg Thieme Verlag. All rights reserved.

<34>
Accession Number
2042275821
Title
Safety and Efficacy of Cerebral Embolic Protection Device During
Transcatheter Aortic Valve Implantation: An Updated Systematic Review and
Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. 107(4) (pp 1146-1155),
2026. Date of Publication: 01 Mar 2026.
Author
de Pontes V.B.; Jaramillo S.; Trevisan T.; Huntermann R.; de Sousa
P.A.M.G.; Silva L.D.D.; Clemente M.R.C.; Garot P.; Gomes W.F.
Institution
(de Pontes, Trevisan) University Centre of Associated Colleges for
Education, Sao Joao da, Boa Vista, Brazil
(Jaramillo) Universidad Austral, Pilar, Argentina
(Huntermann) University Center for the Development of Alto Vale, Rio do
Sul, Brazil
(de Sousa) University of Sao Paulo Medical School, Sao Paulo, Brazil
(Silva) Federal University of Uberlandia, Uberlandia, Brazil
(Clemente) Faculdade de Medicina de Petropolis, Petropolis, Brazil
(Garot) Institut Cardiovasculaire Paris-Sud, Hopital Jacques Cartier,
Ramsay-Sante, Massy, France
(Gomes) Hospital INC, Curitiba, Brazil
(Gomes) Faculdades Pequeno Principe, Curitiba, Brazil
Publisher
John Wiley and Sons Inc
Abstract
Background: Cerebral embolic protection (CEP) devices may mitigate the
risk of embolization and stroke during transcatheter aortic-valve
implantation (TAVI), yet their safety and efficacy remain debated.
<br/>Aim(s): To evaluate the safety and efficacy of CEP during TAVI.
<br/>Method(s): We conducted a systematic search of PubMed, Embase, and
the Cochrane Library from inception through April 2025 for randomized
controlled trials (RCTs) and observational studies comparing TAVI
performed with versus without the Sentinel CEP device. Pooled risk ratios
(RRs), odds ratios (ORs), and 95% confidence intervals (CIs) were
calculated using a random-effects model. <br/>Result(s): Seventeen studies
(4 RCTs and 13 observational cohorts) involving 752,164 patients were
included; among them, 86,916 (11.5%) received the Sentinel device. CEP use
was associated with significantly lower rates of early stroke (within 72
h; RR 0.61; 95% CI 0.40-0.94), any stroke (RR 0.78; 95% CI 0.65-0.94),
30-day stroke (RR 0.47; 95% CI 0.26-0.85), disabling stroke (RR 0.49; 95%
CI 0.29-0.84), and all-cause mortality (RR 0.66; 95% CI 0.49-0.89). No
significant differences were observed in transient major vascular
complications, bleeding events, or acute kidney injury (AKI). In the
analysis restricted to RCTs, stroke and mortality outcomes were similar
between groups, with no significant differences across safety endpoints.
In prespecified subgroup analyses, patients with bicuspid aortic valves
derived no significant benefit from CEP (OR O.80; 95% CI 0.40-1.61),
whereas those with prior stroke experienced a reduced risk of recurrent
stroke (RR 0.61; 95% CI 0.45-0.82). <br/>Conclusion(s): This meta-analysis
suggests that the Sentinel CEP device is associated with lower risks of
stroke and mortality following TAVI, without increasing the incidence of
vascular complications, bleeding, or AKI.<br/>Copyright &#xa9; 2026 Wiley
Periodicals LLC.

<35>
Accession Number
2043608796
Title
Sleep Disordered-Breathing and Aortic Valve Stenosis: A Systematic Review
and Meta-Analysis.
Source
Sleep Medicine Research. 16(4) (pp 202-208), 2025. Date of Publication: 01
Dec 2025.
Author
Ramadan H.
Institution
(Ramadan) Pharmacy Department, Agamy Medical District, Ministry of Health
and Population, Agamy, Egypt
Publisher
Korean Society of Sleep Medicine
Abstract
Background and Objective Sleep-disordered breathing (SDB), including
obstructive sleep apnea (OSA) and central sleep apnea (CSA), is common in
older adults and linked to cardiovascular disease. Aortic stenosis (AS),
is another prevalent condition in this population. The interaction between
SDB and AS remains unclear, particularly regarding outcomes after surgical
aortic valve replacement or transcatheter aortic valve implantation. This
review systematically examines the prevalence, clinical impact, and
potential bidirectional relationship between SDB and AS. Methods Following
PRISMA guidelines, multiple databases were searched. Eligible
observational studies included adults with both AS and SDB, reporting
prevalence or comparative outcomes. Data extraction included study
characteristics, diagnostic methods, interventions, and prevalence
estimates. Quality assessment employed JBI and Newcastle-Ottawa tools.
Meta-analyses were performed using odds ratios (OR), standardized mean
differences, and prevalence estimates with random or fixed effects models
based on heterogeneity. Results A total of 11 studies met inclusion
criteria (9 prevalence-focused, 2 comparative). Pooled prevalence of SDB
in AS patients was 76% (95% confidence interval [CI]: 63%-89%). Both OSA
(49%) and CSA (51%) were observed. Male sex was more common among patients
with SDB (OR=1.68, 95% CI: 1.07-2.62). Body mass index (BMI) tended to be
higher in OSA than CSA, though not consistently significant. In
comparative analyses, patients with SDB showed higher odds of AS (OR=1.16,
95% CI: 1.14-1.17). Conclusions SDB is highly prevalent in AS and may
contribute to disease progression. Findings suggest a possible
bidirectional association influenced by sex and BMI. Larger well-matched
cohorts with long-term follow-up before and after valve interventions are
needed to clarify causality and treatment effects.<br/>Copyright &#xa9;
2025 The Korean Society of Sleep Medicine. This is an Open Access article
distributed under the terms of the Creative Commons Attribution
Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0)
which permits unrestricted non-commercial use, distribution, and
reproduction in any medium, provided the original work is properly cited.

<36>
Accession Number
2043853016
Title
Effects of Perioperative Intravenous Magnesium Sulphate Infusion on
Prevention of Myocardial Injury and Arrhythmia in Patients Undergoing
Off-Pump Coronary Artery Bypass Surgery: A Prospective Placebo Controlled
Study.
Source
International Journal of Pharmaceutical Quality Assurance. 16(12) (pp
246-251), 2025. Date of Publication: 2025.
Author
Mazumder P.; Saha E.; Hazra S.
Institution
(Mazumder) Department of Cardiac Anesthesiology, Medical College &
Hospital, Kolkata, 88 College Street, Kolkata, India
(Saha) Department of Anesthesiology, RS Medical College & Hospital,
Kolkata, 138 AJC Bose Road, Kolkata, India
(Hazra) Department of Anesthesiology, Medical College Hospital, 88 College
Street, Kolkata, India
Publisher
Dr. Yashwant Research Labs Pvt. Ltd.
Abstract
Introduction: Perioperative myocardial injury and cardiac arrhythmias
remain common complications in patients undergoing off-pump coronary
artery bypass (OPCAB) surgery despite avoidance of cardiopulmonary bypass.
Magnesium sulphate has known anti-arrhythmic and cardioprotective
properties, but its role in preventing myocardial injury and arrhythmias
in OPCAB surgery remains inadequately defined. <br/>Aim(s): To evaluate
the effect of perioperative intravenous magnesium sulphate infusion on the
prevention of myocardial injury and cardiac arrhythmias in patients
undergoing off-pump coronary artery bypass surgery. <br/>Material(s) and
Method(s): This prospective, randomized, placebo-controlled, double-blind
clinical trial was conducted over a period of one year in the Department
of Cardiac Anesthesia at NH- Rabindranath Tagore International Institute
of Cardiac Sciences, Kolkata. Ethical permission was issued from RN
Tagore. The study included 100 adult patients aged 18-75 years of either
gender who were scheduled to undergo elective off-pump coronary artery
bypass surgery. Patients were divided to two groups to receive either
intravenous magnesium sulphate infusion 2 gm intraoperative and 1 gm each
twice post-operatively at 6 hours and 12 hours post cabg. Placebo group
received Normal saline at same time interval. <br/>Result(s): In our
study, baseline demographics and cardiac characteristics were comparable
between groups. Mean age was 62.4 +/-8.1 vs 61.7 +/-7.9 years (p = 0.650),
BMI 26.8 +/-3.2 vs 27.1 +/-3.5 kg / m2 (p = 0.720), and LVEF 55 +/-6% vs
54 +/-7% (p = 0.450). Male patients were 72% vs 68% (p = 0.680),
hypertension 56% vs 60% (p = 0.680), diabetes 44% vs 48% (p = 0.690), and
smokers 40% vs 36% (p = 0.670). Heart rates (Baseline, Post-protamine,
Post-operative at 24 hours) were 73 +/-10, 78 +/-8, 85 +/-7 vs 76 +/-10,
80 +/-9, 90 +/-8 bpm Differences at baseline and post-protamine were not
significant (p = 0.24, 0.45), but at 24 hours the Magnesium group had a
significantly lower heart rate (p = 0.02); MAP differences were
non-significant (p = 0.41, 0.97, 0.97). Postoperative myocardial injury
was significantly less in Magnesium treated group over control as judged
by TropI (1.2 +/-0.5 vs 2.1 +/-0.8 ng / ml, p = 0.001), CKMB (18 +/-6 vs
28 +/-10 U / L, p = 0.002 and BNP (120 +/-40 vs 160 +/-50, p = 0.005)).
Postoperative cardiac arrhythmia was also significantly less in magnesium
treated patients over control group like atrial fibrillation (8% vs 24%, p
= 0.03 and ventricular tachycardia (2% vs 10%, p = 0.09), need for
antiarrhythmic drugs (12% vs 30%, p = 0.03). <br/>Conclusion(s):
Perioperative intravenous magnesium sulphate infusion appears to be an
effective and safe strategy for reducing myocardial injury and preventing
cardiac arrhythmias in patients undergoing off-pump coronary artery bypass
surgery. Its routine use may contribute to improved perioperative cardiac
outcomes in this patient population. Magnesium modestly reduced
postoperative heart rate at 24 hours without affecting blood pressure,
indicating a mild cardioprotective effect.<br/>Copyright &#xa9; This is an
Open Access article that uses a funding model which does not charge
readers or their institutions for access and distributed under the terms
of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access
Initiative (http://www.budapestopenaccessinitiative.org/read), which
permit unrestricted use, distribution, and reproduction in any medium,
provided original work is properly credited.

<37>
[Use Link to view the full text]
Accession Number
2032793584
Title
Factors Associated With Coronary Angiography Performed Within 6 Months of
Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Source
Circulation: Cardiovascular Interventions. 17(6) (pp 457-473), 2024. Date
of Publication: 01 Jun 2024.
Author
Spertus J.A.; Broderick S.; Rockhold F.W.; Demchenko E.; Grossman G.B.;
Stone G.W.; Mancini G.B.J.; Hochman J.S.; Boden W.E.; Mavromatis K.; Doan
J.; Linefsky J.; Lee R.; Patel R.; Miller T.; Cho S.Y.; Milbrandt S.;
Shelstad D.; Banerjee S.; Kamath P.; Tejani I.; Reynolds H.R.; Newman
J.D.; Bangalore S.; Phillips L.M.; Saric M.; Abdul-Nour K.; Schley A.;
Golden H.; Stone P.H.; Osseni H.; Wiyarand C.; Douglass P.; Pomeroy H.;
Craft A.; Harvey B.; Jang J.J.; Anaya O.; Yee G.; Goold P.; Weitz S.;
Giovannone S.; Pritchard L.; Arnold S.; Gans R.; O'Keefe J.H.; Kennedy P.;
Shapiro M.D.; Ganesan S.; Schlichting D.; Naher A.; Fein S.A.; Stewart
W.L.; Torosoff M.T.; Salmi K.M.; Lyubarova R.; Mookherjee S.; Drzymalski
K.; McFalls E.O.; Garcia S.A.; Bertog S.C.; Johnson D.K.; Siddiqui R.A.;
Herrmann R.R.; Ishani A.; Hansen R.A.; Khouri M.G.; Arges K.; LeFevre M.;
Tomfohr J.; Goldberg J.L.; Byrne K.A.; Zappernick T.; Goldweit R.; Canada
S.; Kakade M.; Mieses P.; Cohen R.A.; Mirrer B.; Navarro V.; Rantinella
M.; Rodriguez J.; Mancilla O.; Winchester D.E.; Stinson S.; Kronenberg M.;
Weyand T.; Crook S.C.; Heitner J.F.; Ho J.; Khan S.; Mohamed M.; Dauber
I.M.; Soltau M.R.; Rose D.K.; Wimmer R.J.; Siegel K.E.; Derbyshire S.;
Cannan C.; Dixon M.; Leonard G.; Sudarshan S.; Heard C.; Gabriel V.;
Desire S.; Mehta P.K.; McDaniel M.; Rashid F.; Lerakis S.; Asier S.;
Quyyumi A.; Patel K.; Wenger N.K.; Hedgepeth C.M.; Gillis J.; Hurlburt H.;
Manocchia M.; Rosen A.; Moore S.; Congdon E.; Sahul Z.; Brandt G.;
Marchelletta N.; Wippler K.; Leung S.; Reda H.; Ziada K.; Setty S.;
Halverson K.E.; Roraff C.; Thorsen J.; Barua R.S.; Ojajuni A.; Olurinde
O.; Surineni K.; Hage F.; Valaiyapathi B.; Davies J.E.; Leesar M.; Heo J.;
Iskandrian A.; Al Solaiman F.; Dajani K.; Kartje C.M.; El-Hajjar M.;
Mesropian P.D.; Sacco J.; Rawlins M.; McCandless B.; Thomson J.; Orgera
M.; Sidhu M.S.; Rogge M.C.; Arif I.; Bunke J.; Kerr H.; Unterbrink K.;
Fannon J.; Burman C.; Trejo J.F.; Dubin M.F.; Fletcher G.; Lane G.E.;
Neeson L.M.; Parikh P.P.; Pollak P.M.; Shapiro B.P.; Landolfo K.;
Gemignani A.; Beaudry S.; O'Rourke D.; Meadows J.L.; Tirado S.A.; Halliday
J.; Julian P.; Call J.T.; Lane S.M.; Stanford J.L.; Hannan J.; Bojar R.;
Arsenault P.; Kumar D.; Sigel P.; Mukai J.; Martin E.T.; Brooks M.;
Vorobiof G.; Douangvila L.; Gevorgyan R.; Moor-Man A.; Ranjbaran F.; Smith
B.; Ohmart C.; Kinlay S.; Hamburger R.J.; Rocco T.P.; Ly S.; Bhatt D.L.;
Quinn M.C.; Croce K.; Temiyasathit S.; Quin J.A.; Do J.; Anumpa J.; Tobin
D.; Zenati M.; Faxon D.P.; Rayos G.; Langdon J.; Bayer M.W.; Seedhom A.;
O'Malley A.; Sullenberger L.; Orvis E.; Kumkumian G.; Murphy M.; Greenberg
A.; Iraola M.; Sedlis S.P.; Maranan L.C.; Donnino R.M.; Lorin J.;
Tamis-Holland J.E.; Malinay A.; Kornberg R.; Leber R.; Saba S.; Edillo
C.P.; Lee M.W.; Small D.R.; Nona W.; Alexander P.B.; Rehman I.; Badami U.;
Ostrander A.; Wasmiller S.; Marzo K.; Drewes W.; Patel D.; Robbins I.H.;
Levite H.A.; White J.M.; Shetty S.; Hallam A.; Patel M.; Hamroff G.S.;
Spooner B.J.; Hollenweger L.M.; Little R.W.; Little H.; Zimbelman B.D.;
Little T.; Lui C.Y.; Eskelson N.A.; Smith B.R.; Vezina D.P.; Khor L.L.;
Abraham J.D.; Bull D.A.; McKellar S.H.; Booth D.; Taul Y.; Kotter J.;
Rodgers C.; Abdel-Latif A.; Isaacs J.; Bulkley V.; Hu B.; Kaneshiro R.;
Labovitz A.J.; Berlowitz M.; Kirby B.J.; Rogal P.; Tran N.N.; McFarren C.;
Jahrsdorfer C.; Matar F.; Caldeira C.; Maron D.J.; Rodriguez F.; Yunis R.;
Schnittger I.; Patro J.; Fearon W.F.; Deedwania P.; Vega A.; Reddy K.;
Sweeny J.; Bloise-Adames H.; Jimenez S.; Vrestil N.S.; Bhandari R.;
Spizzieri C.; Schade D.; Yost R.; Hochberg C.P.; Beardsley P.; Fine D.;
Salerno W.D.; Tancredi J.; Arakelian P.; Mathus S.; O'Neill D.; Wyman R.;
Burkhardt J.; Hosino S.; Lubyanaya O.A.; Salas J.D.; Zarka A.; Aguirre M.;
Shah A.V.; Dhawan M.; Parra D.; Tran T.; Haldis T.; Fowler-Lehman K.;
Spitzer N.; Riedberger C.; Weick C.; Kohn J.A.; Girotra S.; Drum C.;
Miller-Cox K.; Ollinger A.; Almousalli O.; Capasso-Gulve E.; Loehr A.M.;
Mosley M.; Krishnam M.S.; Heydari S.; Mil-Liken J.C.; Lundeen A.M.; Patel
P.M.; Karanjah E.; Seto A.H.; Marfori W.C.; Harley K.T.; Hernandez-Rangel
E.; Gibson M.A.; Singh P.; Allen B.J.; Coram R.; Webb A.M.; Fridell E.;
Wilson H.; Thomas S.; Kim A.; Schwartz R.G.; Wilmot P.; Chen W.; El
Shahawy M.; Stevens R.; Stafford J.; Black L.; Abernethy W.B.; Hull A.B.;
Lim O.J.; Tucker H.C.; Putnam N.C.; Hall L.L.; Cauthren T.; Tucker T.;
Zurick A.; Horton H.; Orga J.; Meyer T.M.; White J.R.; Morford R.G.;
Baumann C.; Rutkin B.; Seeratan V.; Bokhari S.; Jimenez M.; Sokol S.I.;
Schultz C.; Meisner J.; Russo J.; Hamzeh I.; Misra A.; Huda Z.; Wall M.;
Boan A.; De Rosen V.L.; Alam M.; Turner M.C.; Hinton C.R.; Mulhearn T.J.;
Good A.P.; Archer B.A.; Dionne J.S.; Allardyce C.A.; Sikora L.N.; Czerniak
J.H.; Mull J.A.; Ferguson E.; Laube F.; Shammas N.W.; Shammas G.A.;
Christensen L.; Park H.; Chilton R.; Hecht J.; Nguyen P.K.; Vo D.; Hirsch
J.; Jezior M.; Bindeman J.; Salkind S.; Desimone L.-A.; Gordon P.C.;
Felix-Stern L.; Crain T.; Gomes J.; Gordon C.; Stenberg R.; Mann A.;
McCreary T.; Pedalino R.P.; Cobos S.E.; Dwyer R.R.; Espinosa D.; Quiles
K.J.; Wiesel J.; Juang G.J.; Gopaul C.; Hultberg K.; Huk T.; Hussain A.;
Al-Amoodi M.; Zambrano Y.; Rodriguez S.M.; Milner T.; Wohns D.; Mulder A.;
Van Oosterhout S.; Lader E.W.; Meyer M.; Mumma M.; Clapp N.L.; Barrentine
H.; Dharmarajan L.; Jose J.M.; Manchery J.; McGarvey J.F.X.; McKinney V.;
Schwarz L.; Downes T.R.; Kaczkowski S.M.; Luckasen G.J.; Jaskowiak A.J.;
Klitch J.; Cheong B.; Dees D.; Potluri S.; Vasquez P.; Mastouri R.A.;
Breall J.A.; Hannemann E.L.; Revtyak G.E.; Foltz J.M.; Bazeley J.W.;
DeRosa E.; Jorgenson B.; Riestenberg-Smith J.; Giedd K.; Old W.; Bariciano
R.; Burt F.; Sokhon K.; Waldron J.; Mayon M.; Gopal D.; Valeti U.S.;
Peichel G.A.; Kobashigawa J.; Starks B.; Garcia L.; Thottam M.; Anand A.;
Govindan S.C.; Raj J.; Nair R.G.; Ravindran R.; Rajalekshmi V.S.;
Manjunath C.N.; Nataraj N.; Moorthy N.; Nayak S.; Manjunath S.C.;
Mylarappa M.; Narayanappa S.; Pandit N.; Bajaj S.; Nath R.K.; Yadav V.;
Mishra G.; Dwivedi S.K.; Tewari R.; Narain V.S.; Mishra M.; Chandra S.;
Patel S.; Wander G.S.; Tandon R.; Ralhan S.; Kaur B.; Aslam N.; Gupta S.;
Pharmacy B.; Goyal A.; Bhargava B.; Suvarna C.; Karthikeyan G.;
Ramakrishnan S.; Seth S.; Yadav R.; Singh S.; Roy A.; Parakh N.; Verma
S.K.; Narang R.; Mishra S.; Naik N.; Sharma G.; Choudhary S.K.; Patel C.;
Gulati G.; Sharma S.; Bahl V.K.; Mathew A.; Kurian B.M.; Punnoose E.;
Gadkari M.A.; Karwa S.R.; Gadage S.; Kolhe S.; Pillay T.U.; Satheesh S.;
Vindhya R.J.; Jain P.; Seth A.; Meharwal Z.S.; Mathur A.; Verma A.; Bhatia
M.; Sachdeva A.; Devi T.I.; Jungla N.; Rani K.M.; Menon R.; Reddy M.S.;
Oomman A.; Sidh R.R.; Mao R.; Ramakrishnan T.; Solomon H.; Francis R.;
Priya V.P.; Khan S.P.; Preethi K.; Kumar N.; Grant P.; Hande S.; Sonawane
P.; Kachru R.; Dubey A.; Rawat K.; Kumar A.V.K.; Ganapathi S.; Jayakumar
K.; Vineeth C.P.; Sivadasanpillai H.; Chacko M.; Sasidharan B.; Babu S.;
Kapilamoorthy T.R.; Christopher J.; Reddy S.; Polamuri P.; Rani M.; Kaul
U.; Arambam P.; Singh B.; Senior R.; Fox K.A.A.; Carruthers K.; Elghamaz
A.; Gurunathan S.; Karogiannis N.; Young G.M.; Shah B.N.; Kinsey C.;
Trimlett R.H.J.; Kavalakkat R.; Rubens M.B.; Evans J.; Nicol E.D.; Hassan
I.; Mittal T.K.; Hampson R.; Gamma R.A.; Williams S.; Holland K.; Swan K.;
de Belder M.A.; Atkinson B.; Thambyrajah J.; Nageh T.; Kunhunny S.; Davies
J.R.; Lindsay S.J.; Atkinson C.; Kurian J.; Krannila C.; Jamil H.; Vinod
M.; Raheem O.; Hoye A.; Chaytor L.; Cox L.; Morrow J.; Rowe K.; Donnelly
P.; Kelly S.; Valecka B.; Regan S.; Turnbull D.; Chauhan A.; Fleming C.;
Ghosh A.; Gratrix K.; Preston S.; Barr C.; Cartwright A.; Alfakih K.;
Knighton A.; Byrne J.; Martin K.; Webb I.; Henriksen P.; Flint L.;
Harrison J.; OKane P.; Lake-Man N.; Ljubez A.; de Silva R.; Conway D.S.G.;
Wright J.; Exley D.; Sirker A.A.; Andiapen M.; Richards A.J.; Hoole S.P.;
Wong L.; Witherow F.N.; Munro M.J.; Harbinson M.; McEvoy M.; Walsh S.; Bao
B.; Brown C.; Douglas H.; Luckie M.; Charles T.; Kolakaluri L.; Phillips
H.; Sobolewska J.; Morby L.; Hallett K.; Corbett C.; Winstanley L.;
Jeetley P.; Smit A.; Patel N.; Kotecha T.; Travill C.; Gent S.; Karimullah
I.; Hussain N.; Al-Bustami M.; Braganza D.; Haines F.; Taaffe J.;
Henderson R.; Burton J.; Pointon K.; Colton M.; Naik S.; King R.; Mathew
T.; Brown A.; Docherty A.; Berry C.; McCloy L.; Collison D.; Robb K.;
Roditi G.; Paterson C.; Crawford W.; Kelly J.; McGregor L.; Moriarty A.J.;
Mackin A.; Glover J.D.; Knight J.P.; Pradhan J.; Mikhail G.; Bose T.;
Francis D.P.; Dzavik V.; Proietti A.; Brousseau M.; Corfias M.; Blaise P.;
Harvey L.; Diaz A.; Rheault P.; Barrero M.; Gagne C.-E.; Alarie P.;
Pepin-Dubois Y.; Arcand L.; Costa R.; Roy I.; Sia Y.T.; Montpetit E.;
Lemay C.; Gisbert A.; Gervais P.; Rheault A.; Drouin K.; Phaneuf D.C.;
Bergeron C.; Gosselin G.; Shelley C.; Masson C.; Garg P.; Carr S.; Bone
C.; Chow B.J.W.; Moga E.; Hessian R.C.; Kourzenkova J.; Beanlands R.S.;
Walter O.; Davies R.F.; Bainey K.R.; Hogg N.; Welsh S.; Bagai A.; Wald R.;
Goodman S.; Graham J.J.; Peterson M.; Bello O.; Chow C.-M.; Abramson B.;
Cheema A.N.; Syed I.; Vakani M.T.; Hussain M.; Kushniriuk K.; Cha J.; Otis
J.; Otis R.; Howarth A.G.; Seib M.M.; Rivest S.M.; Sandonato R.; Chow J.;
Starovoytov A.; Uchida N.; Meadows N.; Uxa A.; Asif N.; Tavares S.;
Galiwango P.; Bozek B.; Kassam S.; Shier M.; Mukherjee A.; Larmand L.-A.;
Ricci A.J.; Janmohamed A.; Hart B.; Lam A.; Marucci J.; Tai S.; Mehta S.;
Brons S.; Beck C.; Wong G.; Etherington K.; Arumairajah T.; Udell J.;
Aprile M.; Karlsson S.; Webber S.; Genereux P.; Mercure C.; Hameed A.;
Aedy N.; Daba L.; Farquharson F.; Siddiqui A.; Lopes R.D.; Hueb W.;
Takiuti M.E.; Rezende P.C.; Silva E.E.R.; Hueb A.C.; Smanio P.E.P.;
Caetano L.P.; de Quadros A.S.; Kalil R.A.K.; Deiro A.P.; da Costa Vieira
J.L.; Muller A.M.; Grossmann G.; de Moraes M.A.P.; de Oliveira P.P.;
Ascoli B.M.; Bridi L.; Poletti S.Z.; Savaris S.; Vitola J.V.; Cerci R.J.;
Zier S.S.; Farias F.R.; Veiga V.; Fernandes M.M.; Marin-Neto J.A.; Schmidt
A.; de Oliveira Lima Filho M.; da Cunha D.F.; Oliveira R.M.; Chierice
J.R.A.; Polanczyk C.A.; Rucatti G.G.; Furtado M.V.; Igansi F.; Smidt L.F.;
Haeffner M.P.; Carvalho A.C.; Almeida V.; Pucci G.; de Souza G.S.; Lyra
F.; Alves A.R.; Almeida M.; dos Santos V.; Dracoulakis M.D.A.; Oliveira
N.S.; Lima R.G.S.D.; Figueiredo E.; Azevedo B.E.P.; Caramori P.R.; Santos
M.B.; Germann A.; Gomes V.; Homem R.; Magedanz E.; Tumelero R.; Laimer R.;
Tognon A.; Dall'Orto F.; Mesquita C.T.; Santos R.P.; Colafranseschi A.S.;
Oliveira A.C.; Carvalho L.A.; Palazzo I.C.; Sousa A.S.; da Silva E.E.R.;
de Barros e Silva P.G.M.; Okada M.Y.; de Padua Silva Baptista L.; Batista
A.P.; Rodrigues M.J.; Rabaca A.N.; de Resende M.V.C.; Saraiva J.F.; Trama
L.M.; de Souza Ormundo C.T.; Vicente C.; Costantini C.; Pinheiro C.; Komar
D.; Ruzyllo W.; Demkow M.; Pracon R.; Kepka C.; Teresinska A.; Walesiak
O.; Kryczka K.; Malinowska K.; Henzel J.; Solecki M.; Kaczmarska E.;
Mazurek T.; Maksym J.; Wojtera K.; Fojt A.; Szczerba E.; Drozdz J.;
Czarniak B.; Frach M.; Szymczyk K.; Niedzwiecka I.; Sobczak S.; Ciurus T.;
Jakubowski P.; Misztal-Teodorczyk M.; Teodorczyk D.; Swiderek M.; Fratczak
A.; Wojtala E.; Szkopiak M.; Lebioda P.; Wlodarczyk M.; Plachcinska A.;
Kusmierek J.; Miller M.; Marciniak H.; Wojtczak-Soska K.; Luczak K.;
Tarchalski T.; Cichocka-Radwan A.; Szwed H.; Karwowski J.; Szulczyk G.A.;
Witkowski A.; Kukula K.; Celinska-Spodar M.; Zalewska J.; Gajos G.; Bury
K.; Pruszczyk P.; Labyk A.; Roik M.; Szramowska A.; Zdonczyk O.;
Loboz-Grudzien K.; Jaroch J.; Sokalski L.; Brzezinska B.; Lesiak M.;
Lanocha M.; Reczuch K.W.; Kolodziej A.; Kalarus Z.; Swiatkowski A.; Szulik
M.; Musial W.J.; Marcinkiewicz-Siemion M.; Bockeria O.; Bockeria L.;
Petrosyan K.; Kudzoeva Z.; Trifonova T.; Aripova N.; Chernyavskiy A.M.;
Naryshkin I.A.; Kretov E.I.; Kuleshova A.; Grazhdankin I.O.; Malaev D.;
Bershtein L.L.; Sayganov S.A.; Subbotina I.; Kuzmina-Krutetskaya A.M.;
Gumerova V.; Zbyshevskaya E.V.; Katamadze N.O.; Demchenko E.A.; Nikolaeva
O.B.; Kozlov P.S.; Kozulin V.Y.; Lubinskaya E.I.; Lopez-Sendon J.L.;
Lopez-Sendon J.; Fernandez-Figares V.; Castro A.; Salicio E.R.; Guzman G.;
Galeote G.; Valbuena S.; Peteiro J.; Martinez-Ruiz M.D.; Perez-Fernandez
R.; Blanco-Calvo M.; Cuenca-Castillo J.J.; Alonso-Alvarez E.; Flores-Rios
X.; Garcia-Gonzalez P.; Prada-Delgado O.; Barge-Caballero G.; Juanatey
J.R.G.; Amigo J.S.; Bayarri M.S.; Nunez V.P.; Sanchez R.O.; Alvarez B.C.;
Gil C.P.; Monzonis A.M.; Sionis A.; Martinez A.F.; Perales M.V.; Padro
J.M.; Penaranda A.S.; Picart J.G.; Iglesias A.G.; Marimon X.G.-M.; Llado
G.P.; Costa F.C.; Miro V.; Igual B.; Diez J.L.; Calvillo P.; Ortuno F.M.;
Chavarri M.V.; Giner M.Q.; Montolliu A.T.; Aniorte A.I.R.; Bermudez E.P.;
Caravaca J.M.R.; De La Morena G.; Blancas M.G.; Canavate O.; Guerrero S.;
Riera S.; Luena J.E.C.; Lasala M.; Fernandez-Aviles F.; Lorenzo M.;
Sobrino O.; Vazquez A.; Jiang L.; Chen J.; Dong H.; He P.; Xia C.; Yang
J.; Zhong Q.; Wu Y.; Tian Y.; Li D.; Ma Y.; Yang Y.; Ma X.; Yu Z.; Zhao
Q.; Ji Z.; Li C.; Zhu B.; Yang X.; Chen M.; Chi H.; Zhang J.; Lin W.; Jing
R.; Liu J.; Zeng H.; Zhou Q.; Xu C.; Li Z.; Xiong L.; Fu X.; Gao D.; Jiang
D.; Leng R.; Yuan Q.; Zhang L.; Bai Z.; Li J.; Qi J.; Wang F.; Wang H.;
Yang B.; Yue Z.; Zhang Z.; Wang S.; Dong Y.; Mao J.; Zhang B.; Cheng G.;
Li X.; Yao X.; Zhong N.; Zhou N.; Huang Y.; Zhou P.; Fang X.; Su W.; Zeng
Q.; Kunwu Y.; Peng Y.; Su X.; Wang C.; Zhao Y.; Li Q.; Geng Y.; Wang Y.;
Nie S.-P.; Fan J.-Y.; Feng S.-T.; Wang X.; Yan Y.; Zhang H.-M.; Yu Q.; Chi
L.; Liu F.; Chen H.; Jiang J.; Li H.; Wang J.; Han Y.; Xu L.; Zhang S.;
Liu Z.; Chen G.; Hu R.; Perna G.P.; Pietrucci F.; Marini M.; Gabrielli G.;
Provasoli S.; Di Donato A.; Verna E.; Monti L.; Nardi B.; Di Chiara A.;
Pezzetta F.; Mortara A.; Casali V.; Galvani M.; Attanasio C.; Ottani F.;
Sicuro M.; Leone G.; Pisano F.; Bare C.; Calabro P.; Fimiani F.; Formisano
T.; Tarantini G.; Barioli A.; Cucchini U.; Ramani F.; Andres A.L.; Racca
E.; Rolfo F.; Goletto C.; Briguori C.; De Micco F.; Amati R.; Di Marco S.;
Vergoni W.; Tricoli M.; Russo A.; Villella M.; Fanelli R.; Poh K.-K.; Chai
P.; Lau T.; Loh J.P.; Tay E.L.; Teoh K.; Tan S.-Y.V.; Teo L.L.; Sia W.C.;
Ong C.-C.; Leong A.W.; Wong R.C.; Loh P.-H.; Kofidis T.; Chan W.X.; Chan
K.H.; Foo D.; Yan L.H.; Kong J.L.K.; Er C.M.; Jafary F.-H.H.; Chua T.;
Ismail N.; Kyaw M.T.; Yip D.; Doerr R.; Stumpf J.; Grahl D.; Matschke K.;
Guenther F.; Simonis G.; Bonin K.; Kadalie C.T.; Sechtem U.; Wenzelburger
I.; Ong P.; Gruensfelder S.; Schulze P.C.; Goebel B.; Lenk K.; Nickenig
G.; Sinning J.-M.; Weber M.; Werner N.; Schuchlenz H.; Steinmaurer G.;
Weikl S.; Lang I.M.; Winter M.-P.; Andric T.; Huber K.; Maximilian T.;
Gabriele J.-K.; Claudia W.; Bernhard J.; Florian E.; Keltai M.; Vertes A.;
Sebo J.; Davidovits Z.; Matics L.; Varga A.; Agoston G.; Fontos G.; Dekany
G.; Merkely B.; Bartykowszki A.; Maurovich-Horvat P.; Kerecsen G.; Jakal
A.; Hinic S.; Djokic J.; Zdravkovic M.; Mudrenovic V.; Crnokrak B.;
Beleslin B.D.; Boskovic N.N.; Djordjevic-Dikic A.D.; Petrovic M.T.; Giga
V.L.; Dobric M.R.; Stepanovic J.J.; Markovic Z.Z.; Mladenovic A.S.;
Cemerlic-Adjic N.; Velicki L.; Pupic L.; Davidovic G.; Simovic S.M.; Vucic
R.; Dekleva M.N.; Martinovic M.S.; Stevanovic G.; Stankovic G.; Dobric M.;
Apostolovic S.; Martinovic S.S.; Stanojevic D.; Escobedo J.; de
Jesus-Perez R.; Juarez B.; Baleon-Espinosa R.; Campos-Santaolalla A.S.;
Duran-Cortes E.; Flores-Palacios J.M.; Garcia-Rincon A.; Jimenez-Santos
M.; Penafiel J.V.; Ortega-Ramirez J.A.; Valdespino-Estrada A.; Rosas E.A.;
Brassetti M.F.C.; Anaya D.A.V.; Garcia M.P.; Juarez I.E.C.; Rovalo M.M.;
Rodriguez E.D.M.; Selvanayagam J.B.; Rankin J.; Murphy D.; Lee S.; Joseph
M.X.; Thomas P.; Thambar S.T.; Chaplin M.D.; Boer S.C.; Beltrame J.F.;
Stansborough J.K.; Black M.; Hillis G.S.; Bonner M.M.; Ireland K.F.;
Venn-Edmonds C.; Steg P.-G.; Thobois C.; Thuaire C.; Tachot E.; Dutoiu T.;
Laure C.; Vassaliere C.; Steg P.G.; Abergel H.; Juliard J.-M.; Fuentes A.;
Slama M.S.; Eliahou L.; Mahmoud R.E.; Dubourg O.; Michaud P.; Nicollet E.;
Hadjih S.; Goube P.; Brito P.; Barone-Rochette G.; Furber A.; Cornet C.;
Biere L.; Rautureau J.; Juceviciene A.; Kalibataite-Rutkauskiene I.;
Keinaite L.; Laucevicius A.; Laukyte M.; Celutkiene J.; Mikolaitiene G.;
Smigelskaite A.; Tamasauskiene I.; Urboniene A.; Kedhi E.; Timmer J.;
Bouwhuis I.; Hermanides R.; Nijmeijer L.; Kaplan E.; Riezebos R.K.; Samadi
P.; Schoep J.J.M.; van Dongen E.; Janzen E.M.; Niehe S.R.; Suryapranata
H.; Ahoud S.; van Vugt S.; Ramos R.; Cacela D.; Santana A.; Fiarresga A.;
Sousa L.; Marques H.; Patricio L.; Selas M.; Bernanrdes L.; Silva F.; Rio
P.; Freixo C.; Carvalho R.; Ferreira R.; Silva T.; Rodrigues I.; Modas P.;
Portugal G.; Fragata J.; Pinto F.J.; Cabrita I.Z.; Menezes M.N.; Rocha A.;
Lopes G.C.; Figueiras F.P.; Almeida A.G.; Coelho A.; Silva P.C.; Capinha
M.; Nobre A.; Caetano M.I.; Francisco A.R.; Silva S.; Ferreira N.; Lopes
R.L.; Diaz R.; Guzman L.; Tinnirello V.; Figal J.C.; Mungo M.N.; Mendiz
O.; Cortes C.; Favaloro R.R.; Alvarez C.; Garcia M.; Courtis J.; Godoy V.;
Zeballos G.; Schiavi L.; Actis M.V.; Rubio M.; Scaro G.; Devlin G.P.; Low
L.; Fisher R.; Scales J.; Abercrombie K.; Stewart R.A.H.; Howell L.;
Patten C.; Benatar J.; Kedev S.; Mitevska I.P.; Kostovska E.S.; Pejkov H.;
Held C.; Eggers K.; Frostfelt G.; Bjorklund C.; Johnston N.; Andreasson
M.; Olsowka M.; Essermark M.; Akerblom A.; Soveri I.; Aspberg J.; Persson
L.; Beyar R.; Nikolsky E.; Sharir T.; Harel O.; Elian D.; Kerner A.;
Bentzvi M.; Massalha S.; Helmer L.; Fukuda K.; Ueda I.; Kohsaka S.; Fujita
J.; Yasuda S.; Furukawa A.; Nagai T.; Otsuka F.; Nishimura S.; Nakano S.;
Goetschalckx K.; Robesyn V.; Van de Werf F.; Claes K.; Hung C.-L.; Yang
Y.-H.; Yun C.-H.; Hou C.J.-Y.; Kuo J.-Y.; Yeh H.-I.; Hung T.-C.; Li J.-Y.;
Chien C.-Y.; Tsai C.-T.; Liu C.-C.; Yu F.-C.; Lin Y.-H.; Lan W.-R.; Yen
C.-H.; Tsai J.-P.; Sung K.-T.; Ntsekhe M.; Pandie S.; Philander C.;
Viljoen C.A.; Mtana N.; De Andrade M.; Maggioni A.P.; Moccetti T.; Anesini
A.; Rossi M.G.; Maspoli S.; Mombelli M.; Abdelhamid M.; Talaat A.; Adel
A.; Kamal A.; Mahrous H.; El Kaffas S.; El Fishawy H.; Pop C.; Claudia M.;
Popescu B.A.; Ginghina C.; Rosca M.; Deleanu D.; Beladan C.C.; Iliescu
V.A.; Al-Mallah M.H.; Zahrani S.; Aljzeeri A.; Najm H.; Alghamdi A.; Ramos
W.E.M.; Davila M.A.M.; Kuanprasert S.; Prommintikul A.; Nawarawong W.;
Khwakhong S.; Woragidpoonpol S.; Chaiyasri A.; Tepsuwan T.; Mekara W.;
Taksaudom N.; Kulthawong S.; Rimsukcharoenchai C.; Amaritakomol A.;
Euathrongchit J.; Wannasopha Y.; Yamwong S.; Panpunuan P.; Sritara P.;
Aramcharoen S.; Meemuk K.; White H.D.; Alsweiler C.; Khairuddin A.;
Mokhtar N.S.; Hadi H.A.; Basri N.A.; Yahaya S.A.; Yusnida I.; Hashim H.;
Bugiardini R.
Institution
(Pracon, Ruzyllo) National Institute of Cardiology, Warsaw, Poland
(Spertus) Saint Luke's Mid America Heart Institute, University of
Missouri-Kansas City, Durham, NC, United States
(Broderick, Rockhold) Duke Clinical Research Institute, Durham, NC, United
States
(Bangalore, Newman, Reynolds, Hochman) Cardiovascular Clinical Research
Center, New York University Grossman School of Medicine, Durham, NC,
United States
(Rockhold) Department of Biostatistics and Bioinformatics, Duke University
School of Medicine, Durham, NC, United States
(Demchenko) Almazov National Medical Research Centre, Saint Petersburg,
Russian Federation
(Nageh) Southend University Hospital, United Kingdom
(Grossman) Moinhos de Vento Hospital, Porto Alegre, Brazil
(Grossman) Cardionuclear Clinic, Porto Alegre, Brazil
(Mavromatis) Emory University, Atlanta VA Healthcare System, GA, United
States
(Manjunath) Sri Jayadeva Institute of Cardiovascular Sciences and
Research, Bengaluru, India
(Smanio) Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
(Stone) Icahn School of Medicine at Mount Sinai, New York, NY, United
States
(Mancini) Center for Cardiovascular Innovation, The University of British
Columbia, Vancouver, Canada
(Boden) VA New England Healthcare System, Boston University School of
Medicine, MA, United States
(Maron) Department of Medicine, Stanford University, CA, United States
(Boden, Mavromatis, Doan) Atlanta VA Medical Center, Decatur, GA, United
States
(Linefsky, Lee, Patel, Miller, Cho) Mayo Clinic, Rochester, MN, United
States
(Milbrandt, Shelstad, Banerjee, Kamath) V.A. North Texas Health Care
System, Dallas, TX, United States
(Tejani) NYU Langone Medical Center-Bellevue Hospital, New York, NY,
United States
(Reynolds, Newman, Bangalore, Donnino, Phillips, Saric, Abdul-Nour,
Schley) Henry Ford Health System, Detroit, MI, United States
(Golden, Stone, Osseni) Brigham & Women's Hospital, Harvard Medical
School, Boston, MA, United States
(Wiyarand, Douglass, Pomeroy, Craft, Harvey, Jang, Anaya) Kaiser
Permanente San Jose, San Jose, CA, United States
(Yee, Goold, Weitz, Giovannone) Cardiology Associates of Schenectady P.C.,
Schenectady, NY, United States
(Pritchard, Arnold, Gans) Saint Luke's Hospital, Kansas City, MO, United
States
(O'Keefe, Kennedy, Shapiro, Ganesan) Oregon Health & Science University,
Portland, OR, United States
(Schlichting, Naher) Albany Medical Center Hospital, Albany, NY, United
States
(Fein, Stewart, Torosoff, Salmi, Lyubarova, Mookherjee, Drzymalski,
McFalls) Minneapolis VAMC, Minneapolis, MN, United States
(Garcia, Bertog, Johnson, Siddiqui, Herrmann, Ishani, Hansen, Khouri,
Arges) Duke University Medical Center, Durham, NC, United States
(LeFevre, Tomfohr, Goldberg, Byrne) Louis Stokes Cleveland Veterans
Affairs Medical Center, Cleveland, OH, United States
(Zappernick, Goldweit, Canada) Englewood Hospital and Medical Center,
Englewood, NJ, United States
(Kakade) NYU-HHC Woodhull Hospital, Brooklyn, NY, United States
(Mieses, Cohen, Mirrer, Navarro, Rantinella, Rodriguez, Mancilla,
Winchester, Stinson) Malcom Randall VAMC, Gainesville, FL, United States
(Kronenberg, Weyand) Vanderbilt University Medical Center, Nashville, TN,
United States
(Rogal, Crook, McFarren, Heitner, Ho) New York -Presbyterian/Brooklyn
Methodist Hospital, Brooklyn, NY, United States
(Khan, Mohamed, Dauber, Soltau) South Denver Cardiology Associates, P.C.,
Littleton, CO, United States
(Rose, Wimmer, Siegel, Derbyshire, Cannan, Dixon) Providence Heart and
Vascular Institute, Portland, OR, United States
(Leonard, Sudarshan, Heard) Wichita Falls Heart Clinic, Wichita Falls, TX,
United States
(Gabriel, Desire, Mehta) Emory University, Atlanta, GA, United States
(McDaniel, Rashid, Lerakis, Asier, Quyyumi, Patel, Wenger, Hedgepeth,
Gillis) Kent Hospital, Warwick, RI, United States
(Hurlburt, Manocchia, Rosen, Moore, Congdon, Sahul, Brandt) Michigan
Heart, PC, Ypsilanti, MI, United States
(Marchelletta, Wippler, Booth, Taul) University of Kentucky, Lexington,
KY, United States
(Leung, Isaacs, Abdel-Latif, Bulkley, Reda, Rodgers, Ziada, Setty,
Halverson) Gundersen Lutheran Medical Center, La Crosse, WI, United States
(Roraff, Thorsen, Barua, Ojajuni) Kansas City VA Medical Center, Kansas
City, MO, United States
(Olurinde, Surineni, Hage, Valaiyapathi) UAB Vascular Biology and
Hypertension Program, Birmingham, AL, United States
(Caldeira, Davies, Leesar, Heo, Iskandrian, Al Solaiman, Singh, Dajani,
Kartje) Loyola University Medical Center, Maywood, IL, United States
(El-Hajjar) Samuel Stratton VA Medical Center of Albany NY, Albany, NY,
United States
(Mesropian, Sacco, Rawlins, McCandless, Thomson, Orgera, Sidhu, Rogge)
Cincinnati VA Medical Center, Cincinnati, OH, United States
(Arif, Bunke, Kerr, Unterbrink, Fannon, Burman, Trejo, Dubin) Mayo Clinic
Florida, Jacksonville, FL, United States
(Fletcher, Lane, Neeson, Parikh, Pollak, Shapiro, Landolfo, Gemignani,
Beaudry) VAMC-White River Junction, White River Junction, VT, United
States
(O'Rourke, Meadows, Tirado) VA Connecticut Healthcare System, West Haven,
CT, United States
(Halliday, Julian, Call, Lane) Winchester Cardiology and Vascular
Medicine, PC, Winchester, VA, United States
(Stanford, Hannan) Saint Vincent Hospital, Worcester Medical Center,
Worcester, MA, United States
(Bojar, Arsenault, Kumar, Sigel, Mukai, Martin, Brooks) Oklahoma Heart
Institute, Tulsa, OK, United States
(Vorobiof, Douangvila) Ronald Reagan UCLA Medical Center, Los Angeles, CA,
United States
(Gevorgyan, Moor-Man, Ranjbaran) University of Washington Medical Center,
Seattle, WA, United States
(Smith, Ohmart, Kinlay) VA Boston Healthcare System, West Roxbury, MA,
United States
(Hamburger, Rocco, Ly, Bhatt, Quinn, Croce, Temiyasathit, Quin, Do,
Anumpa, Tobin, Zenati, Faxon, Rayos, Langdon) Daytona Heart Group, Daytona
Beach, FL, United States
(Bayer, Seedhom, O'Malley) Capital Cardiology Associates, Albany, NY,
United States
(Sullenberger, Orvis, Kumkumian, Murphy) NIH Heart Center, Suburban
Hospital, Bethesda, MD, United States
(Greenberg, Iraola, Sedlis, Maranan) VA New York Harbor Health Care
System, New York, NY, United States
(Donnino, Lorin, Tamis-Holland, Malinay) Mount Sinai Saint Luke's
Hospital, Ridgewood, NJ, United States
(Kornberg, Leber, Saba, Edillo) Providence - Providence Park Hospital,
Southfield, MI, United States
(Lee, Small, Nona, Alexander, Rehman, Badami, Ostrander) Covenant Medical
Center, Inc., Saginaw, MI, United States
(Wasmiller, Marzo, Drewes) NYU Winthrop, Mineola, NY, United States
(Patel, Robbins) AtlantiCare Regional Medical Center, Pomona, NJ, United
States
(Levite, White, Shetty, Hallam, Patel, Hamroff, Spooner) NYP Medical
Medical Group Hudson Valley Cardiology, Cortlandt Manor, NY, United States
(Hollenweger, Little, Little) Houston Heart & Vascular Associates,
Houston, TX, United States
(Zimbelman, Little, Lui, Eskelson) Salt Lake City VA Medical Center, Salt
Lake City, UT, United States
(Smith, Vezina, Khor, Abraham, Bull, McKellar, Booth, Taul) Lexington VA
Medical Center, Lexington, KY, United States
(Kotter, Rodgers, Abdel-Latif, Isaacs, Bulkley, Hu, Kaneshiro) Palo Alto
Medical Foundation Research Institute, Palo Alto, CA, United States
(Labovitz) University of South Florida, Tampa, FL, United States
(Berlowitz, Kirby, Rogal, Tran, McFarren, Jahrsdorfer, Matar, Caldeira,
Maron) Stanford University School of Medicine, Stanford, CA, United States
(Rodriguez, Yunis, Schnittger, Patro, Fearon, Deedwania, Vega) UCSF -
Fresno Community Regional Medical Center, Fresno, CA, United States
(Reddy, Sweeny, Bloise-Adames) Icahn School of Medicine at Mount Sinai,
New York, NY, United States
(Jimenez, Vrestil, Bhandari, Spizzieri, Schade) Holy Spirit Hospital
Cardiovascular Institute, Camp Hill, PA, United States
(Yost, Hochberg, Beardsley) Boston Medical Center, Boston, MA, United
States
(Fine, Salerno, Tancredi) Hackensack University Medical Center, Saddle
Brook, NJ, United States
(Arakelian, Mathus, O'Neill, Wyman, Burkhardt) Torrance Memorial Medical
Center, Torrance, CA, United States
(Hosino, Lubyanaya) Coastal Heart Medical Group, Santa Ana, CA, United
States
(Salas, Zarka, Aguirre, Shah, Dhawan, Parra, Tran, Haldis, Weick) Sanford
Health, Fargo, ND, United States
(Fowler-Lehman, Spitzer, Riedberger, Weick, Kohn) NYU New York Medical
Associates, New York, NY, United States
(Cobos, Quiles, Girotra, Drum) University of Iowa Hospitals and Clinics,
Iowa City, IA, United States
(Miller-Cox, Ollinger, Almousalli, Capasso-Gulve) Advanced Heart Care
Group, Fairview Heights, IL, United States
(Loehr, Mosley, Krishnam, Heydari) University of California Irvine Medical
Center, Orange, CA, United States
(Mil-Liken, Lundeen, Patel, Karanjah, Seto, Marfori, Harley,
Hernandez-Rangel, Gibson, Singh, Allen, Coram, Webb) University of
Louisville, Louisville, KY, United States
(Fridell, Wilson, Thomas, Kim) University of Rochester, Rochester, NY,
United States
(Schwartz, Wilmot, Chen, El Shahawy, Stevens) Cardiovascular Center of
Sarasota, Sarasota, FL, United States
(Stafford, Black) University of Maryland Medical Center, Baltimore, MD,
United States
(Abernethy, Hull) Asheville Cardiology Associates, Asheville, NC, United
States
(Lim, Tucker, Putnam, Hall, Cauthren, Tucker, Zurick, Horton) Saint Thomas
Hospital, Nashville, TN, United States
(Orga, Meyer, White) Stroobants Cardiovascular Center, Lynchburg, VA,
United States
(Morford, Baumann, Rutkin, Seeratan) Northwell Health - Manhasset,
Manhasset, NY, United States
(Bokhari, Jimenez) Columbia University Medical Center, New York, NY,
United States
(Sokol, Schultz) Jacobi Medical Center, Bronx, NY, United States
(Meisner, Russo, Hamzeh) Baylor College of Medicine, Houston, TX, United
States
(Misra, Huda, Wall, Boan, De Rosen, Alam, Turner, Hinton) Cardiovascular
Specialists of Southwest Louisiana, Lake Charles, LA, United States
(Mulhearn, Good, Archer) Ohio Health Grant Medical Center, Columbus, OH,
United States
(Dionne, Allardyce, Sikora, Czerniak, Mull, Ferguson, Laube, Shammas,
Shammas) Midwest Cardiovascular Research Foundation, Davenport, IA, United
States
(Christensen, Park, Chilton, Hecht) Audie Murphy V.A., San Antonio, TX,
United States
(Nguyen, Vo) VA Palo Alto Healthcare System, Palo Alto, CA, United States
(Hirsch, Jezior, Bindeman) Walter Reed National Military Medical Center,
Bethesda, MD, United States
(Salkind, Espinosa) Miriam Hospital, Providence, RI, United States
(Desimone, Gordon, Felix-Stern, Crain, Gomes, Gordon, Stenberg, Mann)
Conemaugh Valley Memorial Hospital, Johnstown, PA, United States
(McCreary, Pedalino, Cobos) NYU-HHC Kings County Hospital Center,
Brooklyn, NY, United States
(Dwyer, Espinosa, Quiles, Wiesel) New York University - Langone
Cardiovascular Associates, Flushing, NY, United States
(Juang, Gopaul) Coney Island Hospital, Brooklyn, NY, United States
(Hultberg, Huk, Hussain, Al-Amoodi, Zambrano) Yuma Regional Medical
Center, Yuma, AZ, United States
(Rodriguez, Milner, Wohns, Mulder) Spectrum Health, Grand Rapids, MI,
United States
(Van Oosterhout, Lader, Meyer) Mid Valley Cardiology, Kingston, NY, United
States
(Mumma, Clapp) Sarasota Memorial Hospital, Sarasota, FL, United States
(Barrentine, Dharmarajan, Jose) NYU-HHC Lincoln Medical and Mental Health
Center, Bronx, NY, United States
(Manchery, McGarvey, McKinney) Doylestown Health Cardiology, Doylestown,
PA, United States
(Schwarz, Downes, Kaczkowski) Medical Center of the Rockies, Loveland, CO,
United States
(Luckasen, Jaskowiak, Klitch, Cheong, Dees) Baylor St. Luke's Medical
Center, Houston, TX, United States
(Potluri, Vasquez) Baylor Research Institute, Legacy Heart Center, Plano,
TX, United States
(Mastouri) Indiana University, Krannert Institute of Cardiology,
Indianapolis, IN, United States
(Breall, Hannemann, Revtyak, Foltz, Bazeley, Li, DeRosa) HealthEast Saint
Joseph's Hospital, St. Paul, MN, United States
(Jorgenson, Riestenberg-Smith, Giedd) Beth Israel Medical Center, New
York, NY, United States
(Old, Bariciano) Cardiovascular Associates, Ltd., Chesapeake, VA, United
States
(Burt) Saint Luke's Hospital and Health Network, Bethlehem, PA, United
States
(Sokhon, Waldron) Medicus Alliance Clinical Research Org., Inc., Sugar
land, TX, United States
(Mayon, Gopal) The Heart Hospital Baylor, Plano, TX, United States
(Valeti, Peichel) University of Minnesota, Minneapolis, MN, United States
(Kobashigawa, Starks) Cedars Sinai Medical Center, Beverly Hills, CA,
United States
(Garcia, Thottam, Bhargava, Anand) Government Medical College, Calicut,
India
(Govindan, Raj, Nair, Ravindran, Rajalekshmi, Manjunath, Nataraj) Sri
Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru,
India
(Moorthy, Nayak, Manjunath, Mylarappa, Narayanappa, Pandit, Bajaj) Dr Ram
Manohar Lohia Hospital, New Delhi, India
(Nath, Yadav, Mishra, Dwivedi, Tewari) King George's Medical University,
Department of Cardiology, Lucknow, India
(Narain, Mishra, Chandra, Patel, Singh, Wander) Hero DMC Heart Institute,
Dayanand Medical College and Hospital, Ludhiana, India
(Tandon, Ralhan, Kaur, Aslam, Gupta, Pharmacy, Goyal, Bhargava, Suvarna)
All India Institute of Medical Sciences, New Delhi, India
(Karthikeyan, Ramakrishnan, Seth, Yadav, Singh, Roy, Parakh, Verma,
Narang, Mishra, Naik, Sharma, Choudhary, Patel, Gulati, Sharma, Bahl,
Mathew, Kurian) MOSC Medical College Hospital, Kolenchery, India
(Punnoose, Gadkari, Karwa) KEM Hospital Pune, Pune, India
(Gadage, Kolhe, Pillay, Satheesh, Vindhya) Jawaharlal Institute of
Postgraduate Medical Education & Research (JIPMER), Pondicherry, India
(Jain) Fortis Escort Heart Institute, New Delhi, India
(Seth, Meharwal, Mathur, Verma, Kaul, Bhatia, Sachdeva, Devi, Jungla,
Christopher, Rani) Gurunanak CARE Hospital, Hyderabad, India
(Menon, Reddy, Kumar, Preethi, Oomman, Sidh) Apollo Research and
Innovation, Chennai, India
(Mao, Ramakrishnan, Solomon, Francis, Naik, Priya) Apollo Research &
Innovations, Hyderabad, India
(Khan, Christopher, Preethi) CARE Nampally, Hyderabad, India
(Kumar, Grant, Hande) Ruby Hall Clinic, Grant Medical Foundation, Pune,
India
(Sonawane, Kachru, Dubey) Fortis Healthcare Fl.t Lt. Rajan Dhall Hospital,
New Delhi, India
(Rawat, Kumar) Sree Chitra Tirunal Institute for Medical Sciences and
Technology, Trivandrum, India
(Ganapathi, Jayakumar, Vineeth, Sivadasanpillai, Chacko, Sasidharan, Babu,
Kapilamoorthy, Christopher, Reddy) CARE Hospital, Hyderabad, India
(Polamuri, Rani, Kaul, Arambam) Batra Hospital and Medical Research Centre
(BHMRC), New Delhi, India
(Singh, Senior, Fox, Young, Carruthers) Northwick Park Hospital Harrow,
Royal Brompton Hospital London, Harrow, United Kingdom
(Elghamaz, Gurunathan, Karogiannis, Young, Shah, Kinsey, Trimlett,
Kavalakkat, Rubens, Evans, Nicol, Hassan, Mittal, Hampson, Gamma,
Williams) Broomfield Hospital, Chelmsford, United Kingdom
(Holland, Swan, de Belder, Atkinson) The James Cook University Hospital,
Middlesbrough, Middlesbrough, United Kingdom
(Thambyrajah, Nageh, Kunhunny) Southend University Hospital, Westcliffe on
Sea, United Kingdom
(Davies, Lindsay, Atkinson) Bradford Royal Infirmary, Bradford, United
Kingdom
(Kurian, Krannila, Jamil, Vinod, Raheem, Hoye, Chaytor) The University of
Hull, Castle Hill Hospital, Cottingham, United Kingdom
(Cox, Morrow, Rowe, Donnelly, Kelly) South Eastern Health and Social Care,
Belfast, United Kingdom
(Valecka, Regan, Turnbull, Chauhan, Fleming) Blackpool Teaching Hospitals,
Blackpool, United Kingdom
(Ghosh, Gratrix, Preston, Barr, Cartwright) Russells Hall Hospital,
Dudley, United Kingdom
(Alfakih, Knighton) King's College NHS Foundation Hospital, London, United
Kingdom
(Byrne, Martin, Webb, Henriksen, Flint) Royal Infirmary of Edinburgh,
Edinburgh, United Kingdom
(Harrison, OKane, Lake-Man) Royal Bournemouth Hospital, Bourneouth, United
Kingdom
(Ljubez, de Silva) Bedford Hospital NHS Trust, Bedford, United Kingdom
(Conway, Wright) Pinderfields Hospital, Wakefield, United Kingdom
(Exley, Sirker, Andiapen) University College London Hospitals NHS
Foundation Trust, London, United Kingdom
(Richards) BartsHealth NHS Trust, United Kingdom
(Hoole, Wong) Papworth Hospital, Cambridge, United Kingdom
(Witherow, Munro) Dorset County Hospital, Dorchester, United Kingdom
(Johnston, Bao) Belfast Trust, Belfast, United Kingdom
(Harbinson, Bao, McEvoy, Walsh, Bao, Brown, Douglas, Luckie, Charles)
Central Manchester University Hospital, Manchester, United Kingdom
(Kolakaluri, Phillips, Sobolewska, Morby) The Pennine Acute Hospitals NHS
Trust, Oldham, United Kingdom
(Hallett, Corbett, Winstanley, Jeetley, Smit) Royal Free London NHS
Foundation Trust, London, United Kingdom
(Patel, Kotecha, Travill, Gent) Luton and Dunstable University Hospital
NHS FT, Luton, United Kingdom
(Karimullah, Hussain, Al-Bustami, Braganza, Haines) Peterborough City
Hospital, Peterborough, United Kingdom
(Taaffe, Henderson, Burton) Nottingham University Hospitals, Nottingham,
United Kingdom
(Pointon, Colton, Naik, King, Mathew, Brown) University of Glasgow,
Clydebank, United Kingdom
(Docherty, Berry, McCloy, Collison, Robb, Roditi, Paterson, Crawford,
Kelly, McGregor, Moriarty, Mackin) Cardiovascular Research Unit, Craigavon
Area Hospital, Craigavon, United Kingdom
(Glover, Knight) Hampshire Hospitals NHS Foundation Trust, Basingstoke,
United Kingdom
(Pradhan, Mikhail, Bose) Imperial College Healthcare NHS Trust, London,
United Kingdom
(Francis, Dzavik, Goodman, Gosselin, Proietti) Montreal Heart Institute,
Montreal, QC, Canada
(Brousseau, Corfias, Blaise, Harvey, Diaz) Centre Hospitalier de Regional
Trois-Rivieres, Trois-Rivieres, QC, Canada
(Rheault, Barrero, Gagne, Alarie, Pepin-Dubois, Arcand, Costa, Roy, Sia,
Montpetit, Lemay, Gisbert, Gervais, Rheault, Drouin) CISSSL - Hopital
Pierre-Le Gardeur, Terrebonne, QC, Canada
(Phaneuf, Bergeron, Gosselin, Shelley, Masson, Garg, Carr) London Health
Sciences Centre, London, ON, Canada
(Bone, Chow, Moga) University of Ottawa Heart Institute, Ottawa, ON,
Canada
(Hessian, Kourzenkova, Beanlands, Walter, Davies, Bainey, Hogg) University
of Alberta, Edmonton, AB, Canada
(Welsh, Cheema) St. Michael's Hospital, Toronto, ON, Canada
(Bagai, Wald, Goodman, Kushniriuk, Graham, Hussain, Peterson, Bello, Chow,
Abramson, Cheema, Syed) Dixie Medical Group, Mississauga, ON, Canada
(Vakani, Hussain, Kushniriuk, Cha, Otis) Dr James Cha, Oshawa, ON, Canada
(Otis, Howarth, Seib) University of Calgary, Calgary, AB, Canada
(Rivest, Sandonato, Wong, Chow) Vancouver General Hospital, Vancouver, BC,
Canada
(Starovoytov, Uchida, Meadows, Uxa, Asif) University Health Network,
Toronto, ON, Canada
(Tavares, Galiwango, Bozek) Scarborough Cardiology Research, Scarborough,
ON, Canada
(Kassam, Shier, Mukherjee, Larmand, Ricci, Janmohamed, Hart, Lam, Marucci)
West Lincoln Memorial Hospital East Grimsby, ON, Canada
(Tai, Mehta, Brons) Hamilton General Hospital, Hamilton, ON, Canada
(Beck, Wong, Etherington, Arumairajah, Udell, Aprile) Women's College
Hospital, Toronto, ON, Canada
(Karlsson, Webber, Genereux, Mercure) Centre Integre Universitaire de
Sante et de Services Sociaux du Montreal, Montreal, QC, Canada
(Hameed, Aedy) Saint Catharines General Hospital, Catharines, ON, Canada
(Daba, Farquharson) Northwest GTA Cardiovascular and Heart Rhythm Program,
Vaughan, ON, Canada
(Siddiqui, Carvalho, Lopes, Hueb, Takiuti) Heart Institute (InCor),
University of Sao Paulo, Sao Paulo, Brazil
(Rezende, Silva, Hueb, Smanio, Caetano) Instituto Dante Pazzanese de
Cardiologia, Sao Paulo, Brazil
(de Quadros) Instituto de Cardiologia de Porto Alegre, Porto Alegre,
Brazil
(Kalil, Deiro, da Costa Vieira, Muller, Grossmann, de Moraes, de Oliveira,
Ascoli, Bridi, Poletti, Savaris, Vitola) Quanta Diagnostico & Terapia,
Curitiba, Brazil
(Cerci, Zier, Farias, Veiga, Fernandes, Marin-Neto) Hospital das Clinicas
da Faculdade de Medicina de Ribeirao Preto, Universidade de Sao Paulo,
Ribeirao Preto, Brazil
(Schmidt, de Oliveira Lima Filho, da Cunha, Oliveira, Chierice, Polanczyk,
Rucatti) Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
(Furtado, Igansi, Smidt, Haeffner, Carvalho, Almeida) Unifesp - Hospital
Sao Paulo, Sao Paulo, Brazil
(Pucci, de Souza, Lyra, Alves, Almeida) Fundacao Bahiana de Cardilogia,
Salvador, Brazil
(dos Santos, Dracoulakis, Oliveira) Hospital da Bahia, Salvador, Brazil
(Lima, Figueiredo, Azevedo) Hospital Lifecenter, Belo Horizonte, Brazil
(Caramori, Santos) Hospital Sao Lucas da Pontificia Universidade Catolica
do Rio Grande do Sol, Porto Alegre, Brazil
(Germann, Gomes, Homem, Magedanz, Tumelero, Laimer) Hospital Sao Vicente
de Paulo Fundo, Brazil
(Tognon, Dall'Orto) Hospital Maternidade e Pronto Socorro Santa Lucia,
Pocos de Caldas, Brazil
(Mesquita, Santos) Hospital Pro-Cardiaco Botafogo, Brazil
(Colafranseschi, Oliveira, Carvalho, Palazzo, Sousa, da Silva) Hospital
TotalCor, Sao Paulo, Brazil
(de Barros e Silva, Okada, de Padua Silva Baptista, Batista, Rodrigues,
Rabaca, de Resende, Saraiva, Trama) Hospital Celso Pierro, Sao Paulo,
Brazil
(Silva, de Souza Ormundo, Vicente, Costantini, Pinheiro, Pracon) Hospital
Cardiologico Costantini, Curitiba, Brazil
(Komar, Ruzyllo, Szwed, Demkow, Pracon) Coronary and Structural Heart
Diseases Department, Institute of Cardiology, Warsaw, Poland
(Kepka, Teresinska, Walesiak, Kryczka, Malinowska, Henzel, Solecki,
Kaczmarska, Mazurek, Maksym) Medical University of Warsaw, Warszawa,
Poland
(Wojtera, Fojt, Szczerba, Drozdz) Cardiology Clinic, Medical University in
Lodz, Lodz, Poland
(Czarniak, Frach, Szymczyk, Niedzwiecka, Sobczak, Ciurus, Jakubowski,
Misztal-Teodorczyk, Teodorczyk, Swiderek, Fratczak, Wojtala, Szkopiak,
Lebioda, Wlodarczyk, Plachcinska, Kusmierek, Miller, Marciniak,
Wojtczak-Soska, Luczak, Tarchalski, Cichocka-Radwan, Szwed, Karwowski)
National Institute of Cardiology, Warsaw, Warsaw, Poland
(Szulczyk, Witkowski) Department of Interventional Cardiology & Angiology,
Institute of Cardiology, Warsaw, Poland
(Kukula, Celinska-Spodar, Zalewska, Gajos) Department of Coronary Disease,
John Paul II Hospital, Jagiellonian University Medical College, Krakow,
Poland
(Bury, Pruszczyk, Labyk) Department of Internal Medicine and Cardiology,
Infant Jesus Teaching Hospital, Medical University of Warsaw, Warszawa,
Poland
(Roik, Szramowska, Zdonczyk, Loboz-Grudzien, Jaroch) T.Marciniak Hospital,
Wroclaw, Poland
(Sokalski, Brzezinska, Lesiak) Szpital Kliniczny Przemienienia Panskiego,
Poznan, Poland
(Lanocha, Reczuch, Kolodziej) Military Hospital, Medical University,
Wroclaw, Poland
(Kalarus) Medical University of Silesia, School of Medicine, The Division
of Dentistry, Department of Cardiology, Congenital Heart Diseases and
Electrotherapy, Silesian Center for Heart Diseases, Zabrze, Poland
(Swiatkowski, Szulik, Musial, Marcinkiewicz-Siemion) University Hospital
in Bialystok, Bialystok, Poland
(Bockeria, Bockeria) National Medical Research Center for Cardiovascuar
Surgery, Moscow, Russian Federation
(Petrosyan, Kudzoeva, Trifonova, Aripova, Chernyavskiy, Naryshkin)
E.Meshalkin National Medical Research Center, The Ministry of Health of
the Russian Federation, Novosibirsk, Russian Federation
(Kretov, Kuleshova, Grazhdankin, Malaev, Bershtein) North-Western State
Medical University, Saint Petersburg, Russian Federation
(Sayganov, Subbotina, Kuzmina-Krutetskaya, Gumerova, Zbyshevskaya,
Katamadze, Demchenko, Nikolaeva) Federal Almazov North-West Medical
Research Centre, Saint Petersburg, Russian Federation
(Kozlov, Kozulin, Lubinskaya, Lopez-Sendon, Castro, Lopez-Sendon,
Fernandez-Figares) Hospital La Paz. IdiPaz, Madrid, Spain
(Castro, Salicio, Guzman, Galeote, Valbuena, Peteiro) Complexo
Hospitalario Universitario A Coruna (CHUAC) Sergas, Department of
Cardiology, INIBIC A Coruna. CIBER-CV., Universidad de A Coruna, A Coruna,
Spain
(Martinez-Ruiz, Perez-Fernandez, Blanco-Calvo, Cuenca-Castillo,
Alonso-Alvarez, Flores-Rios, Garcia-Gonzalez, Prada-Delgado,
Barge-Caballero, Juanatey, Amigo) Hospital Clinico Universitario de
Santiago, Santiago de Compostela, Spain
(Bayarri, Nunez, Sanchez, Alvarez, Gil, Monzonis, Sionis, Martinez)
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
(Perales, Padro, Penaranda, Picart, Iglesias, Marimon, Llado, Costa, Miro,
Igual) Hospital Universitario y Politecnico La Fe, Valencia, Spain
(Diez, Calvillo, Ortuno) HUVA, Hospital Clinico Universitario Virgen De La
Arrixaca, Murcia, Spain
(Chavarri, Giner, Montolliu, Aniorte, Bermudez, Caravaca, De La Morena,
Blancas, Canavate) Hospital De Bellvitge, Barcelona, Spain
(Guerrero, Riera, Luena, Luena) Hospital Universitario Miguel Servet,
Zaragoza, Spain
(Lasala, Fernandez-Aviles, Lorenzo) Hospital General Universitario
Gregorio Maranon, Madrid, Spain
(Sobrino, Vazquez, Jiang, Chen, Dong) Guangdong General Hospital,
Guangzhou, China
(He, Xia, Yang, Zhong, Wu, Tian) Chinese Academy of Medical Sciences,
Fuwai Hospital, Beijing, China
(Li) First Affiliated Hospital of Xinjiang Medical University, Urumqi,
China
(Ma, Li, Yang, Ma, Yu, Zhao, Ji, Li) Tangshan Gongren Hospital, Tangshan,
China
(Zhang, Zhao, Zhu, Yang, Chen) Beijing Chao-yang Hospital, Capital Medical
University, Beijing, China
(Chi, Wang, Zhang, Lin, Jing) TEDA International Cardiovascular Hospital,
Tianjing, China
(Liu, Zeng, Zhou) Tongji Medical College, Wuhan, China
(Xu, Li, Li, Xiong, Fu, Gao) The First Affiliated Hospital of Zhengzhou
University, Zhengzhou, China
(Jiang, Leng, Wang, Yuan, Zhang, Yang, Bai) Shanxi Cardiovascular
Hospital, Taiyuan, China
(Li, Qi, Wang, Wang, Yang, Yue, Zhang, Wang, Dong) Qingdao Fuwai Hospital,
Qingdao, China
(Mao, Zhang, Cheng, Li) Shanxi Provincial People's Hospital, Xian, China
(Yao, Zhong, Zhou, Zhao, Huang) The Second Affiliated Hospital of
Zhengzhou University, Zhengzhou, China
(Zhou, Fang, Su) Liangxiang Hospital, Beijing, Fangshan District, Beijing,
China
(Zeng, Kunwu) Wuhan Union Hospital, Tongji Medical College, Huazhong
Science and Tech University, Wuhan, China
(Peng, Su, Su, Wang) Wuhan Asia Heart Hospital, Wuhan, China
(Zhao, Li, Geng) Affiliated Hospital of Jining Medical University, Jining,
China
(Wang, Nie, Fan) Beijing Anzhen Hospital, Beijing, China
(Feng, Wang, Yan, Zhang, Yu, Chi) Affiliated Zhongshan Hospital of Dalian
University, Dalian, China
(Liu, Wang, Chen) The Second Affiliated Hospital Zhejiang University
School of Medicine, Hangzhou, China
(Jiang, Li, Wang, Han) Peking Union Medical College Hospital, Beijing,
China
(Xu, Zhang, Liu, Liu, Chen, Hu, Maggioni, Perna, Pietrucci) Cardiology and
CCU - Ospedali Riuniti Ancona, Ancona, Italy
(Marini, Gabrielli, Provasoli, Di Donato) Ospedale di Circolo e Fondazione
Macchi, Varese, Italy
(Verna, Monti) Humanitas Research Hospital, Rozzano (MI), Rozzano, Italy
(Nardi, Di Chiara, Pezzetta) Azienda Servizi Sanitaria n.3 Alto
Friuli-Collinare-Medio Friuli, Tolmezzo, Italy
(Mortara, Casali) Policlinico di Monza, Monza, MB, Monza, Italy
(Galvani, Attanasio) Ospedale "G.B. Morgagni - L. Pierantoni" Forli (AUSL
della Romagna), Forli, Italy
(Ottani, Sicuro, Leone) Ospedale Regionale Umberto Parini, Aosta, Italy
(Pisano, Bare, Calabro, Fimiani) AORN Dei Colli "V. Monaldi" UOC
Cardiologia Universita della Campania "L.Vanvitelli", Napoli, Italy
(Formisano, Tarantini, Barioli) University of Padua- Cardiology Clinic,
Padua, Italy
(Cucchini, Ramani, Andres, Racca, Rolfo) Azienda Ospedaliera S. Croce e
Carle, Cuneo, Italy
(Goletto, Briguori, De Micco) Clinica Mediterranea, Naples, Italy
(Amati, Di Marco) UO Cardiologia Ospedale SS Cosma e Damiano, Pescia,
Italy
(Vergoni, Tricoli, Russo, Villella) IRCCS "Casa Sollievo della
Sofferenza", San Giovanni Rotondo, Italy
(Fanelli, White, Alsweiler, Poh) National University Heart Center
Singapore, Singapore, Singapore
(Chai, Lau, Loh, Tay, Teoh, Tan, Teo, Sia, Ong, Leong, Wong, Loh, Kofidis,
Chan, Chan, Foo, Yan) Tan Tock Seng Hospital, Singapore, Singapore
(Kong, Er, Jafary, Chua, Ismail) National Heart Centre Singapore,
Singapore, Singapore
(Kyaw, Yip, Doerr) Praxisklinik Herz und Gefaesse, Dresden, Germany
(Stumpf, Grahl, Matschke, Guenther, Simonis, Bonin, Kadalie, Sechtem,
Wenzelburger) Robert-Bosch-Krankenhaus, Stuttgart, Germany
(Ong, Gruensfelder, Schulze) University Hospital Jena, Jena, Germany
(Goebel, Lenk, Nickenig, Sinning) Universitatsklinikum Bonn, Bonn, Germany
(Weber, Werner, Lang, Huber, Schuchlenz, Steinmaurer) LKH Graz West, Graz,
Austria
(Weikl, Lang, Winter) Medical University of Vienna, Department of
Cardiology, Vienna, Austria
(Andric) Wilhelminen Hospital Vienna, Vienna, Austria
(Huber, Maximilian, Gabriele, Claudia, Bernhard, Florian, Keltai, Vertes,
Sebo) Eszszk- Szent Istvan Hospital, Budapest, Hungary
(Davidovits, Matics, Varga, Agoston) University of Szeged, Szeged, Hungary
(Fontos, Dekany) George Gottsegen National Institute of Cardiology,
Budapest, Hungary
(Merkely, Bartykowszki) Heart and Vascular Center, Semmelweis University,
Budapest, Hungary
(Maurovich-Horvat, Kerecsen, Jakal) Military Hospital, Budapest, Budapest,
Hungary
(Hinic, Djokic) University Hospital Center Bezanijska Kosa, Belgrade,
Serbia
(Zdravkovic, Mudrenovic, Crnokrak, Beleslin) Faculty of Medicine,
University of Belgrade, Cardiology Clinic, Clinical Center of Serbia,
Belgrade, Serbia
(Boskovic, Djordjevic-Dikic, Petrovic, Giga, Dobric, Stepanovic, Markovic,
Mladenovic, Cemerlic-Adjic, Velicki) Institute of Cardiovascular Diseases
Vojvodina, Sremska Kamenica, Serbia
(Pupic, Davidovic, Simovic) Clinical Center Kragujevac, Kragujevac, Serbia
(Vucic, Dekleva, Martinovic) University Clinical Hospital Zvezdara,
Belgrade, Serbia
(Stevanovic, Stankovic, Dobric) Clinical Center of Serbia, Belgrade,
Serbia
(Apostolovic, Martinovic) Clinic for Cardiovascular Diseases, Clinical
Center Nis, Nis, Serbia
(Stanojevic, Escobedo, de Jesus-Perez, Juarez) Instituto Mexicano del
Seguro Social, Mexico
(Baleon-Espinosa, Campos-Santaolalla, Duran-Cortes, Flores-Palacios,
Garcia-Rincon, Jimenez-Santos, Penafiel, Ortega-Ramirez,
Valdespino-Estrada, Rosas, Brassetti, Selvanayagam) Instituto Nacional de
Cardiologia "Ignacio Chavez", Mexico City, Mexico
(Anaya, Garcia, Juarez, Rovalo, Rodriguez, Selvanayagam, Rankin, Murphy,
Lee) Flinders Medical Centre, Adelaide, Australia
(Joseph, Thomas, Thambar, Chaplin) John Hunter Hospital, New Lambton
Heights, Australia
(Boer, Beltrame, Stansborough) The Queen Elizabeth Hospital, Woodville
South, Australia
(Black, Hillis, Bonner) Royal Perth Hospital, Perth, Australia
(Ireland, Venn-Edmonds, Steg, Abergel, Juliard, Thobois) C.H. Louis
Pasteur, Chartres, France
(Thuaire, Tachot, Dutoiu, Laure, Vassaliere, Steg, Abergel) Bichat
Hospital, Paris, France
(Juliard, Fuentes, Slama, Eliahou) Antoine-Beclere Hospital, Clamart,
France
(Mahmoud, Dubourg) Ambroise Pare Hospital, Boulogne, France
(Michaud, Nicollet, Hadjih) Centre Hospitalier Sud Francilien,
Corbeil-Essonnes, France
(Goube, Brito, Barone-Rochette, Barone-Rochette) Grenoble University
Hospital, Grenoble, France
(Furber, Cornet) Centre Hospitalier Universitaire d'Angers, Angers, France
(Biere, Rautureau, Juceviciene) Vilnius University Hospital Santariskes
Clinic, Vilnius, Lithuania
(Kalibataite-Rutkauskiene, Keinaite, Laucevicius, Laukyte, Celutkiene,
Mikolaitiene, Smigelskaite, Tamasauskiene, Urboniene, Kedhi) Isala
Klinieken, Zwolle, Netherlands
(Timmer, Bouwhuis, Hermanides, Nijmeijer, Kaplan, Riezebos) Cardio
Research Hartcentrum OLVG, Amsterdam, Netherlands
(Samadi, Schoep, van Dongen, Janzen, Niehe, Suryapranata, Ahoud)
Radboudumc, Nijmegen, Netherlands
(van Vugt, Ramos) Hospital de Santa Marta, Lisbon, Portugal
(Cacela, Santana, Fiarresga, Sousa, Marques, Patricio, Selas, Bernanrdes,
Silva, Rio, Freixo, Carvalho, Ferreira, Silva, Rodrigues, Modas, Portugal,
Fragata, Pinto, Cabrita) Santa Maria University Hospital, Cardiology
Department, CHLN, Lisbon, Portugal
(Menezes, Rocha, Lopes, Figueiras, Almeida, Coelho, Silva, Capinha, Nobre,
Caetano, Francisco, Silva, Ferreira) Centro Hospitalar de Vila Nova de
Gaia/Espinho, EPE, Vila Nova de Gaia, Portugal
(Lopes, Diaz, Guzman, Tinnirello) Instituto Medico DAMIC, Cordoba,
Argentina
(Figal, Mungo) Fundacion Favaloro, Ciudad Autonoma de Buenos Aires,
Argentina
(Mendiz, Cortes, Favaloro, Alvarez, Garcia) Hospital Italiano Regional del
Sur Bahia Blanca, Bahia Blanca, Argentina
(Courtis, Godoy) Clinica Romagosa and Clinica De La Familia, Cordoba,
Spain
(Zeballos, Schiavi, Actis) Clinica Del Prado, Cordoba, Spain
(Rubio) Clinica Privada Velez Sarsfield, Cordoba, Spain
(Scaro, Devlin, Low) Waikato Hospital, Hamilton, New Zealand
(Fisher, Scales, Abercrombie, Stewart) Auckland City Hospital, Auckland,
New Zealand
(Howell, Patten, Benatar, Kedev, Held) University Clinic of Cardiology,
Skopje, North Macedonia
(Mitevska, Kostovska, Pejkov, Held) Uppsala University, Uppsala, Sweden
(Eggers, Frostfelt, Bjorklund, Johnston, Andreasson, Olsowka, Essermark,
Akerblom, Soveri, Aspberg, Persson, Sharir) Karolinska Institutet,
Danderyd Hospital, Stockholm, Sweden
(Beyar, Nikolsky, Sharir, Harel) Assuta Medical Centers, Tel-Aviv, Israel
(Elian, Kerner, Bentzvi) Rambam Medical Center, Haifa, Israel
(Massalha, Helmer, Kohsaka, Fukuda, Ueda) Keio University, Shinjuku-ku,
Japan
(Kohsaka, Fujita, Yasuda, Furukawa) National Cerebral and Cardiovascular
Center, Kanae Hirase, RN, -4, Suita-shi, Japan
(Nagai, Otsuka, Nishimura, Nakano) Saitama Medical University, Hidaka,
Japan
(Van de Werf, Goetschalckx, Robesyn) University Hospital Leuven, Leuven,
Belgium
(Van de Werf, Claes, Hung, Yang) Mackay Memorial Hospital, Taipei City,
Taiwan (Republic of China)
(Yun, Hou, Kuo, Yeh, Hung, Li, Chien, Tsai, Liu, Yu, Lin, Lan, Yen, Tsai,
Sung, Ntsekhe) Groote Schuur Hospital, University of Cape Town, Cape Town,
South Africa
(Pandie, Philander, Viljoen, Mtana, De Andrade, Maggioni, Moccetti,
Anesini) Cardiocentro, Lugano, Switzerland
(Rossi, Maspoli, Mombelli, Abdelhamid, Talaat) Cairo University, Cairo,
Egypt
(Adel, Kamal, Mahrous, El Kaffas, El Fishawy, Pop) Emergency County
Hospital Baia Mare, Bucharest, Romania
(Claudia, Popescu) Emergency Institute of Cardiovascular Diseases ''Prof.
Dr. C. C. Iliescu'', Bucharest, Romania
(Ginghina, Rosca, Deleanu, Beladan, Iliescu, Al-Mallah, Zahrani) King
AbdulAziz Cardiac Center, Central Province, Saudi Arabia
(Aljzeeri, Najm, Alghamdi, Ramos) Instituto Neuro Cardiovascular De Las
Americas, Mirafloes, Peru
(Davila, Kuanprasert) Maharaj Nakorn Chiang Mai Hospital, Chiang Mai,
Thailand
(Prommintikul, Nawarawong, Khwakhong, Woragidpoonpol, Chaiyasri, Tepsuwan,
Mekara, Taksaudom, Kulthawong, Rimsukcharoenchai, Amaritakomol,
Euathrongchit, Wannasopha, Yamwong, Panpunuan) Ramathibodi Hospital,
Bangkok, Thailand
(Sritara, Aramcharoen, Meemuk, White, Alsweiler, Khairuddin, Mokhtar)
Institut Jantung Negara, Kuala Lumpur, Malaysia
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: ISCHEMIA (International Study of Comparative Health
Effectiveness With Medical and Invasive Approaches) did not find an
overall reduction in cardiovascular events with an initial invasive versus
conservative management strategy in chronic coronary disease; however,
there were conservative strategy participants who underwent invasive
coronary angiography early postrandomization (within 6 months).
Identifying factors associated with angiography in conservative strategy
participants will inform clinical decision-making in patients with chronic
coronary disease. <br/>METHOD(S): Factors independently associated with
angiography performed within 6 months of randomization were identified
using Fine and Gray proportional subdistribution hazard models, including
demographics, region of randomization, medical history, risk factor
control, symptoms, ischemia severity, coronary anatomy based on
protocol-mandated coronary computed tomography angiography, and medication
use. <br/>RESULT(S): Among 2591 conservative strategy participants,
angiography within 6 months of randomization occurred in 8.7% (4.7% for a
suspected primary end point event, 1.6% for persistent symptoms, and 2.6%
due to protocol nonadherence) and was associated with the following
baseline characteristics: enrollment in Europe versus Asia (hazard ratio
[HR], 1.81 [95% CI, 1.14-2.86]), daily and weekly versus no angina (HR,
5.97 [95% CI, 2.78-12.86] and 2.63 [95% CI, 1.51-4.58], respectively),
poor to fair versus good to excellent health status (HR, 2.02 [95% CI,
1.23-3.32]) assessed with Seattle Angina Questionnaire, and new/more
frequent angina prerandomization (HR, 1.80 [95% CI, 1.34-2.40]). Baseline
low-density lipoprotein cholesterol <70 mg/dL was associated with a lower
risk of angiography (HR, 0.65 [95% CI, 0.46-0.91) but not baseline
ischemia severity nor the presence of multivessel or proximal left
anterior descending artery stenosis >70% on coronary computed tomography
angiography. <br/>CONCLUSION(S): Among ISCHEMIA participants randomized to
the conservative strategy, angiography within 6 months of randomization
was performed in <10% of patients. It was associated with frequent or
increasing baseline angina and poor quality of life but not with objective
markers of disease severity. Well-controlled baseline low-density
lipoprotein cholesterol was associated with a reduced likelihood of
angiography. These findings point to the importance of a comprehensive
assessment of symptoms and a review of guideline-directed medical therapy
goals when deciding the initial treatment strategy for chronic coronary
disease. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique
identifier: NCT01471522. GRAPHIC ABSTRACT: A graphic abstract is available
for this article.<br/>Copyright &#xa9; 2024 American Heart Association,
Inc.

<38>
Accession Number
2043269975
Title
Ultrasound-guided pecto-intercostal fascial plane block for chronic
postoperative pain after cardiac surgery via median sternotomy: study
protocol for a randomized controlled trial.
Source
Trials. 27(1) (no pagination), 2026. Article Number: 143. Date of
Publication: 01 Dec 2026.
Author
Yao J.; Shen F.; Chen Y.; Cai W.; Lu X.; Wang Z.; Li B.; Xie J.; Tan X.;
Sun J.
Institution
(Yao, Shen, Chen, Cai, Lu, Wang, Li, Xie, Tan, Sun) Department of
Anesthesiology & Key Laboratory of Clinical Science and Research, Zhongda
Hospital, Southeast University, No. 87 Dingjiaqiao, Jiangsu Province,
Nanjing City, China
Publisher
BioMed Central Ltd
Abstract
Background: Median sternotomy As per our journal style, article titles
should not include capitalised letters unless these are proper
nouns/acronyms. We have therefore used the article title
"Ultrasound-guided Pecto-intercostal fascial plane block for chronic
postoperative pain after cardiac surgery via median sternotomy: study
protocol for a randomized controlled trial" as opposed to
"Ultrasound-guided Pecto-intercostal Fascial Plane Block for Chronic
Postoperative Pain after Cardiac Surgery via Median Sternotomy: study
protocol for a randomized controlled trial". Please check if this is
correct.remains the preferred incision technique for cardiac surgery.
Consequently, postoperative pain is a prevalent complication following
such procedures, potentially leading to delayed recovery and a diminished
quality of life for patients. The parasternal intercostal fascial plane
block (PIFPB) is a superficial regional anesthetic technique targeting the
interfacial plane between the pectoralis major and internal intercostal
muscles. Currently, no randomized controlled trials have evaluated the
impact of PIFPB on chronic pain following cardiac surgery via median
sternotomy. To address this knowledge gap, we conducted a prospective,
randomized, double-blind, placebo-controlled trial specifically designed
to evaluate the effect of preoperative PIFPB on chronic pain incidence in
patients undergoing median sternotomy for cardiac surgery. <br/>Method(s):
This study protocol has been approved by the Ethics Review Committee of
Zhongda Hospital, Southeast University. We plan to enroll 304 adult
patients scheduled for cardiac surgery via median sternotomy under general
anesthesia. Participants will be randomly allocated to one of two groups:
the PIFPB group will receive a single injection of 40 ml of 0.375%
ropivacaine hydrochloride administered, while the control group will
receive an equivalent volume of 0.9% saline placebo. The primary outcome
is the incidence of chronic pain at 3 months post-surgery.
<br/>Discussion(s): This is a novel randomized controlled trial designed
to evaluate the impact of preoperative ultrasound-guided single
parasternal intercostal fascia plane block on the incidence of chronic
post-surgical pain (CPSP) in patients undergoing cardiac surgery via
median sternotomy. The study will comprehensively describe the severity of
postoperative acute and chronic pain, as well as associated clinical
outcomes, in this patient population. Our findings may provide a
foundation for optimizing analgesic strategies in cardiac surgery via
median thoracotomy, further elucidate the role of regional anesthesia in
postoperative chronic pain development, and ultimately improve
postoperative quality of life for these patients. Trial registration: The
trial protocol was prospectively registered with the China Clinical Trial
Registry on June 16, 2025, (trial identifier:
ChiCTR2500104378).<br/>Copyright &#xa9; The Author(s) 2026.

<39>
Accession Number
2043246449
Title
Optimization of Venoarterial Extracorporeal Membrane Oxygenation Weaning:
Hemodynamic Targets, Predictive Indicators, and Future Algorithm.
Source
Reviews in Cardiovascular Medicine. 27(1) (no pagination), 2026. Article
Number: 43438. Date of Publication: 2026.
Author
Li Y.; Zhu Y.; Wu Z.
Institution
(Li, Wu) The Fourth School of Clinical Medicine, Zhejiang Chinese Medical
University, Hangzhou First People's Hospital, Zhejiang, Hangzhou, China
(Zhu) Department of Critical Care, Affiliated Hangzhou First People's
Hospital, School of Medicine, Westlake University, Zhejiang, Hangzhou,
China
Publisher
IMR Press Limited
Abstract
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a
life-saving intervention for patients with refractory cardiogenic shock or
cardiac arrest. However, weaning from VA-ECMO remains challenging and
significantly affects patient prognosis. This systematic review examined
the multifactorial determinants underlying successful VA-ECMO weaning,
highlighting the critical need for integrated evaluation of biventricular
function, hemodynamic stability, and microcirculatory perfusion. Key
predictive parameters encompass both macrocirculatory indices (including
left and right ventricular performance) and metabolic parameters, all of
which col-lectively inform evidence-based weaning decisions. Advanced
imaging techniques and multidimensional assessment tools have emerged as
promising strategies for optimizing weaning protocols. Pharmacological
strategies and precise volume optimization are important for improving
weaning success. However, gaps in standardized weaning protocols and
bridging therapy algorithms highlight critical, unmet needs. Thus, future
efforts should focus on developing dynamic predictive models that
incorporate real-time hemodynamic data and on the clinical implementation
of microcirculatory assessment technologies.<br/>Copyright &#xa9; 2026 The
Author(s).

<40>
Accession Number
2043320425
Title
Complete Revascularization in Older Patients With Myocardial Infarction
With or Without Complex Nonculprit Lesions.
Source
Circulation: Cardiovascular Interventions. 18(11) (pp e015902), 2025. Date
of Publication: 01 Nov 2025.
Author
Sarti A.; Erriquez A.; Dal Passo B.; Casella G.; Guiducci V.; Moreno R.;
Escaned J.; Marchini F.; Cocco M.; Verardi F.M.; Clo S.; Caglioni S.;
Farina J.; Barbato E.; Vadala G.; Cavazza C.; Capecchi A.; Gallo F.; Campo
G.; Biscaglia S.
Institution
(Sarti, Erriquez, Dal Passo, Marchini, Cocco, Verardi, Clo, Caglioni,
Farina, Campo, Biscaglia) Cardiology Unit, Azienda Ospedaliero
Universitaria di Ferrara, Italy
(Casella, Capecchi) Cardiology Unit, Ospedale Maggiore, Bologna, Italy
(Guiducci) Cardiology Unit, Azienda USL-IRCCS Reggio Emilia, S. Maria
Nuova Hospital, Italy
(Moreno) Centro de Investigacion Biomedica en Red en Enfermedades
Cardiovasculares (CIBERCV), Madrid, Spain
(Moreno) Instituto de Investigacion Hospital La Paz (IDIPAZ), University
Hospital La Paz, Madrid, Spain
(Escaned) Hospital Clinico San Carlos IDISCC, Complutense University of
Madrid, Calle del Prof Martin Lagos, Spain
(Barbato) Department of Clinical and Molecular Medicine, Sapienza
University of Rome, Italy
(Vadala) Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone,
Palermo, Italy
(Cavazza) Cardiovascular Department, Infermi Hospital, Rimini, Italy
(Gallo) Cardiology Unit, Department of Cardio-Thoracic and Vascular
Sciences, Ospedale dell'Angelo, Venezia Mestre, Italy
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: - The FIRE trial (Functional Assessment in Elderly Myocardial
Infarction Patients With Multivessel Disease) showed the superiority of
complete revascularization in older patients with myocardial infarction
(MI) and multivessel disease. Whether this result applies equally to
patients at higher risk of ischemic events due to nonculprit lesion
complexity is unclear. <br/>METHOD(S): - Overall, 1445 patients were
randomized to culprit-only or complete revascularization. In this
prespecified analysis, patients were divided into those with or without at
least 1 complex nonculprit lesion. A nonculprit lesion was defined as
complex if it met any of the following criteria: angiographic heavy
calcification, ostial lesion, true bifurcation lesion involving
side-branches >2.5 mm, in-stent restenosis, or long-lesions (estimated
stent length >28 mm). The primary outcome comprised a composite of death,
MI, stroke, or revascularization at 3 years. The key secondary outcome was
a composite of cardiovascular death or MI. The safety outcome included a
composite of contrast-associated acute kidney injury, stroke, and Bleeding
Academic Research Consortium 3 to 5. <br/>RESULT(S): - Overall, 641
patients (44%, complex subgroup) had at least 1 complex nonculprit lesion,
whereas 804 patients (56%, noncomplex subgroup) did not. After adjustment
for potential confounders, patients in the complex subgroup were at higher
risk of 3-year cardiovascular death or MI (hazard risk [HR], 1.32 [95% CI,
1.01-1.74]), MI (HR, 2.33 [95% CI, 1.44-3.78]) and ischemia-driven
coronary revascularization (HR, 2.28 [95% CI, 1.46-3.56]). Complete
revascularization reduced the primary outcome in both the complex (HR,
0.75 [95% CI, 0.56-0.99]) and noncomplex (HR, 0.71 [95% CI, 0.53-0.95])
subgroups, with no significant interaction (P for interaction=0.625).
Similarly, no evidence of heterogeneity related to nonculprit lesion
complexity was observed for either key secondary or safety end points.
<br/>CONCLUSION(S): - In older patients with MI and multivessel disease,
physiology-guided complete revascularization reduced ischemic events,
regardless of the complexity of nonculprit lesions. REGISTRATION: - URL:
https://www.clinicaltrials.gov; Unique identifier:
NCT03772743.<br/>Copyright &#xa9; 2025 American Heart Association, Inc.

<41>
[Use Link to view the full text]
Accession Number
2043523533
Title
Electroconvulsive Therapy in Solid Organ Transplant Recipients.
Source
Journal of ECT. Publish Ahead of Print (no pagination), 2026. Date of
Publication: 2026.
Author
Yu C.-H.; Su P.-L.; Hung Y.-T.; Chen Y.-J.; Chen C.Y.; Lee C.-P.; Lin C.
Institution
(Yu, Chen, Chen, Lin) Department of Psychiatry, Keelung Chang Gung
Memorial Hospital, Keelung, Taiwan (Republic of China)
(Su, Lee) Department of Psychiatry, Linkou Chang Gung Memorial Hospital,
Taoyuan, Taiwan (Republic of China)
(Hung) Department of Anesthesiology, Linkou Chang Gung Memorial Hospital,
Taoyuan, Taiwan (Republic of China)
(Chen, Lee, Lin) College of Medicine, Chang Gung University, Taoyuan
County, Taiwan (Republic of China)
(Lin) Community Medicine Research Center, Chang Gung Memorial Hospital,
Keelung, Taiwan (Republic of China)
Publisher
Lippincott Williams and Wilkins
Abstract
Psychotic disorders in solid organ transplant recipients present complex
diagnostic and therapeutic challenges. Tacrolimus, a commonly used
immunosuppressant, is associated with neuropsychiatric side effects, yet
discontinuation carries the risk of graft rejection. We describe a
65-year-old heart transplant recipient who developed very late-onset
schizophrenia-like psychosis 54 weeks after transplantation while on
tacrolimus. His psychotic symptoms-including hallucinations and
delusions-were refractory to multiple antipsychotics, including clozapine,
but responded substantially to bifrontal electroconvulsive therapy (ECT),
with preservation of cardiac graft function. A relapse later improved with
a second course of ECT. To contextualize this case, we reviewed 18
published reports of ECT in solid organ transplant recipients. Across
depression, psychosis, catatonia, and suicidality, ECT consistently
demonstrated effectiveness with mostly mild and manageable side effects,
while rare severe complications were attributable to underlying medical
conditions rather than ECT itself. These findings suggest that ECT is an
effective consideration for refractory psychiatric syndromes in transplant
recipients, even when immunosuppressant regimens cannot be altered.
Careful pre-ECT evaluation, interdisciplinary collaboration, and vigilant
peri-procedural monitoring remain essential for optimizing outcomes in
this medically fragile population.<br/>Copyright &#xa9; 2026

<42>
[Use Link to view the full text]
Accession Number
2043312838
Title
Contemporary evidence for intravascular imaging-guided percutaneous
coronary intervention: a systematic review and meta-analysis of 21812
patients from 18 randomized controlled trials.
Source
Journal of Cardiovascular Medicine. 27(1) (pp 28-38), 2026. Date of
Publication: 01 Jan 2026.
Author
Almouaalamy N.N.; Aljadani H.H.; Ahmed R.A.; Arzoun O.A.; Malki A.T.;
Wazzan M.A.; Alweal B.S.; Alsarraj R.A.; AlRahimi J.S.
Institution
(AlRahimi) Department of Cardiology, King Faisal Cardiac Center, King
Abdulaziz Medical City, Ministry of National Guard Health Affairs, Italy
(Almouaalamy, Aljadani, Arzoun, Malki, Wazzan, Alweal, Alsarraj) King
Abdullah International Medical Research Centre, Italy
(Ahmed) College of Medicine, King Saud bin Abdulaziz University for Health
Sciences, Saudi Arabia
(Ahmed) General Medicine Practice Program, Batterjee Medical College for
Science and Technology, Jeddah, Saudi Arabia
Publisher
Lippincott Williams and Wilkins
Abstract
Background - Coronary artery disease (CAD) remains a leading cause of
global morbidity and mortality. This meta-analysis aimed to compare
clinical outcomes of intravascular imaging-guided percutaneous coronary
intervention (PCI) versus angiography - or fractional flow reserve
(FFR)-guided PCI. Methods - We systematically searched six databases
through October 2024 for randomized controlled trials (RCTs) comparing
intravascular ultrasound (IVUS)-guided or optical coherence tomography
(OCT)-guided PCI versus angiography-guided or FFR-guided PCI. Primary
outcomes included target-vessel failure (TVF), myocardial infarction (MI),
mortality, stent thrombosis, repeat revascularization, and
contrast-induced nephropathy. Risk ratios (RRs) were pooled using a
random-effects model. Results - Eighteen RCTs including 21812 patients
(11215 imaging-guided; 10597 angiography/FFR-guided) were analyzed.
Imaging-guided PCI was associated with lower risks of TVF (RR: 0.66; 95%
CI: 0.58-0.74), cardiac death (RR: 0.56; 95% CI: 0.44-0.71), all-cause
mortality (RR: 0.77; 95% CI: 0.64-0.93), MI (RR: 0.84; 95% CI: 0.71-0.99),
and definite stent thrombosis (RR: 0.41; 95% CI: 0.27-0.62). No
significant differences were observed in repeat revascularization (RR:
0.99; 95% CI: 0.75-1.31) or contrast-induced nephropathy (RR: 1.08; 95%
CI: 0.64-1.83). Although relative risk reductions were significant,
absolute event rates were low, resulting in modest absolute risk
reductions. Conclusion - Intravascular imaging-guided PCI significantly
improves key clinical outcomes, including mortality, MI, and stent
thrombosis, compared with angiography-guided or FFR-guided PCI. These
findings support broader implementation of IVUS and OCT in contemporary
PCI, especially in patients with complex coronary disease.<br/>Copyright
&#xa9; 2026 Italian Federation of Cardiology - I.F.C. All rights reserved.

<43>
Accession Number
2043263104
Title
Programmed intermittent paravertebral bolus infusion reduces the incidence
of postoperative chronic pain three months after thoracoscopic surgery in
elderly patients: an observational study.
Source
Perioperative Medicine. 15(1) (no pagination), 2026. Article Number: 17.
Date of Publication: 01 Dec 2026.
Author
Wang L.; Sun Y.; Gao G.; Liu T.; Chen B.; Kang W.; Liu W.
Institution
(Wang, Sun, Gao, Liu, Chen, Liu) Department of Anesthesiology, Beijing
Chest Hospital, Capital Medical University, Beijing Tuberculosis and
Thoracic Tumor Research Institution, No. 97 Ma Chang, Tongzhou District,
Beijing, China
(Kang) Department for disease prevention and control, Beijing Chest
Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic
Tumor Research Institution, Beijing, China
Publisher
BioMed Central Ltd
Abstract
Objectives: The aim of this study was to examine the association between
programmed intermittent paravertebral bolus infusion and chronic
post-surgical pain (CPSP), including pain components and pain
distribution, following video-assisted thoracoscopic surgery (VATS) in
elderly patients. <br/>Design(s): An Observational Study. <br/>Setting(s):
This study was conducted at Beijing Chest Hospital, Capital Medical
University. <br/>Participant(s): Elderly patients undergoing VATS.
<br/>Intervention(s): Patients in the paravertebral group received
programmed intermittent paravertebral bolus infusion with local
anesthetics postoperatively, while patients in the intravenous group
received patient controlled intravenous analgesia (PCIA) with sufentanil.
<br/>Measurements and Main Results: CPSP in our study was defined
according to the International Classification of Diseases (ICD-11). Among
the 242 elderly patients, Group P had a lower incidence of persistent pain
at 3 months postoperatively compared to Group I (3.5% versus 13.4%, p =
0.014). Group P also had a lower incidence of anterior chest pain than
Group I at both 1 month (p = 0.005) and 3 months (p = 0.020)
postoperatively. Additionally, at 3 months, Group P had a lower incidence
of neuropathic pain than the Group I (p = 0.021). Furthermore, Group P
demonstrated reduced rates of pricking pain and hyperesthesia compared to
Group I (p = 0.024; p = 0.042). <br/>Conclusion(s): Programmed
intermittent paravertebral bolus infusion reduces the incidence of
postoperative chronic pain in patients undergoing thoracic surgery. It
also decreases the occurrence of neuropathic pain three months after
surgery.<br/>Copyright &#xa9; The Author(s) 2026.

<44>
Accession Number
2041584408
Title
Propofol-supplemented cardioplegia: A multicenter blinded 3-group
randomized trial (Propofol for Myocardial Protection Trial 2: ProMPT2).
Source
Journal of Thoracic and Cardiovascular Surgery. 171(3) (pp 649-658), 2026.
Date of Publication: 01 Mar 2026.
Author
Angelini G.D.; Smartt H.J.M.; Joyce K.; Heys R.; Maishman R.; Culliford
L.; de Jesus S.E.; Fitzgerald B.M.; Suleiman M.S.; Punjabi P.; Nwaejike
N.; Downes R.; Gibbison B.; Rogers C.A.
Institution
(Angelini, Suleiman, Gibbison) Bristol Heart Institute, University of
Bristol, Bristol, United Kingdom
(Smartt, Joyce, Heys, Maishman, Culliford, de Jesus, Fitzgerald, Rogers)
Bristol Trials Centre, Bristol Medical School, University of Bristol,
Bristol, United Kingdom
(Punjabi) National Heart and Lung Institute, Imperial College London,
London, United Kingdom
(Punjabi) Hammersmith Hospital, Imperial College Healthcare NHS Trust,
London, United Kingdom
(Nwaejike) Wythenshawe Hospital, Manchester University NHS Foundation
Trust, Manchester, United Kingdom
(Downes) Perfusion Department, University Hospitals Bristol and Weston NHS
Foundation Trust, Bristol, United Kingdom
Publisher
Elsevier Inc.
Abstract
Objective: Coronary artery bypass grafting using cardiopulmonary bypass
and cardioplegic arrest is an effective treatment for coronary artery
disease. Research suggests supplementing the cardioplegia solution with
propofol may be cardioprotective. Our aim was to compare the safety and
efficacy of supplementing the cardioplegia solution with different doses
of propofol in adults undergoing first-time surgery. <br/>Method(s): A
blinded, parallel group randomized controlled trial conducted in 3
hospitals in the United Kingdom compared a cardioplegia solution
supplemented with high-dose propofol (concentration 12 mug/mL), low-dose
propofol (concentration 6 mug/mL), and placebo (saline). Primary outcome
was cardiac troponin T measurements over the first 48 hours after surgery.
Participants were followed for 12 months. <br/>Result(s): In total, 240
participants, median age 66 years, 90% male, were randomly allocated: 78
to high-dose propofol, 80 to low-dose propofol, and 82 to placebo. In
total, 239 participants were included in the primary analysis. Geometric
mean cardiac troponin release at 48 hours (95% confidence interval) was
145 ng/L (125-168), 162 ng/L (138-191), and 150 ng/L (125-180) in the
high-dose propofol, low-dose propofol, and placebo groups, respectively
(adjusted geometric mean ratio 1.06; 95% confidence interval, 0.97-1.15; P
= .20, for pairwise comparisons between high- and low-dose propofol and
between low-dose propofol and placebo). A total of 96 adverse events that
prolonged the hospital stay or were life-threatening were reported (33,
26, and 37 in the high-dose propofol, low-dose propofol, and placebo
groups, respectively), as well as 4 deaths (1 low-dose propofol group, 3
placebo group). <br/>Conclusion(s): Propofol supplementation of warm blood
cardioplegia at both the lower and higher concentrations is safe, but
there is no evidence to suggest either dose is
cardioprotective.<br/>Copyright &#xa9; 2025 The Authors

<45>
Accession Number
2042410907
Title
Low- Versus High-capacity Impella for CS After AMI: A Systematic Review
and Pooled Data Analysis.
Source
Catheterization and Cardiovascular Interventions. 107(4) (pp 1246-1253),
2026. Date of Publication: 01 Mar 2026.
Author
Haberman D.; Verma B.; Abusnina W.; Galo J.; Chitturi K.R.; Lupu L.;
Cellamare M.; Zhang C.; Chaturvedi A.; Khalil M.S.; Sawant V.; Ben-Dor I.;
Balsara K.; Hashim H.; Waksman R.
Institution
(Haberman, Verma, Abusnina, Galo, Chitturi, Lupu, Cellamare, Zhang,
Chaturvedi, Sawant, Ben-Dor, Hashim, Waksman) Section of Interventional
Cardiology, MedStar Washington Hospital Center, WA, United States
(Khalil) Department of Internal Medicine, MedStar Washington Hospital
Center, WA, United States
(Balsara) Department of Cardiothoracic Surgery, MedStar Washington
Hospital Center, WA, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Acute myocardial infarction with cardiogenic shock (AMI-CS)
remains highly fatal despite advances in revascularization and intensive
care. The Impella, a micro-axial pump, offers a potential balance of
hemodynamic support and minimal invasiveness. <br/>Aim(s): This study
examined its optimal configuration of low- versus high-capacity for
effectiveness and safety. <br/>Method(s): We conducted a systematic review
and pooled analysis of 20 studies, including three randomized controlled
trials (RCTs) and 3896 AMI-CS patients, comparing high-capacity (Impella
5.0/5.5) versus low-capacity (Impella 2.5/CP) devices. The primary outcome
was in-hospital or 30-day mortality, with secondary endpoints including
mortality on support, ischemic and bleeding complications, acute kidney
injury requiring renal replacement therapy (RRT), and hemolysis.
<br/>Result(s): Among the included patients, 2022 received low-capacity
Impella, while 771 received high-capacity Impella. The high-capacity
Impella group demonstrated lower in-hospital or 30-day mortality (41.4%
vs. 45.4%; p = 0.045) and significantly reduced mortality on support
(17.9% vs. 46.1%; p < 0.001). Major bleeding events (1.4% vs. 6.0%; p <
0.001) and ischemic complications (3.9% vs. 5.9%; p = 0.05) were also
lower in the high-capacity group. However, transfusion requirements were
higher in the high-capacity Impella cohort (52.1% vs. 23.1%; p < 0.001).
There were no significant differences in stroke rates (4.3% vs. 4.3%; p =
1.0) or AKI requiring RRT (36.5% vs. 34.9%; p = 0.69). <br/>Conclusion(s):
High-capacity Impella, when compared to low-capacity devices, may provide
superior survival benefits and lower complication rates, particularly in
reducing ischemic and major bleeding events, in AMI-CS patients. These
findings support the early consideration of high-capacity Impella in
treatment algorithms.<br/>Copyright &#xa9; 2026 Wiley Periodicals LLC.

<46>
Accession Number
2042393331
Title
Conscious Sedation Versus General Anesthesia for Percutaneous Left Atrial
Appendage Occlusion: A Systematic Review and Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. 107(4) (pp 1189-1197),
2026. Date of Publication: 01 Mar 2026.
Author
Jain H.; Passey S.; Jain J.; Soni K.; Pushparaji B.; Ahmed R.; Jhand A.S.;
Khera S.; Goldsweig A.M.
Institution
(Jain) Department of Internal Medicine, All India Institute of Medical
Sciences, Jodhpur, India
(Passey) Department of Internal Medicine, University of Connecticut Health
Center, Farmington, CT, United States
(Jain) Department of Internal Medicine, Allegheny General Hospital, Drexel
University School of Medicine, Pittsburgh, PA, United States
(Soni) Department of Internal Medicine, SUNY Upstate Medical University,
Syracuse, NY, United States
(Pushparaji) Division of Cardiovascular Medicine, Department of Medicine,
MetroHealth Medical Center, Cleveland, Ohio, United States
(Ahmed) Department of Cardiology, National Heart and Lung Institute,
Imperial College London, London, United Kingdom
(Jhand) Department of Cardiovascular Medicine, Heart and Vascular
Institute, Geisinger Medical Center, Danville, PA, United States
(Khera) The Zena and Michael A. Wiener Cardiovascular Institute, Icahn
School of Medicine at Mount Sinai, New York City, NY, United States
(Goldsweig) Department of Cardiovascular Medicine, Baystate Medical Center
and Division of Cardiovascular Medicine, University of
Massachusetts-Baystate, Springfield, Massachusetts, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Percutaneous left atrial appendage occlusion (LAAO) has
traditionally been performed under general anesthesia (GA) to maintain
patient comfort and immobility, especially in the setting of
transesophageal echocardiography. <br/>Aim(s): We aimed to compare the
safety and efficacy of conscious sedation (CS) compared to GA for LAAO,
concurrent with the expansion of intracardiac echocardiography guidance.
<br/>Method(s): A systematic search of the PubMed, Embase, Cochrane
Central, and Scopus databases was conducted through December 2024 for
studies comparing CS versus GA for LAAO. For outcomes of procedural
complications and characteristics, random-effects models were used to
calculate the mean difference (MD), odds ratio (OR), and risk ratio (RR)
effect estimates with 95% confidence intervals (CIs). <br/>Result(s): Four
studies with 1540 patients undergoing LAAO were included (CS = 678, GA =
862). CS was associated with significantly shorter total procedural time
[MD -11.95 min; 95% CI -19.52 to -2.78; p = 0.009] and a lower volume of
contrast media [MD -31.90 mL; 95% CI -56.72 to -7.08; p = 0.01]. No
significant differences were noted for total fluoroscopy time, total
length of hospital stay, device success, all-cause mortality,
cardiovascular mortality, stroke, device-related thrombus, and peri-device
leak > 5 mm. <br/>Conclusion(s): Percutaneous LAAO using CS allows for
faster procedures and lower contrast media volumes compared to GA without
compromising device success and clinical outcomes. Randomized studies with
longer follow-ups are necessary to understand the long-term outcomes of
percutaneous LAAO using CS.<br/>Copyright &#xa9; 2026 Wiley Periodicals
LLC.

<47>
Accession Number
2043244503
Title
McGrath videolaryngoscopy versus direct laryngoscopy for rapid sequence
intubation: A multicenter randomized clinical trial.
Source
Journal of Clinical Anesthesia. 110 (no pagination), 2026. Article Number:
112148. Date of Publication: 01 Mar 2026.
Author
Tire Y.; Sertcakacilar G.; Ekrami E.; Yazar M.A.; Oner A.A.; Orhan M.K.;
Ugural A.; Patterson W.M.; Zengin S.N.G.; Kilinc M.; Boyacioglu S.;
Cekmecelioglu B.T.; Kozanhan B.; Kurt R.
Institution
(Tire, Yazar, Oner, Orhan, Ugural, Kozanhan) Department of Anesthesiology
and Reanimation, Konya City Hospital, University of Health Sciences,
Konya, Turkey
(Sertcakacilar, Zengin, Kilinc, Boyacioglu) Department of Anesthesiology,
Bakirkoy Dr. Sadi Konuk Research and Education Hospital, Istanbul, Turkey
(Ekrami, Cekmecelioglu) Division of Multi-Specialty Anesthesiology,
Department of Anesthesiology & Pain Management, Cleveland Clinic,
Cleveland, OH, United States
(Patterson) Department of Quantitative Health Sciences, Cleveland Clinic,
Cleveland, OH, United States
(Kurt) Department of Anesthesia and Intensive Care Medicine,
Ordensklinikum Linz, Linz, Austria
(Tire, Sertcakacilar, Ekrami, Yazar, Cekmecelioglu, Kurt) OUTCOMES
RESEARCH Consortium, Houston, TX, United States
(Kurt) Karl Landsteiner Institute for perioperative medicine, Linz,
Austria
Publisher
Elsevier Inc.
Abstract
Background Videolaryngoscopy has been proposed to improve glottic
visualization and intubation success during rapid sequence intubation
(RSI). Evidence on the effectiveness of the McGrath videolaryngoscope in
this setting remains limited. Methods In this multicenter,
patient-blinded, randomized trial, 400 adults undergoing elective
non-cardiac surgery requiring RSI were assigned to McGrath
videolaryngoscopy (VL, n = 193) or direct laryngoscopy (DL, n = 201). The
primary outcome was glottic visualization using the modified
Cormack-Lehane (CL) classification. Secondary outcomes included
first-attempt intubation success, number of attempts, intubation failure,
and time to intubation. Safety outcomes included airway injury and
postoperative complications. Results Glottic visualization did not differ
significantly between groups (Grade 1 view: VL 46.6% vs DL 42.3%; OR 1.24,
95% CI 0.85-1.79; P = 0.26). First-attempt success was similar (VL 86.5%
vs DL 87.6%; P = 0.76). Intubation failure occurred in 1.6% of VL and 0.5%
of DL cases ( P = 0.29). Median time to intubation was longer with VL (35
s vs 30 s; HR 1.27; 95% CI 1.04-1.56; P = 0.016). Rates of airway trauma
and postoperative complications were low and comparable. Conclusions In
adult patients undergoing RSI, McGrath videolaryngoscopy did not improve
glottic visualization or first-pass intubation success compared with
direct laryngoscopy, and was associated with a modestly longer intubation
time. Adverse events were infrequent and similar. These findings suggest
that the routine use of McGrath for RSI may not confer clinical benefit in
low-risk elective surgical populations.<br/>Copyright &#xa9; 2026 Elsevier
Inc.

<48>
Accession Number
2042004264
Title
Effects of Bariatric Surgery on the Pharmacokinetics of Cardiovascular
Drugs: A Systematic Review and Meta-Analysis.
Source
Obesity Surgery. 36(2) (pp 804-817), 2026. Date of Publication: 01 Feb
2026.
Author
Zarinfar Y.; Babaei S.; Majidzadeh M.J.; Masoumipoya Z.; Gheymati A.;
Eslami V.
Institution
(Zarinfar) School of Medicine, Shahid Beheshti University of Medical
Science, Tehran, Iran, Islamic Republic of
(Babaei, Majidzadeh, Masoumipoya) Department of Medicine, Arak University
of Medical Science, Arak, Iran, Islamic Republic of
(Gheymati) Tehran University of Medical Sciences, School of Pharmacy,
Tehran, Iran, Islamic Republic of
(Eslami) Shahid Beheshti University of Medical Sciences, Cardiovascular
Research Center, Shahid Modarres Hospital, Tehran, Iran, Islamic Republic
of
Publisher
Springer
Abstract
Background: Obesity is a global health issue associated with increased
cardiovascular risk. Bariatric surgery is the most effective long-term
treatment for severe obesity, but it may alter drug pharmacokinetics,
impacting the management of cardiovascular medications. <br/>Method(s): A
systematic review and meta-analysis were conducted according to PRISMA
2020 guidelines. Four databases (PubMed, Embase, Web of Science, Scopus)
were searched for studies examining the pharmacokinetics of cardiovascular
drugs before and after bariatric surgery. After duplicate removal, titles
and abstracts were screened, followed by a full-text review with inclusion
criteria of adult patients undergoing bariatric surgery who reported
pharmacokinetic or pharmacodynamic outcomes for cardiovascular drugs.
Meta-analysis was performed using a random-effects model in R (meta and
metafor packages), with effect sizes and heterogeneity (I2) reported.
<br/>Result(s): From 817 identified records, 24 studies met the inclusion
criteria, revealing that bariatric surgery has varied and drug-specific
effects on the pharmacokinetics of cardiovascular medications. Among
anticoagulants, systemic exposure of all of them did not significantly
change. Rivaroxaban and apixaban pharmacokinetics remained largely
unchanged, and warfarin dosing requirements slightly decreased. The impact
of beta-blockers was highly dependent on the specific drug and
formulation; peak concentrations (Cmax) of atenolol increased slightly,
whereas those of immediate-release metoprolol tended to increase, but both
types of carvedilols (S- and R-carvedilol) and controlled-release
metoprolol and propranolol showed a decrease. Regarding statins,
atorvastatin absorption was significantly delayed, as shown by a prolonged
time to peak concentration Tmax (pooled SMD = 0.99, p < 0.05), without a
significant change in Cmax (slightly decreased). Both rosuvastatin and
simvastatin showed transient changes in exposure, which normalized over
time. <br/>Conclusion(s): Bariatric surgery can significantly impact the
pharmacokinetics of cardiovascular drugs, especially atorvastatin and
beta-blockers, highlighting the need for individualized dose adjustments
and therapeutic monitoring. These findings provide essential evidence for
optimizing cardiovascular pharmacotherapy in post-bariatric surgery
patients, supporting the development of tailored dosing
guidelines.<br/>Copyright &#xa9; The Author(s), under exclusive licence to
Springer Science+Business Media, LLC, part of Springer Nature 2025.

<49>
[Use Link to view the full text]
Accession Number
2043519104
Title
Short-term and long-term outcomes in rheumatoid arthritis patients
following percutaneous coronary intervention: A systematic review and
meta-analysis.
Source
Medicine (United States). 104(37) (pp e44458), 2025. Date of Publication:
12 Sep 2025.
Author
Khadka S.; Timilsina B.; Ammembal A.; Chowdhury F.; Suwal K.; Shrestha B.;
Adhikari B.N.; Acharya B.; Baniya R.; Gyawali S.; Shah S.K.; Thapa R.
Institution
(Khadka) Department of Medicine, UPMC Harrisburg, Harrisburg, PA, United
States
(Timilsina) Department of Medicine, Virtua Our lady of Lourdes Hospital,
Camden, NJ, United States
(Ammembal) Department of Medicine, Kasturba Medical College, Manipal,
India
(Chowdhury) Department of Psychiatry, Chittagong Medical College Hospital,
Chattogram, Bangladesh
(Suwal) Department of Orthodontics, Nepal Medical College, Kathmandu,
Nepal
(Shrestha) Institute of Medicine, Tribhuvan University Teaching Hospital,
Kathmandu, Nepal
(Adhikari) Department of Pediatrics, Kanti Children's Hospital,
Maharajgunj, Kathmandu, Nepal
(Acharya) Department of Medicine, Kist Medical College and Teaching
Hospital, Lalitpur, Nepal
(Baniya) Department of Medicine, Nepal Medical College and Teaching
Hospital, Kathmandu, Nepal
(Gyawali) Department of General Surgery, Tribhuvan University Teaching
Hospital, Kathmandu, Nepal
(Shah) Department of Hospital Administration, Chitwan Medical College,
Chitwan, Nepal
(Thapa) Department of Surgery, Nepal Cancer Hospital and Research Center.
Lalitpur, Nepal
Publisher
Lippincott Williams and Wilkins
Abstract
Background: - Rheumatoid arthritis (RA) is associated with an elevated
risk of cardiovascular disease and necessitates repeat revascularization
procedures, including percutaneous coronary intervention (PCI). However,
extensive data on outcomes following PCI in this cohort remain scarce.
This systematic review and meta-analysis sought to evaluate the short- and
long-term cardiovascular outcomes in RA patients following PCI.
<br/>Method(s): - We conducted a search of PubMed, Embase, Google Scholar,
and Cochrane Central for studies published until October 2024 that
compared RA and non-RA cohorts' post-PCI. The primary outcomes encompassed
major adverse cardiovascular events, myocardial infarction, repeat
revascularization, and overall mortality. The pooled odds ratio (OR) with
95% confidence intervals was computed utilizing random-effects models. A
sensitivity analysis was conducted using a leave-one-out meta-analysis.
<br/>Result(s): - Our search identified 9 qualifying studies, encompassing
nearly 1 million patients (174, 229 with RA and 9771, 911 without RA).
Individuals with RA exhibited a markedly elevated risk of short-term
stroke compared to non-RA patients (OR: 0.81, 95% CI: 0.6-1.02). Long-term
follow-up found an elevated risk of myocardial infarction (OR: 1.08, 95%
CI: 1.01-1.16), stroke (OR: 1.09, 95% CI: 1.07-1.11), major adverse
cardiovascular events (OR: 1.12, 95% CI: 0.99-1.24), and repeat
revascularization (OR: 1.09, 95% CI: 1.07-1.11) among patients with RA.
The sensitivity analysis revealed no significant difference, even after
the exclusion of each study. <br/>Conclusion(s): - This comprehensive
meta-analysis revealed that patients with RA have markedly poorer clinical
outcomes post-PCI, particularly in the long term. The results underline
the necessity for tailored peri-procedural approaches and ongoing
monitoring in RA patients.<br/>Copyright &#xa9; 2025

<50>
Accession Number
2043534386
Title
Per-Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for
Cardiovascular Event Prevention-Diuretic Comparison Project.
Source
Journal of the American Heart Association. 15(3) (pp 1-9), 2026. Article
Number: e046142. Date of Publication: 30 Jan 2026.
Author
Anand S.T.; Hau C.; Davenport M.J.; Ishani A.; Cushman W.C.; Glassman
P.A.; Taylor A.A.; Lew R.A.; Ferguson R.E.; Leatherman S.M.
Institution
(Anand, Hau, Davenport, Lew, Ferguson, Leatherman) Cooperative Studies
Program Coordinating Center, VA Boston Healthcare System, Boston, MA,
United States
(Ishani) Minneapolis VA Healthcare System, Minneapolis, MN, United States
(Ishani) Department of Medicine, University of Minnesota, MN, United
States
(Cushman) Medical Service, Memphis VA Medical Center, Memphis, TN, United
States
(Cushman) Department of Preventive Medicine, University of Tennessee
Health Science Center, Memphis, TN, United States
(Glassman) Pharmacy Benefits Management Services, Department of Veterans
Affairs, Washington, DC, United States
(Glassman) VA Greater Los Angeles Healthcare System, Los Angeles, CA,
United States
(Glassman) David Geffen School of Medicine at UCLA, Los Angeles, CA,
United States
(Taylor) Michael E. DeBakey VA Medical Center, Houston, TX, United States
(Taylor) Department of Medicine, Baylor College of Medicine, Houston, TX,
United States
(Lew, Leatherman) Department of Biostatistics, Boston University School of
Public Health, Boston, MA, United States
(Ferguson, Leatherman) Department of MedicineBoston University Chobanian
and Avedisian School of Medicine, Boston, MA, United States
Publisher
American Heart Association Inc.
Abstract
BACKGROUND: The DCP (Diuretic Comparison Project), a pragmatic trial,
evaluated whether chlorthalidone compared with hydrochlorothiazide would
reduce the risk of nonfatal cardiovascular disease or noncancer-related
death. The intent-to-treat analysis found no difference in such comparison
(hazard ratio, 1.04 [95% CI, 0.94-1.16]). The objective of the current
study is to estimate the per-protocol effect of chlorthalidone (12.5/25 mg
daily) compared with hydrochlorothiazide (25/50 mg daily) in preventing
major adverse cardiovascular events among older patients with
hypertension. <br/>METHOD(S): The effect of adhering to treatment
strategies was assessed by censoring at first instance of nonadherence,
defined as a gap (>90-day gap in drug coverage), switch (switching between
study medications), and discontinuation (stop taking
chlorthalidone/hydrochlorothiazide altogether for >90 days before the end
of the study). The primary outcome was a composite of nonfatal myocardial
infarction, stroke, heart failure resulting in hospitalization, urgent
coronary revascularization for unstable angina, and noncancer-related
death. Using inverse probability weighting, we evaluated the per-protocol
effect of chlorthalidone and hydrochlorothiazide using DCP trial data.
<br/>RESULT(S): Nonadherence was found in 5476 (40%) participants; among
8047 (60%) adherents, 3905 (49%) were randomized to chlorthalidone and
4142 (51%) to hydrochlorothiazide. After censoring time when participants
deviated from the assigned treatments, the estimated 5-year risk ratio of
the composite primary outcome of nonfatal cardiovascular disease and
noncancer-related death was 1.36 (95% CI, 0.96-2.12) in chlorthalidone
compared with hydrochlorothiazide. <br/>CONCLUSION(S): The per-protocol
analysis indicated a lower risk with hydrochlorothiazide compared with
chlorthalidone in preventing nonfatal cardiovascular disease and
noncancer-related death; however, this difference was not statistically
significant using dispensation data to identify adherence.<br/>Copyright
&#xa9; 2026 The Author(s).

<51>
Accession Number
2039418881
Title
SEPAR Recommendations on Vaccination for Chronic Respiratory Patients.
Source
Archivos de Bronconeumologia. 62(3) (pp 177-184), 2026. Date of
Publication: 01 Mar 2026.
Author
de Miguel-Diez J.; Torres-Castro R.; Sanz Herrero F.; Menendez Villanueva
R.; Solis Gomez B.; Quiros Fernandez S.; Perez Rojo R.; Mora Cuesta V.M.;
Entrenas Castillo M.; Serrano Fernandez L.; Cabrera Martinez M.M.; Mediano
O.; Garcia-Ortega A.; Garcia Rivero J.L.; de la Rosa-Carrillo D.
Institution
(de Miguel-Diez) Servicio de Neumologia, Hospital General Universitario
Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon
(IiSGM), Facultad de Medicina, Universidad Complutense de Madrid, Madrid,
Spain
(Torres-Castro) Servicio de Neumologia, Hospital Clinic de Barcelona,
Barcelona, Spain
(Torres-Castro) Departamento de Kinesiologia, Universidad de Chile, Chile
(Sanz Herrero) Servicio de Neumologia, Consorcio Hospital General
Universitario de Valencia, Valencia, Spain
(Menendez Villanueva) Instituto de Investigacion Sanitaria La Fe,
Valencia, Spain
(Solis Gomez) Servicio de Pediatria, Seccion Neumologia Pediatrica,
Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
(Quiros Fernandez) Servicio de Neumologia, Hospital Universitario Basurto,
Bilbao, Spain
(Perez Rojo) Servicio de Neumologia Hospital Universitario 12 de Octubre,
Madrid, Instituto de investigacion i+12, Spain
(Mora Cuesta) Unidad de trasplante pulmonar del Servicio de Neumologia,
Hospital Universitario Marques de Valdecilla, Instituto de Investigacion
Valdecilla (IDIVAL), Santander, Spain
(Entrenas Castillo) Servicio de Neumologia, Hospital QuironSalud, Cordoba,
Spain
(Serrano Fernandez) Servicio de Neumologia, Hospital Universitario Cruces,
Instituto de Investigacion Sanitaria Biobizkaia, Bizkaia, Barakaldo, Spain
(Cabrera Martinez) Enfermera de Atencion Primaria, Adeje, Servicio Canario
de la Salud, Gerencia de Santa Cruz de Tenerife, Spain
(Mediano) Unidad de Sueno, Servicio de Neumologia, Hospital Universitario
de Guadalajara, Guadalajara, Spain
(Mediano) Centro de Investigacion Biomedica en Red de Enfermedades
Respiratorias (CIBERES), Madrid, Spain
(Mediano) Departamento de Medicina, Universidad de Alcala, Alcala de
Henares, Madrid, Instituto de Investigacion Sanitaria de Castilla La
Mancha (IDISCAM), Toledo, Spain
(Garcia-Ortega, de la Rosa-Carrillo) Servicio de Neumologia, Hospital
Universitario Doctor Peset, Fundacion para el Fomento de la Investigacion
Sanitaria y Biomedica de la Comunidad Valenciana (FISABIO), Valencia,
Spain
(Garcia Rivero) Servicio de Neumologia, Hospital Universitario Marques de
Valdecilla, Instituto de Investigacion Valdecilla (IDIVAL), Santander,
Spain
(de la Rosa-Carrillo) Servicio de Neumologia, Hospital de la Santa Creu i
Sant Pau, Barcelona, Spain
Publisher
Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR)
Abstract
Vaccines are a fundamental public health tool, particularly effective in
preventing respiratory infections. Their importance is amplified in
patients with chronic respiratory diseases, who are more susceptible to
acute infections such as influenza, pneumococcus, COVID-19, respiratory
syncytial virus (RSV), pertussis, and herpes zoster. These individuals
face an increased risk of severe infections, exacerbations,
hospitalizations, and mortality. Vaccination against influenza,
pneumococcus, and SARS-CoV-2 significantly reduces these adverse outcomes.
Evidence also supports the use of vaccines against RSV, pertussis, and
herpes zoster in this population. In specific cases, tailored immunization
strategies are warranted. The Spanish Society of Pulmonology and Thoracic
Surgery (SEPAR) strongly advocates for systematic vaccination in patients
with chronic respiratory diseases. This document provides clear and
up-to-date recommendations based on the available evidence to support
clinical practice and standardize vaccination strategies. These
recommendations aim to reduce complications, improve quality of life, and
enhance public health outcomes in this vulnerable
population.<br/>Copyright &#xa9; 2025 SEPAR

<52>
Accession Number
2043593438
Title
From scalpel to robot: evolution and outlook of oncologic robotic surgery
in Colombia.
Source
Journal of Robotic Surgery. 20(1) (no pagination), 2026. Article Number:
303. Date of Publication: 01 Dec 2026.
Author
Gonzalez C.V.J.; Hanssen A.; Dominguez Alvarado G.A.; Rodriguez M.L.L.;
Pertuz M.F.P.
Institution
(Gonzalez) Chief Operating Rooms at Clinica de Marly and Robotic Surgeon,
Bogota, Colombia
(Hanssen) Chief of the Surgical Deparment at Clinica Iberoamericana at
Barranquilla, Barranquilla, Colombia
(Hanssen) Universidad Libre, Barranquilla, Colombia
(Dominguez Alvarado, Rodriguez, Pertuz) Autonomous University of
Bucaramanga, Bucaramanga, Colombia
(Gonzalez) National University of Colombia, Bogota, Colombia
Publisher
Springer Nature
Abstract
Introduction: Robotic surgery has transformed the management of oncologic
pathologies by offering minimally invasive approaches with improved
precision and outcomes. In Colombia, despite its progressive adoption, the
scientific literature remains scarce, limiting comprehensive evaluation of
its national impact. <br/>Objective(s): To analyze the evolution, current
status, and future perspectives of robotic surgery in oncology within
Colombia, emphasizing its clinical benefits, technological milestones,
limitations, and integration with artificial intelligence. <br/>Method(s):
A narrative review was conducted using national and international
databases. Articles published between 2014 and 2025 concerning robotic
surgery in Colombia-with a focus on oncologic applications-were included.
<br/>Result(s): he review identified multiple national milestones that
mark Colombia's gradual integration of robotic surgery into oncologic
practice. Notably, the first documented use of the da Vinci
system in 2014 for transoral robotic surgery (TORS) highlighted enhanced
visualization and functional preservation in head and neck cancer. A 2019
multicenter study on robotic thoracic surgery reported zero conversions to
thoracotomy, low complication rates, and a learning curve evidenced by
progressive reductions in operative time. In gastrointestinal oncology, a
2023 study demonstrated successful implementation with acceptable
conversion rates (7.3%) and a 90-day mortality rate of 2.9%. The most
recent data from the National Cancer Institute in 2025 showed that robotic
rectal cancer surgeries achieved complete mesorectal excision in over 80%
of cases, with minimal conversion (4.6%) and acceptable complication
rates. Across all specialties, robotic surgery was associated with
favorable outcomes in terms of surgical precision, oncologic safety, and
recovery time. However, limitations related to cost, equipment
availability, and training infrastructure were recurrent themes. Moreover,
gaps persist in specialties such as gynecologic oncology and
hepatobiliopancreatic surgery, reflecting the uneven adoption of robotics
across disciplines. <br/>Conclusion(s): Despite limited publications,
current Colombian evidence supports the feasibility, safety, and oncologic
effectiveness of robotic surgery. The future of oncologic care in the
country hinges on sustained investment, training, and the incorporation of
AI-driven innovations to democratize access and optimize outcomes in
complex surgical oncology.<br/>Copyright &#xa9; The Author(s), under
exclusive licence to Springer-Verlag London Ltd., part of Springer Nature
2025.

<53>
Accession Number
2043626591
Title
Sex-related differences in long-term mortality after coronary artery
bypass graft surgery: A systematic review and meta-analysis.
Source
International Journal of Cardiology: Cardiovascular Risk and Prevention.
29 (no pagination), 2026. Article Number: 200611. Date of Publication: 01
Jun 2026.
Author
Zhang D.T.; Dhaliwal S.; Tajeshwar N.; Stevens G.A.; Al-Sadawi M.; Tao M.
Institution
(Zhang, Dhaliwal) Division of Cardiology, Department of Medicine, Stony
Brook Medicine, Stony Brook, NY, United States
(Tajeshwar) Division of Cardiology, Department of Medicine, Albany Medical
Center, Albany, NY, United States
(Stevens) University of Massachusetts Chan Medical School, Worcester, MA,
United States
(Al-Sadawi) Cardiovascular Division, Department of Medicine, University of
Minnesota, Minneapolis, MN, United States
(Tao) Heart & Vascular Institute, Hartford Healthcare Medical Group,
Hartford, CT, United States
Publisher
Elsevier B.V.
Abstract
Background This meta-analysis assessed the sex-related differences in
long-term mortality (>=7 years) after coronary artery bypass graft (CABG)
surgery. Methods We searched the databases Ovid MEDLINE, Embase, and Web
of Science for studies reporting sex-specific differences in mortality
following CABG. The search was not restricted to time or publication
status. The primary endpoint of interest was long-term mortality (>=7 year
or longer). Results A total of 1289 studies resulted from literature
search. A total of 19 studies with 277,224 patients (60,858 women and
216,369 men) were included. The mean age was higher in women than men
(66.5 vs. 63.1 years). Our analysis demonstrated that female sex was
associated with higher long-term mortality (>=7 years) following CABG
(odds ratio 1.17; 95% confidence interval 1.05-1.30; p < 0.01).
Conclusions Our results suggest that women had higher long-term mortality
following CABG compared with men. It is the largest study to date of
sex-specific differences in long-term mortality (>=7 years).<br/>Copyright
&#xa9; 2026 The Authors.

<54>
Accession Number
2041792792
Title
Clinical Outcomes of Transcatheter Versus Surgical Management of Coronary
Artery Disease and Aortic Stenosis.
Source
Catheterization and Cardiovascular Interventions. 107(4) (pp 885-887),
2026. Date of Publication: 01 Mar 2026.
Author
Ktenopoulos N.; Apostolos A.; Karampinos K.; Vlachakis P.; Karanasos A.;
Drakopoulou M.; Synetos A.; Latsios G.; Tsioufis K.; Toutouzas K.
Institution
(Ktenopoulos, Apostolos, Karampinos, Vlachakis, Drakopoulou, Synetos,
Latsios, Tsioufis, Toutouzas) First Department of Cardiology, Hippokration
General Hospital of Athens, National and Kapodistrian University of
Athens, Athens, Greece
(Ktenopoulos, Apostolos, Karampinos, Vlachakis, Drakopoulou, Synetos,
Latsios, Tsioufis, Toutouzas) Unit of Structural Heart Diseases, First
Department of Cardiology, Medical School, Hippocration General Hospital of
Athens, National and Kapodistrian University of Athens, Athens, Greece
(Apostolos) Royal Brompton and Harefield Hospitals, Guy's and St Thomas'
NHS Foundation Trust, London, United Kingdom
(Karanasos) Department of Cardiology, Patras University Hospital, Patras,
Greece
Publisher
John Wiley and Sons Inc

<55>
Accession Number
2037707856
Title
Gabapentin as an adjunct to multimodal pain regimens in surgical patients:
The gap placebo-controlled rct and economic evaluation.
Source
Health Technology Assessment. 30(9) (no pagination), 2026. Date of
Publication: 2026.
Author
Baos S.; Smith T.W.; Lui M.; Stokes E.A.; Jiang J.; Pufulete M.; Gibbison
B.; Rogers C.A.
Institution
(Baos, Smith, Lui, Rogers) Bristol Trials Centre, Bristol Medical School,
University of Bristol, Bristol, United Kingdom
(Stokes, Jiang) Health Economics Research Centre, Nuffield Department of
Population Health, University of Oxford, Oxford, United Kingdom
(Pufulete, Gibbison) Bristol Heart Institute, Bristol Medical School,
University of Bristol, Bristol, United Kingdom
(Gibbison) Bristol Royal Infirmary, University Hospitals Bristol and
Weston NHS Foundation Trust, Bristol, United Kingdom
Publisher
NIHR Journals Library
Abstract
Background: Gabapentin is an anticonvulsant medication with a United
Kingdom licence to treat partial seizures and neuropathic pain. It is used
off-licence for acute pain and is frequently added to multimodal analgesic
regimens after surgery to try and reduce opioid use while controlling pain
effectively. <br/>Objective(s): To test the hypothesis that gabapentin
reduces opioid use after major surgery and speeds up recovery, thereby
reducing postoperative hospital length of stay compared to standard
multimodal analgesia. Design, setting and participants: The GAP study was
a multicentre, blinded, randomised controlled trial in patients aged > 18
years, undergoing cardiac, thoracic or abdominal surgery with an expected
postoperative stay of >2 days in seven National Health Service hospitals.
The trial was designed to provide 90% power to detect a difference of
12.5% in the proportion of participants discharged by the median length of
stay in each specialty (500 participants/specialty), which was reduced to
80% (340 participants/specialty) due to COVID-19-related recruitment
challenges. <br/>Intervention(s): Participants were randomised 1: 1
(stratified by surgical specialty) to receive either gabapentin (600 mg
before surgery, 300 mg twice daily for 2 days after surgery) or placebo as
an adjunct to multimodal pain regimens. <br/>Main Outcome Measure(s):
Primary outcome was length of stay. Secondary outcomes included acute and
chronic (Brief Pain Inventory) pain, total opioid use, adverse health
events, health-related quality of life (-EQ-5D-5L, Short Form
questionnaire-12 items physical component score and mental component
score), resource use; cost-effectiveness (outcome measure quality-adjusted
life-years using EQ-5D, five-level version). <br/>Result(s): One thousand
one hundred and ninety-six (cardiac 500, thoracic 346, abdominal 350)
participants consented and were randomised. Baseline characteristics were
well balanced across the two groups: Median age: 68 years; male sex
796/1195 (66.4%). Of the participants, 223/1195 (18.7%) did not receive
all prescribed medication or received medication out of window. There was
no difference in length of stay; median placebo (n = 589): 6.15,
gabapentin (n = 595): 5.94 days [hazard ratio for discharge 1.07, 95%
confidence interval (0.95 to 1.20), p = 0.26]. Opioid use in-hospital
differed between surgical specialties (p = 0.001); in the abdominal
specialty, it was significantly lower in the gabapentin group in 4 of the
first 5 postoperative days [range-26% (-46% to 0%) to-36% (-52% to-14%)],
with no differences in the cardiac specialty nor in the thoracic specialty
beyond day 2. During follow-up, opioid use was similar in the two groups
across all specialties. Acute pain beyond 24 hours was similar (p > 0.15).
The incidence of one or more serious adverse events was placebo: 189/595
(31.7%); gabapentin: 195/599 (32.6%). Health-related quality of life was
similar [EQ-5D: Mean difference-0.014 (-0.036 to 0.009), Short Form
questionnaire-12 items physical component score:-0.87 (-1.71 to-0.04),
Short Form questionnaire-12 items mental component score: At 4 weeks 0.74
(-1.71 to 0.42) and 4 months-0.55 (-1.61 to 0.51)]. Differences in costs
and quality-adjusted life-years favoured placebo, and gabapentin was not
considered cost-effective. <br/>Limitation(s): * GAP study tests the
application of gabapentin to major body cavity surgery, but not major
non-body cavity surgery, or non-major surgery. * The fixed dose and
limited duration of gabapentin may reduce applicability to certain
populations. * Reducing the power to 80% reduced the ability of the trial
to detect a beneficial effect of gabapentin. <br/>Conclusion(s): Among
patients undergoing major cardiac, thoracic and abdominal surgery, adding
gabapentin to multimodal analgesic regimes did not result in a change in
length of stay, opiate use in two specialties, acute pain, or
health-related quality of life, nor was it cost-effective. Future work:
Trials to assess the place of gabapentin in major non-body cavity surgery
(e.g. joint replacement), or nonmajor (e.g. day-care) surgery should be
considered. Trial registration: This trial is registered as Current
Controlled Trials ISRCTN63614165.<br/>Copyright &#xa9; 2026 Baos et al.

<56>
Accession Number
2043574070
Title
Efficacy of SGLT2 Inhibitors on Clinical Outcomes After Transcatheter
Aortic Valve Replacement: A Systematic Review and Meta-Analysis.
Source
Endocrinology, Diabetes and Metabolism. 9(2) (no pagination), 2026.
Article Number: e70184. Date of Publication: 01 Mar 2026.
Author
Daniyal S.M.; Khatoon N.M.; Rasool A.; Gul I.; Tabish S.; Asifa S.; Khalid
A.; Aftab Z.; Burhan M.; Fahim S.L.; Gondal H.T.; Nadir M.A.; Ahmed S.Z.;
Ashraf D.A.; Ahmed S.
Institution
(Daniyal, Khatoon, Rasool, Gul, Tabish, Asifa, Khalid, Aftab, Burhan,
Fahim, Gondal, Ahmed) Department of Medicine, Dow University of Health
Sciences, Karachi, Pakistan
(Nadir) Department of Medicine, Allama Iqbal Medical College, Lahore,
Pakistan
(Ashraf) Department of Medicine, TruGift Health LLC, Wilmington, DE,
United States
(Ahmed) Department of Medicine, Sir Salimullah Medical College, Dhaka,
Bangladesh
Publisher
John Wiley and Sons Inc
Abstract
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve
cardiovascular (CV) outcomes in patients with heart failure (HF) and type
2 diabetes. Their effect in patients undergoing transcatheter aortic valve
replacement (TAVR) for severe aortic stenosis (AS), however, remains
unclear. This study evaluated whether SGLT2 inhibitors reduce all-cause
mortality and HF hospitalisations after TAVR. <br/>Method(s): A systematic
search of PubMed, ScienceDirect, Cochrane (CENTRAL), Scopus and Embase was
performed through April 2025 for studies comparing post-TAVR outcomes
between SGLT2 inhibitor users and non-users. Outcomes of interest included
a composite of all-cause mortality or heart failure (HF) hospitalisation,
along with the individual components of all-cause mortality and HF
hospitalisation. All outcomes were extracted at 1 year. Pooled hazard
ratios (HRs) with 95% confidence intervals (CIs) were calculated using a
random-effects model. Heterogeneity was quantified using I²
statistics. Analyses were conducted in R (version 4.4.2). <br/>Result(s):
Three studies (1 RCT, 2 Observational) comprising 3187 patients met
inclusion criteria. SGLT2 inhibitor use was associated with a reduced risk
of the composite outcome (HR: 0.75; 95% CI: 0.65, 0.86; p < 0.01).
Individually, therapy lowered all-cause mortality (HR: 0.72; 95% CI: 0.53,
0.96; p = 0.03) and HF hospitalisations (HR: 0.74; 95% CI: 0.61, 0.90; p <
0.01). <br/>Conclusion(s): In patients with severe AS undergoing TAVR,
SGLT2 inhibitors were associated with significant reductions in all-cause
mortality and HF hospitalisations. These findings suggest a promising role
for SGLT2 inhibitors in improving post-TAVR outcomes. However, given the
limited data, larger randomised clinical trials are necessary to
consolidate these findings. Trial Registration:
CRD420251132729.<br/>Copyright &#xa9; 2026 The Author(s). Endocrinology,
Diabetes & Metabolism published by John Wiley & Sons Ltd.

<57>
Accession Number
2036376260
Title
Effects of physiotherapy on breathing cycle after thoracic surgery
measured with impedance pneumography in a prospective clinical comparison.
Source
General Thoracic and Cardiovascular Surgery. 74(3) (pp 286-294), 2026.
Date of Publication: 01 Mar 2026.
Author
Lahteenmaki S.; Juutinen M.; Viik J.; Mahrberg H.; Laurikka J.
Institution
(Lahteenmaki, Juutinen, Viik, Laurikka) Faculty of Medicine and Health
Technology, Tampere University, Tampere, Finland
(Mahrberg, Laurikka) Tampere University Heart Hospital, Tampere, Finland
Publisher
Springer
Abstract
Objectives: Impedance pneumography (IP) records respiratory cycle and
provides non-invasive means to evaluate changes after thoracic surgery.
This comparative study evaluated if changes after thoracic surgery can be
modified by two pulmonary rehabilitation modalities. <br/>Method(s): 88
patients undergoing thoracic surgery were randomly allocated to either
positive expiratory pressure (PEP) or inspiratory muscle training (IMT)
physiotherapy group. Physiotherapy was performed and IP recorded
preoperatively and at first and second postoperative days (POD1 and POD2)
during tidal breathing. Full three timepoint IP data were collected from
81 patients (42 in the PEP group, 39 in the IMT group). Average
inspiration and expiration time in seconds (TinspAvg and TexpAvg) and
average breathing frequencies (BrthFreqAvg) were calculated from a 10-min
measurement period and assessed as primary outcomes. Results were also
assessed in blocks of different surgical techniques (thoracotomy or VATS)
and the extent of surgery (pulmonary resection or minor thoracic
operation). <br/>Result(s): TinspAvg and TexpAvg decreased after surgery
but started to increase in the IMT group between POD1 and POD2 with no
significant difference compared to PEP group. Among patients operated with
thoracotomy TexpAvg was slightly but insignificantly higher in the IMT
group at POD2. The ratio between the time of expiration and the time of
inspiration (EI ratio) was significantly higher in the IMT group with
thoracotomy (difference between groups over three timepoints, (p = 0.044)
and at POD1 (p = 0.015)). <br/>Conclusion(s): IMT seemed to enhance
expiration specifically among thoracotomy patients and thus may provide
means for enhancing the recovery after thoracic operations. Clinical trial
registration: NCT02931617/U.S. National Library of Medicine,
ClinicalTrials.gov.<br/>Copyright &#xa9; The Author(s) 2025.

<58>
Accession Number
2034451415
Title
Reexploring the STRESS Trial: Subgroup Postoperative Outcomes Following
Methylprednisolone for Infant Heart Surgery.
Source
Pediatric Cardiology. 47(3) (pp 1026-1034), 2026. Date of Publication: 01
Mar 2026.
Author
Sunthankar S.D.; Hill K.D.; Jacobs J.P.; Baldwin H.S.; Jacobs M.L.; Li
J.S.; Graham E.M.; Resheidat A.M.; Amula V.; Bleiweis M.S.; Wald E.L.;
Eghtesady P.; Scott J.P.; Anderson B.R.; Swartz M.F.; Benscoter A.;
Ravekes W.; Kannankeril P.J.
Institution
(Sunthankar, Baldwin, Kannankeril) Division of Pediatric Cardiology and
Center for Pediatric Precision Medicine, Department of Pediatrics,
Vanderbilt University Medical Center, 2220 Children's Way; Suite 5230,
Nashville, TN, United States
(Hill, Li) Division of Pediatric Cardiology, Duke University Medical
Center, Durham, NC, United States
(Jacobs, Bleiweis) Division of Cardiac Surgery, University of Florida,
Gainesville, FL, United States
(Jacobs) Division of Cardiac Surgery, Johns Hopkins School of Medicine,
Baltimore, MD, United States
(Graham) Division of Pediatric Cardiology, Medical University of South
Carolina, Charleston, SC, United States
(Resheidat) Division of Pediatric Cardiac Anesthesiology, Texas Children's
Hospital, Baylor College of Medicine, Houston, TX, United States
(Amula) Division of Critical Care, Department of Pediatrics, Primary
Children's Hospital, Salt Lake City, UT, United States
(Wald) Division of Pediatric Cardiology, Northwestern University Feinberg
School of Medicine, Chicago, IL, United States
(Eghtesady) Division of Cardiac Surgery, Washington University School of
Medicine, St. Louis, MO, United States
(Scott) Division of Pediatric Cardiology, Medical College of Wisconsin,
Madison, WI, United States
(Anderson) Division of Pediatric Cardiology, Icahn School of Medicine at
Mt Sinai, New York, NY, United States
(Swartz) Division of Cardiac Surgery, University of Rochester, Rochester,
NY, United States
(Benscoter) Division of Pediatric Cardiology, Cincinnati Children's
Hospital, Cincinnati, OH, United States
(Ravekes) Division of Pediatric Cardiology, Johns Hopkins School of
Medicine, Baltimore, MD, United States
Publisher
Springer
Abstract
Objective Assess the association between intraoperative methylprednisolone
and specific postoperative outcomes among subgroups undergoing infant
heart surgery. <br/>Design(s): Subpopulation analyses of The Steroids to
Reduce Systemic Inflammation after Infant Heart Surgery trial, a
double-blind randomized placebo-controlled trial. <br/>Setting(s): 24
congenital heart centers. <br/>Patient(s): Infants (< 1 year old)
undergoing heart surgery with cardiopulmonary bypass. Patients stratified
by Society of Thoracic Surgeons-European Association for Cardio-Thoracic
Surgery Congenital Heart Surgery (STAT) Mortality Category, age,
gestational age, and presence of chromosomal or syndromic diagnosis (CSD).
<br/>Intervention(s): Methylprednisolone (30 mg/kg) versus placebo
administered into cardiopulmonary bypass pump-priming fluid.
<br/>Measurements and Main Results: Outcomes included death, heart
transplantation, mechanical circulatory support, reinterventions, and
hospital length of stay. Ranked composite outcome (death, transplant, or
one of 13 major complications) was compared between placebo and
methylprednisolone for each subgroup using the win ratio.
Methylprednisolone did not reduce odds of death, transplant, or mechanical
circulatory support for any subgroup. Those receiving methylprednisolone
had fewer catheterization or surgical reinterventions after STAT Category
1-3 operations [OR 0.50 (0.29-0.86)]; and fewer reoperations for bleeding
among patients undergoing STAT Category 1-3 operations [OR 0.28
(0.09-0.87)], term infants [OR 0.30 (0.12-0.76)], and those without CSD
[OR 0.22 (0.07-0.68)]. Length of stay was no different between
methylprednisolone versus placebo. Those without chromosomal or syndromic
diagnosis demonstrated a favorable association for methylprednisolone [win
ratio 1.28 (1.01-1.61)] for the composite outcome. <br/>Conclusion(s):
Exploratory subpopulation analyses, although underpowered, suggest that
methylprednisolone is not associated with significant harm and may benefit
certain subpopulations<br/>Copyright &#xa9; The Author(s) 2025.

<59>
Accession Number
2043876458
Title
Early Versus Late Extubation in Pediatric Cardiac Surgery: A Systematic
Review.
Source
World Journal for Pediatric and Congenital Heart Surgery. (no
pagination), 2026. Date of Publication: 2026.
Author
Usmani S.U.R.; Javed H.; Sajid A.; Shahzad M.; Siddiqui A.; Ziaulhaq A.
Institution
(Usmani, Javed, Sajid, Shahzad, Siddiqui, Ziaulhaq) Dow Medical College,
Dow University of Health Sciences, Karachi, Pakistan
Publisher
SAGE Publications Inc.
Abstract
Background: Early extubation (EE) and immediate extubation (IE) after
pediatric cardiac surgery are increasingly being studied with the aim of
lowering hospital and intensive care unit (ICU) stays, and postoperative
complications. The aim of this systematic review was to assess the
outcomes of EE and IE versus traditional delayed extubation (DE) in
children undergoing surgery for congenital heart disease. <br/>Method(s):
This study was conducted in line with the PRISMA guidelines. Articles
comparing outcomes of EE versus DE in pediatric patients undergoing
cardiac surgery between 2014 and 2023 were identified using PubMed, Web of
Science, and CENTRAL. The Newcastle-Ottawa scale was employed to assess
the quality of the included studies. <br/>Result(s): A total of 22 studies
including 8359 patients were included. Two IE studies and 6 EE studies
reported significantly higher reintubation rates as compared with DE,
indicating variability across populations and practices. The ICU length of
stay was notably shorter for the IE group in 7 studies and for the EE
group in 7 studies as compared with DE; 1 IE study reported a longer ICU
stay. Six studies in the IE group and 5 in the EE group showed
significantly shorter hospital stays as compared with DE. Lastly, 2
studies in the EE group showed higher mortality than in the DE group.
<br/>Conclusion(s): In a selective population, EE proved advantageous with
quicker recovery and less use of resources. However, to optimize patient
selection and outcomes, standardization of the procedures and additional
prospective research are needed.<br/>Copyright &#xa9; The Author(s) 2026

<60>
Accession Number
2042093890
Title
The Effects of Tranexamic Acid on Renal Outcomes in Patients Undergoing
Cardiovascular Surgery: A Systematic Review and Meta-Analysis Compliant
With Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(3) (pp 844-854),
2026. Date of Publication: 01 Mar 2026.
Author
Zhang B.; He L.-X.; Yao Y.-T.
Institution
(Zhang) Department of Anesthesiology, Tianjin Union Medical Center,
Tianjin, China
(He) Department of Anesthesiology, Fuwai Yunnan Cardiovascular Hospital,
Kunming, China
(Yao) Department of Anesthesiology, Fuwai Hospital, National Center for
Cardiovascular Diseases, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
(Yao) Center of Outcomes Research, Department of Anesthesiology, Critical
Care and Pain Medicine, University of Texas, Houston, TX, United States
(Yao) Outcomes Research Consortium, Houston, TX, United States
Publisher
W.B. Saunders
Abstract
Objective: To assess how tranexamic acid (TXA) influences the renal
outcomes of cardiovascular surgical patients. <br/>Design(s): Systematic
review and meta-analysis of randomized controlled trials (RCTs).
<br/>Setting(s): The operating room. <br/>Participant(s): Cardiovascular
surgical patients. <br/>Intervention(s): TXA or placebo. <br/>Measurements
and Main Results: The primary outcome of interest included the incidence
of postoperative (PO) acute kidney injury (AKI). Secondary outcomes of
interest included PO-serum creatinine (SCr) levels, PO-blood urea nitrogen
(BUN) levels, intraoperative urine output volumes, the length of stay
(LOS) in the intensive care unit, the LOS in the hospital, and the 30-day
mortality rate postoperatively. A database search yielded 19 RCTs
including 6,450 patients, and 3,280 patients were allocated to the TXA
group and 3,170 to the control group (placebo). Meta-analysis suggested
that TXA did not influence the incidence of PO-AKI (4.2% v 4.3%; odds
ratio [OR], 0.96; 95% CI, 0.75-1.22; p = 0.72). Meta-analysis also
demonstrated that PO-SCr levels (weighted mean difference [WMD], 2.38; 95%
CI, -2.80 to 7.56; p = 0.37) and PO-BUN levels (WMD, -0.16; 95% CI, -0.92
to 0.61; p = 0.69) were comparable between the TXA group and the control
group, and that TXA did not influence PO-SCr and PO-BUN levels.
Additionally, TXA did not influence the incidence of patients' 30-day
mortality postoperatively (1.1% v 1.6%; OR, 0.71; 95% CI, 0.46 to 1.09; p
= 0.12). <br/>Conclusion(s): This current study suggested that TXA
administration did not influence renal outcomes in cardiovascular surgical
patients.<br/>Copyright &#xa9; 2025 Elsevier Inc.

<61>
Accession Number
2043500781
Title
Type B Aortic Dissection Management Strategies: National Survey,
Systematic Review, and Pooled Clinician Perceptions.
Source
Journal of Vascular Diseases. 5(1) (no pagination), 2026. Article Number:
2. Date of Publication: 01 Feb 2026.
Author
Kordzadeh A.; Rhodes K.M.
Institution
(Kordzadeh) Department of Vascular, Endovascular and Renal Access Surgery,
Mid & South Essex NHS Foundation Trust, Basildon Hospital, Nether Mayne,
Essex, Basildon, United Kingdom
(Rhodes) Department of Emergency Medicine, Mid & South Essex NHS
Foundation Trust, Broomfield Hospital, Essex, Chelmsford, United Kingdom
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Type B Aortic Dissection (TBAD) management relies on risk
stratification, yet evidence-based tool adoption remains inconsistent in
National Health Services (NHSs). Bridging the gap between Emergency
Medicine (EM) and Vascular Surgery remains essential for timely diagnosis,
optimal risk stratification, and appropriate intervention to improve
outcomes and reduce mortality. <br/>Method(s): A cross-sectional survey of
EM consultants yielded n = 173 valid responses from n = 33 units across
the UK. Subgroup analyses were conducted using a Chi-square test (p <
0.05) alongside descriptive analysis. A pooled prevalence analysis of the
literature, utilizing a random-effects model at a 95% confidence interval
(CI), served as a benchmark for perception analysis. Agreement was
evaluated using Bland-Altman analysis, incorporating upper, lower, and
overall bias of agreeability. <br/>Result(s): Access to a rapid Computed
Tomography Angiogram (CTA) was 70% (95% CI: 63.3-76.8%, p < 0.001), while
32% had standard operating procedures (SOPs) for TBAD (95% CI:
25.3-39.1%), and 26% were aware of any decision tool (95% CI: 20.6-33.6%).
Labetalol as a first-line antihypertensive was more common amongst least
experience (p < 0.05). TBAD diagnosis increased 1.6-fold with every 4
years of additional experience (p < 0.05). Perception analysis showed
strong agreement for pain (characteristics and location), hypertension,
gender, and age with moderate-to-low agreement for other factors with a
reported bias of 23.58% (-38.20% to 85.36%) (p = 0.02).
<br/>Conclusion(s): The survey suggests a degree of misperception and
inconsistency in recognition of most and least prevalence factors for TBAD
suspicion and management. This outcome advocates targeted strategies to
enhance diagnostic accuracy using tools aligned with NHS resources and
QALY frameworks. Furthermore, upon recognition of the most prevalent
factors, CTA and specialist referral is advocated.<br/>Copyright &#xa9;
2026 by the authors.

<62>
Accession Number
2043240004
Title
Melatonin or ramelteon for the prevention of postoperative delirium in
elderly patients: A systematic review and meta-analysis of randomized
clinical trials.
Source
Journal of Clinical Anesthesia. 110 (no pagination), 2026. Article Number:
112151. Date of Publication: 01 Mar 2026.
Author
Borges J.M.M.F.; Mendes R.G.; Silva R.P.; Pivetta H.B.; Miranda R.L.;
Alles I.; Nascimento T.S.
Institution
(Borges) Department of Medicine, Padre Albino University Center, Sao
Paulo, Catanduva, Brazil
(Mendes, Miranda) Department of Medicine, Federal University of Minas
Gerais, Minas Gerais, Belo Horizonte, Brazil
(Silva) Department of Medicine, Federal University of Maranhao, Maranhao,
Sao Luis, Brazil
(Pivetta) Department of Medicine, University of South of Santa Catarina,
Santa Catarina, Pedra Branca, Brazil
(Alles) Department of Medicine, University of Santa Cruz do Sul, Rio
Grande do Sul, Santa Cruz do Sul, Brazil
(Nascimento) Department of Anesthesia, University of Iowa, Iowa City, IA,
United States
Publisher
Elsevier Inc.
Abstract
Introduction Postoperative delirium (POD)-an acute, fluctuating
disturbance in attention and awareness-is common among elderly surgical
patients and is associated with morbidity, mortality, prolonged
hospitalization, and increased costs. Melatonin has been investigated for
POD prevention, but its perioperative effectiveness and safety remain
uncertain. We conducted a systematic review and meta-analysis to assess
whether perioperative melatonin or ramelteon reduces POD incidence in
elderly surgical patients. Methods This meta-analysis included randomized
controlled trials (RCTs) of elderly patients (>60 years) undergoing
surgery, comparing perioperative melatonin or ramelteon (a melatonin
receptor agonist) with placebo or non-pharmacological interventions for
the prevention and treatment of POD. Secondary outcomes included sedation,
pain, and length of hospital stay. A comprehensive search was conducted
across PubMed, Embase, and Cochrane databases. We utilized a
random-effects model with 95% Confidence Intervals. Pooled-effect sizes
were measured with Mean Difference (MD) or Standardized Mean Difference
(SMD) for continuous outcomes and Risk Ratio (RR) for binary outcomes.
Heterogeneity was assessed with I2 statistics. Statistical analyses were
performed using R v4.5.0. Results Sixteen RCTs (n = 2115; 48.7%
intervention) were included; 12 evaluated melatonin and 4 ramelteon.
Overall, postoperative delirium occurred in 188/895 patients (21.0%)
receiving melatonergic agents and 254/893 patients (28.4%) in control
groups, corresponding to a significant reduction in POD (RR 0.72; 95% CI
0.56-0.92; p = 0.009). In melatonin-only trials, delirium incidence was
163/729 (22.4%) versus 230/732 (31.4%) in controls (RR 0.67; 95% CI
0.52-0.88; p = 0.004), whereas ramelteon showed no significant effect
(25/166 [15.1%] vs 24/161 [14.9%]; RR 0.98; 95% CI 0.47-2.01; p = 0.948).
Trials using melatonin doses >=5 mg demonstrated a greater reduction in
POD, with delirium occurring in 57/314 patients (18.2%) in the melatonin
group compared with 113/308 patients (36.7%) in control groups (RR 0.52;
95% CI 0.40-0.68; p < 0.001). No significant differences were found for
pain, Ramsay Sedation Score, or length of stay. Heterogeneity was moderate
to high for several analyses, and the certainty of evidence for POD was
rated low. Conclusion Perioperative melatonin was associated with reduced
POD in elderly surgical patients, with an apparent dose-response at >=5
mg. Ramelteon did not demonstrate benefit in the available trials. Given
heterogeneity and low certainty, findings-especially dose effects-should
be interpreted cautiously.<br/>Copyright &#xa9; 2026 Elsevier Inc.

<63>
Accession Number
2042800156
Title
Effects of erythropoietin administration on allogeneic blood transfusion
requirements in adults undergoing surgery: a systematic review and
meta-analysis.
Source
Frontiers in Medicine. 12 (no pagination), 2026. Article Number: 1712121.
Date of Publication: 2026.
Author
Chen J.; Liu B.; Cao H.; Tian T.; He J.
Institution
(Chen, Cao, Tian, He) Department of Laboratory Medicine, Chongqing
Jiangjin District Second People's Hospital, Chongqing, China
(Liu) Department of Urology, Chongqing Jiangjin District Second People's
Hospital, Chongqing, China
Publisher
Frontiers Media SA
Abstract
Background: Erythropoietin is commonly integrated into blood management
strategies for surgical patients, yet its administration may lead to
adverse outcomes. This systematic review and meta-analysis assesses the
impact of erythropoietin administration on perioperative transfusion
requirements and adverse events. <br/>Method(s): A comprehensive search
across four databases was conducted from inception to 30 July 2025 to
identify randomized controlled trials involving adult surgical patients.
The methodological quality of the included studies was evaluated using the
Cochrane Risk of Bias Assessment Tool. The outcome measures included
transfusion rates, volume of allogeneic red blood cell transfusions per
patient unit, mortality rates, postoperative infection rates,
transfusion-related complications, venous thromboembolism rates, and
length of hospital stay. Effect sizes were reported using relative risk
(RR) and standardized mean difference (SMD). We used GRADE to assess the
quality of evidence for each outcome. <br/>Result(s): Preoperative
erythropoietin administration reduces transfusion rates (RR = 0.63, 95% CI
= 0.53-0.75, p = 0.000) and mean transfusion volumes (SMD = -0.33, 95% CI
= -0.42 to -0.24, p = 0.000) in surgical patients. No significant impact
was observed on mortality, postoperative infection incidence,
postoperative complications, adverse reactions, venous thromboembolic
events, and length of hospital stay. Subgroup analyses showed significant
reductions in transfusion rates for cardiac surgery, orthopedic surgery,
gastrointestinal surgery, gynecological abdominal surgery, and other types
of surgery. <br/>Conclusion(s): The available evidence supports the
efficacy of preoperative human erythropoietin administration in reducing
transfusion requirements and the average number of transfusion units in
adult surgical patients. No significant differences were observed in
postoperative mortality, complication rate, adverse event rate, venous
thromboembolic events (including deep vein thrombosis and pulmonary
embolism), and hospital stay after preoperative administration of
erythropoietin.<br/>Copyright &#xa9; 2026 Chen, Liu, Cao, Tian and He.

<64>
Accession Number
2043894853
Title
The effectiveness of the AI-based RehabLung mobile rehabilitation system
on cardiopulmonary function and user satisfaction in lung cancer patients
undergoing thoracic surgery: a protocol for a two-arm randomized clinical
trial.
Source
Therapeutic Advances in Respiratory Disease. 20 (no pagination), 2026.
Date of Publication: 01 Jan 2026.
Author
Yang H.-L.; Hung C.-H.; Huang Y.-T.; Cheng H.-C.; Tseng Y.-L.; Su J.-M.;
Tsai K.-L.
Institution
(Yang, Huang, Cheng) Institute of Allied Health Sciences, College of
Medicine, National Cheng Kung University, Tainan City, Taiwan (Republic of
China)
(Tseng) Department of Surgery, National Cheng Kung University Hospital,
College of Medicine, National Cheng Kung University, Tainan City, Taiwan
(Republic of China)
(Su) Department of Information and Learning Technology, National
University of Tainan, Tainan City, Taiwan (Republic of China)
(Tsai) Institute of Allied Health Sciences, College of Medicine, National
Cheng Kung University, Tainan City, Taiwan (Republic of China)
(Tsai) Department of Physical Therapy, College of Medicine, National Cheng
Kung University, Tainan, Taiwan (Republic of China)
Publisher
SAGE Publications Ltd
Abstract
Background: Postoperative recovery following lung cancer surgery can be
challenging owing to various cardiorespiratory complications. Pulmonary
rehabilitation is crucial during both the preoperative and postoperative
periods. However, because of limited resources and accessibility,
innovative approaches are necessary to improve rehabilitation outcomes.
This study aimed to evaluate the effectiveness of the RehabLung App, a
novel AI-based mobile application integrating vision recognition, gamified
feedback, and web-based patient management to support personalized lung
rehabilitation through telerehabilitation and real-time monitoring.
<br/>Objective(s): This study outlines the protocol for a randomized
controlled trial involving patients with lung cancer undergoing thoracic
surgery. <br/>Design(s): Assessor-blinded (single-blind), two-arm,
parallel-group randomized controlled trial (1:1 allocation) conducted at a
single medical center. Methods and analysis: The intervention will include
individualized exercise prescriptions delivered five times per week for 8
weeks via the App, which adapts based on weekly assessments of clinical
parameters and real-time performance data. Primary outcomes include forced
expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), as
well as cardiopulmonary fitness assessed at baseline and at postoperative
weeks 5 and 8. Secondary outcomes include respiratory muscle strength,
diaphragmatic function, and user satisfaction, which are evaluated using a
custom questionnaire informed by technology acceptance models. In
addition, clinically meaningful endpoints will be collected, including
morbidity, mortality, and length of stay. Frailty will be assessed
preoperatively using the Clinical Frailty Scale, and validated
patient-reported outcomes (EORTC QLQ-C30) will be administered to evaluate
quality of life and symptom burden. Ethics: The study has been approved by
the Institutional Review Board at National Cheng Kung University Hospital
(A-ER-111-055). <br/>Discussion(s): We hypothesize that patients using the
RehabLung App may demonstrate improvements in pulmonary function, exercise
tolerance, diaphragmatic function, and rehabilitation adherence compared
with those receiving standard care. The system's real-time feedback and
risk alerts may facilitate timely intervention and could potentially
improve engagement. <br/>Conclusion(s): The implementation of the
RehabLung App in lung cancer surgery care may enhance the effectiveness
and accessibility of pulmonary rehabilitation. This protocol describes an
AI-enhanced telerehabilitation system that may support individualized
recovery strategies and could potentially improve both clinical outcomes
and patient engagement. Trial Registration: Registration Date;2024,09,19;
ClinicalTrials.gov (Identifier: NCT06600503).<br/>Copyright &#xa9; The
Author(s), 2026. This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 License
(https://creativecommons.org/licenses/by-nc/4.0/) which permits
non-commercial use, reproduction and distribution of the work without
further permission provided the original work is attributed as specified
on the SAGE and Open Access pages
(https://us.sagepub.com/en-us/nam/open-access-at-sage).

<65>
Accession Number
2043554402
Title
Effect of Reversal Agents on Postoperative Cognitive Disorders Following
General Anesthesia in the Elderly Population: A Systematic Review and
Meta-Analysis.
Source
Diagnostics. 16(4) (no pagination), 2026. Article Number: 535. Date of
Publication: 01 Feb 2026.
Author
Chan J.Y.; Singh B.S.S.; Nachiappan R.; Mohd Faizal N.F.J.; Song Z.X.;
Mohd F.H.; Abdullah F.H.; Izaham A.
Institution
(Chan, Singh, Nachiappan, Mohd Faizal, Song, Mohd, Abdullah, Izaham)
Department of Anaesthesiology and Intensive Care, Faculty of Medicine,
Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak,
Cheras, Kuala Lumpur, Malaysia
(Abdullah, Izaham) Department of Anaesthesiology and Intensive Care,
Hospital Canselor Tuanku Muhriz, Jalan Yaacob Latif, Bandar Tun Razak,
Cheras, Kuala Lumpur, Malaysia
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Perioperative neurocognitive disorders (PND),
including postoperative delirium and cognitive dysfunction (POCD),
represent significant complications in elderly surgical patients
undergoing general anesthesia. The choice of neuromuscular blockade
reversal agent may influence POCD risk through different mechanisms and
side effects. This systematic review and meta-analysis evaluated the
comparative effect of neostigmine versus sugammadex on POCD incidence in
elderly patients. <br/>Method(s): A systematic search of PubMed, Web of
Science, Scopus, and Google Scholar was conducted from database inception
to September 2025, following PRISMA 2020 guidelines with PROSPERO
registration (CRD420251058187). Randomized controlled trials involving
elderly patients (>=60 years) undergoing general anesthesia with
neuromuscular blockade were included, comparing neostigmine and sugammadex
for reversal. Primary outcomes included POCD incidence, assessed using
validated cognitive tools, including the Mini-Mental State Examination and
Montreal Cognitive Assessment. Meta-analysis was performed using Review
Manager 5.4.1, with results expressed as odds ratios (ORs) and 95%
confidence intervals (CIs). <br/>Result(s): Six randomized controlled
trials involving 795 elderly patients published between 2017 and 2024 met
the inclusion criteria. Studies encompassed non-cardiac surgery,
robotic-assisted radical cystectomy, and pars plana vitrectomy. Pooled
meta-analysis showed neostigmine was associated with a higher risk of POCD
than sugammadex (OR 1.74, 95% CI 1.00-3.02, p = 0.05), with low
heterogeneity (I² = 39%). Secondary outcomes, including
prevention of POCD, management strategies, and related complications, were
inconsistently reported and unavailable across all six RCTs. Subgroup
analysis stratified by neostigmine dosage demonstrated that administration
of a higher dose (>=0.04 mg/kg) was associated with reduced POCD incidence
compared to a lower dose (<0.04 mg/kg) (OR 0.31, 95% CI 0.15-0.63, p =
0.001), with negligible heterogeneity (I² = 0%).
<br/>Conclusion(s): This meta-analysis suggests that sugammadex may be
associated with reduced early postoperative neurocognitive disorders
compared to neostigmine in elderly patients, likely through rapid
neuromuscular blockade reversal that minimizes residual paralysis and
respiratory complications.<br/>Copyright &#xa9; 2026 by the authors.

<66>
Accession Number
2042805451
Title
Anticipating stroke in patients undergoing transcatheter aortic valve
replacement.
Source
Expert Review of Medical Devices. 23(3) (pp 271-283), 2026. Date of
Publication: 2026.
Author
Hajj J.; Zalaquett Z.; Harb S.; Kapadia S.
Institution
(Hajj, Zalaquett, Harb, Kapadia) Department of Cardiovascular Medicine,
Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH,
United States
Publisher
Taylor and Francis Ltd.
Abstract
Introduction: Transcatheter aortic valve replacement (TAVR) has
transformed treatment of severe aortic stenosis, offering a less invasive
alternative to surgery. Despite advances, stroke remains a serious
complication, impacting morbidity, mortality, and long-term cognitive
function, thus the need for effective prevention strategies. Areas
covered: Based on a targeted review of the PubMed literature, this review
addresses mechanisms and risk factors for stroke after TAVR and evaluates
current preventive approaches. Cerebral embolic protection devices
(CEPDs), particularly the Sentinel system, are discussed alongside other
devices. Antithrombotic strategies before, during, and after TAVR are also
reviewed, emphasizing the balance between thromboembolic protection and
bleeding risk in an elderly population. Expert opinion: While some studies
suggest CEPDs may reduce stroke, randomized trials have not confirmed
broad and robust benefit, and high cost limits routine adoption. Future
work should focus on high-risk subgroups, device refinement, and
large-scale trials. For now, individualized antithrombotic therapy and
selective CEPD use remain central to stroke prevention in
TAVR.<br/>Copyright &#xa9; 2026 Informa UK Limited, trading as Taylor &
Francis Group.

<67>
Accession Number
2042172243
Title
Perioperative Multimodal General Anesthesia Focusing on Specific Central
Nervous System Targets Does Not Reduce Postoperative Interleukin-6 and
Neurofilament Light Levels in Patients Undergoing Cardiac Surgeries: A
Randomized Controlled Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. 40(3) (pp 814-824),
2026. Date of Publication: 01 Mar 2026.
Author
Janga S.R.; Li M.H.; Kveraga K.; Ramachandran R.V.; Sharkey A.; Bose R.;
Sehgal S.; Brown E.N.; Subramaniam B.
Institution
(Janga, Li, Kveraga, Sharkey, Bose, Sehgal, Subramaniam) Department of
Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical
Center, Boston, MA, United States
(Ramachandran) Department of Anesthesiology and Pain Medicine, University
of Washington, Seattle, WA, United States
(Brown) Department of Anesthesia, Critical Care and Pain Medicine,
Massachusetts General Hospital, Boston, MA, United States
Publisher
W.B. Saunders
Abstract
Objectives: Interleukin-6 (IL-6) and neurofilament light chain (NFL) are
predictive biomarkers of postoperative delirium in patients undergoing
cardiac surgery. This study was designed to compare postoperative changes
in IL-6 and NFL between patients receiving multimodal general anesthesia
(MMGA) guided by electroencephalography (EEG) versus standard-of-care
anesthesia. <br/>Design(s): Randomized, controlled, investigator-blinded
clinical trial. <br/>Setting(s): A single-center, tertiary referral
hospital. <br/>Participant(s): Adults >=60 years old undergoing coronary
artery bypass grafting, valve, or combined procedures.
<br/>Intervention(s): MMGA included intraoperative EEG monitoring, total
intravenous anesthesia with propofol, remifentanil, ketamine,
dexmedetomidine, pecto-intercostal fascial block, and postoperative
pecto-intercostal fascial block. Controls received inhaled anesthetics and
intravenous fentanyl, without EEG guidance. <br/>Measurements and Main
Results: IL-6 and NFL were measured at baseline, postoperative day 1, and
postoperative day 2. EEG was recorded intraoperatively and
postoperatively. Cognition was assessed using the Confusion Assessment
Method and Montreal Cognitive Assessment up to 6 months. No significant
differences were observed in IL-6 or NFL levels at any time point.
Delirium incidence and long-term cognitive dysfunction were also similar.
However, burst suppression duration was significantly longer in the MMGA
group (mean = 4.83 minutes, standard deviation = 3.47) versus controls
(mean = 1.68 minutes, standard deviation = 2.2), particularly during and
after cardiopulmonary bypass in male patients. <br/>Conclusion(s): MMGA
did not reduce postoperative IL-6 or NFL levels, nor did it improve
neurocognitive outcomes, compared with standard of care. The higher burst
suppression in the MMGA group underscores the need for structured EEG
education among cardiac anesthesiologists. Future studies should explore
other EEG metrics and multimodal strategies for perioperative brain
protection.<br/>Copyright &#xa9; 2025 Elsevier Inc.

<68>
Accession Number
2043577450
Title
Clinical Impact of Diabetes Mellitus After Intravascular Imaging-Guided
PCI vs Coronary Artery Bypass Grafting.
Source
JACC: Cardiovascular Interventions. 19(5) (pp 555-567), 2026. Date of
Publication: 09 Mar 2026.
Author
Gim D.H.; Cho Y.H.; Sung K.; Kim W.S.; Lee S.-J.; Kwon W.; Lee J.-Y.; Lee
S.H.; Shin D.; Lee S.Y.; Kim S.M.; Yun K.H.; Cho J.Y.; Kim C.J.; Ahn
H.-S.; Nam C.-W.; Yoon H.-J.; Park Y.H.; Lee W.S.; Choi K.H.; Park T.K.;
Yang J.H.; Choi S.-H.; Gwon H.-C.; Song Y.B.; Hahn J.-Y.; Jeong D.S.; Lee
J.M.
Institution
(Gim, Lee, Choi, Park, Yang, Choi, Gwon, Song, Hahn, Lee) Division of
Cardiology, Department of Medicine, Heart Vascular Stroke Institute,
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,
South Korea
(Cho, Sung, Kim, Jeong) Department of Thoracic and Cardiovascular Surgery,
Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Seoul, South Korea
(Lee, Kwon, Lee) Kangbuk Samsung Hospital, Sungkyunkwan University School
of Medicine, Seoul, South Korea
(Lee) Department of Internal Medicine and Cardiovascular Center, Chonnam
National University Hospital, Gwangju, South Korea
(Shin) Department of Cardiology, St. Francis Hospital and Heart Center,
Roslyn, NY, United States
(Lee, Kim) Chungbuk National University Hospital, Chungbuk National
University College of Medicine, Cheongju, South Korea
(Lee) Chung-Ang University College of Medicine, Chung-Ang University
Gwangmyeong Hospital, Gwangmyeong, South Korea
(Yun, Cho) Wonkwang University Hospital, Iksan, South Korea
(Kim, Ahn) The Catholic University of Korea, Uijeongbu St. Mary's
Hospital, Seoul, South Korea
(Nam, Yoon) Keimyung University Dongsan Hospital, Daegu, South Korea
(Park) Samsung Changwon Hospital, Sungkyunkwan University School of
Medicine, Changwon, South Korea
(Lee) Chung-Ang University College of Medicine, Chung-Ang University
Hospital, Seoul, South Korea
Publisher
Elsevier Inc.
Abstract
Background Coronary artery bypass grafting (CABG) is the standard
revascularization method for patients with diabetes mellitus (DM) and
complex coronary artery disease. However, with significant advances in
percutaneous coronary intervention (PCI), particularly the use of
intravascular imaging (IVI), it is uncertain whether contemporary
IVI-guided PCI can achieve clinical outcomes comparable with those of
CABG. Objectives The aim of this study was to compare the clinical
outcomes of IVI-guided PCI, angiography-guided PCI, and CABG in DM
patients with left main or 3-vessel disease. Methods A total of 3,402 DM
patients with left main or 3-vessel disease were included from individual
patient-level data of the RENOVATE-COMPLEX-PCI (Randomized Controlled
Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on
Clinical Outcomes After Complex Percutaneous Coronary Intervention) trial
and the institutional registries of Samsung Medical Center (n = 6,962).
The primary outcome, which was a composite of all-cause death, nonfatal
myocardial infarction, or stroke at 3 years was compared among IVI-guided
PCI, angiography-guided PCI, and CABG. Results In the DM population, the
cumulative incidence of the primary outcome at 3 years was 20.1% for
angiography-guided PCI, 11.4% for IVI-guided PCI, and 12.4% for CABG. PCI
was associated with a significantly higher risk for primary outcome (17.0%
vs 12.4%; HR: 1.91; 95% CI: 1.50-2.44; P < 0.001). However, the risk for
the primary outcome was comparable between the IVI-guided PCI and CABG
groups (11.4% vs 12.4%; HR: 0.88; 95% CI: 0.58-1.32; P = 0.525). A
propensity score-matched analysis yielded similar results (HR: 0.85; 95%
CI: 0.53-1.36; P = 0.507). Conclusions In this hypothesis-generating
study, PCI was associated with significantly higher risk for all-cause
death, nonfatal myocardial infarction, or stroke at 3 years than CABG in
DM patients with left main or 3-vessel disease. However, IVI-guided PCI
had comparable risk for clinical events compared with CABG in DM patients.
Further randomized controlled trial is needed to confirm this finding.
(Randomized Controlled Trial of Intravascular Imaging Guidance Versus
Angiography-Guidance on Clinical Outcomes After Complex Percutaneous
Coronary Intervention [RENOVATE-COMPLEX-PCI], NCT03381872 ; institutional
cardiovascular catheterization database of Samsung Medical Center
[Long-Term Outcomes and Prognostic Factors in Patient Undergoing CABG or
PCI], NCT03870815 ; institutional CABG database of Samsung Medical Center,
NCT03870815 )<br/>Copyright &#xa9; 2026 American College of Cardiology
Foundation.

<69>
Accession Number
2043457224
Title
Simulation in robotic-assisted thoracic surgery: a systematic review.
Source
Journal of Robotic Surgery. 20(1) (no pagination), 2026. Article Number:
296. Date of Publication: 01 Dec 2026.
Author
Walji H.D.; de Rosenzweig P.G.-D.S.; Jesani H.; Martin-Ucar A.;
Hernandez-Arenas L.
Institution
(Walji, de Rosenzweig, Jesani, Martin-Ucar, Hernandez-Arenas) Department
of Cardio-Thoracic Surgery, University Hospitals Coventry and
Warwickshire, Clifford Bridge Road, Coventry, United Kingdom
Publisher
Springer Nature
Abstract
Method: A literature search was conducted across three databases using
terms: robot* AND simulat* AND thora* OR chest* from January 2010 to
December 2025. Themes regarding development of a robotic surgical program
were identified. The papers were critically appraised and scored using the
MMERSQI tool. <br/>Result(s): Out of 455 articles, 24 full-text articles
were reviewed, and ten included in the final review. Three themes emerged:
competency assessment, skills development, and MDT education. Studies
indicated minimally invasive surgery skills can predict robotic skill
acquisition. There is conflicting evidence on whether simulation sets a
benchmark for competency or enhances surgical skills. Translation of
improvements from simulation to clinical practice remains unclear.
Simulation was also highlighted as a method to ensure team members develop
together and offer organisations learning opportunities.
<br/>Conclusion(s): Recommendations on incorporating simulation into a
RATS program include: prioritize surgeons experienced in minimally
invasive techniques for early introduction to RATS via simulation; avoid
using simulation benchmarking as the sole marker of competence; use
virtual simulation-based learning for familiarity with robotic systems but
do not accept it as surgical experience for certification; and emphasize
MDT simulation for improved teamwork and organizational
learning.<br/>Copyright &#xa9; The Author(s), under exclusive licence to
Springer-Verlag London Ltd., part of Springer Nature 2026.

<70>
Accession Number
2043417383
Title
Direct oral anticoagulants versus vitamin K antagonists after heart valve
bioprosthetic replacement or repair: A systematic review and
meta-analysis.
Source
Archives of Cardiovascular Diseases. (no pagination), 2026. Date of
Publication: 2026.
Author
Bruno V.D.; Lester T.; Poletti E.; Celmeta B.; Viva T.; Bisogno A.; Miceli
A.; Glauber M.
Institution
(Bruno, Celmeta, Viva, Bisogno, Miceli, Glauber) Department of Minimally
Invasive Cardiac Surgery, IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan,
Italy
(Lester) School of Medicine, University of Bristol, Bristol, United
Kingdom
(Poletti) Department of Cardiology, Hartcentrum Middelheim ZNA, Antwerp,
Belgium
Publisher
Elsevier Masson s.r.l.
Abstract
Vitamin K antagonists are used as a temporary anticoagulation method after
bioprosthetic valve replacement or repair. However, the novel direct oral
anticoagulants may be a preferred method of anticoagulation because of
their improved patient compliance. This meta-analysis aimed to evaluate
the safety of direct oral anticoagulants versus vitamin K antagonists
after biological valve replacement or repair. A systematic review and
meta-analysis were performed for studies reporting the effect of direct
oral anticoagulants versus vitamin K antagonists after biological valve
replacement or repair. The inclusion criteria were studies of adults
undergoing bioprosthetic mitral or aortic valve replacement or repair,
comparing direct oral anticoagulants versus vitamin K antagonists in the
early postoperative period. The main outcomes were thromboembolic and
bleeding events, and short- and mid-term death rates. Six observational
studies and one randomized controlled trial were included, with a total of
2994 direct oral anticoagulant recipients and 16,894 vitamin K antagonist
recipients. There were no significant differences between the groups in
terms of thromboembolic events (odds ratio: 0.82, 95% confidence interval:
0.45-1.49; P = 0.52) or bleeding events (odds ratio: 0.89, 95% confidence
interval: 0.70-1.14, P = 0.36). Higher 30-day and mid-term death rates
were observed in patients receiving direct oral anticoagulants, but this
analysis was reported inconsistently, and was heavily influenced by a
single study. In a mixed population of individuals undergoing
bioprosthetic valve replacement or repair, there was no statistically
significant difference between direct oral anticoagulants and vitamin K
antagonists in terms of reducing thromboembolic or bleeding events.
Further studies are needed to establish the optimal anticoagulation
regimen in this context.<br/>Copyright &#xa9; 2026 Elsevier Masson SAS.

<71>
Accession Number
650221744
Title
Effects of combined Triflow, deep breathing and coughing exercises on
postoperative pulmonary function after mitral valve replacement: a
randomized controlled trial.
Source
BMC surgery. 26(1) (no pagination), 2026. Date of Publication: 10 Feb
2026.
Author
Akinci N.; Eren E.
Institution
(Akinci) Department of Nursing, Faculty of Health Sciences, Fenerbahce
University, Istanbul, Turkey
(Eren) Department of Nursing, Faculty of Health Sciences, Istanbul Medipol
University, Istanbul, Turkey
Abstract
BACKGROUND: Postoperative pulmonary complications remain a major cause of
morbidity after cardiac valve surgery. Although incentive spirometry
(Triflow) is routinely used in postoperative care, evidence regarding the
additional benefits of combining Triflow with deep breathing and coughing
exercises remains limited. This study aimed to evaluate the effects of
combined Triflow, deep breathing, and coughing exercises on postoperative
pulmonary function in adult patients undergoing mitral valve replacement.
<br/>METHOD(S): This randomized controlled, single-blind trial was
conducted between May and August 2025 in a private hospital in Istanbul. A
total of 60 adult patients undergoing mitral valve replacement were
randomly allocated to an experimental group (n = 30) or a control group (n
= 30) using simple randomization. The experimental group performed Triflow
combined with deep breathing and coughing exercises, while the control
group performed Triflow alone. <br/>RESULT(S): Postoperative SpO2 levels
were significantly higher in the experimental group at T1 (p = 0.009; 95%
CI: 0.46-3.14), T2 (p < 0.001; 95% CI: 1.57-3.43), and T3 (p < 0.001; 95%
CI: 2.72-4.54). The FEV1/FVC ratio increased significantly in the
experimental group compared with the control group at discharge (p <
0.001; 95% CI: 4.46-6.41). Respiratory rate was significantly higher in
the experimental group at T1 (p < 0.001; 95% CI: 1.68-4.45), T2 (p <
0.001; 95% CI: 3.34-6.26), and T3 (p < 0.001; 95% CI: 5.23-8.37).
Hematocrit levels were significantly lower in the experimental group at T1
(p = 0.039; 95% CI: -8.32 to - 0.24), T2 (p = 0.007; 95% CI: -8.29 to -
1.40), and T3 (p = 0.034; 95% CI: -6.54 to - 0.28). Pain scores were
significantly lower in the experimental group at T1 (p < 0.001; 95% CI:
-2.82 to - 1.71) and T2 (p < 0.001; 95% CI: -1.98 to - 1.08). Time to
first mobilization was significantly shorter in the experimental group (p
< 0.001; 95% CI: -2.94 to - 1.26). No postoperative pulmonary
complications were observed in either group. <br/>CONCLUSION(S): The
combined application of Triflow, deep breathing, and coughing exercises
was associated with significant improvements in postoperative pulmonary
function, oxygen saturation, pain reduction, and earlier mobilization
compared with Triflow alone in patients undergoing mitral valve
replacement. These findings suggest that a structured, combined
respiratory exercise protocol may provide additional clinical benefits in
the early postoperative period. TRIAL REGISTRATION: ClinicalTrials.gov
Identifier NCT06997224 (First registered on 15 May 2025).<br/>Copyright
&#xa9; 2026. The Author(s).

<72>
Accession Number
2040868914
Title
The harvesting technique affects the production of nitric oxide and
endothelin in the internal thoracic artery graft.
Source
Journal of Thoracic and Cardiovascular Surgery. 171(3) (pp 640-648), 2026.
Date of Publication: 01 Mar 2026.
Author
Iino K.; Yoshioka K.; Iba T.; Ito Y.; Sakai A.; Harlyjoy B.C.; Yamamoto
Y.; Ando H.; Naito H.; Takemura H.
Institution
(Iino, Sakai, Yamamoto, Takemura) Department of Cardiovascular Surgery,
Kanazawa University, Kanazawa, Japan
(Yoshioka, Harlyjoy, Naito) Department of Vascular Physiology, Kanazawa
University, Kanazawa, Japan
(Iba, Ando) Department of Cellular and Molecular Function Analysis,
Kanazawa University, Kanazawa, Japan
(Ito) Department of Molecular and Cellular Pathology, Kanazawa University,
Kanazawa, Japan
Publisher
Elsevier Inc.
Abstract
Objective: To assess the production of nitric oxide and endothelin in
off-pump coronary artery bypass grafting by comparing 2 techniques of
internal thoracic artery preparation: skeletonized and pedicled without
endothoracic fascia. <br/>Method(s): In this prospective, randomized
clinical study, 40 patients undergoing off-pump coronary artery bypass
grafting were randomized according to internal thoracic artery preparation
technique into the skeletonized or pedicled (without endothoracic fascia)
groups (n = 20 each). Endothelial expression of CD31 was evaluated by
means of immunohistochemistry and en face immunofluorescence. Nitric oxide
and cyclic guanosine monophosphate levels in internal thoracic artery
plasma, as well as cyclic guanosine monophosphate and endothelin-1 levels
in unused internal thoracic artery segments, were measured using
enzyme-linked immunosorbent assays. Endothelin-1 mRNA expression was
assessed by in situ hybridization. <br/>Result(s): Skeletonized internal
thoracic artery showed areas of poor endothelial continuity, whereas the
pedicled internal thoracic artery without endothoracic fascia retained a
uniform endothelium on immunostaining. This injury was accompanied by the
absence of endothelial nitric oxide synthase immunostaining at regions of
endothelial denudation. Plasma nitric oxide concentration was
significantly lower, and endothelin-1 release from tissue extracts
significantly greater, in skeletonized internal thoracic artery compared
with pedicled internal thoracic artery without endothoracic fascia. In
situ hybridization assay showed that endothelin-1 (EDN1) mRNA expression
is upregulated in endothelial cells remaining in skeletonized internal
thoracic artery. <br/>Conclusion(s): Reduced nitric oxide release and
increased endothelin-1 release was observed in skeletonized internal
thoracic artery compared with atraumatically prepared pedicled internal
thoracic artery without endothoracic fascia. These observations may
influence graft performance.<br/>Copyright &#xa9; 2025 The Authors

<73>
Accession Number
2036422691
Title
Prognostic value of left atrial strain in significant aortic valve
disease: a systematic review and meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 12 (no pagination), 2025. Article
Number: 1667871. Date of Publication: 2025.
Author
Chen N.; Gu W.; Wu J.
Institution
(Chen) Department of Echocardiography, The First Affiliated Hospital of
Dalian Medical University, Dalian, China
(Gu, Wu) Department of Echocardiography, The Second Affiliated Hospital of
Dalian Medical University, Dalian, China
Publisher
Frontiers Media SA
Abstract
Background: Previous studies on aortic valve disease have mainly focused
on the left ventricle, but increasing evidence suggests that left atrial
strain also has prognostic value in significant aortic valve disease.
<br/>Objective(s): To systematically evaluate the prognostic value of left
atrial strain in significant aortic valve disease. <br/>Method(s):
Multiple electronic databases were searched for studies evaluating
significant aortic stenosis (AS) or aortic regurgitation (AR) using peak
left atrial longitudinal strain (PALS) from the inception of each database
to 1 February 2025. There were no language or regional restrictions. The
primary endpoint was a composite outcome comprising all-cause mortality,
hospitalization for heart failure, aortic valve replacement, pulmonary
hypertension, and postoperative new-onset atrial fibrillation.
<br/>Result(s): A total of 25 studies were included, involving 7,195
patients, with 2,039 (28%) patients experiencing primary endpoint events.
The PALS was lower in the positive group (EVENT+) compared to the negative
group (EVENT-) (SMD = -1.03, 95% CI [-1.22, -0.84], p < 0.05). For each
unit increase in PALS, the risk of the primary endpoint event decreased by
7% (HR = 0.93, 95% CI [0.91, 0.96], p < 0.001). PALS exhibited consistent
incremental predictive value in both the AR and AS cohorts, although the
strength of its effect and the underlying mechanisms varied between
groups. <br/>Conclusion(s): PALS is an independent predictor of adverse
cardiovascular events in patients with significant aortic valve disease.
PALS has certain value in the prognosis of significant aortic valve
disease. Systematic Review Registration: [www.crd.york.ac.uk/prospero/],
identifier [CRD 42024623883].<br/>Copyright 2025 Chen, Gu and Wu.

<74>
Accession Number
2033028861
Title
Enhancing heart and circulatory well-being through optimized radial artery
techniques: a meta-analysis of hemostasis and patient comfort.
Source
Frontiers in Cardiovascular Medicine. 11 (no pagination), 2024. Article
Number: 1412479. Date of Publication: 2024.
Author
Yang Y.; Zhu H.; Zai G.
Institution
(Yang, Zhu, Zai) Department of Cardiovascular Medicine, Capital Medical
University, Beijing LuHe Hospital, Beijing, China
Publisher
Frontiers Media SA
Abstract
Objective: This meta-analysis elucidates the efficacy of the Transradial
Band Device (TR Band) in minimizing complications like radial artery
occlusion and hematoma, preserving heart health, and enhancing blood flow
post-transradial catheterization. <br/>Method(s): A comprehensive
literature search across databases including PubMed, Cochrane, and Embase
examined the impact of radial artery compression techniques and
decompression times on complications. Data from 13 studies were analyzed
using R 4.1.2 with fixed-effects and random-effects models. The
Newcastle-Ottawa Scale assessed the risk of bias in observational cohort
studies. <br/>Result(s): In our meta-analysis, we evaluated data from
various studies encompassing different air volumes in transradial band
devices across several outcomes including bleeding, hematoma, radial
artery occlusion (RAO), Visual Analog Scale (VAS) scores, and compression
time. The collective analysis integrated findings from 11 studies,
totaling 4,679 patients. No significant difference in bleeding risk (OR
1.04, 95% CI 0.60-1.82, p > 0.05, I² = 78%), hematoma incidence
(OR 0.96, 95% CI 0.78-1.19, p > 0.05, I² = 0%), or RAO
incidence (OR 0.96, 95% CI 0.78-1.19, p > 0.05, I² = 0%) was
observed between the "Less air" and "15 ml air" groups. However, the "Less
air" group reported significantly higher VAS scores indicating increased
pain or discomfort (Mean Difference 0.25, 95% CI 0.09-0.41, p < 0.05,
I² = 0%). Compression time analyses showed no significant
difference between groups (Mean Difference -17.73, 95% CI -54.65-19.20, p
> 0.05, I² = 99%). Sensitivity analyses confirmed the stability
of these findings, and Egger's test indicated no significant publication
bias across the outcomes. This synthesis highlights the nuanced impact of
air volume adjustments in transradial bands on patient outcomes,
emphasizing the necessity for further research and standardized protocols
to optimize patient safety and comfort post-intervention.
<br/>Conclusion(s): The TR Band, when utilized with optimized air
volume/pressure, maintains an essential balance between ensuring
hemostasis and enhancing patient comfort without elevating the risk of
radial artery complications. These findings support the careful selection
of TR Band settings to optimize clinical outcomes in patients undergoing
transradial cardiac procedures. Further research is warranted to establish
standardized guidelines for the most effective use of TR Band in various
clinical scenarios.<br/>Copyright 2025 Yang, Zhu and Zai.

<75>
Accession Number
2043421799
Title
Ezetimibe alone for over 75 years old as a primary prevention to decrease
cardiovascular events.
Source
Annals of Medicine. 58(1) (no pagination), 2026. Article Number: 2634484.
Date of Publication: 2026.
Author
Vuorio A.; Kovanen P.T.; Strandberg T.
Institution
(Vuorio) Mehilainen, Aviapolis Health Center, Vantaa, Finland
(Vuorio) Department of Forensic Medicine, University of Helsinki,
Helsinki, Finland
(Kovanen) Wihuri Research Institute, Helsinki, Finland
(Strandberg) University of Helsinki and Helsinki University Hospital,
Helsinki, Finland
(Strandberg) Center for Life Course Health Research, University of Oulu,
Oulu, Finland
Publisher
Taylor and Francis Ltd.
Abstract
The EWTOPIA 75 (Ezetimibe Lipid-Lowering Trial on Prevention of
Atherosclerotic Cardiovascular Disease in 75 or Older) study supports the
reduction in the risk of atherosclerotic cardiovascular disease (ASCVD)
events with ezetimibe without statin therapy in persons aged >=75 years
without a history of coronary artery disease. This evidence has also been
incorporated into the 2025 Focused Update of the 2019 ESC/EAS Guidelines
for the management of dyslipidaemias. What might then be the potential
explanations for the observed benefit of ezetimibe to prevent ASCVD in the
EWTOPIA 75 study? First, cholesterol absorption efficiency generally
increases with age. Therefore, cholesterol absorption-lowering
medications, such as ezetimibe, are particularly beneficial in individuals
aged 75 years and older, in whom low cholesterol absorption has been
associated with fewer recurrent ASCVD events. It is also worth noting that
ezetimibe may be more effective than a particular statin in reducing
non-high-density lipoprotein cholesterol (non-HDL-C), which includes
lipoprotein remnant particles. Therefore, the benefits of the achieved
low-density lipoprotein cholesterol (LDL-C) levels are not directly
comparable between ezetimibe and statin therapy. It remains to be verified
in future studies whether ezetimibe monotherapy would be helpful,
specifically in older patients. If so, one possible explanation is that,
even in the absence of clinical ASCVD, ezetimibe slows and stabilizes the
atherosclerotic process that is still advancing. Finally, a trade-off
between a less effective LDL-C lowering but a low frequency of adverse
effects and drug interactions could lead to better long-term adherence in
the setting of primary prevention.<br/>Copyright &#xa9; 2026 The
Author(s). Published by Informa UK Limited, trading as Taylor & Francis
Group.

<76>
Accession Number
2043566337
Title
Totally Endoscopic Approach for Aortic Valve Replacement: A Systematic
Review and Single-Arm Meta-Analysis.
Source
Medicina (Lithuania). 62(2) (no pagination), 2026. Article Number: 339.
Date of Publication: 01 Feb 2026.
Author
Anghel F.; Bistriceanu M.I.A.; Toma C.V.; Ursu C.G.; Danet A.; Blindaru
A.D.C.; Popescu M.-A.; Paun M.-A.; Parsan V.-I.; Margineanu T.C.; Cristea
D.I.; Cristea C.F.; Ceausu A.-M.; Boboruta R.A.; Udrea V.-N.A.; Andreescu
D.I.; Badiu C.-C.
Institution
(Anghel, Danet, Blindaru, Badiu) Department of Cardiovascular Surgery,
Emergency University Hospital of Bucharest, Bucharest, Romania
(Anghel, Bistriceanu, Toma, Ursu, Danet, Blindaru, Popescu, Paun, Parsan,
Margineanu, Cristea, Cristea, Ceausu, Boboruta, Udrea, Andreescu, Badiu)
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy,
Bucharest, Romania
(Anghel) Curtin Medical School, Curtin University, Perth, Australia
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background and Objectives: Totally endoscopic aortic valve replacement
(TE-AVR) is a minimally invasive technique offering potential benefits of
reduced surgical trauma and faster recovery compared with median
sternotomy or other minimally invasive access. While isolated aortic valve
replacement (AVR) is well established through conventional and minimally
invasive access, large-scale evidence for the totally endoscopic approach
remains limited. This meta-analysis aimed to systematically assess the
safety and feasibility of TE-AVR by aggregating perioperative outcomes,
including mortality, stroke, conversion, bleeding, paravalvular leak
(PVL), and atrial fibrillation (AF). <br/>Material(s) and Method(s): A
systematic search of PubMed, Embase, and the Cochrane Library was
performed, following PRISMA 2020 guidelines. Observational studies and
randomized controlled trials reporting outcomes of totally endoscopic or
thoracoscopic AVR were eligible. After independent screening and
selection, data were analyzed using a single-arm proportion model.
Leave-one-out sensitivity analyses were performed to evaluate the
influence of individual studies. The protocol was registered in PROSPERO
(CRD42024610128). <br/>Result(s): A total of 11 studies comprising 1135
patients were included. The pooled perioperative mortality was 0.00% (95%
CI 0.00-0.23; I² = 0.0%), indicating highly consistent results
across cohorts. The stroke incidence was 0.69% (95% CI 0.00-2.07;
I² = 42.7%), confirming the low cerebrovascular risk of this
approach. Conversion to sternotomy occurred in 0.00% of cases (95% CI
0.00-0.17; I² = 0.0%), with no statistical heterogeneity
observed. Reintervention for bleeding occurred in 1.75% (95% CI 0.34-3.85;
I² = 43.4%), while PVL was reported in 1.24% (95% CI 0.00-4.22;
I² = 64.0%). AF incidence was 10.54% (95% CI 3.79-19.70;
I² = 90.5%), with substantial between-study heterogeneity,
likely related to non-standardized definitions of new-onset AF and
variability in postoperative rhythm monitoring and reporting across
studies. <br/>Conclusion(s): TE-AVR is a safe and feasible technique
associated with very low perioperative mortality, bleeding, and stroke
rates, as well as low PVL incidence. The absent conversion rate in our
pooled analysis highlights the technical reliability of the procedure.
Variability in AF reporting underscores the need for future randomized
studies with harmonized definitions. Overall, TE-AVR offers a promising
minimally invasive alternative for aortic valve replacement, with
potential advantages in recovery (pooled ICU stay 1.86 days), hospital
stay (pooled 7.98 days), and aesthetic outcomes.<br/>Copyright &#xa9; 2026
by the authors.

<77>
Accession Number
2037730479
Title
COMPARISON OF DEXMEDETOMIDINE AND ONDANSETRON FOR PREVENTION OF POST
OPERATIVE NAUSEA AND VOMITING IN LAPAROSCOPIC SURGERIES.
Source
International Journal of Medicine and Public Health. 16(1) (pp 1347-1354),
2026. Date of Publication: 01 Jan 2026.
Author
Choudhary G.; Baloda R.; Kumar S.; Yadav P.; Johar S.
Institution
(Choudhary, Baloda, Yadav, Johar) Department of Anesthesia, PGIMS,
Haryana, Rohtak, India
(Kumar) MH, Haryana, Hisar, India
Publisher
Pink Petals Publications Pvt Ltd
Abstract
Background: Postoperative nausea and vomiting (PONV) remains a common
complication following laparoscopic surgeries, adversely affecting patient
satisfaction, recovery, and healthcare costs. While ondansetron is widely
used for prophylaxis, dexmedetomidine-an alpha-adrenergic agonist with
sedative, analgesic, and antiemetic properties-has emerged as a potential
alternative. The objective is to compare the efficacy and safety of
dexmedetomidine versus ondansetron in preventing PONV in patients
undergoing elective laparoscopic surgery. <br/>Material(s) and Method(s):
In this prospective, randomized, double-blind trial, 90 patients (ASA
I-II) scheduled for laparoscopic procedures under general anesthesia were
divided into two groups. Group I (n=45) received dexmedetomidine 1 mug/kg
diluted in 100 mL normal saline over 10-15 minutes after intubation, while
Group II (n=45) received ondansetron 4 mg intravenously. PONV incidence,
severity, need for rescue antiemetics, hemodynamic parameters, sedation
scores, and adverse events were recorded at 0, 4, and 12 hours
postoperatively. <br/>Result(s): At 0 hours, significantly more patients
in the dexmedetomidine group were free from PONV symptoms compared to the
ondansetron group (68.9% vs. 40%, p=0.034), with vomiting occurring in
only 8.9% vs. 26.7%, respectively. Rescue antiemetic use was also lower in
the dexmedetomidine group at 0 hours (15.6% vs. 40%, p=0.010). No
significant differences were observed at 4 and 12 hours. Dexmedetomidine
was associated with a lower heart rate during surgery but without
significant hemodynamic instability. Sedation profiles were comparable,
and adverse events were minimal in both groups. <br/>Conclusion(s):
Dexmedetomidine is more effective than ondansetron in preventing early
postoperative nausea and vomiting following laparoscopic surgery and
reduces the immediate need for rescue antiemetics, without causing
excessive sedation or clinically significant hemodynamic compromise. It
may be preferred in settings where early PONV control is crucial, though
vigilant monitoring for bradycardia is advised.<br/>Copyright &#xa9; 2026,
Pink Petals Publications Pvt Ltd. All rights reserved.

<78>
Accession Number
2043182065
Title
Factor XII-A New Therapeutic Target? A Systematic Review.
Source
International Journal of Molecular Sciences. 27(3) (no pagination), 2026.
Article Number: 1331. Date of Publication: 01 Feb 2026.
Author
Krajewska K.; Pawlus J.; Ptaszynska K.; Lisowska A.
Institution
(Krajewska, Ptaszynska, Lisowska) Department of Cardiology, Teaching
Hospital in Bialystok, Medical University of Bialystok, Bialystok, Poland
(Pawlus) Department of Haematology Diagnostics, Teaching Hospital in
Bialystok, Medical University of Bialystok, Bialystok, Poland
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Factor XII is a molecule of unclear physiological function that has
attracted increasing research interest across multiple medical
disciplines. In recent years, a substantial body of evidence has emerged
regarding the contribution of factor XII to the pathogenesis of
inflammatory and prothrombotic conditions. FXII has been shown to play a
protective role in FXII-driven coagulation during host defence against
infections and to protect against multi-organ failure in animal models of
sepsis. In acute respiratory distress syndrome (ARDS), FXII activity
contributes to the release of pro-inflammatory mediators and is associated
with severe clinical outcomes; it also induces fibroblast migration in
idiopathic pulmonary fibrosis. FXII deficiency has been associated with
reduced neutrophil adhesion and migration in sterile skin wounds and
immune complex-induced vasculitis. In neurological conditions, FXII
deficiency significantly reduced the number and severity of multiple
sclerosis relapses and decreased the volume of post-traumatic brain
oedema. In heart failure pathogenesis, FXII deficiency and pharmacological
inhibition of FXII activity blocked activation of the
renin-angiotensin-aldosterone system (RAAS) in dilated cardiomyopathy,
increased median survival, and delayed heart failure onset in murine
models. Importantly, FXII inhibition prevented arterial thrombosis without
affecting haemostasis. This review summarises the latest findings on the
contribution of FXII to inflammatory and prothrombotic states across
multiple medical fields, including cardiology. Pharmacological inhibition
of FXII has generated considerable interest as a potential future
therapeutic strategy; however, to date, human studies remain
limited.<br/>Copyright &#xa9; 2026 by the authors.

<79>
Accession Number
2035010619
Title
A Meta-Analysis of Randomized Controlled Trials (RCTs) Investigating the
Efficacy and Safety of Acupuncture in Treating Myocardial
Ischemia/Reperfusion (I/R) Injury.
Source
Cardiology Research and Practice. 2025(1) (no pagination), 2025. Article
Number: 9970541. Date of Publication: 2025.
Author
Xiong J.; Wei Y.; Huang X.; Hu J.; Ling F.; Shang Z.; Qi W.; Zheng Q.; Li
D.; Liang F.
Institution
(Xiong, Wei, Hu, Ling, Qi, Zheng, Liang) College of Acupuncture and Tuina,
Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu,
China
(Huang) The First College of Clinical Medicine, Guangxi University of
Traditional Chinese Medicine, Guangxi, Nanning, China
(Shang) The First College of Clinical Medicine, Nanjing University of
Traditional Chinese Medicine, Jiangsu, Nanjing, China
(Li) Acupuncture Department, The Affiliated Hospital of Chengdu University
of Traditional Chinese Medicine, Sichuan, Chengdu, China
Publisher
John Wiley and Sons Ltd
Abstract
Objectives: This study systematically reviewed and meta-analyzed
randomized controlled trials (RCTs) evaluating the efficacy and safety of
acupuncture in myocardial ischemia/reperfusion (I/R) injury.
<br/>Method(s): A comprehensive literature search was conducted in PubMed,
Cochrane Library, Web of Science, Chinese National Knowledge
Infrastructure, China Science and Technology Journal Database, and Wanfang
from database inception to November 3, 2024. Eligible RCTs assessing
acupuncture for myocardial I/R injury were included. Statistical analyses
were performed using Review Manager 5.3 and Stata 16. <br/>Result(s): A
total of 26 RCTs of moderate methodological quality were included.
Acupuncture significantly reduced myocardial enzyme levels compared to
controls. Inflammatory markers (hs-CRP, TNF-alpha, IL-6, IL-8, and IL-1)
were suppressed, while anti-inflammatory and immunoregulatory factors
(IL-10 and IL-2) increased. Oxidative stress parameters showed
improvements, with reductions in MDA and SOD levels. Echocardiographic
findings demonstrated enhanced cardiac function, reflected by increased
LVEF and LVESV, along with reductions in LVFS, LVEDD, LVEDV, and LVESD.
Additionally, acupuncture alleviated TCM chest pain symptoms, shortened
ICU stays, lowered MACE incidence, and improved 6MWT and SAQ indicators.
No adverse reactions were reported. <br/>Conclusion(s): Acupuncture
attenuates myocardial injury, inflammation, and oxidative stress while
activating anti-inflammatory and immune responses, enhancing cardiac
function, and mitigating ventricular remodeling. Furthermore, it
alleviates chest pain, shortens ICU stays, reduces adverse cardiovascular
events, and improves 6MWT and SAQ indicators.<br/>Copyright &#xa9; 2025
Jian Xiong et al. Cardiology Research and Practice published by John Wiley
& Sons Ltd.

<80>
Accession Number
2043522533
Title
Comparison of 6% hydroxyethyl starch 130/0.4 vs 5% albumin in
cardiopulmonary bypass for cardiac surgery.
Source
World Journal of Cardiology. 18(1) (no pagination), 2026. Article Number:
114123. Date of Publication: 26 Jan 2026.
Author
Alqarni A.; Algarni A.; Chhetri R.
Institution
(Alqarni, Algarni) Department of Cardiology, King Abdullah Medical
Complex, Ministry of Health, Jeddah, Makkah al Mukarramah, Saudi Arabia
(Chhetri) Department of Cardiology, Nepalgunj Medical College, Kohal,
Nepal
Publisher
Baishideng Publishing Group Inc
Abstract
BACKGROUND The choice of priming and volume replacement fluids during
cardiopulmonary bypass (CPB) in cardiac surgery impacts hemodynamic
stability, coagulation, renal function, and patient outcomes. Hydroxyethyl
starch (HES) 130/0.4 and human albumin are commonly used colloids, but
their relative safety and efficacy remain debated. AIM To compare the
outcomes of 6% HES 130/0.4 vs 5% albumin in patients undergoing cardiac
surgery with CPB. METHODS A comprehensive literature search was performed
in PubMed, EMBASE, ScienceDirect, and grey literature sources up to August
2025. Randomized controlled trials and controlled observational studies
comparing 6% HES 130/0.4 with 5% albumin in patients who underwent cardiac
surgery were included. Data extraction and risk of bias assessment
followed PRISMA and Cochrane guidelines. Meta-analyses were conducted
using RevMan 5.4, applying random-effects models. Heterogeneity was
assessed with I² statistics, and meta-regression explored
baseline covariables. Publication bias was evaluated with funnel plots and
the Egger's test. RESULTS Twelve studies involving 908 patients (455 in
the HES group, 453 in the albumin group) were included. No significant
differences were observed between the HES and albumin groups for
postoperative blood loss [mean difference = 42.4 mL, 95% confidence
interval (CI): -90.0 to 174.9; P = 0.53], packed red blood cell
transfusion [odds ratio (OR) = 0.78, 95%CI: 0.65-1.10; P = 0.16)],
mortality (OR = 1.11, 95%CI: 0.63-1.96; P = 0.80), intensive care unit
stay, hospital stay, or postoperative platelet count and creatinine
levels. However, HES was associated with a significantly higher risk of
acute kidney injury (AKI) (OR = 1.79, 95%CI: 1.08-2.97; P = 0.02),
indicating that while many clinical outcomes showed no significant
difference, there is a specific safety concern related to renal function
with HES use. Meta-regression did not identify baseline factors explaining
heterogeneity in bleeding or AKI outcomes (all P > 0.10). No significant
publication bias was detected. CONCLUSION The 6% HES 130/0.4 and 5%
albumin exhibit similar efficacy for volume management in cardiac surgery
with CPB; however, HES is associated with a higher risk of
AKI.<br/>Copyright &#xa9; The Author(s) 2026. Published by Baishideng
Publishing Group Inc. All rights reserved.

<81>
Accession Number
2024797087
Title
Monckeberg's Medial Calcific Sclerosis Makes Traditional Arterial
Doppler's Unreliable in High-Risk Patients with Diabetes.
Source
International Journal of Lower Extremity Wounds. 25(1) (pp 103-108), 2026.
Date of Publication: 01 Mar 2026.
Author
Suludere M.A.; Danesh S.K.; Killeen A.L.; Crisologo P.A.; Malone M.; Siah
M.C.; Lavery L.A.
Institution
(Suludere, Danesh, Killeen, Crisologo, Lavery) Department of Plastic
Surgery, University of Texas Southwestern Medical Center, Dallas, TX,
United States
(Malone) School of Medicine, Western Sydney University, Liverpool, NSW,
Australia
(Siah) Department of Vascular Surgery, University of Texas Southwestern
Medical Center, Dallas, TX, United States
Publisher
SAGE Publications Inc.
Abstract
Objective: To assess Monckeberg's medial calcific sclerosis (MMCS)
severity in patients with a diabetic foot infection. <br/>Method(s): This
was an analysis of 2 randomized clinical trials in which we evaluated the
treatment of 233 patients admitted to the hospital for moderate and severe
foot infections. Arterial calcification was defined as visible radiopaque
arteries on foot and ankle radiographs, recorded as the most distal
visible artery involved (toes, metatarsals, and ankle/hindfoot).
<br/>Result(s): Most subjects (57.1%, n = 133) had MMCS, with extension to
toes in 79 (59.4%), to metatarsals in 32 (24.1%), and to ankle/hindfoot in
22 patients (16.5%). In 7 patients (5.2%) MMCS was solely seen in dorsalis
pedis (DP) artery, in 13 patients (9.8%) in posterior tibialis (PT)
artery, and in 113 patients (85.0%) MMCS was seen in both arteries. Only
29.2% (n = 68) of DP arteries and 34.8% (n = 81) of PT arteries were not
compressible by Doppler. DP and PT arteries were not compressible more
often in MMCS (DP 34.3% vs 20.4%, P = .02 and PT 43.1% vs 21.4%, P < .01),
toe-brachial indices of >=0.7 were significantly more common in people
without MMCS (46.0% vs 67.4%, P < .01). In contrast, there were no
differences in skin perfusion pressure measurements (>50 mmHg; 67.7% vs
68.0%, P = .96), waveforms (biphasic/triphasic 83.5% vs 77.0%, P = .22),
and pulse volume recording (9.6 +/- 3.3 vs 13.7 +/- 36.0) between patients
with and without MMCS. <br/>Conclusion(s): MMCS is common in patients with
diabetic foot infections. MMCS is associated with noncompressible arterial
Doppler studies and likely interferes with the accuracy of arterial
Doppler studies.<br/>Copyright &#xa9; The Author(s) 2023. This article is
distributed under the terms of the Creative Commons Attribution 4.0
License (https://creativecommons.org/licenses/by/4.0/) which permits any
use, reproduction and distribution of the work without further permission
provided the original work is attributed as specified on the SAGE and Open
Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

<82>
Accession Number
2041714223
Title
Reassessing PCI Timing in High Bleeding Risk Patients: Evidence,
Strategies, and Outcomes.
Source
Catheterization and Cardiovascular Interventions. 107(3) (pp 780-794),
2026. Date of Publication: 15 Feb 2026.
Author
Awashra A.; AbuBaha M.; Emara A.; Hamdan A.; Zahran A.; Ibrahem M.; Khayat
N.; Elgendy M.S.; Nouri A.; Rakab M.S.; Akoum A.; Shubietah A.
Institution
(Awashra, AbuBaha, Zahran, Khayat, Nouri) Department of Medicine, An Najah
National University, Nablus, Palestine
(Emara) Faculty of Medicine, Al-Azhar University, Cairo, Egypt
(Hamdan) College of Medicine, QU Health, Qatar University, Doha, Qatar
(Ibrahem, Rakab) Faculty of Medicine, Mansoura University, Mansoura, Egypt
(Elgendy) Faculty of Medicine, Tanta University, Gharbia, Tanta, Egypt
(Akoum) Department of Medicine, Hennepin Healthcare, Minneapolis, MN,
United States
(Shubietah) Department of Medicine, Advocate Illinois Masonic Medical
Center, Chicago, IL, United States
Publisher
John Wiley and Sons Inc
Abstract
Percutaneous coronary intervention (PCI) in patients with high bleeding
risk (HBR) presents a therapeutic challenge, requiring careful balancing
of ischemic prevention and bleeding avoidance. The Academic Research
Consortium High Bleeding Risk (ARC-HBR) criteria provide a standardized
framework for identifying this population, yet optimal PCI timing,
procedural strategies, and antithrombotic regimens remain uncertain. This
review synthesizes data from randomized controlled trials, large-scale
registries, and meta-analyses involving HBR patients undergoing PCI in
settings including stable coronary artery disease, acute coronary
syndromes (ACS), ST-elevation myocardial infarction (STEMI),
post-resuscitation states, and malignancy-related thrombocytopenia.
Special emphasis is placed on procedural approaches (radial vs. femoral
access), device selection (drug-coated balloons, polymer-free drug-eluting
stents), and dual antiplatelet therapy (DAPT) duration. Evidence supports
the safety of abbreviated DAPT regimens (1-3 months) when combined with
bleeding-sparing techniques and devices, with the greatest benefit
observed in patients with a high ischemic burden (e.g., GRACE score >
140). Early invasive management in ACS has been associated with reduced
ischemic endpoints and shorter hospital stays without a significant rise
in major bleeding. Conversely, delayed PCI is advisable in the presence of
active bleeding, recent thrombolysis, or severe coagulopathy. Persistent
limitations include underrepresentation of ARC-HBR patients in trials and
lack of standardized, bleeding risk-tailored timing protocols. PCI in HBR
patients can be performed safely and effectively when guided by
individualized, evidence-based strategies for procedural timing and
antithrombotic therapy. Future directions include integrating
biomarker-driven DAPT modulation and artificial intelligence-based
decision frameworks to optimize outcomes in this high-risk
group.<br/>Copyright &#xa9; 2025 Wiley Periodicals LLC.

<83>
Accession Number
629302263
Title
Comparison of Scientific Publications from Three Different Clinical
Disciplines of German Universities.
Source
Thoracic and Cardiovascular Surgeon. 67(6) (pp 488-493), 2019. Date of
Publication: 06 Sep 2019.
Author
Schwarzer M.; Alscher L.; Doenst T.
Institution
(Schwarzer, Alscher, Doenst) Department of Cardiothoracic Surgery,
University Hospital Jena, Am Klinikum 1, Jena, Germany
Publisher
Georg Thieme Verlag
Abstract
Background Scientific publications are important for the advancement in
medicine. Surgical disciplines including cardiac surgery are frequently
considered not scientifically leading. However, a specific comparison
between surgical and nonsurgical disciplines has not yet been performed.
We thus compared scientific output of German departments of cardiac
surgery with nonsurgical cardiology departments and surgical departments
not addressing the heart (general surgery) of 34 universities in Germany.
Methods For each university, the personnel working at the different
departments were identified on the internet homepage in 2014. We searched
for publications of these persons in 2011 to 2013 on PubMed, identified
author position, coauthors, and type of article, as well as journal impact
factor (JIF). Results There were 931 academic persons in cardiac surgery,
1,486 in general surgery, and 1,814 in cardiology with 12,096 publications
related to these persons on PubMed. Cardiology published most manuscripts,
including manuscripts from research conducted (first author), initiated
(senior author), or both. Cardiac surgery had the least publications and
had fewer authors from other departments or institutions. The average JIF
was higher in cardiology compared with the two surgical disciplines.
However, relating the number of publications to the number of employees in
the departments, the differences were no longer apparent. Conclusion We
conclude that the number of publications in German universities appears to
be a function of the number of academic personnel and not of the
discipline. The lower JIFs in surgery may be due to the smaller surgical
fields and/or due to less high impact interdisciplinary/interinstitutional
publications in surgery.<br/>Copyright &#xa9; 2019 by Thieme Medical
Publishers, Inc.

<84>
Accession Number
2041161321
Title
Ventricular Assist Devices in Adults With Transposition of the Great
Arteries and Systemic Right Ventricle: Systematic Literature Review.
Source
World Journal for Pediatric and Congenital Heart Surgery. 17(2) (pp
263-269), 2026. Date of Publication: 01 Mar 2026.
Author
Abdelkader A.E.A.; Guglin M.
Institution
(Abdelkader, Guglin) Section of Heart Failure/Heart Transplantation/MCS
Services, Indiana University School of Medicine, Indianapolis, IN, United
States
Publisher
SAGE Publications Inc.
Abstract
Background: In adult patients with transposition of the great arteries
(TGA) and systemic right ventricle (sRV), the use of ventricular assist
devices (VADs) is uncommon. <br/>Method(s): We conducted a systematic
review of published studies to examine the indications, hemodynamic
effects, and outcomes of VADs in this patient population. We reviewed
English-language literature for case reports, case series, and reviews
that included individual patient data, such as demographics, hemodynamic
parameters, types of implanted VADs, and outcomes. <br/>Result(s): We
identified 107 patients, 76% (81/107) males, mean age 40.2 +/- 10.6 at the
time of implantation, 38.3% (41/107) with left TGA (L-TGA), and 61.7%
(66/107) with dextro-TGA (D-TGA). The VAD support resulted in hemodynamic
improvement, including a decrease in the mean pulmonary arterial pressure
(45 +/- 15 mm Hg before implantation to 25 +/- 9.3 mm Hg afterwards, P <
.001), pulmonary vascular resistance (6.3 +/- 4.9 Wood units (WU) to 2.4
+/- 1.35 WU, P < .001), right atrial pressure (16.4 +/- 7.3 mm Hg to 9.5
+/- 3.7 mm Hg, P = .009), and pulmonary capillary wedge pressure (25.45
+/- 7.12 mm Hg to 14.25 +/- 5.6 mm Hg, P < .001). The cardiac index
increased from 2.0 +/- 0.5 L/min/m2 to 2.8 +/- 0.6 L/min/m2 (P = .004).
The 1-year survival rate was 80.5%. Eventually, 31 (29%) underwent heart
transplantation, and 48 (54%) remained on VAD at the time of publication.
<br/>Conclusion(s): Durable VADs provide hemodynamic improvement and
excellent survival in adults with a systemic right ventricle. Expanding
the use of VADs for this patient population would be
justified.<br/>Copyright &#xa9; The Author(s) 2025

<85>
Accession Number
2043411396
Title
Transcatheter versus surgical aortic valve replacement in low-risk
patients with severe aortic stenosis: a systematic review and
meta-analysis.
Source
BMC Cardiovascular Disorders. 26(1) (no pagination), 2026. Article Number:
181. Date of Publication: 01 Dec 2026.
Author
Fadl Z.A.; Darwish M.Y.; Moawad W.M.; Aboelmagd N.O.; Fadl G.A.; El
Husseny M.W.A.; Abdelsattar N.K.; Taha T.A.-E.A.
Institution
(Fadl, Darwish, Moawad, Fadl, Abdelsattar, Taha) Faculty of Medicine,
Fayoum University, Fayoum, Egypt
(Aboelmagd) Faculty of Medicine, Qena University, Qena, Egypt
(El Husseny) Department of Adult Cardiology, Aswan Heart Centre, Aswan,
Egypt
(El Husseny) Department of Cardiology, Faculty of medicine, Fayoum
university, Egypt
Publisher
BioMed Central Ltd
Abstract
Background: The optimal revascularization strategy for low-risk patients
with severe aortic stenosis (AS), transcatheter (TAVI) versus surgical
aortic valve replacement (SAVR), remains a subject of ongoing debate,
particularly regarding long-term outcomes. We aimed to synthesize the
evidence on the comparative safety and efficacy of TAVI and SAVR in this
population. <br/>Method(s): We conducted a systematic review and
meta-analysis, searching PubMed, Scopus, Web of Science, and Cochrane
Library until March 2025. We included randomized controlled trials (RCTs)
and comparative observational studies enrolling low-risk patients with
severe AS. Primary outcomes were all-cause mortality and stroke, analyzed
at different time points. Data were pooled using random-effects models,
with subgroup analyses based on study design. <br/>Result(s): Thirty
studies, including 48,210 patients, were included. TAVI was associated
with a significantly lower risk of 30-day mortality (Relative Risk [RR]
0.66, 95% CI 0.50-0.76) and 30-day stroke (RR 0.70, 95% CI 0.53-0.92).
However, in the overall analysis, SAVR was favored for one-year mortality
(RR 1.11, 95% CI 1.01-1.21), with equipoise in long-term follow-up. TAVI
significantly reduced the risks of 30-day major bleeding (RR 0.38, 95% CI
0.21-0.70) and atrial fibrillation (RR 0.41, 95% CI 0.22-0.76).
Conversely, TAVI was associated with a persistently higher risk of
permanent pacemaker implantation (RR 2.44 at 30 days, 95% CI 1.76-3.40)
and paravalvular leakage (RR > 5-fold at both 30 days and 1 year).
<br/>Conclusion(s): In low-risk patients with severe AS, TAVI offers clear
early procedural safety advantages, particularly regarding stroke,
bleeding, and atrial fibrillation. While the overall analysis suggested a
30-day mortality benefit for TAVI and a 1-year mortality benefit for SAVR,
these findings were driven principally by observational data and were not
statistically significant in the subgroup of randomized controlled trials.
These procedural benefits are counterbalanced by a persistently higher
risk of permanent pacemaker implantation and paravalvular leakage with
TAVI. The choice of intervention requires a nuanced, individualized
approach through shared decision-making, weighing early recovery benefits
against device-related risks and the divergence between trial and registry
outcomes.<br/>Copyright &#xa9; The Author(s) 2026.

<86>
Accession Number
631106918
Title
Sutureless versus Stented Bioprostheses for Aortic Valve Replacement: The
Randomized PERSIST-AVR Study Design.
Source
Thoracic and Cardiovascular Surgeon. 68(2) (pp 114-123), 2020. Date of
Publication: 02 Mar 2020.
Author
Lorusso R.; Folliguet T.; Shrestha M.; Meuris B.; Kappetein A.P.; Roselli
E.; Klersy C.; Nozza M.; Verhees L.; Larracas C.; Goisis G.; Fischlein T.
Institution
(Lorusso) Department of Cardio-Thoracic Surgery, Heart and Vascular
Centre, Maastricht University Medical Centre (MUMC +), P. Debyelaan, 25,
Maastricht, Netherlands
(Folliguet) Chirurgie Cardiaque and Transplantation, Assistance Publique
Hopital, Henri Mondor, Universite Paris 12, UPEC, France
(Shrestha) Department of Thoracic and Cardiovascular Surgery, Hannover
Medical School, Hannover, Germany
(Meuris) Cardiac Surgery Department, Universitaire Ziekenhuizen Leuven,
Leuven, Belgium
(Kappetein) Thoraxcenter, Erasmus Medical Centre, Rotterdam, Netherlands
(Roselli) Thoracic and Cardiovascular Surgery, Cleveland Clinic,
Cleveland, OH, United States
(Klersy) Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy
(Nozza, Verhees, Larracas, Goisis) LivaNova Plc, London, United Kingdom
(Fischlein) Department of Cardiac Surgery, Klinikum Nurnberg, Paracelsus
Medical University, Nuremberg, Germany
Publisher
Georg Thieme Verlag
Abstract
Introduction Sutureless biological valves for surgical aortic valve
replacement (SAVR), characterized by the absence of anchoring sutures at
the aortic annulus, are gaining popularity because of ease and
reproducibility of implant, shorter operating times, and enhancement of
minimally invasive approaches. The stentless configuration of the
sutureless valve was designed to achieve optimal hemodynamic performance.
Materials and Methods PERSIST-AVR (PERceval Sutureless Implant versus
STandard Aortic Valve Replacement) is a prospective, randomized, adaptive,
open-label, international, postmarket trial (NCT02673697). The primary
objective of the trial is to assess the safety and efficacy of the
Perceval (LivaNova, London, UK) sutureless bioprosthesis among patients
undergoing SAVR in the presence of severe aortic stenosis to demonstrate
the noninferiority of Perceval as compared with standard sutured stented
bioprosthetic aortic valve as an isolated procedure or combined with
coronary artery bypass grafting. Sample size will be determined adaptively
through interim analyses performed by an Independent Statistical Unit till
a maximum of 1,234 patients, enrolled at ~60 sites in countries where the
device is commercially available. Patients will be followed up for 5 years
after implant. The primary end point is the number of patients free from
major adverse cardiac and cerebrovascular-related events at 1 year.
Additional secondary outcomes will be assessed up to 5 years. Discussion
PERSIST-AVR is the first prospective, randomized study comparing
in-hospital and postdischarge outcomes in a robust population of patients
undergoing SAVR with either the Perceval sutureless bioprosthesis or a
conventional sutured stented bioprosthesis up to 5 years.<br/>Copyright
&#xa9; 2020 American Institute of Physics Inc.. All rights reserved.

<87>
Accession Number
632381648
Title
Bilateral Paravertebral Block versus Thoracic Epidural Analgesia for Pain
Control Post-Cardiac Surgery: A Randomized Controlled Trial.
Source
Thoracic and Cardiovascular Surgeon. 68(5) (pp 409-415), 2020. Date of
Publication: 20 Jul 2020.
Author
El Shora H.A.; El Beleehy A.A.; Abdelwahab A.A.; Ali G.A.; Omran T.E.;
Hassan E.A.; Arafat A.A.
Institution
(El Shora, El Beleehy) Anesthesia and Surgical ICU Department, Faculty of
Medicine-Tanta University, Tanta, Gharbeya, Egypt
(Abdelwahab, Omran, Hassan, Arafat) Department of Cardiothoracic Surgery,
Faculty of Medicine-Tanta University, Al-Giesh Street, Tanta, Gharbeya,
Egypt
(Ali) Department of Cardiothoracic Surgery, Faculty of Medicine-Zagazig
University, Zagazig, Sharkia, Egypt
Publisher
Georg Thieme Verlag
Abstract
Background Adequate pain control after cardiac surgery is essential.
Paravertebral block is a simple technique and avoids the potential
complications of epidural catheters. The objective of this study is to
compare the effect of ultrasound-guided bilateral thoracic paravertebral
block with thoracic epidural block on pain control after cardiac surgery.
Materials and Methods Between March 2016 and 2017, 145 patients who had
cardiac surgery through median sternotomy were randomized by stratified
blocked randomization into two groups. Group I (n = 70 patients) had
bilateral ultrasound-guided thoracic paravertebral block and Group II (n =
75 patients) had thoracic epidural analgesia. The primary end point was
the postoperative visual analogue scale (VAS). The duration of mechanical
ventilation, intensive care unit (ICU), and hospital stay were the
secondary end points. The study design is a randomized parallel
superiority clinical trial. Results Both groups had similar preoperative
and operative characteristics. No significant difference in VAS measured
immediately after endotracheal extubation then after 12, 24, and 48 hours
between groups (p = 0.45). Pain score significantly declined with the
repeated measures (p < 0.001) and the decline was not related to the
treatment group. Postoperative pain was significantly related to diabetes
mellitus (p = 0.039). Six patients in group I (8.5%) required an
additional dose of morphine versus three patients (4%) in group II (p =
0.30). Patients in group I had significantly shorter ICU stay (p = 0.005)
and lower incidence of urinary retention (p = 0.04) and vomiting (p =
0.018). No difference was found in operative complications between groups.
Conclusion This randomized parallel controlled trial demonstrates that
ultrasound-guided paravertebral block is safe and effective method for
relieving post-cardiac surgery sternotomy pain compared with thoracic
epidural analgesia but not superior to it.<br/>Copyright &#xa9; 2020 Georg
Thieme Verlag. All rights reserved.

<88>
Accession Number
626053671
Title
Antiplatelet Therapy versus Anticoagulation after Surgical Bioprosthetic
Aortic Valve Replacement: A Systematic Review and Meta-Analysis.
Source
Thrombosis and Haemostasis. 119(2) (pp 328-339), 2019. Date of
Publication: 22 Jan 2019.
Author
An K.R.; Belley-Cote E.P.; Um K.J.; Gupta S.; McClure G.R.; Jaffer I.H.;
Pandey A.; Spence J.; Van Der Wall S.J.; Eikelboom J.W.; Whitlock R.P.
Institution
(An, Um, McClure) Michael G. DeGroote School of Medicine, McMaster
University, Hamilton, ON, Canada
(Belley-Cote, Gupta, Jaffer, Spence, Whitlock) Department of Clinical
Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
(Belley-Cote) Division of Cardiology, McMaster University, Hamilton, ON,
Canada
(Belley-Cote, Jaffer, Eikelboom, Whitlock) Population Health Research
Institute, Hamilton, ON, Canada
(Gupta, Jaffer, Whitlock) Division of Cardiac Surgery, McMaster
University, Hamilton, ON, Canada
(Pandey) Faculty of Health Sciences, McMaster University, Hamilton, ON,
Canada
(Spence) Department of Anesthesia, McMaster University, Hamilton, ON,
Canada
(Van Der Wall) Department of Thrombosis and Hemostasis, Leiden University
Medical Centre, Leiden University, Leiden, Netherlands
(Eikelboom) Division of Hematology and Thromboembolism, McMaster
University, Hamilton, ON, Canada
(Whitlock) David Braley Cardiac, Vascular, Stroke Research Institute, 237
Barton Street East, Hamilton, ON, Canada
Publisher
Georg Thieme Verlag
Abstract
Background The optimal antithrombotic therapy after surgical bioprosthetic
aortic valve replacement (BAVR) is uncertain. We conducted a systematic
review and meta-analysis of observational studies and randomized
controlled trials (RCTs) comparing antiplatelet therapy and
anticoagulation in patients with surgical BAVR. Methods We searched
Cochrane CENTRAL, MEDLINE and EMBASE from inception to 3 November 2017 for
studies evaluating antiplatelet therapy versus anticoagulation early after
surgical BAVR. We performed title and abstract screening, full-text
review, risk of bias evaluation and data collection independently and in
duplicate. We evaluated overall quality of evidence using the Grading of
Recommendations Assessment, Development and Evaluation framework, and
pooled data using a random effects model. Results We identified 2 RCTs (n
= 397) and 5 observational studies (n = 2,012) meeting our eligibility
criteria. The mean follow-up for all outcomes was 3 months in RCTs, and 10
months for observational studies. Antiplatelet compared with anticoagulant
therapy demonstrated a trend towards fewer major bleeds in RCTs (relative
risk [RR], 0.34; 95% confidence interval [CI], 0.11-1.04, p = 0.06, I
² = 0%, low quality evidence), and significantly fewer major
bleeds in observational studies (RR, 0.34; 95% CI, 0.20-0.58, p <= 0.0001,
I ² = 0%, very low quality evidence), but stroke,
thromboembolism and mortality did not show a significant difference in
either RCTs or observational studies. Conclusion Antiplatelet therapy
demonstrated reduced bleeding risk with no negative effects on stroke,
thromboembolism or mortality compared with anticoagulation therapy after
surgical BAVR. Our confidence in the results is reduced by the low quality
of the available evidence.<br/>Copyright &#xa9; 2019 Georg Thieme Verlag
KG Stuttgart New York.

<89>
Accession Number
625955735
Title
Cardiogenic Necrotizing Enterocolitis: A Clinically Distinct Entity from
Classical Necrotizing Enterocolitis.
Source
European Journal of Pediatric Surgery. 29(1) (pp 14-22), 2019. Date of
Publication: 17 Jan 2019.
Author
Siano E.; Lauriti G.; Ceccanti S.; Zani A.
Institution
(Siano, Zani) Division of General and Thoracic Surgery, Hospital for Sick
Children, 555 University Avenue, Toronto, ON, Canada
(Lauriti) Department of Pediatric Surgery, Spirito Santo Hospital,
Pescara, G. d'Annunzio University, Chieti-Pescara, Italy
(Ceccanti) Pediatric Surgery Unit, Sapienza University of Rome, Azienda
Policlinico Umberto i, Rome, Italy
(Zani) Department of Surgery, University of Toronto, Toronto, ON, Canada
Publisher
Georg Thieme Verlag
Abstract
Aim The main purpose of this study was to investigate if necrotizing
enterocolitis (NEC) has a different presentation and outcome in patients
with congenital heart defect (CHD) (cardiogenic NEC) from those without
(classical NEC). Materials and Methods A systematic review of the
literature on the characteristics of infants with NEC and CHD was
performed by three independent investigators using a defined strategy
(PubMed, Cochrane, Embase, and Web of Science). A meta-analysis was
conducted on studies comparing NEC in infants with CHD and non-CHD infants
using RevMan 5.3. Results Systematic review: Of 7,291 abstracts screened,
126 full-text articles were analyzed and 51 studies were included. NEC had
an incidence of 5.1% in CHD infants (7,728/151,046, range 0-24%) and 0.8%
in non-CHD infants (26,430/3,256,891, range 0.1-8.9%; p < 0.0001). In very
low birth weight infants, NEC occurred in 6.3% of CHD patients
(6,361/100,454pts) and in 8.9% of non-CHD (23,201/257,794pts; p < 0.0001).
In CHD cases, NEC occurred before cardiac surgery in 48% cases and surgery
for NEC was required in 31% infants (2,037/6,683). Meta-analysis: In eight
comparative studies, the incidence of NEC was higher in CHD infants (6%,
768/13,145) than in infants with no CHD (0.9%, 32,625/3,354,323pts; p <
0.00001, odds ratio [OR] 1.84, 95% confidence interval [CI] 1.7-1.9). The
overall mortality was higher in infants with CHD and NEC (38%, 243/640)
than in those without CHD (27%, 6651/24810; p < 0.00001, OR 3.4, 95% CI
2.8-4.1). Conclusion This is the first evidence-based study showing that
infants with cardiogenic NEC have different demographics and outcomes than
those with classical NEC. The risk of developing NEC and the mortality
rate are higher among infants with CHD than in those without. Conversely,
the need for intestinal surgery is lower in babies with cardiogenic NEC
than in those with classical NEC. Further studies are needed to establish
preventative and management interventions that are specific to infants
with or at risk of developing cardiogenic NEC.<br/>Copyright &#xa9; 2019
Georg Thieme Verlag KG Stuttgart - New York.

<90>
Accession Number
629559378
Title
Impact of Prosthesis-Patient Mismatch on Survival after Mitral Valve
Replacement: A Meta-analysis.
Source
Thoracic and Cardiovascular Surgeon. 67(7) (pp 538-545), 2019. Date of
Publication: 11 Oct 2019.
Author
Hwang H.-Y.; Sohn S.-H.; Jang M.-J.
Institution
(Hwang, Sohn, Jang) Medical Research Collaborating Center, Seoul National
University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, South Korea
Publisher
Georg Thieme Verlag
Abstract
Background: Numerous studies have demonstrated a negative impact of
prosthesis-patient mismatch (PPM) on long-term clinical outcomes after
aortic valve replacement. However, the impact of PPM after mitral valve
replacement (MVR) on clinical outcomes is still controversial. This study
was conducted to evaluate the impact of PPM on early and long-term
survival after MVR. <br/>Method(s): A literature search of five databases
was performed. The primary and secondary outcomes were all-cause mortality
and early mortality, respectively. Subgroup analyses were performed
according to the risk of bias, patients' age, proportion of female
patients, and proportion of patients with mechanical MVR. <br/>Result(s):
Eleven nonrandomized studies including 8,072 patients were included in
this meta-analysis. The overall incidence of PPM was 58.0% (range:
10.4-85.9%). The odds ratio of early mortality in nine studies was not
significantly different between the PPM and non-PPM patients (odds ratio:
1.35; 95% confidence interval [CI]: 0.98-1.86). A pooled analysis in 11
studies demonstrated that all-cause mortality after MVR was higher in the
PPM than non-PPM patients (hazard ratio [HR]: 1.39; 95% CI: 1.09-1.77).
This analysis revealed a moderate to high heterogeneity (I 2 = 69.4%).
When pooled analyses were performed in two subgroups according to the
proportion of patients with mechanical MVR, there were low heterogeneity
in each group. No other subgroup analyses demonstrated a significant
difference in the HR of all-cause mortality. Funnel plots and Egger's
tests showed no visually and statistically significant publication bias.
<br/>Conclusion(s): The present meta-analysis indicates that PPM
negatively affects long-term survival after MVR.<br/>Copyright &#xa9; 2019
Georg Thieme Verlag KG Stuttgart New York.

<91>
Accession Number
2043600659
Title
Artificial intelligence in cardiology: a narrative review with focus on
patient outcomes.
Source
Cardiovascular Diagnosis and Therapy. 16(1) (no pagination), 2026. Article
Number: 8. Date of Publication: 28 Feb 2026.
Author
Alexandrou M.; Konstantinidis I.; Orenday J.M.; Strepkos D.; Carvalho
P.E.P.; Kladou E.; Rangan B.V.; Mastrodemos O.C.; Kaur H.; Sandoval Y.;
Brilakis E.S.
Institution
(Alexandrou, Strepkos, Carvalho, Kladou, Rangan, Mastrodemos, Kaur,
Sandoval, Brilakis) Minneapolis Heart Institute, Minneapolis Heart
Institute Foundation, Abbott Northwestern Hospital, Minneapolis, MN,
United States
(Konstantinidis) Yale New Haven Hospital, New Haven, CT, United States
(Orenday) Harlem Hospital Center, New York, NY, United States
Publisher
AME Publishing Company
Abstract
Background and Objective: Artificial intelligence (AI) is rapidly
transforming cardiology through advancements in diagnostic accuracy,
prognostication, and treatment personalization. While evidence for
algorithmic performance is robust, its true impact on patient-centered
outcomes remains unclear. This review aims to evaluate how AI applications
influence patient outcomes in cardiology and identify current limitations
and future directions. <br/>Method(s): A targeted literature search was
conducted in PubMed, Scopus, Embase, and Cochrane databases on May 9 and
23, 2025, using a combination of terms related to AI, cardiology, and
patient outcomes. Filters were applied to include human studies, English
language, and studies published between January 2015 and May 2025. Two
reviewers independently screened articles, and three reviewers reached
consensus for final inclusion. A total of 11 studies met inclusion
criteria. Key Content and Findings: AI tools have demonstrated potential
benefits across multiple domains, including clinical decision support,
cardiac imaging, remote patient monitoring, and patient engagement.
Evidence suggests AI can enhance diagnostic accuracy, procedural
efficiency, and patient self-management. However, most studies report
surrogate or process-related endpoints rather than hard clinical outcomes.
Large-scale randomized trials remain scarce, and improvements in
mortality, hospitalization, and quality of life (QoL) are inconsistently
demonstrated. Ethical considerations, implementation challenges, and
cost-effectiveness concerns persist. <br/>Conclusion(s): AI in cardiology
shows promise for improving patient care, but robust evidence linking its
adoption to improved clinical outcomes is limited. By synthesizing
available findings, this review highlights critical evidence gaps and
provides guidance for future research, which should prioritize prospective
trials focused on patient-centered endpoints and address barriers to
implementation, transparency, and equity.<br/>Copyright &#xa9; AME
Publishing Company.

<92>
Accession Number
2031568089
Title
Isolated Tricuspid Valve Surgery for Functional Tricuspid Regurgitation.
Source
Thoracic and Cardiovascular Surgeon. 73(2) (pp 111-116), 2024. Date of
Publication: 06 Mar 2025.
Author
Kaneyuki D.; Jordan A.M.; Rosen J.L.; Macmillan T.R.; Morris R.J.;
Tchantchaleishvili V.
Institution
(Kaneyuki, Jordan, Rosen, Macmillan, Morris, Tchantchaleishvili) Division
of Cardiac Surgery, Thomas Jefferson University Hospital, Philadelphia,
PA, United States
Publisher
Georg Thieme Verlag
Abstract
Background Severe tricuspid regurgitation (TR) adversely affects long-term
survival; however, isolated tricuspid valve (TV) surgery has been rarely
performed due to high operative mortality. In addition, the previous
literature included heterogeneous TR etiologies. Therefore, we aimed to
elucidate early and long-term outcomes of isolated TV surgery for
functional TR. Methods An electronic search was performed to identify all
relevant studies. Baseline characteristics, perioperative variables, and
clinical outcomes were extracted and pooled for meta-analysis. Results
This meta-analysis included seven studies. Pooled analyses showed that 68%
(35, 89) of patients had preoperative atrial fibrillation or flutter, and
58% (11, 94) had a history of left-sided valve surgery. Seventy-three
percent (65, 80) of patients had at least one physical exam finding of
right-sided heart failure, and 57% (44, 69) were in New York Heart
Association class III or IV. TV replacement was more common than repair.
In TV replacement, bioprosthetic valve (39%, 13, 74) was more common than
mechanical prosthesis (22%, 18, 26). The early mortality rate was 7%.
Twenty percent of patients required a permanent pacemaker postoperatively.
The overall 1- and 5-year survival rates were 84.5 and 69.1%,
respectively. Conclusion More than half of the patients who underwent
isolated TV surgery for functional TR had undergone left-sided valve
surgery and had significant heart failure symptoms at the time of surgery.
Further studies on the surgical indication for concomitant TV surgery at
the time of left-sided valve surgery and the appropriate timing of surgery
for isolated functional TR are needed to improve survival.<br/>Copyright
&#xa9; 2024. Thieme. All rights reserved.

<93>
Accession Number
2043504946
Title
Effect of preoperative prehabilitation on the 6-minute walk distance and
postoperative outcomes in adult patients: meta-analysis.
Source
BJS Open. 10(1) (no pagination), 2026. Article Number: zraf162. Date of
Publication: 01 Feb 2026.
Author
Diaz-Vidal P.; Gil-Casado C.; Fernandez-Vazquez U.; Diz-Ferreira E.;
Luna-Rojas P.; Diz J.C.
Institution
(Diaz-Vidal, Gil-Casado, Fernandez-Vazquez, Diz-Ferreira, Luna-Rojas)
School of Medicine, University of Santiago de Compostela, Santiago de
Compostela, Spain
(Diz-Ferreira, Diz) Well-Move Research Group, Galicia Sur Health Research
Institute (IIS Galicia Sur), Vigo, Spain
(Diz) Department of Anaesthesia and Postoperative Critical Care, Hospital
Alvaro Cunqueiro, Vigo, Spain
(Diz) Department of Functional Biology and Health Sciences, University of
Vigo, Vigo, Spain
Publisher
Oxford University Press
Abstract
Background: Low cardiorespiratory fitness (CRF) has been demonstrated to
be associated with increased perioperative morbidity and mortality.
However, evidence regarding the effect of prehabilitation on CRF and
postoperative outcomes remains inconclusive. <br/>Method(s): A systematic
review and meta-analysis were conducted in accordance with the PRISMA
statement encompassing randomized clinical trials (RCTs) published in
PubMed and Web of Science up to June 2025 on the effects of
prehabilitation with exercise, measured using the 6-minute walk test, for
adult patients undergoing surgery. The primary objective was to examine
the effect of prehabilitation based on physical exercise on the
preoperative physical condition of adults scheduled to undergo elective
surgery, measured as the change in the 6-minute walk distance (6MWD).
Factors associated with changes in the 6MWD and the effect of
prehabilitation on postoperative CRF were analysed, as were the length of
hospital stay and mortality. Effect sizes and their 95% confidence
interval (c.i.) were estimated with a random-effects model.
<br/>Result(s): Of 107 RCTs screened, 21 were included in the analysis,
comprising 1649 patients (828 undergoing prehabilitation) across several
specialities, the most prevalent being cardiac (501 patients), colorectal
(423 patients), and thoracic surgery (364 patients). The prehabilitation
group exhibited a greater improvement in the 6MWD before surgery (mean
difference (MD) 29 m; 95% c.i. 14 to 42 m; P < 0.001; I ² =
84%) and in the first month after surgery (MD 22 m; 95% c.i. 0 to 43 m; P
= 0.05; I ² = 92%). A greater proportion of patients in the
prehabilitation group had a clinically significant improvement in the 6MWD
both before (odds ratio (OR) 2.66; 95% c.i. 1.76 to 4.0; P < 0.001; I
² = 53%) and after (OR 2.59; 95% c.i. 1.05 to 6.35; P = 0.04; I
² = 69%) surgery. There were no differences between the groups
in length of hospital stay (MD -0.24; 95% c.i. -0.65 to 0.17; P = 0.25; I
² = 25%) or mortality (OR 0.71; 95% c.i. 0.26 to 1.92; P = 0.5;
I ² = 0%). <br/>Conclusion(s): Prehabilitation involving
physical exercise before surgery was associated with an improvement in
preoperative CRF. However, no differences were observed between the groups
in length of hospital stay or postoperative mortality. The improvement in
CRF persists in the postoperative period, suggesting a potential benefit
for patient recovery.<br/>Copyright &#xa9; The Author(s) 2026. Published
by Oxford University Press on behalf of BJS Foundation Ltd.

<94>
Accession Number
626675021
Title
Clinical Risk Factors for Postoperative Atrial Fibrillation among Patients
after Cardiac Surgery.
Source
Thoracic and Cardiovascular Surgeon. 67(2) (pp 107-116), 2019. Date of
Publication: 07 Mar 2019.
Author
Yamashita K.; Hu N.; Ranjan R.; Selzman C.H.; Dosdall D.J.
Institution
(Yamashita, Ranjan, Selzman, Dosdall) Nora Eccles Harrison Cardiovascular
Research and Training Institute, University of Utah, 95 South 2000 East,
United States
(Yamashita, Ranjan, Dosdall) Division of Cardiovascular Medicine,
Department of Internal Medicine, University of Utah, Salt Lake City, UT,
United States
(Hu) Huntsman Cancer Institute, University of Utah, Salt Lake City, UT,
United States
(Hu) Division of Epidemiology, Department of Internal Medicine, University
of Utah, Salt Lake City, UT, United States
(Selzman, Dosdall) Division of Cardiothoracic Surgery, Department of
Surgery, University of Utah, Salt Lake City, UT, United States
Publisher
Georg Thieme Verlag
Abstract
Background a?Postoperative atrial fibrillation (POAF) is a common
arrhythmia following cardiac surgery and is associated with increased
health-care costs, complications, and mortality. The etiology of POAF is
incompletely understood and its prediction remains suboptimal. Using data
from published studies, we performed a systemic review and meta-analysis
to identify preoperative clinical risk factors associated with patients at
increased risk of POAF. Methods a?A systematic search of PubMed, MEDLINE,
and EMBASE databases was performed. Results a?Twenty-four studies that
reported univariate analysis results regarding POAF risk factors,
published from 2001 to May 2017, were included in this meta-analysis with
a total number of 36,834 subjects. Eighteen studies were performed in the
United States and Europe and 16 studies were prospective cohort studies.
The standardized mean difference (SMD) between POAF and non-POAF groups
was significantly different (reported as [SMD: 95% confidence interval,
CI]) for age (0.55: 0.47-0.63), left atrial diameter (0.45: 0.15-0.75),
and left ventricular ejection fraction (0.30: 0.14-0.47). The pooled odds
ratios (ORs) (reported as [OR: 95% CI]) demonstrated that heart failure
(1.56: 1.31-1.96), chronic obstructive pulmonary disease (1.36:
1.13-1.64), hypertension (1.29: 1.12-1.48), and myocardial infarction
(1.18: 1.05-1.34) were significant predictors of POAF incidence, while
diabetes was marginally significant (1.06: 1.00-1.13). Conclusion a?The
present analysis suggested that older age and history of heart failure
were significant risk factors for POAF consistently whether the included
studies were prospective or retrospective datasets.<br/>Copyright &#xa9;
2019 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY
10001, USA.

<95>
Accession Number
2043225157
Title
Analgesic efficacy of the subtransverse process interligamentary plane
block in thoracic surgery: A randomized, controlled, non-inferiority
trial.
Source
Journal of Clinical Anesthesia. 110 (no pagination), 2026. Article Number:
112149. Date of Publication: 01 Mar 2026.
Author
Wu W.; Liu Y.; Liu M.; Wu J.; He W.; Shi H.
Institution
(Wu, Liu, Liu, Wu, Shi) Department of Anesthesiology, Shanghai Pulmonary
Hospital, School of Medicine, Tongji University, Shanghai, China
(He) Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School
of Medicine, Tongji University, Shanghai, China
Publisher
Elsevier Inc.
Abstract
Background Clinical evidence on the analgesic efficacy of the
subtransverse process interligamentary plane (STIL) block after thoracic
surgery remains limited. This study aimed to compare the postoperative
analgesic efficacy of the STIL block versus the thoracic paravertebral
block (TPVB) in thoracic surgery. Methods This randomized, non-inferiority
trial enrolled patients undergoing video-assisted thoracoscopic surgery at
a large academic medical center in China. Patients were randomly assigned
(1:1) to receive either the STIL block or TPVB. Both groups received a
single-shot injection of 15 mL of 1% ropivacaine mixed with 2% lidocaine.
The primary outcome was pain intensity during deep inspiration within 48 h
postoperatively, assessed by the area under the curve (AUC) of the numeric
rating scale. A non-inferiority margin of 34 was predefined, and analyses
were performed in both intention-to-treat and per-protocol populations.
Results From February 1, 2023, to December 30, 2024, 114 eligible patients
(median age 58 years [IQR 49-61]; 54.0% female) were enrolled and randomly
assigned to receive either the STIL block ( n = 57) or the TPVB (n = 57).
Nine patients were excluded after randomisation, resulting in 105 patients
included in the per-protocol analysis. In the per-protocol population, the
48-h postoperative pain AUC during deep inspiration was 196.04 +/- 2.50
for the STIL group and 187.49 +/- 4.13 for the TPVB group (mean difference
= 8.59; 95% CI, -0.94 to 18.14). In the intention-to-treat population, the
values were 195.24 +/- 2.49 and 186.44 +/- 4.03, respectively (mean
difference = 9.12; 95% CI, -0.39 to 18.63), both within the predefined
noninferiority margin. No serious adverse events were observed in either
group. Conclusions This randomized clinical trial demonstrates that, in
the studied population, the subtransverse process interligamentary plane
block was non-inferior to the thoracic paravertebral block for
postoperative pain control after thoracic surgery, providing an effective
alternative for analgesia.<br/>Copyright &#xa9; 2026 Elsevier Inc.

<96>
Accession Number
2034220669
Title
Combined Catheter Ablation and Left Atrial Appendage Occlusion in Atrial
Fibrillation: From Data to Clinical Reality.
Source
Cardiovascular Drugs and Therapy. 40(1) (pp 361-392), 2026. Date of
Publication: 01 Feb 2026.
Author
Dimitriadis K.; Adamopoulou E.; Pyrpyris N.; Iliakis P.; Beneki E.;
Konstantinidis D.; Fragkoulis C.; Antonopoulos A.; Papanikolaou A.;
Aznaouridis K.; Aggeli K.; Tsioufis K.
Institution
(Dimitriadis, Adamopoulou, Pyrpyris, Iliakis, Beneki, Konstantinidis,
Fragkoulis, Antonopoulos, Papanikolaou, Aznaouridis, Aggeli, Tsioufis)
First Department of Cardiology, School of Medicine, National and
Kapodistrian University of Athens, Hippokration General Hospital, Vas
Sofias 114, Athens, Greece
Publisher
Springer
Abstract
Purpose: Atrial fibrillation (AF) requires treatment that focuses on two
main goals: symptom control and prevention of thromboembolic events.
Catheter ablation and left atrial appendage occlusion (LAAO) constitute
two well-established treatment methods in selected patients that
accomplish these two goals correspondingly. Recently, there is increasing
interest in performing the two procedures concomitantly in a so-called
"combined" or "one-stop" procedure. This review aims to summarize the
current data on the combined procedure, from the rationale and the
techniques to its clinical efficacy, indications and future directions.
<br/>Method(s): An extensive search has been conducted using the
MEDLINE/PubMed database to identify the relevant studies. <br/>Result(s):
The reported success rates of the combined procedure are very high and
frequently reach 100% when performed by experienced operators. The
periprocedural and follow-up complications are low, the procedure is
cost-effective, while there is significant stroke, bleeding and arrhythmia
incidence reduction that does not seem to be undermined by interference
between the two interventions. There are also a few indications that the
one-stop procedure has a positive effect on left atrial mechanical
function as it has been correlated with left atrial reverse remodeling. On
the other hand, some studies suggest possible increase in peri-device
leaks (PDLs), compared with LAAO alone, which could in turn negatively
affect the clinical outcomes. Most available studies are small and
observational, with a lack of randomized controlled trials.
<br/>Conclusion(s): Catheter ablation and left atrial appendage occlusion
can be safely and effectively combined in a cost-effective single
procedure in carefully selected patients.<br/>Copyright &#xa9; The
Author(s) 2025.

<97>
Accession Number
2041584721
Title
Cryotherapy use in the context of thoracic surgery.
Source
Journal of Thoracic and Cardiovascular Surgery. 171(3) (pp e76-e77), 2026.
Date of Publication: 01 Mar 2026.
Author
Amin A.; Hamead H.; Tenconi S.; Granato F.
Institution
(Amin, Hamead, Tenconi, Granato) Department of Lung Cancer and Thoracic
Surgery, Wythenshawe Hospital, Manchester University NHS Foundation Trust,
Manchester, United Kingdom
Publisher
Elsevier Inc.

<98>
Accession Number
2039490983
Title
Evaluate psychological effects of prolonged fasting in patients undergoing
cardiac surgery.
Source
Cirugia Cardiovascular. 33(1) (pp 5-10), 2026. Date of Publication: 01 Jan
2026.
Author
Moreno Rodriguez J.; Lorenzo Diaz M.; Aranda Domene R.; Canovas Lopez
S.J.; March Salas M.; Alcaraz Garcia M.J.; Perez Morote J.; Sanchez Motos
R.; Amor Vigueras A.; Ponce de Leon Torralba M.; Aviles Alvizu J.M.;
Galindo Rueda M.D.M.; Clemente Murcia M.
Institution
(Moreno Rodriguez, Lorenzo Diaz, Aranda Domene, Canovas Lopez, March
Salas, Alcaraz Garcia, Perez Morote, Sanchez Motos, Amor Vigueras, Ponce
de Leon Torralba, Aviles Alvizu, Galindo Rueda, Clemente Murcia)
Cardiovascular Surgery, Murcian Institute of Biosanitary Research (IMIB),
Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain
Publisher
Sociedad Espanola de Cirugia Cardiovascular y Endovascular (SECCE)
Abstract
Introduction: Comprehensive care of the cardiosurgical patient is
essential to optimize clinical results. In this context, preoperative
strategies play a key role, with accelerated recovery programs (ERAS)
being a promising alternative. <br/>Objective(s): To evaluate the
psychological and metabolic effects of prolonged fasting (>8h) in patients
undergoing elective cardiac surgery, comparing them with a group receiving
carbohydrate supplementation. Methodology: Quasi-experimental, prospective
and randomized study. Patients were assigned to two groups: (1)
Carbohydrate supplementation and (2) Prolonged fasting. Clinical
variables, capillary blood glucose, anxiety (Hamilton Scale), feeling of
hunger and thirst, perceived satisfaction and postoperative complications
were measured. <br/>Result(s): 58 patients were included. The intervention
group presented a lower sensation of hunger and thirst (p<0.001), as well
as a significant reduction in pre-surgical anxiety (p=0.003) compared to
the control group. Perceived satisfaction was also higher in the
intervention group (p=0.047). No significant differences were detected in
capillary blood glucose levels between the groups. Neither was a greater
need for insulin administration observed in either group. Regarding
postoperative complications, no significant differences were observed, nor
were there any cases of mortality attributable to the procedure.
<br/>Conclusion(s): Preoperative supplementation with carbohydrate-rich
fluids improves the patient experience in terms of anxiety and comfort,
without compromising metabolic stability or increasing the incidence of
postoperative complications. The findings found throughout the research
support the incorporation of this strategy into cardiac surgery protocols,
with the potential to optimize patient experience and outcomes.
Introduccion: La atencion integral del paciente cardioquirurgico es
fundamental para optimizar los resultados clinicos. En este contexto, las
estrategias preoperatorias desempenan un papel clave, siendo los programas
de recuperacion acelerada (ERAS) una alternativa prometedora. Objetivo:
Evaluar los efectos psicologicos y metabolicos del ayuno prolongado (>8
horas) en pacientes sometidos a cirugia cardiaca programada, comparandolos
con un grupo que recibe suplementacion con hidratos de carbono.
Metodologia: Estudio cuasiexperimental, prospectivo y aleatorizado. Los
pacientes fueron asignados a dos grupos: 1) Suplementacion con
carbohidratos y 2) Ayuno prolongado. Se midieron variables clinicas,
glucemia, ansiedad (Escala de Hamilton) y satisfaccion percibida.
Resultados: Se incluyeron 58 pacientes. El grupo de intervencion presento
menor sensacion de hambre y sed (p<0.001), asi como una reduccion
significativa de la ansiedad prequirurgica (p=0.003) en comparacion con el
grupo control. La satisfaccion percibida tambien fue mayor en el grupo de
intervencion (p=0,047). No se observaron diferencias significativas en las
complicaciones postoperatorias. Conclusiones: Los hallazgos encontrados a
lo largo de la investigacion respaldan la incorporacion de esta estrategia
en los protocolos de cirugia cardiaca, con el potencial de optimizar la
experiencia y los resultados del paciente.<br/>Copyright &#xa9; 2025
Sociedad Espanola de Cirugia Cardiovascular y Endovascular. Published by
Elsevier Espana, S.L.U. This is an open access article under the CC
BY-NC-ND license. http://creativecommons.org/licenses/by-nc-nd/4.0/

<99>
Accession Number
620125977
Title
Is 300 Seconds ACT Safe and Efficient during MiECC Procedures?.
Source
Thoracic and Cardiovascular Surgeon. 67(3) (pp 191-202), 2019. Date of
Publication: 05 Apr 2019.
Author
Bauer A.; Hausmann H.; Schaarschmidt J.; Szlapka M.; Scharpenberg M.;
Eberle T.; Hasenkam J.M.
Institution
(Bauer, Schaarschmidt) Department of Cardiovascular Perfusion, MediClin
Heart Center Coswig, Lerchenfeld 1, Coswig, Saxony-Anhalt, Germany
(Bauer, Hasenkam) Department of Cardiothoracic and Vascular Surgery,
Aarhus University Hospital, Aarhus, Denmark
(Bauer, Hasenkam) Department of Clinical Medicine, Aarhus University,
Aarhus, Denmark
(Hausmann, Szlapka) Department of Cardiothoracic and Vascular Surgery,
MediClin Heart Center Coswig, Coswig, Saxony-Anhalt, Germany
(Scharpenberg) Competence Center for Clinical Trials Bremen, University of
Bremen, Bremen, Germany
(Eberle) Department of Anesthesia and Intensive Care Medicine, MediClin
Heart Center Coswig, Coswig, Saxony-Anhalt, Germany
Publisher
Georg Thieme Verlag
Abstract
Introduction The recommended minimum activated clotting time (ACT) level
for cardiopulmonary bypass (CPB) of 480 seconds originated from
investigations with bubble oxygenators and uncoated extracorporeal
circulation (ECC) systems. Modern minimal invasive ECC (MiECC) systems are
completely closed circuits containing a membrane oxygenator and a
tip-to-tip surface coating. We hypothesized that surface coating and the
closed-loop design allow the MiECC to safely run with lower ACT levels and
that an ACT level of 300 seconds can be safely applied without
thromboembolic complications. The aim of this study was to investigate the
potential risks during application of reduced heparin levels in patients
undergoing coronary surgery. Methods In this study, 68 patients undergoing
coronary artery bypass grafting with MiECC were randomized to either the
study group with an ACT target of 300 seconds or the control group with an
ACT of 450 seconds. All other factors of MiECC remained unchanged. Results
The study group received significantly less heparin and protamine (heparin
[international units] median [min-max], Red-AC: 32,800 [23,000-51,500] vs.
Full-AC: 50,000 [35,000-65,000] p < 0.001; protamine [international
units], Red-AC: 18,000 [10,000-35,000] vs. Full-AC: 30,000 [20,000-45,000]
p < 0.001). The ACT in the study group was significantly lower at the
start of MiECC (mean +/- standard deviation: study group 400 +/- 112 vs.
control group 633 +/- 177; p < 0.0001). Before termination of CPB the ACT
levels were: study group 344 +/- 60 versus control group 506 +/- 80. In
both groups, the values of the endogenous thrombin potential (ETP)
decreased simultaneously. None of the study participants experienced
thromboembolic complications. Conclusion Since no evidence of increased
thrombin formation (ETP) was found from a laboratory standpoint, we
concluded that the use of MiECC with a reduced anticoagulation strategy
seems possible. This alternative anticoagulation strategy leads to
significant reduction in dosages of both heparin and protamine. We can
confidently move forward with investigating this anticoagulation concept.
However, to establish clinical safety of ACT below 300 seconds, we need
larger clinical studies.<br/>Copyright &#xa9; 2019 Georg Thieme Verlag KG
Stuttgart. New York.

<100>
Accession Number
627945846
Title
Meta-analysis of valve-in-valve transcatheter versus redo surgical aortic
valve replacement.
Source
Thoracic and Cardiovascular Surgeon. 67(4) (pp 243-250), 2019. Date of
Publication: 03 Jun 2019.
Author
Takagi H.; Mitta S.; Ando T.
Institution
(Takagi, Mitta) Department of Cardiovascular Surgery, Shizuoka Medical
Center, 762-1 Nagasawa, Shimizu-cho, Sunto-gun, Shizuoka, Japan
(Ando) Department of Cardiology, Detroit Medical Center, Detroit, United
States
Publisher
Georg Thieme Verlag
Abstract
Objective The objective of this study was to determine whether
valve-in-valve transcatheter aortic valve implantation (VIV-TAVI) is
associated with better survival than redo surgical aortic valve
replacement (SAVR) in patients with degenerated aortic valve
bioprostheses, and we performed a meta-analysis of comparative studies.
Methods To identify all comparative studies of VIV-TAVI versus redo SAVR;
MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials
were searched through October 2017. For each study, data regarding
all-cause mortality in both the VIV-TAVI and redo SAVR groups were used to
generate odds ratios (ORs). To assess selection bias, we generated ORs and
(standardized) mean differences (MDs) for baseline characteristics.
Study-specific estimates were combined in the random-effects model.
Results Of 446 potentially relevant articles screened initially, 6 reports
of retrospective comparative studies enrolling a total of 498 patients
were identified. Pooled analyses of baseline characteristics demonstrated
no statistically significant differences in the proportion of women,
patients with diabetes mellitus, patients with coronary artery disease,
and patients with baseline New York Heart Association functional class of
>=III; baseline ejection fraction; and predicted mortality between the
VIV-TAVI and redo SAVR groups. Patients in the VIV-TAVI group, however,
were significantly older (MD, 4.20 years) and had undergone prior coronary
artery bypass grafting more frequently (OR, 2.19) than those in the redo
SAVR group. Main pooled analyses demonstrated no statistically significant
differences in early (30 days or in-hospital) (OR, 0.91; p = 0.83) and
midterm (180 days-3 years) all-cause mortalities (OR, 1.42; p = 0.21)
between the VIV-TAVI and redo SAVR groups. Conclusion In patients with
degenerated aortic valve bioprostheses, especially elderly or high-risk
patients, VIV-TAVI could be a safe, feasible alternative to redo SAVR. The
lack of randomized data and differences in baseline characteristics in the
present analysis emphasize the need for prospective randomized
trials.<br/>Copyright &#xa9; 2019 Georg Thieme Verlag KG Stuttgart * New
York.

<101>
Accession Number
2043510944
Title
Cost analyses in randomized trials on robot-assisted surgery: systematic
review.
Source
BJS Open. 10(1) (no pagination), 2026. Article Number: zraf161. Date of
Publication: 01 Feb 2026.
Author
Bosscha S.R.J.; Amiri R.; Jamaludin F.; Rovers M.; Besselink M.G.; Van
Hilst J.
Institution
(Bosscha, Amiri, Jamaludin, Besselink, Van Hilst) Department of Surgery,
Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
(Bosscha, Amiri, Jamaludin, Besselink, Van Hilst) Cancer Center Amsterdam,
Amsterdam, Netherlands
(Rovers) Department of Medical Imaging, Radboud University Medical Center,
Nijmegen, Netherlands
(Van Hilst) Department of Surgery, OLVG, Amsterdam, Netherlands
Publisher
Oxford University Press
Abstract
Background Robot-assisted surgery (RAS) is increasingly being used, yet
its cost-effectiveness remains debated. Cost analyses of RAS are therefore
essential but remain challenging. This systematic review evaluated the
quality of cost analyses in randomized clinical trials (RCTs) comparing
RAS with alternative surgical approaches. Methods A systematic review was
performed in PubMed, EMBASE, Cochrane Library, and Web of Science from
inception up to August 2025. RCTs were included if they compared RAS with
other approaches and conducted a cost analysis. Risk of bias was assessed
using the revised Cochrane Risk-of-Bias tool. The methodological quality
and comprehensiveness of cost analyses were evaluated with the Economic
Evaluation Bias Assessment Tool (ECOBIAS) and Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) checklist, respectively. Studies
were evaluated for key structural and component-specific costs of RAS.
Results Overall, 38 RCTs involving 5832 patients were included. Most
studies focused on general surgical procedures (20 RCTs, 53%), followed by
urology (7), gynaecology (7), and cardiothoracic surgery (4). RAS was
compared with laparoscopic surgery in 23 RCTs, open surgery in 14 RCTs,
and another robotic modality in one RCT. Regarding bias, 10 RCTs (26%)
were considered high risk, and 24 (63%) had some concerns. On average,
RCTs met 5 of 11 ECOBIAS criteria and 14 of 28 CHEERS items. Only 15 of 38
RCTs (39%) included key structural costs of RAS, such as robot acquisition
and maintenance, whereas 12 of 38 RCTs (32%) provided a component-specific
cost overview. RAS was more expensive in 33 of 36 RCTs (92%). Conclusion
Randomized trials comparing RAS with other surgical approaches rarely
perform adequate cost assessments and costeffectiveness analyses. The
substantial risk of bias, methodological heterogeneity, and partial cost
reporting observed underline the need for uniform economic evaluation in
RCTs on RAS.<br/>Copyright &#xa9; The Author(s) 2026. Published by Oxford
University Press on behalf of BJS Foundation Ltd.

<102>
Accession Number
2038432593
Title
Comparison of Endoaortic Balloon Occlusion and Transthoracic Aortic Clamp
for Minimally Invasive Cardiac Surgery: Systematic Review and
Meta-analysis.
Source
International Journal of Angiology. 34(3) (pp 176-190), 2025. Date of
Publication: 05 Aug 2025.
Author
Naito N.; Takagi H.
Institution
(Naito, Takagi) Department of Cardiovascular Surgery, Shizuoka Medical
Center, Shizuoka, Japan
Publisher
Thieme Medical Publishers, Inc.
Abstract
This meta-analysis aimed to compare short-term outcomes in patients
undergoing minimally invasive cardiac surgery (MICS) using endoaortic
balloon (EAB) and transthoracic aortic clamp (TAC) techniques. A
comprehensive search of relevant databases was conducted through July
2024. Pooled results were calculated, and subgroup analyses of studies
published during early and late eras were performed. Additionally, a
meta-regression analysis based on the year of publication was conducted to
assess potential influences on outcomes. The systematic review identified
17 non-randomized studies encompassing a total of 8,253 patients. In terms
of intraoperative outcomes, no significant differences were observed in
operation duration, aortic cross-clamp time, cardiopulmonary bypass time,
or rates of sternotomy conversion and iatrogenic aortic dissection.
However, subgroup analysis of early-era studies demonstrated significantly
longer operation times in the EAB cohort (p 1/4 0.03). Meta-regression
analysis indicated that the standardized mean differences in
cardiopulmonary bypass time between the two groups decreased in favor of
EAB as publication years progressed (p 1/4 0.01). For postoperative
outcomes, no significant differences were found in postoperative stroke
rate, the rate of reoperation for bleeding, or length of hospital stay.
However, the EAB group had significantly lower rates of postoperative
atrial fibrillation (OR 1/4 0.82 [0.70-0.95], p < 0.01) and short-term
mortality (OR 1/4 0.60 [0.39-0.92], p 1/4 0.04). This meta-analysis
demonstrated that EAB is associated with perioperative outcomes comparable
to TAC in select patients. The cumulative experience and evolution of
techniques may have contributed to improved outcomes with EAB over
time.<br/>Copyright &#xa9; 2025. International College of Angiology. All
rights reserved.

<103>
Accession Number
650463341
Title
Efficacy of perioperative intravenous lidocaine infusion on postoperative
recovery and analgesia in patients undergoing video-assisted thoracoscopic
surgery: study protocol for a randomised, double-blind, placebo-controlled
trial.
Source
BMJ open. 16(3) (pp e113691), 2026. Date of Publication: 03 Mar 2026.
Author
Omindo W.W.; Xiao Z.; Wang X.; Fu L.; Wang J.; Zhang R.; Ping W.; Zhou B.;
Zhang N.
Institution
(Omindo, Xiao, Wang, Fu, Wang, Zhang, Ping, Zhang) Department of Thoracic
Surgery, Huazhong University of Science and Technology Tongji Medical
College Tongji Hospital, Wuhan, Hubei, China
(Zhou) Department of Anesthesiology, Huazhong University of Science and
Technology Tongji Medical College Tongji Hospital, Wuhan, Hubei, China
Abstract
INTRODUCTION: Despite the minimally invasive nature of video-assisted
thoracoscopic surgery (VATS), moderate-to-severe postoperative pain
remains frequent and impairs recovery. Intravenous lidocaine possesses
multimodal analgesic, antihyperalgesic and anti-inflammatory properties
that may improve pain control and functional outcomes, but robust evidence
in thoracic surgery is lacking. Moreover, its potential to attenuate
neuropathic pain, a key component of chronic post-thoracic pain syndromes,
has not been adequately investigated. This trial will determine whether
continuous perioperative intravenous lidocaine infusion improves recovery,
reduces acute pain intensity and prevents the development of neuropathic
pain after VATS. METHODS AND ANALYSIS: This single-centre, randomised,
double-blind, placebo-controlled trial will enrol 84 adult patients
undergoing elective VATS. Participants will be randomised (1:1) to receive
either intravenous lidocaine (bolus 1 mg/kg at induction followed by
continuous infusion at 1.5 mg/kg/hour intraoperatively and postoperatively
for 24 hours) or matched normal saline postoperatively, with identical
intraoperative management in both groups. The primary outcome is the
incidence of moderate-to-severe movement-evoked pain at 24 hours
postoperatively. Secondary outcomes include pain at 48 and 72 hours,
opioid consumption, pulmonary complications, sleep quality, quality of
recovery, neurocognitive outcomes and chronic neuropathic pain at 3
months. Analyses will follow the intention-to-treat principle. ETHICS AND
DISSEMINATION: The study protocol was approved by the Institutional Review
Board of Tongji Hospital (Reference No. TJ-IRB202509102) and registered in
the Chinese Clinical Trial Registry (ChiCTR2500111163). Written informed
consent will be obtained from all participants. Results will be submitted
to peer-reviewed journals and academic conferences. TRIAL REGISTRATION
NUMBER: ChiCTR2500111163.<br/>Copyright &#xa9; Author(s) (or their
employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use.
See rights and permissions. Published by BMJ Group.

<104>
Accession Number
2043864764
Title
EACTS Expert Consensus Statement on the Ross Procedure in Adult Patients.
Source
European Journal of Cardio-thoracic Surgery. 68(2) (no pagination), 2026.
Article Number: ezaf295. Date of Publication: 01 Feb 2026.
Author
Vojacek J.; Gofus J.; Andreas M.; Bavaria J.E.; Berdajs D.; Casselman
F.P.A.; El-Hamamsy I.; Holubec T.; de Kerchove L.; Milojevic M.; Mulinari
L.; Ouzounian M.; Skillington P.; Takkenberg J.J.M.; Verbrugghe P.
Institution
(Vojacek, Gofus) Department of Cardiac Surgery, Charles University,
Faculty of Medicine, University Hospital in Hradec Kralove, Hradec
Kralove, Czechia
(Andreas) Division of Cardiac Surgery, Department of Surgery, Medical
University Graz, Graz, Austria
(Bavaria) Department of Surgery, Thomas Jefferson University,
Philadelphia, PA, United States
(Berdajs) Department of Cardiac Surgery, University Hospital of Basel,
Basel, Switzerland
(Casselman) Department of Cardiac Surgery, Heart Center Azorg, Aalst,
Belgium
(El-Hamamsy) Department of Cardiovascular Surgery, Mount Sinai Hospital,
Icahn School of Medicine at Mount Sinai, New York, NY, United States
(Holubec) Department of Cardiovascular Surgery, University Heart and
Vascular Centre, University Hospital Frankfurt, Goethe University
Frankfurt, Main, Frankfurt, Germany
(de Kerchove) Division of Cardiothoracic and Vascular Surgery, Cliniques
Universitaires Saint-Luc, Pole de Recherche Cardiovasculaire, Institut de
Recherche Experimentale et Clinique, Universite Catholique de Louvain,
Brussels, Belgium
(Milojevic) Department of Cardiac Surgery and Cardiovascular Research,
Dedinje Cardiovascular Institute, Belgrade, Serbia
(Milojevic) Department of Cardiac Surgery, University Hospital Zurich,
University of Zurich, Zurich, Switzerland
(Mulinari) Pediatric and Congenital Cardiac Surgery, Department of
Surgery, Miller School of Medicine, University of Miami, Miami, FL, United
States
(Ouzounian) Peter Munk Cardiac Centre, University Health Network,
Department of Surgery, University of Toronto, ON, Canada
(Skillington) Department of Cardiothoracic Surgery, Royal Melbourne
Hospital, Epworth Hospital, Melbourne, VIC, Australia
(Takkenberg) Department of Cardio-Thoracic Surgery, Erasmus University
Medical Center, Rotterdam, Netherlands
(Verbrugghe) Department of Cardiac Surgery, UZ Leuven, Leuven, Belgium
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
The Ross procedure, which involves replacing a diseased aortic valve with
the patient's own pulmonary valve (pulmonary autograft), has gained
renewed attention in adult patients due to mounting evidence of excellent
long-term outcomes. With increasing data demonstrating restoration of life
expectancy and improved valve-related outcomes, it is now considered a
viable first-line option for selected young and middle-aged adults with
non-repairable aortic valve disease. Nonetheless, its adoption remains
inconsistent across institutions, partly due to concerns about surgical
complexity, long-term durability, and the need for structured follow-up.
This expert consensus document, commissioned by the European Association
for Cardio-Thoracic Surgery, synthesizes the current evidence and offers
clinical statements for using the Ross procedure in adults. Developed
through a systematic review and informed by the collective experience of a
multidisciplinary panel of internationally recognized experts, the
document addresses key topics including patient selection, technical
refinements, and perioperative management. Emphasis is also placed on the
need for procedural standardization, high-volume surgical expertise, and
longitudinal imaging-based follow-up. Moreover, comparative outcome data
and subgroup considerations are critically appraised, and areas for future
investigation are outlined. This clinical practice document is intended to
assist clinicians and Heart Teams in making informed treatment decisions,
support harmonized implementation across centres, provide technical
considerations to optimize procedural success, and substantially improve
outcomes for patients considered for this complex but promising
procedure.<br/>Copyright &#xa9; European Association for Cardio-Thoracic
Surgery 2025.

<105>
Accession Number
650463222
Title
Heart failure with reduced ejection fraction: A systematic review of
clinical practice guidelines and recommendations.
Source
European heart journal. Quality of care & clinical outcomes. (no
pagination), 2026. Date of Publication: 04 Mar 2026.
Author
Datta S.; Majumder S.; Gulsin G.S.; Banerjee A.; Primus C.P.; Mohammed
S.F.; Ricci F.; Aung N.; Sen G.; Gallagher A.; Chahal C.A.A.; Khanji M.Y.
Institution
(Datta) University College London Hospitals NHS Foundation Trust, London,
United Kingdom
(Majumder) South Tees Hospitals NHS Foundation Trust, Middlesbrough,
United Kingdom
(Gulsin) Department of Cardiovascular Sciences, University of Leicester
and the National Institute for Health Research Leicester Biomedical
Research Centre, Glenfield Hospital, Leicester, United Kingdom
(Banerjee, Primus, Aung, Gallagher, Chahal, Khanji) Barts Heart Centre, St
Bartholomew's Hospital, Barts Health NHS Trust, West Smithfield, London
EC1A 7BE, UK
(Banerjee) University College London Institute of Health Informatics,
University College London, 222 Euston Road, London, United Kingdom
(Mohammed) Department of Cardiology, Creighton University School of
Medicine, Omaha, NE 68124, USA
(Ricci, Aung, Chahal, Khanji) William Harvey Research Institute, NIHR
Barts Biomedical Research Centre, Queen Mary University of London,
Charterhouse Square, London, United Kingdom
(Ricci) Institute for Advanced Biomedical Technologies, "G. d'Annunzio"
University of Chieti-Pescara, Via Luigi Polacchi 11 - 66100 Chieti, Italy
(Ricci) Department of Neuroscience, Imaging and Clinical Sciences, "G.
d'Annunzio" University of Chieti-Pescara, Via dei Vestini 33 - 66100
Chieti, Italy
(Sen) Department of Cardiology, King's College Hospital NHS Foundation
Trust, Denmark Hill, London, United Kingdom
(Sen) British Heart Foundation Centre of Research Excellence, School of
Cardiovascular and Metabolic Medicine and Sciences, King's College London,
London, United Kingdom
(Gallagher, Khanji) Newham University Hospital, Barts Health NHS Trust,
Glen Road, London, United Kingdom
(Chahal) Center for Inherited Cardiovascular Diseases, WellSpan Health,
157 N Reading Rd. Ephrata PA 17522, United States
Abstract
Heart failure with reduced ejection fraction (HFrEF) accounts for over
half of heart failure cases and its management is directed by
international clinical practice guidelines. To evaluate current
recommendations, we conducted a systematic review of guidelines on the
diagnosis and management of HFrEF in adults. MEDLINE and EMBASE were
searched on 10 November 2024 for publications within the past decade, and
websites of relevant medical societies were reviewed. Twelve guidelines
were identified, of which seven met predefined AGREE II criteria for
methodological 'rigour of development' and were included in the final
analysis. Across the selected guidelines, there was broad consensus on the
prevention of heart failure, the definition of HFrEF, and the initial
diagnostic approach. Recommended investigations included coronary CT
angiography, cardiac magnetic resonance imaging, and invasive coronary
angiography in selected patients. There was also agreement on the
principles of pharmacological management, with consistent endorsement of
foundational therapies such as renin-angiotensin-aldosterone system (RAAS)
inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and
sodium-glucose cotransporter 2 inhibitors. However, key differences
emerged regarding thresholds for serum natriuretic peptides, sequencing of
RAAS inhibitors, and device-based therapies including implantable
defibrillators in non-ischaemic HFrEF, cardiac resynchronization therapy,
and indications for coronary revascularization. Variability was also noted
in staging, particularly the identification and management of stage A
(at-risk) and stage B (pre-heart failure). Only a minority of guidelines
addressed common comorbidities such as iron deficiency, atrial
fibrillation, obesity, sleep-disordered breathing, and frailty. Our
findings underscore the need for greater harmonization to standardize and
optimize HFrEF care worldwide.<br/>Copyright &#xa9; The Author(s) 2026.
Published by Oxford University Press on behalf of the European Society of
Cardiology.

<106>
Accession Number
650462485
Title
Machine learning for the prediction of acute kidney injury post cardiac
surgery: a systematic review and meta-analysis.
Source
BMC medical informatics and decision making. (no pagination), 2026. Date
of Publication: 03 Mar 2026.
Author
Aftab R.A.; Butt Z.A.; Ibrahim B.; Kun L.S.
Institution
(Aftab) Department of Clinical Pharmacy and Pharmacy Practice, Faculty of
Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia
(Butt, Ibrahim) Department of Clinical Pharmacy and Pharmacy Practice,
Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia
(Kun) Department of Medicine, Faculty of Medicine, Universiti Malaya,
Kuala Lumpur, Malaysia

<107>
Accession Number
2043701402
Title
Association between prognostic nutritional index and prognosis of patients
receiving coronary artery bypass grafting surgery: a systematic review and
meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article
Number: 1673038. Date of Publication: 2026.
Author
Lei Y.; Wang W.; Hua C.; Chen Y.
Institution
(Lei, Wang, Hua, Chen) Department of Rehabilitation Medicine, The First
Affiliated Hospital of Chongqing Medical and Pharmaceutical College,
Chongqing, China
Publisher
Frontiers Media SA
Abstract
Objectives: To conduct the first systematic review and meta-analysis to
assess the association between prognostic nutritional index (PNI) and
prognosis of patients receiving coronary artery bypass grafting surgery
(CABG). <br/>Method(s): We conducted a systematic literature search via
PubMed, Embase, Web of Science, and Cochrane until March 2025, for studies
that evaluated the association between PNI and prognosis of patients
receiving CABG. All-cause mortality and acute kidney injury (AKI) were the
primary outcomes. Odds ratios (OR) and 95% confidence intervals (CI) were
used for data pooling. In addition, sensitivity analysis and subgroup
analysis were performed to evaluate the stability of the results and
potential sources of heterogeneity. All data analyses were conducted using
Review Manager 5.4 and STATA 15.1 software. <br/>Result(s): A total of 11
studies including 11,444 patients were included in the meta-analysis. The
results showed that, compared with the low PNI group, the high PNI group
had a significantly lower all-cause mortality rate (OR: 0.81; 95% CI:
0.72, 0.90) and a significantly lower risk of acute kidney injury (OR:
0.82; 95% CI: 0.77, 0.86). Sensitivity analyses confirmed that the
associations between PNI and all-cause mortality and AKI were stable.
<br/>Conclusion(s): PNI can effectively predict postoperative all-cause
mortality and AKI in patients undergoing CABG. Considering the inevitable
heterogeneity and potential publication bias in this article, more
large-scale, multicenter, prospective cohort studies are needed in the
future to assess the predictive value of PNI for prognosis after CABG and
to identify its influencing factors. Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251077959, PROSPERO
CRD420251077959.<br/>Copyright 2026 Lei, Wang, Hua and Chen.

<108>
Accession Number
650450813
Title
Side Branch Protection in Coronary Bifurcation Stenting: A Systematic
Review & Meta-Analysis of Jailed Wire versus Jailed Balloon Technique.
Source
The American journal of cardiology. (no pagination), 2026. Date of
Publication: 28 Feb 2026.
Author
Lee J.V.; Emmanuela M.; Patricio A.; Theja D.A.; Lee J.B.; Fahendra N.A.;
Wahjoepramono N.N.D.
Institution
(Lee, Emmanuela) Faculty of Medicine, Universitas Pelita Harapan,
Tangerang, Indonesia
(Patricio, Theja, Lee, Fahendra) Faculty of Medicine, Atma Jaya Catholic
University of Indonesia, Jakarta, Indonesia
(Wahjoepramono) Department of Cardiology and Vascular Medicine, Siloam
Hospital Lippo Village, Tangerang, Indonesia
Abstract
Bifurcation Percutaneous Coronary Intervention (PCI) remains technically
challenging and considered high risk to procedural complications,
particularly Side Branch (SB) occlusion. The Jailed Wire Technique (JWT)
is commonly recommended for SB protection; however, it does not fully
prevent the complication. The Jailed Balloon Technique (JBT) was
introduced to provide more active protection, but previous evidence has
been inconsistent. This study aimed to provide updated evidence on the
effectiveness of JBT versus JWT for SB protection during bifurcation PCI.
PubMed, ScienceDirect, and the Cochrane Library were searched for
randomized trials and cohort studies comparing JBT and JWT in patients
undergoing bifurcation PCI. The primary endpoints were procedure-related
adverse events, including SB occlusion, coronary dissection, and
peri-procedural Myocardial Infarction (MI). Secondary endpoints included
all-cause mortality, cardiac death, Target-lesion Revascularization (TLR),
and Major Adverse Cardiovascular Events (MACE). Odds ratios (ORs) with 95%
confidence intervals (CIs) were calculated as a measure. Study quality was
assessed using the Newcastle-Ottawa Scale and RoB 2.0 tool. Ten studies
involving 2,329 patients were included (793 JBT and 1,536 JWT). The risk
of SB occlusion was lower in JBT group compared to JWT group (OR = 0.31,
95% CI 0.20-0.48; p < 0.00001). There were no significant differences
between the two techniques in coronary dissection, peri-procedural MI,
all-cause mortality, cardiac death, TLR, or MACE. All studies were
considered good quality. In conclusion, the use of JBT was associated with
a reduced risk of SB occlusion during bifurcation PCI, while both
techniques demonstrated comparable outcomes for other procedural and
long-term clinical outcomes.<br/>Copyright &#xa9; 2026 Elsevier Inc. All
rights reserved.

<109>
Accession Number
2044044053
Title
Transcatheter aortic valve replacement for mixed aortic valve disease: An
updated meta-analysis and systematic review.
Source
American Journal of the Medical Sciences. (no pagination), 2026. Date of
Publication: 2026.
Author
Kidess G.G.; Hamza M.; Basit J.; Alraiyes M.; Alraies M.C.
Institution
(Kidess) Department of Internal Medicine, The University of Chicago
Medical Center, Chicago, IL, United States
(Hamza) Department of Hospital Medicine, Gurthrie Cortland Regional
Medical Center, Cortland, NY, United States
(Basit) Department of Internal Medicine, Rawalpindi Medical University,
Rawalpindi, Pakistan
(Alraiyes) Department of Interventional Cardiology Research, Detroit
Medical Center/Wayne State University, Detroit, MI, United States
(Alraies) Cardiovascular Unit, Detroit Medical Center/Wayne State
University, Detroit, MI, United States
Publisher
Elsevier B.V.
Abstract
Background: Mixed aortic valve disease (MAVD) is defined by the presence
of concurrent aortic stenosis (AS) and aortic regurgitation (AR).
Transcatheter aortic valve replacement (TAVR) is effective in MAVD
patients with mortality rates comparable to pure aortic stenosis (PAS).
While most TAVR complications also occur at similar rates between the MAVD
and PAS populations, recent studies have shown conflicting results.
<br/>Method(s): A systematic literature review was conducted on PubMed and
Embase for studies on the outcomes of TAVR in MAVD from inception until
May 2024. Primary outcomes were short- and long-term mortality. Secondary
outcomes were paravalvular regurgitation (PVR), vascular and bleeding
complications, pacemaker implantation, and cerebrovascular complications.
A random-effects model was used to pool risk ratios (RR) and 95 %
confidence intervals (CI). <br/>Result(s): Eleven observational studies,
including 133,558 patients, were included in the analysis. There were no
significant differences in primary endpoints (p > 0.05). MAVD was
associated with a higher risk of paravalvular regurgitation (RR: 1.29, 95
% CI: 1.07-1.55) and higher risk of vascular complications (RR: 1.20, 95 %
CI: 1.01-1.44). No significant differences were noted in other secondary
outcomes (p > 0.05), although there was a nonsignificant trend towards a
decreased risk of cerebrovascular complications associated with TAVR in
MAVD patients. <br/>Conclusion(s): TAVR is an intervention with similar
mortality and complication risk in MAVD and PAS patients. Future research
is needed to further clarify the outcomes of TAVR in patients with MAVD,
especially regarding cerebrovascular complications, long-term mortality,
and the association of paravalvular regurgitation with
mortality.<br/>Copyright &#xa9; 2026 Southern Society for Clinical
Investigation

<110>
Accession Number
650443414
Title
Rapid deployment valves: current position on the market and future
directions.
Source
Expert review of medical devices. (no pagination), 2026. Date of
Publication: 01 Mar 2026.
Author
Szecel D.; Van den Bosch M.; Meuris B.
Institution
(Szecel, Van den Bosch, Meuris) Department of Cardiovascular Sciences,
Katholieke Universiteit Leuven, Leuven, Belgium
Abstract
INTRODUCTION: With an estimated prevalence of nine million people
worldwide, calcific aortic valve stenosis is the most common valvular
heart disease in North America and Western Europe. Although transcatheter
procedures have expanded considerably over the past decade, surgical
aortic valve replacement (SAVR) remains a reliable and trusted therapeutic
option. Sutureless (SU) and rapid deployment valves (RDVs) are
bioprostheses specifically designed for implantation during SAVR using few
or no sutures.These prostheses offer well-recognized advantages, including
ease of implantation and shorter operative times, although higher rates of
permanent pacemaker implantation have been reported. Their use is also
well documented in the context of minimally invasive surgery. AREAS
COVERED: This article presents a narrative overview of the current
evidence on the benefits, limitations, and typical clinical indications of
SU/RDV prostheses. Recent developments and potential future applications
are also discussed. EXPERT OPINION: In the context of a rapidly evolving
treatment paradigm for aortic valve stenosis, SU and RDV prostheses have
demonstrated their value as reliable devices for surgical valve
replacement. Continued clinical research will be essential to better
delineate which patients may benefit most as part of an individualized,
lifetime valve-management strategy.

<111>
Accession Number
2043665789
Title
Left ventricular systolic recovery after TAVI in severe aortic stenosis: A
systematic review and meta-analysis.
Source
International Journal of Cardiology: Cardiovascular Risk and Prevention.
29 (no pagination), 2026. Article Number: 200610. Date of Publication: 01
Jun 2026.
Author
Hasabo E.A.; Elgadi A.; Ahmed A.S.; Alfadul E.S.A.; Hemmeda L.; Elnaiem
W.; Qasba R.K.; Elzomor H.; Sawabi R.; Baqal O.; Ruck A.; Saleh N.;
Soliman O.
Institution
(Hasabo, Soliman) Royal College of Surgeons in Ireland (RCSI) University
of Medicine and Health Sciences, Dublin, Ireland
(Hasabo, Sawabi, Soliman) Cardiovascular Research Institute Dublin, and
Department of Cardiology, Mater Private Network, Dublin, Ireland
(Elgadi, Ahmed, Alfadul, Hemmeda, Elnaiem) Faculty of Medicine, University
of Khartoum, Khartoum, Sudan
(Qasba) Sher-i-Kashmir Institute of Medical Sciences, Srinagar, India
(Qasba) Green Life Medical College and Hospital, Dhaka, Bangladesh
(Elzomor) Department of Cardiology, University of Galway, Galway, Ireland
(Baqal) Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ,
United States
(Ruck, Saleh) Department of Cardiology, Karolinska University Hospital,
Stockholm, Sweden
(Soliman) Euro Heart Foundation, Netherlands
Publisher
Elsevier B.V.
Abstract
Background Severe aortic stenosis (AS) imposes chronic pressure overload
on the left ventricle (LV), leading to adverse remodeling and systolic
dysfunction. While transcatheter aortic valve implantation (TAVI) can
reverse this process, the overall prevalence and predictors of LV
functional recovery are not fully understood. This study aims to assess
the left ventricular ejection fraction (LVEF) recovery following TAVI.
Methods A meta-analysis was conducted in accordance with PRISMA
guidelines. The PubMed, Scopus, Web of Science, and Cochrane databases
were searched from inception through November 2024 for studies reporting
on LVEF improvement after TAVI in patients with severe AS. The primary
outcome was LVEF improvement, defined as an absolute increase of >=10%
from baseline. A random-effects model was employed for all pooled analyses
to account for inter-study heterogeneity. Results Eighteen studies
encompassing 4782 patients met the inclusion criteria. In the subgroup of
patients with reduced LVEF, 14 studies with a total of 3182 patients
reported a LV systolic recovery of 49% (95% CI: 40-57; I2 = 97%). The
recovery was observed across all follow-up periods, from immediately
post-procedure to one-year. A meta-regression has identified that baseline
LVEF is a predictor of LV systolic recovery (beta = -0.042 (95% CI:
[-0.075, -0.008], p = 0.018, I2 = 93.31%). Conclusions TAVI is associated
with substantial LV systolic recovery in nearly half of all patients with
pre-existing systolic dysfunction. These findings underscore the
prognostic importance of myocardial recovery in this high-risk patient
population and can inform clinical decision-making and patient
counseling.<br/>Copyright &#xa9; 2026. Published by Elsevier B.V.

<112>
Accession Number
2044019324
Title
Effectiveness and safety of antifibrinolytic agents in off-pump coronary
artery bypass grafting: a systematic review and meta-analysis.
Source
Brazilian Journal of Anesthesiology (English Edition). 76(2) (no
pagination), 2026. Article Number: 844731. Date of Publication: 01 Mar
2026.
Author
Marchesani J.L.W.C.; Leite e Silva M.H.; Thomaz M.S.; Wolff D.B.; Almeida
E.C.L.; Costa M.D.S.S.
Institution
(Marchesani, Leite e Silva, Thomaz, Wolff, Almeida) Faculdade de Medicina
da Universidade Federal de Minas Gerais, MG, Belo Horizonte, Brazil
(Costa) Faculdade de Medicina da Universidade Federal de Minas Gerais,
Department of Surgery, MG, Belo Horizonte, Brazil
Publisher
Elsevier Editora Ltda
Abstract
Background: Coronary Artery Bypass Grafting (CABG) is the most widely used
cardiac intervention and can be accomplished without an extracorporeal
circulation off-pump. The benefits of antifibrinolytics in off-pump CABG
have yet to be demonstrated. <br/>Method(s): Randomized Controlled Trials
(RCTs) and observational studies comparing the use of antifibrinolytic
agents (tranexamic acid, aprotinin, and epsilon-aminocaproic) versus
controls in patients undergoing off-pump CABG were searched in the PubMed,
Embase, and Cochrane databases. Outcomes included thromboembolic events,
in-hospital mortality, overall mortality, bleeding, Intensive Care Unit
(ICU) length of stay, and blood product transfusions. Meta-analyses were
conducted using the Inverse Variance method under a random-effects model,
with p < 0.05 considered statistically significant. <br/>Result(s): Of the
23,149 patients in 20 RCTs and seven observational studies, 51% received
antifibrinolytic agents (tranexamic acid or aprotinin). Observational and
randomized designs were analyzed separately in primary subgroup analyses.
Significant reduction was found for overall mortality (RR = 0.72; [95% CI
0.54-0.95]) in the RCT subgroup. Red-blood-cell transfusion requirements
were reduced (RR = 0.65; [95% CI 0.53, 0.78]) as well as Platelets (RR =
0.59; [95% CI 0.41, 0.84]) and fresh-frozen-plasma (RR = 0.39; [95% CI
0.36, 0.42]) transfusion requirement. The RCT subgroup showed a reduction
in thromboembolic events (RR = 0.55; [95% CI 0.39, 0.79]).
<br/>Conclusion(s): In off-pump CABG, antifibrinolytics reduced the need
for blood transfusion while reducing thromboembolic events and overall
mortality in RCT subgroups, while pooled analyses combining RCTs and
observational studies did not demonstrate significant reductions. Prospero
Link:
https://www.crd.york.ac.uk/PROSPERO/view/CRD42024545640<br/>Copyright
&#xa9; 2026 Sociedade Brasileira de Anestesiologia

<113>
Accession Number
2043950097
Title
Intravenous Lidocaine in Video-Assisted Thoracoscopic Surgery: A
Systematic Review and Meta-analysis of Randomized Controlled Trials.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2026.
Date of Publication: 2026.
Author
Mamun M.A.; Saleem Y.; El-Tahlawy Y.; Mahmood W.U.; Lubbad O.; Kabir T.
Institution
(Mamun, Saleem, El-Tahlawy, Mahmood, Lubbad) Brighton and Sussex Medical
School, Brighton, United Kingdom
(Kabir) Queen Elizabeth The Queen Mother Hospital, Margate, United Kingdom
Publisher
W.B. Saunders
Abstract
Effective postoperative recovery after video-assisted thoracoscopic
surgery (VATS) remains a significant challenge, with patients frequently
experiencing moderate to severe pain, pulmonary decline, and postoperative
nausea and vomiting (PONV) despite modern multimodal analgesia.
Intravenous lidocaine has been proposed as an opioid-sparing adjunct with
systemic analgesic and antihyperalgesia properties, but its role in VATS
is uncertain. This systematic review and meta-analysis identified a total
of 31 studies, of which 9 randomized controlled trials involving 672
patients met the inclusion criteria and were included in the final
quantitative and qualitative synthesis. Five trials (n = 328) assessing
24-hour opioid use and 3 trials (n = 242) assessing 48-hour use showed no
reduction in postoperative morphine consumption with lidocaine. Similarly,
pooled movement pain scores at 24 and 48 hours (3 trials, n = 200 each)
demonstrated no significant difference between groups. Although 4 trials
(n = 272) reported a marked reduction in intraoperative remifentanil
requirements, this did not translate into improved postoperative
analgesia. In contrast, lidocaine produced a consistently favorable
antiemetic effect: 5 trials (n = 360) showed a significant reduction in
PONV with negligible heterogeneity. Limitations included small sample
sizes, varying bolus and infusion regimens, heterogeneity in background
analgesic protocols, and incomplete reporting of outcomes such as
inflammatory markers and pulmonary physiology, all of which reduce
confidence in effect estimates. Overall, current evidence indicates that
while intravenous lidocaine is safe and offers a reproducible reduction in
PONV, it does not improve postoperative pain or opioid consumption
following VATS. Larger, standardized trials are required to determine
whether specific subgroups or dosing strategies may yield a greater
benefit in thoracic minimally invasive surgery.<br/>Copyright &#xa9; 2026
The Author(s)

<114>
Accession Number
2043667333
Title
Major publications in the critical care pharmacotherapy literature: 2025.
Source
Journal of Critical Care. 94 (no pagination), 2026. Article Number:
155508. Date of Publication: 01 Aug 2026.
Author
Highsmith E.A.; Arellano D.; Bash K.; Bielewicz B.J.; Dehne L.M.; Erich
B.J.; Fjeld K.; Garcia I.; Hatton C.; Li M.; Mores K.; Sacha G.L.; Saldana
S.; Esteves A.M.
Institution
(Highsmith, Arellano) The University of Texas MD Anderson Cancer Center,
1515 Holcombe Blvd, Houston, TX, United States
(Bash, Sacha) The Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, United
States
(Bielewicz) University of Pittsburgh Medical Center, 200 Lothrop St,
Pittsburgh, PA, United States
(Dehne) UC Health - Cincinnati Medical Center, Bellevue Ave, Cincinnati,
OH, United States
(Erich) The University of Kansas Health System, 4000 Cambridge St, Kansas
City, KS, United States
(Fjeld, Esteves) Dartmouth-Hitchcock Medical Center, One Medical Center
Drive, Lebanon, NH, United States
(Garcia) ASPIRE Trials Program, Division of Pulmonary, Critical Care, and
Sleep Medicine, New York University Grossman School of Medicine, 550 1st
Ave, New York, NY, United States
(Hatton) Maine Health Maine Medical Center, 22 Bramhall St, Portland, ME,
United States
(Li) Westchester Medical Center, 100 Woods Rd, Valhalla, NY, United States
(Mores) Northwestern Memorial Hospital, 251 E Huron St, Chicago, IL,
United States
(Saldana) Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA,
United States
Publisher
W.B. Saunders
Abstract
Objectives To summarize and provide clinical insights on the most
impactful publications related to critical care pharmacotherapy in 2025.
Methods A systematic search of PubMed/Medical Literature Analysis and
Retrieval System Online (MEDLINE) was conducted between January 1, 2025
and October 5, 2025. Inclusion criteria consisted of randomized controlled
trials with prospective study designs evaluating a critically ill adult
patient population receiving pharmacotherapeutic interventions and
reporting clinical endpoints. A multi-disciplinary and geographically
diverse group of critical care clinicians was assembled and an a-priori
defined three-round modified Delphi process was performed, with a focus on
the publications determined to be the most impactful or novel. Results The
systematic search yielded a total of 1609 articles for review and 1566
were excluded, leaving 43 articles to be included in the modified Delphi
process. In each round, articles were scored based on their overall
contribution to the literature and novelty with articles achieving a score
at or above the median progressing to the next modified Delphi round. The
six included articles are summarized. Article topics include alternative
sedation options in mechanically ventilated patients, thrombolytic usage
in acute ischemic strokes, management of coagulopathic bleeding following
cardiac surgery, and use of corticosteroids in severe community-acquired
pneumonia. Conclusions This concise review identified, summarized, and
offered insights on the most relevant critical care pharmacotherapy
publications in the year 2025.<br/>Copyright &#xa9; 2026 Elsevier Inc.

<115>
Accession Number
650443601
Title
Innovative socio-sanitary rehabilitation models in central nervous system
disorders: a systematic review.
Source
Frontiers in public health. 14 (pp 1742821), 2026. Date of Publication:
2026.
Author
Morlino G.; Chimienti M.; Zerellari O.; Shkreli R.; Ndreca D.; Stefanidhi
K.; Gjergji S.; Leonforte F.; Nicosia V.; Mistretta A.; Buonomo E.; Liotta
G.; Palombi L.
Institution
(Morlino, Chimienti, Zerellari, Shkreli, Ndreca, Stefanidhi, Gjergji,
Buonomo, Palombi) Catholic University Our Lady of Good Counsel, Tirana,
Albania
(Morlino, Chimienti, Liotta) Department of Biomedicine and Prevention,
University of Rome Tor Vergata, Rome, Italy
(Leonforte) Department of Integrated Hygiene, Organizational and Service
Activities (Structural Department), Health Management, University Hospital
Polyclinic "G. Rodolico - San Marco", Catania, Italy
(Nicosia, Mistretta) Department of Medical and Surgical Sciences and
Advanced Technologies "G.F Ingrassia", University of Catania, Catania,
Italy
Abstract
Introduction: Because neurological disorders profoundly affect patients'
lives, care models are increasingly oriented toward an integrated clinical
and socio-sanitary approach. This being said, the actual context of this
integration and the literature itself presents notable gaps and
inconsistencies. The aim of this study was to review the existing
literature to provide an overview of the current implementation of these
services, while identifying gaps and potential areas for improvement.
Methodology: We conducted a systematic review following the PRISMA
guidelines including only peer-reviewed articles retrieved from PubMed,
Scopus, and Web of Science that focused on neurological conditions and
socio-sanitary services. For each peer-reviewed study, we identified
specific characteristics to review them. <br/>Result(s): Sixty-four
studies were included, with stroke as the most frequently studied
condition, followed by Alzheimer's disease, multiple sclerosis,
Parkinson's disease, and spinal cord injury. Most of the services were
embedded within public health systems with a prevalence of home or
territorial-setting. <br/>Conclusion(s): The review identifies promising
evidence of positive impacts associated with socio-sanitary services,
particularly in relation to functional outcomes, patient satisfaction and
support for community living. At the same time there are important gaps in
their implementation, integration, and the methodological consistency of
existing studies. Across multiple settings, continuity of care appears
fragmented, and case management functions are inconsistently implemented
or, in some cases, entirely absent. Together, these findings suggest that
while socio-sanitary models can offer meaningful benefits, persistent gaps
in coordination and follow-up represent key structural barriers to
achieving effective and sustainable integration.<br/>Copyright &#xa9; 2026
Morlino, Chimienti, Zerellari, Shkreli, Ndreca, Stefanidhi, Gjergji,
Leonforte, Nicosia, Mistretta, Buonomo, Liotta and Palombi.

<116>
Accession Number
650429279
Title
Efficacy and Safety of No-Touch versus Conventional Saphenous Vein
Harvesting in Coronary Artery Bypass Grafting: A Systematic Review and
Meta-Analysis of Randomized Controlled Trials.
Source
Cardiology. (pp 1-23), 2026. Date of Publication: 27 Feb 2026.
Author
Chen X.; Zhang X.; Xiang X.; Fang X.; Wei F.; Liu Y.; Feng S.
Abstract
INTRODUCTION: Saphenous vein graft (SVG) failure is a key determinant of
long-term outcomes after coronary artery bypass grafting (CABG),
particularly in individuals with multivessel disease or diabetes. This
meta-analysis aimed to evaluate whether the no-touch SVG harvesting
technique reduces graft occlusion and improves cardiovascular outcomes
compared with the conventional approach. <br/>METHOD(S): A comprehensive
literature search of PubMed, Embase, Web of Science, and the Cochrane
Library was conducted up to May 2025 to identify randomized controlled
trials (RCTs) comparing the no-touch and conventional saphenous vein
harvesting techniques in CABG. A random-effects model was used for
meta-analysis, and the certainty of evidence was evaluated using the GRADE
framework. <br/>RESULT(S): Eight RCTs involving 4,258 CABG patients
(no-touch: 2,144; conventional: 2,114) were included. The no-touch
technique significantly reduced the risk of vein graft occlusion (RR,
0.59; 95% CI: 0.47-0.73; P < 0.00001; I2 = 31%). Subgroup analyses
confirmed the consistency of this effect across regions and follow-up
durations. Although differences in secondary outcomes-including all-cause
and cardiovascular mortality, myocardial infarction, stroke, and repeat
revascularization-were not statistically significant, most effect
estimates favored the no-touch approach. The certainty of evidence was
rated as moderate for the primary and several secondary outcomes according
to the GRADE assessment. <br/>CONCLUSION(S): This meta-analysis shows that
no-touch saphenous vein harvesting is associated with a lower risk of
graft occlusion compared with conventional harvesting in CABG. However,
current randomized evidence does not demonstrate a definitive improvement
in major cardiovascular outcomes. These findings highlight the need to
balance angiographic benefits against potential trade-offs and underscore
the need for large-scale, event-driven randomized trials to clarify the
net clinical benefit of this technique.<br/>Copyright S. Karger AG, Basel.

<117>
Accession Number
650418425
Title
Design and rationale of the COMPARE-TAVI 2 trial: An all-comers
head-to-head comparison of Evolut FX+ and Sapien 3 Ultra Resilia
transcatheter heart valves.
Source
American heart journal. (pp 107387), 2026. Date of Publication: 23 Feb
2026.
Author
Thim T.; Nissen H.; Niemela M.; Eftekhari A.; Jalanko M.; Savontaus M.;
Jaaskelainen P.; Hensey M.; Jensen R.V.; Norgaard B.L.; Frederiksen C.A.;
Vase H.O.; Pedersen L.; Sorensen H.T.; Christiansen E.H.; Terkelsen C.J.
Institution
(Thim, Norgaard, Frederiksen, Christiansen) Department of Cardiology,
Aarhus University Hospital, Aarhus, Denmark; Department of Clinical
Medicine, Aarhus University, Aarhus, Denmark
(Nissen) Department of Cardiology, Odense University Hospital, Odense,
Denmark
(Niemela) Department of Cardiology, Oulu University Hospital, Oulu,
Finland; Research Unit of Biomedicine and Internal Medicine, Medical
Research Center Oulu, University of Oulu, Oulu, Finland
(Eftekhari) Department of Cardiology, Aalborg University Hospital,
Aalborg, Denmark
(Jalanko) Department of Cardiology, Helsinki University Hospital,
Helsinki, Finland
(Savontaus) Heart Center, Turku University Hospital, Turku, Finland
(Jaaskelainen) Heart Center, Kuopio University Hospital, Kuopio, Finland
(Hensey) Department of Cardiology, St James's Hospital, Dublin, Ireland
(Jensen, Vase) Department of Cardiology, Aarhus University Hospital,
Aarhus, Denmark
(Pedersen) Department of Clinical Epidemiology, Aarhus University Hospital
and Aarhus University, Aarhus, Denmark
(Sorensen) Department of Clinical Epidemiology, Center for Population
Medicine, Aarhus University Hospital and Aarhus University, Aarhus,
Denmark
(Terkelsen) Department of Cardiology, Aarhus University Hospital, Aarhus,
Denmark; Department of Clinical Medicine, Aarhus University, Aarhus,
Denmark. Electronic address: chriterk@rm.dk
Abstract
INTRODUCTION: The COMPARE-TAVI trial framework was launched for direct
comparison of transcatheter aortic valve implantation (TAVI) valves. The
COMPARE-TAVI 1 trial, comparing Myval/Myval Octacor versus Sapien 3/Sapien
3 Ultra transcatheter heart valves (THVs), was recently published. Here,
we present the design and rationale for the COMPARE-TAVI 2 trial comparing
the Evolut FX+ self-expandable THV with the Sapien 3 Ultra Resilia
balloon-expandable THV. METHODS AND ANALYSIS: In the COMPARE-TAVI 2 trial
(ClinicalTrials.gov NCT06470022), patients will be randomized 1:1 between
the THVs. The trial will test whether the Evolut FX+ self-expandable THV
is non-inferior to the Sapien 3 Ultra Resilia balloon-expandable THV in
terms of the combined 1-year primary composite endpoint of all-cause
mortality, stroke, moderate/severe total aortic regurgitation, or
moderate/severe hemodynamic THV deterioration, according to VARC-3
criteria. If non-inferiority is proven, superiority analyses may apply.
Based on a power of 80%, alpha level of 0.05, one-sided test,
non-inferiority margin of 4.5%, and expected event rate of 12%, the
necessary sample size has been estimated to be 1364 patients. Prespecified
secondary endpoints, including long-term follow-up for 10 years, will also
be investigated. SUMMARY: The COMPARE-TAVI 2 will provide important
information on the short- and long-term outcomes among patients treated
with the Evolut FX+ self-expandable and the Sapien 3 Ultra Resilia
balloon-expandable THVs.<br/>Copyright &#xa9; 2026 The Author(s).
Published by Elsevier Inc. All rights reserved.

<118>
Accession Number
650431310
Title
Beta-Blockers in Patients with Myocardial Infarction and No Heart Failure:
A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Source
The Canadian journal of cardiology. (no pagination), 2026. Date of
Publication: 26 Feb 2026.
Author
Kawtharany H.; Rayyan A.; Mestarihi A.; Hamarsha Q.; Choaib A.; Azzam M.;
Arora S.
Institution
(Kawtharany) Department of Internal Medicine, St Louis University School
of Medicine, St louis, MO, United States
(Rayyan, Mestarihi) Department of Internal Medicine, College of Medicine,
University of Central Florida/ HCA North Florida, Gainesville, FL, Puerto
Rico
(Hamarsha, Choaib, Azzam) Evidence-Based Practice and Impact Center,
Department of Internal Medicine, University of Kansas Medical Center,
Kansas City, KS, United States
(Arora) Division of Cardiology, St louis University Hospital/SSM Health,
St louis, MO, United States
Abstract
BACKGROUND: beta-blockers have an established role in patients with
myocardial infarction (MI) and left ventricular ejection fraction (LVEF)
<40%. In those with LVEF >40%, emerging new trials have inconsistent
results. We conducted a meta-analysis to evaluate the outcomes of
beta-blocker therapy compared no beta-blocker therapy in patients with MI
and LVEF >40% METHODS: We searched PubMed, Embase, and CENTRAL for
randomized clinical trials (RCTs) published after 2000. Meta-analyses
estimated hazard ratio (HR) or risk ratio (RR) with 95% confidence
intervals (CI) using RevMan web. <br/>RESULT(S): Five RCTs (N = 19,826)
met the inclusion criteria, with 9,892 patients (49.8%) were randomized to
beta-blockers and 9,934 (50.2%) to no beta-blockers. All trials enrolled
patients with MI and LVEF >40%. Meta-analysis demonstrated that
beta-blockers were not associated with significant reduction in all-cause
mortality (HR 0.98, 95% CI 0.85-1.13), cardiac mortality (HR 1.16, 95% CI
0.89-1.51), unplanned coronary revascularization (HR 1.01, 95% CI
0.87-1.17), or malignant ventricular arrhythmia (RR 0.87, 95% CI
0.51-1.48). beta-blockers were associated with a trend toward lower MI (HR
0.88, 95% CI 0.77-1.00) and new onset heart failure (HF) (HR 0.82, 95% CI
0.63-1.07). beta-blockers were not associated with an increase in
symptomatic AV block (HR 1.06, 95% CI 0.83-1.34), or stroke (RR 1.16, 95%
CI 0.9-1.48). <br/>CONCLUSION(S): In patients with MI with LVEF >40%,
beta-blockers were not associated with a significant effect on any
outcome; beta-blockers were associated with a trend toward lower MI and
HF.<br/>Copyright &#xa9; 2026. Published by Elsevier Inc.

<119>
Accession Number
2043982588
Title
Letter to the Editor "Fractional Flow Reserve in Aortic Stenosis:
Pathophysiological Considerations and Clinical Implications" regarding:
"Fractional Flow Reserve Versus Angiography-Guided Revascularisation in
Patients With Severe Aortic Stenosis: A Systematic Review" by Mridha et
al. Heart Lung Circ. 2025;34:556-565.
Source
Heart Lung and Circulation. 35(3) (pp e39-e40), 2026. Date of Publication:
01 Mar 2026.
Author
Skalidis I.; Laforgia P.; Hovasse T.; Garot P.; Akodad M.
Institution
(Skalidis, Laforgia, Hovasse, Garot, Akodad) Institut Cardiovasculaire
Paris-Sud, Hopital Jacques Cartier, Ramsay-Sante, Massy, France
(Skalidis) Department of Cardiology, HFR - Fribourg Kantonal Hospital and
University, Fribourg, Switzerland
Publisher
Elsevier Ltd

<120>
Accession Number
2043685300
Title
The effects of Traditional Chinese Medicine on cardiac function after
percutaneous coronary intervention: a meta-analysis and systematic review.
Source
Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article
Number: 1619928. Date of Publication: 2026.
Author
Wang M.; Fan S.; Xia L.; Wang Z.; Ren J.
Institution
(Wang, Fan, Wang, Ren) College of Traditional Chinese Medicine, Changchun
University of Chinese Medicine, Jilin, Changchun, China
(Xia) Affiliated Hospital to Changchun University of Chinese Medicine,
Jilin, Changchun, China
Publisher
Frontiers Media SA
Abstract
Objective: This systematic review aimed to synthesize and summarize
current evidence regarding the effects of Traditional Chinese Medicine
(TCM) on cardiac function in patients with coronary heart disease (CHD)
following percutaneous coronary intervention (PCI). <br/>Method(s): A
comprehensive search was conducted in PubMed, Embase, the Cochrane
Library, China National Knowledge Infrastructure (CNKI), Wanfang Database,
the Chinese Biomedical Literature Database (CBM), and the Chinese
Scientific and Technological Journal Database (VIP). Relevant conference
papers were also manually screened. Studies evaluating the clinical
efficacy of TCM combined with conventional Western medicine for CHD after
PCI were selected based on predefined inclusion and exclusion criteria.
The methodological quality of the included studies was assessed using the
RoB 2. Data extraction was performed independently, and Stata software was
used for meta-analysis. <br/>Result(s): 12 studies involving a total of
6,383 patients were included. Compared with conventional Western medicine
alone, integrated TCM and Western therapy significantly reduced the
incidence of in-stent restenosis (ISR) and non-fatal myocardial infarction
after PCI (p < 0.05). However, no significant differences were observed in
cardiac mortality or the incidence of coronary artery bypass grafting
(CABG) between the two treatment approaches (p > 0.05).
<br/>Conclusion(s): The combination of TCM with conventional Western
therapy may reduce ISR and non-fatal myocardial infarction in CHD patients
after PCI compared with Western medicine alone, suggesting potential
benefits for improving post-PCI clinical outcomes.<br/>Copyright 2026
Wang, Fan, Xia, Wang and Ren.

<121>
Accession Number
2043677766
Title
Mortality after urgent versus elective transcatheter aortic valve
replacement: a systematic review and meta-analysis using reconstructed
individual patient data from Kaplan-Meier curves.
Source
BMC Cardiovascular Disorders. 26(1) (no pagination), 2026. Article Number:
187. Date of Publication: 01 Dec 2026.
Author
Babaei M.; Fallahtafti P.; Mohammadi N.S.H.; Azarboo A.; Habibzadeh A.;
Azizpour A.; Rashedi S.; Mattumpuram J.; Mohsen A.; Hosseini Z.; Soleimani
H.; Kolte D.
Institution
(Babaei) Vascular Disease and Thrombosis Research Center, Rajaie
Cardiovascular Institute, Tehran, Iran, Islamic Republic of
(Babaei, Hosseini) Cardiovascular Intervention Research Center, Rajaie
Cardiovascular Institute, Tehran, Iran, Islamic Republic of
(Fallahtafti, Mohammadi, Azarboo) Tehran Heart Center, Cardiovascular
Diseases Research Institute, Tehran University of Medical Sciences,
Tehran, Iran, Islamic Republic of
(Habibzadeh, Azizpour) School of Medicine, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Rashedi) Thrombosis Research Group, Brigham and Women's Hospital, Harvard
Medical School, Boston, MA, United States
(Rashedi) Division of Cardiovascular Medicine, Brigham and Women's
Hospital, Harvard Medical School, Boston, United States
(Mattumpuram) Division of Cardiology, University of Louisville School of
Medicine, Louisville, KY, United States
(Mohsen) Division of Cardiology, Loma Linda University Medical Center,
Loma Linda, CA, United States
(Soleimani) Department of Cardiology, Imam Khomeini Hospital Complex,
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Kolte) Cardiology Division, Massachusetts General Hospital and Harvard
Medical School, Boston, MA, United States
Publisher
BioMed Central Ltd
Abstract
Background: Urgent transcatheter aortic valve replacement (TAVR),
performed during unplanned hospitalizations, is linked to worse outcomes
compared with elective TAVR. However, temporal trends in mortality remains
poorly understood. This study aimed to compare survival after urgent
versus elective TAVR using a reconstructed individual patient data (IPD)
meta-analysis. <br/>Method(s): PubMed, Embase, and Scopus were searched
through August 2025. Studies reporting Kaplan-Meier (KM) survival curves
for urgent versus elective TAVR were included. Survival data were
digitally extracted from published KM curves, and IPD were reconstructed
algorithmically using a two-stage approach. Kaplan-Meier curves and Cox
frailty models estimated survival and hazard ratios (HRs). Landmark
analysis at one-year post-procedure and restricted mean survival time
(RMST) were also employed to compare survival. <br/>Result(s): Eleven
studies including 77,108 patients were identified. Kaplan-Meier curves
were available for 76,108 patients (urgent: 5,683; elective: 71,425) and
used for reconstructed IPD analysis. Urgent TAVR was associated with
higher early mortality (HR 1.83, 95% CI: 1.73-1.93; p < 0.001), with
convergence beyond one year (HR 1.01, 95% CI: 0.84-1.22; p = 0.83). RMST
analysis demonstrated a 6.5-month overall survival advantage in favor of
elective TAVR (p = 0.001). <br/>Conclusion(s): Urgent TAVR is associated
with significantly increased early mortality compared with elective TAVR.
These findings highlight the prognostic implications of procedural timing
and support early referral for elective intervention in patients with
severe AS.<br/>Copyright &#xa9; The Author(s) 2026.

<122>
Accession Number
2043645457
Title
Comparison of the efficacy and safety of thoracic epidural and
paravertebral block in postoperative analgesia after thoracic surgery: a
meta-analysis of randomized trials.
Source
Frontiers in Medicine. 13 (no pagination), 2026. Article Number: 1747430.
Date of Publication: 2026.
Author
Qi X.; Li Z.; Zhou L.; Wang J.; Zhang X.
Institution
(Qi) Department of Pancreatic Surgery, Weifang People's Hospital,
Shandong, Weifang, China
(Li, Zhou, Wang, Zhang) Department of Critical Care Medicine, Weifang
People's Hospital, Shandong, Weifang, China
Publisher
Frontiers Media SA
Abstract
Objectives: Paravertebral block (PVB) and thoracic epidural analgesia
(TEA) are commonly used methods for pain relief after open chest surgery.
However, due to their different characteristics, there are still
controversies regarding the analgesic effect and safety of these two
methods after chest surgery. This report represents the latest
meta-analysis on this topic. <br/>Method(s): We searched PubMed, Embase,
and Cochrane Library and identified randomized controlled trials on the
use of paravertebral block and thoracic epidural analgesia after thoracic
surgery. Two researchers independently screened the identified studies.
The efficacy and safety of the two different analgesic methods were
compared and analyzed. A meta-analysis was conducted using RevMan 5.4
software. This study has been registered in PROSPERO (CRD420251208232).
<br/>Result(s): Thirty-five trials were included. Compared with
paravertebral block (PVB), thoracic epidural analgesia (TEA) provided
significantly lower pain scores at 24 h postoperatively (Resting: MD 0.41,
P = 0.03; Movement: MD 0.40, P = 0.03). However, no significant
differences were observed at 48 h. PVB was associated with a significantly
lower risk of complications, including hypotension (OR 0.13, P < 0.00001),
postoperative nausea and vomiting (OR 0.38, P = 0.0004), and urinary
retention (OR 0.23, P < 0.0001). Pulmonary complication rates were
comparable between groups (OR 0.61, P = 0.06). <br/>Conclusion(s): While
TEA demonstrated slightly superior resting and movement pain control at
the 24-h, these differences were no longer significant by 48 h. Most
notably, PVB was associated with a significantly lower risk of
hypotension, postoperative nausea and vomiting, and urinary retention.
Overall, PVB is a safer and equally effective alternative to TEA for
thoracic surgery.<br/>Copyright &#xa9; 2026 Qi, Li, Zhou, Wang and Zhang.

<123>
Accession Number
650428784
Title
Effects of preconditioning with one-lung ventilation on perioperative
oxygenation and oxidative stress in thoracoscopic surgery: a prospective
single-center randomized controlled clinical trial.
Source
BMC anesthesiology. (no pagination), 2026. Date of Publication: 28 Feb
2026.
Author
Lin J.; Du X.; Zhang W.; Wu C.; Zhao D.; Fang J.
Institution
(Lin) Department of Anesthesiology, Guangzhou Women and Children's Medical
Center, Guangzhou Medical University, Guangzhou, China
(Du, Fang) Department of Anesthesiology, First Affiliated Hospital, Sun
Yat-sen University, Guangzhou, China
(Zhang) Department of Anesthesiology, Seventh Affiliated Hospital of Sun
Yat-sen University, Shenzhen, China
(Wu) Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun
Yat-Sen University, Guangzhou, China
(Zhao) Department of Anesthesiology, Shenzhen People's Hospital, Second
Clinical Medical College, Jinan University, First Affiliated Hospital,
Southern University of Science and Technology, Shenzhen, China
Abstract
BACKGROUND: Hypoxemia is a common and clinically significant problem
during one-lung ventilation (OLV). Prophylactic ventilation strategies to
prevent OLV-associated hypoxemia and lung injury remain insufficiently
defined. <br/>METHOD(S): Patients scheduled for elective video-assisted
thoracoscopic lung lobectomy or segmentectomy were enrolled and randomly
assigned into a preconditioning group or a control group. After anesthesia
induction, a visual double-lumen endotracheal tube was inserted. The
preconditioning group underwent three cycles of OLV preconditioning
protocol before surgery: 2 min OLV -> 2 min two-lung ventilation (TLV) ->
4 min OLV -> 4 min TLV -> 6 min OLV -> 6 min TLV. The control group
received conventional OLV only. Ventilation parameters: the tidal volume
was set at 6 mL/kg during OLV and 8 mL/kg during TLV. Respiratory rate was
adjusted to maintain an end-tidal carbon dioxide partial pressure of 35-45
mmHg. The primary outcome was the oxygenation index (arterial partial
pressure of oxygen/fraction of inspired oxygen, PaO2/FiO2). Secondary
outcomes included perioperative oxidative stress markers and the incidence
of postoperative pulmonary complications (PPCs) within 7 days after
surgery. <br/>RESULT(S): Seventy-four patients were included in the final
analysis. The oxygenation index decreased in both groups after initiation
of OLV, reaching its lowest value at 30 min. At this time point, the
preconditioning group showed a significantly higher oxygenation index than
the control group (209 +/- 64 vs. 145 +/- 43 mmHg, P < 0.001). No
significant differences were observed between the two groups in
perioperative superoxide dismutase (SOD) levels [168 +/- 16 vs. 160 +/- 21
U/mL, P = 0.302] or in the incidence of PPCs (10/38 vs. 16/36, P = 0.105).
<br/>CONCLUSION(S): OLV preconditioning improved intraoperative
oxygenation during thoracic surgery, but did not significantly affect
perioperative oxidative stress or the incidence of PPCs. TRIAL
REGISTRATION: The study was retrospectively registered in the Chinese
Clinical Trial Registry on April 8, 2021, (http://www.chictr.org.cn,
ChiCTR2100045203).<br/>Copyright &#xa9; 2026. The Author(s).

<124>
Accession Number
650429447
Title
Does ventilator circuit disconnection during lateral positioning reduces
the rate of double-lumen endotracheal tube displacement in thoracic
surgery? a study protocol for a randomized controlled trial.
Source
Trials. (no pagination), 2026. Date of Publication: 28 Feb 2026.
Author
Lv S.; Lv M.; Du W.; Zou Z.; Zheng K.; Qu J.; Han X.; Mao J.
Institution
(Lv, Lv, Du, Zou, Zheng, Han, Mao) Department of Anesthesiology and
Perioperative Medicine, Shandong Provincial Hospital Affiliated to
Shandong First Medical University, Jinan, Shandong, China
(Qu) Shandong First Medical University, Jinan, Shandong, China
Abstract
BACKGROUND: Double-lumen endobronchial tube (DLT) displacement often
occurs in patients undergoing thoracic surgery after lateral positioning.
There are no clinical studies investigating the effect of disconnection of
the breathing circuit with DLT on the incidence of displacement after
lateral positioning. Therefore, the aim of this study is to investigate
the effect of disconnection of the breathing circuit with DLT on the rate
of DLT displacement after lateral positioning in patients undergoing
thoracic surgery. <br/>METHOD(S): A single-blind, parallel-group,
randomized controlled study will be conducted. We will recruit 256
patients who are scheduled to undergo elective thoracic surgery. The
participants will be randomly allocated to the disconnected breathing
circuit group and the connected breathing circuit group. The primary
outcome is the rate of DLT displacement identified via the flexible
bronchoscopy before and after lateral positioning. The secondary outcomes
are the effect of lung collapse, peripheral oxygen saturation at 5 and 10
min after one-lung ventilation, and the length of stay in the
post-anesthesia care unit (PACU). <br/>DISCUSSION(S): Several studies have
shown promising results in reducing the incidence of DLT displacement
during lateral positioning. However, no studies have investigated the
effect of the disconnection of the breathing circuit from the DLT on the
rate of DLT displacement after lateral positioning. We expect that
disconnecting the breathing circuit when changing the patient from supine
to lateral position will avoid unintended tube traction, thus reducing the
incidence of DLT displacement. TRIAL REGISTRATION: The study protocol was
registered at Clinical Trials (https://register. CLINICALTRIALS: gov/)
with registration number: NCT06182371 on November 21, 2023.<br/>Copyright
&#xa9; 2026. The Author(s).

<125>
Accession Number
650434299
Title
The intra-aortic balloon pump in action-A systematic review and
meta-analysis of hemodynamic effects.
Source
Canadian Journal of Anesthesia. Conference: 2023 CAS Annual Meeting. Los
Angeles, CA United States. 70(2 Supplement) (pp S227-S229), 2023. Date of
Publication: 01 Oct 2023.
Author
Miao J.; Deschenes I.; Lipes J.; Yang S.S.
Institution
(Miao, Deschenes, Lipes, Yang) Faculty of Medicine, McGill University,
Montreal, QC, Canada
Publisher
Springer
Abstract
INTRODUCTION The intra-aortic balloon pump (IABP) is one of the most
frequently used mechanical circulatory support devices in clinical
practice.1 It operates by counter-pulsation, whereby a balloon catheter
placed in the proximal descending aorta deflates in systole and inflates
in diastole. Thus, the functions of this device are to increase cardiac
output and diastolic coronary perfusion. The IABP is deployed in
cardiogenic shock from myocardial infarction, refractory heart failure,
cardiac surgery, and high-risk percutaneous coronary interventions. The
American Heart Association/American College of Cardiology recently
assigned the IABP a Class IIa recommendation based on recent trials
showing limited mortality benefit in myocardial infarction.2,3
Nonetheless, it remains a relevant tool in clinical practice thanks to its
ease of use and low complication rate compared to other mechanical
circulatory support devices.1 This systematic review and meta-analysis
highlight the applied hemodynamic impacts of the IABP to guide clinicians
on its effectiveness in various clinical scenarios. METHODS We searched
MEDLINE, EMBASE, CENTRAL, Web of Science databases, Google Scholar and
reference lists of resulting studies, from database inception to 27 August
2021, for observational studies and randomized controlled trials
evaluating the hemodynamic effects of the intra-aortic balloon pump in
adults older than 18 yr of age. The primary outcome will be change in
cardiac index, while secondary outcomes include changes in systolic and
diastolic blood pressure, pulmonary artery occlusion pressure, central
venous pressure, heart rate and systemic vascular resistance. Outcomes
related to IABP use will be examined in myocardial infarction, heart
failure, and cardiac surgery subgroups. Risk of bias assessment was
performed by two independent reviewers using the Joanna Briggs Institute
Critical Appraisal Tool. Primary and secondary outcomes are presented as
mean differences with 95% confidence intervals. RESULTS 1895 studies were
identified, and 28 were included for analysis. Overall, cardiac index
increased by 0.53 L-1 min-1 m2 (95% CI 0.39, 0.68). This effect was most
pronounced in the cardiac surgery population, with an increase of 0.73 L-1
min-1 m2 (95% CI, 0.39, 1.06). Cardiac index increased by 0.45 L-1 min-1
m2 (95% CI 0.19, 0.72) and 0.28 L-1 min-1 m2 (95% CI, 0.24, 0.32) in the
myocardial infarction and heart failure groups respectively. A significant
increase was found in diastolic blood pressure (20.63 mm Hg; 95% CI, 5.68,
changes. Central venous pressure (-1.72 mm Hg; 95% CI, -2.77, -0.67),
pulmonary artery occlusion pressure (-4.12 mm Hg; 95% CI, -6.11, -2.14),
and systemic vascular resistance (-149.81 dyn*sec/cm5; 95% CI, -222.6,
-77) all decreased significantly. DISCUSSION IABP increases cardiac output
in all subgroups, while showing surrogates of increased coronary perfusion
(increased diastolic pressure) and increased forward flow (reduced
pulmonary artery occlusion pressure and central venous pressure).
Limitations include heterogeneity in concomitant therapy (i.e., inotrope
use) due to the complexity of care in these populations, and in timing of
hemodynamic measurements after IABP installation. Nonetheless, given a
mortality rate of 40-60% in cardiogenic shock despite medical therapy,4
the results of this systematic review and meta-analysis demonstrated that
the intraaortic balloon pump remains a clinically useful tool for patients
in cardiogenic shock and in cardiac surgery.

<126>
Accession Number
650418821
Title
Association of duration of amino acids infusion and renal protection: a
secondary analysis of the PROTECTION trial.
Source
British journal of anaesthesia. (no pagination), 2026. Date of
Publication: 24 Feb 2026.
Author
Landoni G.; Oriani A.; Ti L.K.; Losiggio R.; Bradic N.; Pruna A.; Burrell
A.; Pieri M.; Hodgson C.L.; D'Amico F.; Ranucci M.; Oliva F.M.; Comis M.;
Calabro M.G.; Viscido C.; Ajello S.; Ferrod F.; Fresilli S.; Guarracino
F.; Damiani D.; Pisano A.; Bonizzoni M.A.; Silvetti S.; Pontillo D.; Neri
G.; Scquizzato T.; Bosco V.; Marmiere M.; Carmosino M.; Labanca R.;
Federici F.; Giardina G.; Baiardo Redaelli M.; Belletti A.; Costamagna A.;
Fominskiy E.; Arangino C.; Scandroglio A.M.; Monti G.; Cortegiani A.;
Paternoster G.; Bove T.; Bellomo R.; Zangrillo A.; Monaco F.
Institution
(Landoni, Pieri, Monti, Zangrillo) Department of Anesthesia and Intensive
Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of
Medicine, Vita-Salute San Raffaele University, Milan, Italy
(Oriani, Losiggio, Pruna, D'Amico, Oliva, Calabro, Ajello, Fresilli,
Damiani, Bonizzoni, Pontillo, Scquizzato, Marmiere, Labanca, Giardina,
Belletti, Fominskiy, Scandroglio) Department of Anesthesia and Intensive
Care, IRCCS San Raffaele Scientific Institute, Milan, Italy
(Ti) Department of Anaesthesia, National University Hospital, Singapore
(Bradic) Clinic for Anaesthesiology, Resuscitation and Intensive Medicine,
University Hospital Dubrava, Zagreb, Croatia; Department of Nursing,
University North, Varazdin, Croatia
(Burrell) Australian and New Zealand Intensive Care Research Centre
(ANZIC-RC), School of Public Health and Preventive Medicine, Monash
University, Melbourne, Australia; Department of Intensive Care and
Hyperbaric Medicine, The Alfred, Melbourne, Australia
(Hodgson) Australian and New Zealand Intensive Care Research Centre
(ANZIC-RC), School of Public Health and Preventive Medicine, Monash
University, Melbourne, Australia; Intensive Care Unit and Physiotherapy
Department, The Alfred Hospital, Melbourne, Australia; Department of
Critical Care, University of Melbourne, Melbourne, Australia
(Ranucci) Department of Cardiovascular Anaesthesia and Intensive Care,
IRCCS Policlinico San Donato, San Donato Milanese, Italy
(Comis, Viscido, Ferrod) S.C. Anestesia e Rianimazione Cardiovascolare,
A.O. Ordine Mauriziano Umberto I di Torino, Turin, Italy
(Guarracino) Department of Cardiothoracic and Vascular Anaesthesia and
Intensive Care, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
(Pisano) Cardiac Anesthesia and Intensive Care Unit, Monaldi Hospital,
Naples, Italy
(Silvetti) Department of Cardiac Anaesthesia and Intensive Care, Ospedale
Policlinico San Martino IRCCS-IRCCS Cardiovascular Network, Genoa, Italy
(Neri, Bosco) Anesthesia and Intensive Care, Department of Medical and
Surgical Sciences, Magna Graecia University, Catanzaro, Italy
(Carmosino) Department of Health Sciences, School of Medicine, University
of Basilicata, Potenza, Italy
(Federici) Anestesia e Rianimazione, Rome, Italy
(Baiardo Redaelli) Department of Biotechnologies and Life Sciences,
University of Insubria, Varese, Italy; General and Neurosurgical Intensive
Care Units, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi,
Varese, Italy
(Costamagna) Department of Anaesthesia, Intensive Care and Emergency,
'Citta della Salute e della Scienza' University Hospital, Turin, Italy
(Arangino) Department of Cardiothoracic Anaesthesia and Intensive Care,
IRCCS Centro Cardiologico Monzino, Milan, Italy
(Cortegiani) Department of Precision Medicine in Medical, Surgical and
Critical Care Area (Me.Pre.C.C.), University of Palermo, Palermo, Italy;
General Intensive Care Unit, University Hospital Policlinico 'Paolo
Giaccone', Palermo, Italy
(Paternoster) Department of Health Sciences, School of Medicine,
University of Basilicata, Potenza, Italy; Department of Health Sciences,
School of Medicine, University of Basilicata, Anaesthesia and ICU, San
Carlo Hospital, Potenza, Italy
(Bove) Department of Basic Biotechnological Sciences, Intensive Care
Peri-Operative Clinics, Universita Cattolica del Sacro Cuore, Rome, Italy;
Department of Emergency, Anaesthesiology and Reanimetion Sciences,
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
(Bellomo) Australian and New Zealand Intensive Care Research Centre
(ANZIC-RC), School of Public Health and Preventive Medicine, Monash
University, Melbourne, Australia; Department of Critical Care, University
of Melbourne, Melbourne, Australia
(Monaco) Department of Medical and Surgical Sciences (DIMEC), Alma Mater
Studiorum - University of Bologna, Bologna, Italy; Cardiothoracic and
Vascular Anaesthesia and Intensive Care, IRCCS Azienda
Ospedaliero-Universitaria Sant'Orsola, Bologna, Italy
Abstract
BACKGROUND: Intravenous amino acids (AA) reduce acute kidney injury (AKI)
in adult patients undergoing cardiac surgery. Because the optimal duration
of AA infusion is unknown, we investigated the effect of AA infusion
duration on AKI and survival. <br/>METHOD(S): In a secondary post hoc
analysis of the PROTECTION randomised double-blind placebo-controlled
trial, we divided patients into brief (<=48 h) or prolonged (>48 h but
<=72 h) AA infusion. The primary objective was to assess whether the
direction of the effects on AKI and ICU mortality was consistent across
subgroups. <br/>RESULT(S): A total of 3481/3511 patients had available
data. Brief and prolonged AA infusion had similar magnitude and direction
of effect on AKI (interaction P=0.89), with a risk reduction of 3.8% (25%
to 21%) and 5.7% (44% to 38%), respectively. Brief AA infusion showed a
reduction in the use of renal replacement therapy, whereas prolonged
infusion showed no effect. The effects of AA on intensive care unit
mortality were discordant (a reduction from 1.9% to 1.0% in the brief
infusion group, and an increase from 2.5% to 3.5% in the prolonged
infusion group; interaction P=0.04). <br/>CONCLUSION(S): The effect of AA
on AKI was consistent across subgroups, whereas they had opposing effects
on survival in patients receiving brief or prolonged study drug infusion
and in favour of the brief infusion group. Although these results are
hypothesis generating, centres that are following European guidelines and
PROTECTION trial results and are implementing AA in clinical practice
should consider AA infusion lasting <=48 h. CLINICAL TRIAL REGISTRATION:
NCT03709264.<br/>Copyright &#xa9; 2026 British Journal of Anaesthesia.
Published by Elsevier Ltd. All rights reserved.

<127>
Accession Number
650430649
Title
Timeless therapeutics: cardiac indications for vitamin K antagonists in
clinical practice.
Source
Heart (British Cardiac Society). (no pagination), 2026. Date of
Publication: 27 Feb 2026.
Author
Kempers E.K.; Acampo-de Jong M.J.J.; Ten Cate H.; De Caterina R.; Kruip
M.J.H.A.
Institution
(Kempers, Kruip) Haematology, Erasmus Medical Center, Rotterdam,
Netherlands
(Acampo-de Jong) Vascular Medicine, Maastricht University Medical Centre+,
Maastricht, Netherlands
(Ten Cate) Thrombosis Expert Centre, Maastricht UMC+, Maastricht,
Netherlands
(De Caterina) University of Pisa School of Medicine and Surgery, Pisa,
Italy
Abstract
Anticoagulation is a critical component in the treatment of cardiovascular
diseases. Large randomised controlled trials have demonstrated that direct
oral anticoagulants (DOACs) are effective and safe for stroke prevention
in patients with atrial fibrillation (AF) and treatment or prevention of
venous thromboembolism. Nevertheless, for specific cardiac indications and
patient characteristics, vitamin K antagonists (VKAs) rather than DOACs
are either preferred, or the benefit of DOACs in comparison to VKAs
remains uncertain. These include, among others, mechanical heart valves,
AF associated with moderate-to-severe mitral stenosis, left ventricular or
atrial thrombus, and older patients with frailty. As VKAs will continue to
play a vital role in the management of patients with cardiovascular
diseases in the foreseeable future, this review discusses cardiac
indications and patient characteristics that necessitate the use of VKAs
and general management principles of VKA therapy.<br/>Copyright &#xa9;
Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No
commercial re-use. See rights and permissions. Published by BMJ Group.

<128>
Accession Number
2043911151
Title
Unintended retained surgical items: a systematic review of 743 cases.
Source
International Journal for Quality in Health Care. 38(1) (no pagination),
2026. Article Number: mzag013. Date of Publication: 01 Jan 2026.
Author
Park S.-H.; Cho Y.S.
Institution
(Park) Soonchunhyang University, School of Nusing, Chungnam, Asan, South
Korea
(Cho) Department of Nursing, Seoil University, Seoul, South Korea
Publisher
Oxford University Press
Abstract
Background Despite efforts to count and verify surgical items before skin
closure, retained surgical items (RSIs) continue to be reported in
hospital settings. This study systematically analyzed both the impact and
characteristics of RSI on patients by reviewing relevant studies published
since 2000. Methods MEDLINE, EMBASE, and CINAHL databases were searched.
Case reports or case studies reporting items unintentionally left inside
the patient's body during invasive procedures were included. Two reviewers
independently extracted data and assessed study quality using the Joanna
Briggs Institute's Critical Appraisal Checklist for Case Reports. Results
Data from 634 studies included 743 RSI cases across 78 countries.
Incidence was higher in women aged 20-49 than in men. RSI occurred across
all age groups and surgical sites, with cesarean section, cholecystectomy,
hysterectomy, coronary bypass, and appendectomy accounting for 34.6% of
cases. The time to discovery of RSI was 24.3months (median), with 22.6% of
cases taking over 10years. Most patients (60.0% except not reported)
initially presented to another hospital, with pain (54.9%) as the primary
complaint; symptom duration was 4.1months (median). Computed tomography
was the most frequently used diagnostic method (40.3%), and RSI was
confirmed prior to re-surgery in only 24.9% of patients. Surgical
intervention was performed in 90.8% of cases, although some patients
either declined surgery or did not receive treatment. Most types of RSI
(92.0%) involved surgical items subjected to counting. While 56.3% of
patients recovered well, 2.6% died. The hospital stay after surgery was
5days (median). Conclusion RSI is a socially unacceptable never event, but
it continues to occur worldwide. The symptoms are often common and
nonspecific, making diagnosis difficult without clear information about
prior surgeries. This review highlights the ongoing problem of RSIs and
emphasizes that preventing them requires multiple technical measures and a
strong culture of surgical safety.<br/>Copyright &#xa9; The Author(s)
2026. Published by Oxford University Press on behalf of International
Society for Quality in Health Care. All rights reserved.

<129>
Accession Number
2043938443
Title
Interdisciplinary and Cross-Sectoral Perioperative Care Model in Cardiac
Surgery: ERAS Implementation in the Setting of Minimally Invasive Heart
Valve Surgery (INCREASE)-Results of a Randomized Controlled Trial.
Source
European Journal of Cardio-thoracic Surgery. 68(2) (no pagination), 2026.
Article Number: ezag061. Date of Publication: 01 Feb 2026.
Author
Petersen J.; Stock S.; Brettschneider C.; Dolata L.; Dumps C.; Lowe B.;
Nijman E.; Ozga A.-K.; Reichenspurner H.; Schmid M.E.; Schulte-Uentrop L.;
Vettorazzi E.; Zapf A.; Zastrow I.; Klotz S.G.R.; Girdauskas E.
Institution
(Petersen, Reichenspurner, Girdauskas) Department of Cardiovascular
Surgery, University Heart and Vascular Center, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany
(Petersen, Reichenspurner, Girdauskas) DZHK, German Centre for
Cardiovascular Research, partner site North, Hamburg, Germany
(Stock, Schmid, Girdauskas) Department of Cardiothoracic Surgery,
University Hospital Augsburg, Augsburg, Germany
(Brettschneider) Department of Health Economics and Health Services
Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
(Dolata, Zastrow) Department of Patient and Care Management, University
Medical Center Hamburg-Eppendorf, Hamburg, Germany
(Dumps) Faculty of Medicine, University of Augsburg, Anesthesiology and
Operative Intensive Care, Augsburg, Germany
(Lowe) Department of Psychosomatic Medicine and Psychotherapy, University
Medical Center Hamburg-Eppendorf, Hamburg, Germany
(Nijman) Department of Physiotherapy and Occupational Therapy, University
Hospital Augsburg, Augsburg, Germany
(Ozga, Vettorazzi, Zapf) Institute of Medical Biometry and Epidemiology,
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
(Schulte-Uentrop) Department of Anesthesiology, Center of Anesthesiology
and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf,
Hamburg, Germany
(Klotz) Department of Physiotherapy, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany
Publisher
European Association for Cardio-Thoracic Surgery
Abstract
Objectives: Enhanced recovery after surgery (ERAS) protocols are
patient-centred, interprofessional perioperative care models aimed at
reducing hospital stays, complications, healthcare costs, and improving
patient satisfaction. Evidence for ERAS in cardiac surgery is scarce;
therefore, we aimed to assess its efficacy and safety in minimally
invasive heart valve surgery (MIHS). <br/>Method(s): Interdisciplinary
Perioperative Care in Minimally Invasive Heart Valve Surgery (INCREASE) is
a randomized-controlled trial that compares ERAS with standard care in
MIHS. The intervention group (IG) received ERAS-based treatment; the
control group (CG) standard care. Co-primary end-points were in-hospital
stay for cardiovascular reasons within 1 year postoperatively (superiority
hypothesis) and physical performance (6-minute walk test [6MWT]) at
discharge (non-inferiority hypothesis). Superiority hypothesis was tested
primarily in surgically treated patients (modified intention to treat
population), while non-inferiority hypothesis was tested in per protocol
population. Results In total, 201 patients scheduled for MIHS were
randomized (IG: 101; CG: 100). Total weighted in-hospital stay within 1
year was non-significantly shorter in the IG (adjusted mean difference
-2.7 days, 95% confidence interval (CI) (-6.3, 0.9), 1-sided P =.07).
Sensitivity analyses favoured the IG (adjusted ratio 0.71, 95% CI, 0.6,
0.85). For 6MWT, adjusted mean difference was -14%, 95% CI (-43%, 15%)
exceeding the non-inferiority margin of -15% (1-sided P =.48). Without
baseline adjustment, 6MWT values revealed a mean difference between groups
of -1%, 95% CI (-10%, 8%), reaching non-inferiority of the IG. Safety
outcomes were comparable with the exception of an unexpected higher rate
of post-operative atrial fibrillation in patients randomized to ERAS.
<br/>Conclusion(s): ERAS is feasible and safe in MIHS. The trial did not
demonstrate a reduction in length of hospital stay during the first
postoperative year in the population studied. Exploratory analyses suggest
that further evaluation of ERAS concepts is justified.<br/>Copyright
&#xa9; The Author(s) 2026. Published by Oxford University Press on behalf
of the European Association for Cardio-Thoracic Surgery.

<130>
Accession Number
2043948858
Title
Low-dose direct oral anticoagulation vs dual antiplatelet therapy after
left atrial appendage occlusion: 1-year results from the ADALA trial.
Source
Revista Espanola de Cardiologia. (no pagination), 2026. Date of
Publication: 2026.
Author
Flores-Umanzor E.; Cruz-Gonzalez I.; Cepas-Guillen P.; Millan X.;
Antunez-Muinos P.; Asmarats L.; Laffond A.; Regueiro A.; Lopez-Tejero S.;
Li C.-H.P.; Sanchis L.; Rodes-Cabau J.; Arzamendi D.; Freixa X.
Institution
(Flores-Umanzor, Cepas-Guillen, Antunez-Muinos, Regueiro, Sanchis,
Rodes-Cabau, Freixa) Departamento de Cardiologia, Instituto
Cardiovascular, Instituto de Investigaciones Biomedicas August Pi i Sunyer
(IDIBAPS), Hospital Clinic, Barcelona, Spain
(Cruz-Gonzalez, Laffond, Lopez-Tejero) Departamento de Cardiologia,
Instituto de Investigacion Biomedica de Salamanca (IBSAL), Hospital
Universitario de Salamanca, Salamanca, Spain
(Cruz-Gonzalez, Laffond, Lopez-Tejero) Centro de Investigacion Biomedica
en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud
Carlos III, Madrid, Spain
(Millan, Asmarats, Li, Arzamendi) Departamento de Cardiologia, Hospital
Universitario de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain
(Rodes-Cabau) Quebec Heart and Lung Institute, Laval University, Quebec
City, Quebec, Canada
Publisher
Ediciones Doyma, S.L.
Abstract
Introduction and objectives: The ADALA trial showed a more favorable
efficacy-safety profile with low-dose direct oral anticoagulation
(LD-DOAC) vs dual antiplatelet therapy (DAPT) at 3 months after left
atrial appendage occlusion (LAAO). However, outcomes after switching both
regimens to single antiplatelet therapy (SAPT) remain uncertain. This
study reports the 1-year results, focusing on outcomes after the switch to
SAPT. <br/>Method(s): The ADALA trial was a multicenter, randomized
clinical trial that enrolled 91 patients with atrial fibrillation and
contraindications to oral anticoagulation. After successful LAAO,
participants were randomized to receive LD-DOAC or DAPT for 3 months,
after which all patients transitioned to SAPT. The primary endpoint was a
composite of thromboembolic events, device-related thrombus (DRT), or
major bleeding at 1-year. <br/>Result(s): At 12 months, the primary
endpoint was significantly lower in the LD-DOAC group compared with the
DAPT group (9.1% vs 32.6%; HR, 0.25; 95%CI, 0.08-0.74; P = .013), mainly
driven by a reduction in DRT (0% vs 11.6%; P = .023). Major bleeding was
numerically lower with LD-DOAC (9.1% vs 19.6%; P = .167), and total
bleeding events were significantly reduced (13.6% vs 37.0%; P = .013).
Landmark analysis showed significant differences during the initial 3
months (P < .001) but not from 3 to 12 months (P = .195). All DRT cases
treated with LD-DOAC (n = 4) resolved completely without bleeding.
<br/>Conclusion(s): LD-DOAC reduced thromboembolic and bleeding events
compared with DAPT during the first year after LAAO, driven by a marked
reduction in early DRT. No DRT events occurred after LD-DOAC withdrawal,
supporting a strategy of LD-DOAC for 3 months followed by SAPT in this
high-risk population.<br/>Copyright &#xa9; 2025

<131>
Accession Number
2043559800
Title
Erector Spinae Plane Block Versus Thoracic Paravertebral Block for
Postoperative Analgesia in Thoracic Surgery: A Systematic Review and
Meta-Analysis of Randomized and Observational Studies.
Source
Journal of Clinical Medicine. 15(4) (no pagination), 2026. Article Number:
1370. Date of Publication: 01 Feb 2026.
Author
Choi Y.J.; Kang H.; Kim S.H.
Institution
(Choi) Department of Anesthesiology and Pain Medicine, Korea University
Ansan Hospital, Korea University College of Medicine, Ansan, South Korea
(Kang) Department of Anesthesiology and Pain Medicine, Chung-Ang
University College of Medicine, 84 Heukseok-ro, Dongjak-gu, Seoul, South
Korea
(Kim) Department of Anesthesiology and Pain Medicine, Chosun University
Hospital, College of Medicine, Chosun University, 365 Pilmun-daero,
Dong-gu, Gwangju, South Korea
(Kim) Medical Research Institute, Chosun University, 309 Pilmun-daero,
Dong-gu, Gwangju, South Korea
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Both erector spinae plane block (ESPB) and thoracic
paravertebral block (TPVB) are widely used for thoracic surgery analgesia,
but comparative evidence remains inconsistent. This meta-analysis compared
their analgesic efficacy and safety with time-stratified analyses and
trial sequential analysis (TSA). <br/>Method(s): We searched MEDLINE,
Embase, Web of Science, and CENTRAL (inception to January 2026) for
randomized controlled trials (RCTs) and observational studies comparing
ESPB with TPVB in adults undergoing thoracic surgery. Primary outcomes
were pain scores at rest and during coughing at 0-6 h, 24 h, and 48 h
postoperatively. Secondary outcomes included opioid consumption and
adverse events. Random-effects meta-analyses were performed. Evidence
certainty was assessed using GRADE. <br/>Result(s): Twenty-five studies
(22 RCTs, 3 observational studies; 1847 patients) were included. TPVB
provided superior early analgesia (0-6 h) at rest (SMD 0.25, 95% CI
0.03-0.47) and during coughing (SMD 0.28, 95% CI 0.02-0.54); TSA confirmed
firm evidence for early pain at rest. Pain scores at 24 h and 48 h were
comparable between techniques. TPVB reduced 24 h opioid consumption (SMD
0.42, 95% CI 0.11-0.73), but evidence certainty was low due to
heterogeneity and insufficient information size by TSA. No differences
were observed in postoperative nausea and vomiting or hypotension.
<br/>Conclusion(s): ESPB and TPVB provide comparable analgesia beyond the
early postoperative period. TPVB demonstrates superior early analgesia
(0-6 h) with firm evidence, but opioid-sparing effects remain uncertain.
Both techniques are safe. ESPB represents a practical alternative to TPVB,
particularly where technical simplicity is prioritized.<br/>Copyright
&#xa9; 2026 by the authors.

<132>
Accession Number
2043805222
Title
Surgical management of double outlet right ventricle with outflow
obstruction: a systematic review of biventricular strategies.
Source
Cardiology in the Young. (no pagination), 2026. Date of Publication:
2026.
Author
Semyashkin A.; Nesteruk J.; Ben Mime L.
Institution
(Semyashkin) Department of Pediatric Cardiac Surgery, Klinikum Stuttgart
Olgahospital Frauenklinik, Germany
(Nesteruk) University Heart Center Freiburg Bad Krozingen, Germany
(Ben Mime) Center for Congenital Heart Defects, Pediatric Heart Center,
Pediatric Heart Surgery, HDZ-NRW, University Hospital of the Ruhr
University Bochum, Medical Faculty OWL University Bielefeld, Bad
Oeynhausen, Germany
Publisher
Cambridge University Press
Abstract
Background: Double outlet right ventricle is a heterogeneous congenital
defect in which both great arteries arise predominantly from the right
ventricle. Several operative strategies exist, but contemporary paediatric
outcome data have not been systematically synthesised. <br/>Material(s)
and Method(s): A systematic search of PubMed, Embase, Scopus, the Cochrane
Library, and medRxiv (2000-2025) identified cohort studies and case series
including >=10 children undergoing biventricular repair strategies
reported in double outlet right ventricle cohorts, including
intraventricular rerouting procedures, root-based realignment techniques,
and neonatal pathway operations such as the Yasui procedure. Two reviewers
independently screened studies, extracted anatomical and operative data,
and assessed risk of bias. Early mortality and 10-year survival were
pooled using random-effects models with logit transformation.
<br/>Result(s): Thirteen studies (413 children; median follow-up ~7 years)
met inclusion criteria. Early mortality ranged from 0% to 6.8%. Pooled
early mortality was 2.7% for Rastelli, 3.6% for REV, and 5.8% for
Nikaidoh/Bex operations. Ten-year survival exceeded 90% across all major
strategies. Conduit replacement was frequent after Rastelli and
Nikaidoh/Bex repair. REV avoided a conduit but required right ventricular
outflow tract reinterventions in about one-quarter of patients.
Nikaidoh/Bex procedures provided durable left ventricular outflow but
showed 19-35% conduit failure. Yasui repairs achieved excellent neonatal
survival but required frequent conduit replacement. <br/>Conclusion(s):
Contemporary double outlet right ventricle repair provides excellent
long-term survival with early mortality <6%. Procedure selection should
consider ventricular septal defect position, risk of postoperative left
ventricular outflow tract obstruction, coronary anatomy, and patient
size.<br/>Copyright &#xa9; The Author(s), 2026. Published by Cambridge
University Press.

<133>
Accession Number
2043612065
Title
Conduction abnormalities after TAVI and their role in patient management:
a systematic review.
Source
Frontiers in Cardiovascular Medicine. 13 (no pagination), 2026. Article
Number: 1706176. Date of Publication: 2026.
Author
Tudorancea I.; Popa I.P.; Haba M.U.C.; Popa S.; Onofrei V.; Serban D.N.;
Serban I.L.; Costache-Enache I.I.; Iliescu R.; Loghin C.
Institution
(Tudorancea, Popa, Haba, Popa, Onofrei, Serban, Serban, Costache-Enache,
Iliescu) Grigore T. Popa University of Medicine and Pharmacy, Iasi,
Romania
(Tudorancea, Haba, Onofrei, Costache-Enache) Cardiology Clinic, "Saint
Spiridon" County Clinical Emergency Hospital, Iasi, Romania
(Iliescu) Transcend Research Centre, Iasi, Romania
(Loghin) Division of Cardiology, Department of Internal Medicine, UTHealth
McGovern Medical School, Houston, TX, United States
Publisher
Frontiers Media SA
Abstract
Objective: Transcatheter aortic valve implantation (TAVI) is associated
with a relatively high incidence of permanent pacemaker implantation
(PPM-I). We aimed to evaluate the existing literature on
electrocardiographic (ECG) changes before and after TAVI, identify
predictors for PPM-I, and suggest a standardized post-TAVI ECG monitoring
protocol. <br/>Method(s): A systematic literature review was conducted
across multiple databases, including PubMed, Web of Science, and JSTOR, to
identify studies published between 2001 and 2024. <br/>Result(s): From an
initial pool of 24,170 records, 17 studies met the inclusion criteria.
Pre-existing right bundle branch block and significant prolongation of ECG
intervals were identified as strong predictors of PPM-I. Following TAVI,
new-onset left bundle branch block, prolonged PR interval, and QRS complex
widening were the most common ECG changes. <br/>Conclusion(s): Systematic
periprocedural ECG monitoring during TAVI is of paramount importance for
the early recognition of conduction abnormalities (CAs) that predict the
need for PPM-I.<br/>Copyright 2026 Tudorancea, Popa, Haba, Popa, Onofrei,
Serban, Serban, Costache-Enache, Iliescu and Loghin.

<134>
[Use Link to view the full text]
Accession Number
2043317969
Title
Pre-TAVI CT Angiography for Coronary Artery Disease Assessment: A
Systematic Review and Meta-Analysis of Clinical Outcomes.
Source
Circulation: Cardiovascular Interventions. Publish Ahead of Print (pp
e016074), 2026. Date of Publication: 29 Jan 2026.
Author
Rahmati S.; Nasrollahizadeh A.; Kolte D.; Khalique O.K.; Biering-Sorensen
T.; Hosseini K.
Institution
(Rahmati, Nasrollahizadeh, Hosseini) Tehran Heart Center, Cardiovascular
Diseases Research Institute, Tehran University of Medical Sciences, Iran,
Islamic Republic of
(Kolte) Cardiology Division, Massachusetts General Hospital, Boston
(Khalique) St Francis Hospital and Heart Center, Roslyn, NY
(Biering-Sorensen, Hosseini) Department of Cardiology, Copenhagen
University Hospital-Herlev and Gentofte, Denmark
(Biering-Sorensen, Hosseini) Department of Biomedical Sciences, Center for
Translational Cardiology and Pragmatic Randomized Trials, Faculty of
Health and Medical Sciences, University of Copenhagen, Denmark
(Biering-Sorensen) Department of Cardiology, Copenhagen University
Hospital-Rigshospitalet, Denmark
(Biering-Sorensen) Steno Diabetes Center Copenhagen, Herlev, Denmark
Publisher
Lippincott Williams and Wilkins

<135>
Accession Number
2043821214
Title
Comparison of Ozaki and Ross procedures for paediatric aortic valve
disease: a systematic review and meta-analysis.
Source
Cardiology in the Young. (no pagination), 2026. Date of Publication:
2026.
Author
Lu Q.; Xu K.; Li P.; Wang P.; Huang P.; Yuan Z.; Liu J.
Institution
(Lu, Xu, Li, Wang, Huang, Yuan, Liu) Capital Medical University, Nanchong,
China
Publisher
Cambridge University Press
Abstract
Objectives: To compare the clinical efficacy and prognosis of Ozaki
procedure and Ross procedure in the treatment of paediatric aortic valve
disease. <br/>Method(s): According to the predetermined inclusion and
exclusion criteria, relevant clinical studies were comprehensively
searched in three databases, and relevant data were extracted for analysis
and comparison. <br/>Result(s): This meta-analysis included four
retrospective cohort studies with a total of 243 patients (117 undergoing
Ozaki procedure and 126 undergoing Ross procedure). There were no
significant difference in the in-hospital all-cause mortality [odds ratio
= 1.38; 95% confidence interval: 0.38, 5.07, p = 0.63] and all-cause
mortality during the follow-up period [odds ratio = 1.85; 95% confidence
interval: 0.54, 6.32, p = 0.32] between Ozaki procedure and Ross
procedure. The reoperation on the aortic valve [odds ratio = 10.48; 95%
confidence interval: 2.22, 49.40, p = 0.003] was higher in the Ozaki
procedure than in the Ross procedure. There were no patients who underwent
pulmonary valve reoperation after Ozaki procedure [odds ratio = 0.21; 95%
confidence interval: 0.03, 1.23, p = 0.08]. The cumulative reoperation
rate after Ozaki procedure [odds ratio = 2.29; 95% confidence interval:
0.93, 5.66, p = 0.07] was higher than that of Ross procedure, but the
difference was not statistically significant. The cardiopulmonary bypass
time after Ozaki procedure [odds ratio = -32.09; 95% confidence
interval:-45.05, -19.14, p < 0.00001] was shorter than that of Ross
procedure. The incidence of postoperative complications [odds ratio =
0.24; 95% confidence interval: 0.04, 1.62, p = 0.14], aortic
cross-clamping time [odds ratio = -20.39; 95% confidence interval: -43.68,
2.90, p = 0.09], ventilator assistance time [odds ratio = 1.71; 95%
confidence interval: -42.70, 46.13, p = 0.94], and ICU time [odds ratio =
-0.38; 95% confidence interval: -0.93, 0.16, p = 0.17] in Ozaki procedure
was not statistically significant compared to Ross procedure.
<br/>Conclusion(s): In the treatment of children with aortic valve
disease, there is no statistically significant difference between the
Ozaki procedure and the Ross procedure in terms of freedom from
reoperation and all-cause mortality.<br/>Copyright &#xa9; The Author(s),
2026. Published by Cambridge University Press.